National Health (Listing of Pharmaceutical Benefits) Amendment (Maximum Dispensed Quantities September Update) Instrument 2024
National Health Act 1953
I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953.
Dated 30 August 2024
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
1 Name...............................................1
2 Commencement.........................................1
3 Authority.............................................1
4 Schedules.............................................1
Schedule 1—Amendments 2
National Health (Listing of Pharmaceutical Benefits) Instrument 2024
(PB 26 of 2024). 2
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 September 2024 | 1 September 2024 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
3 Authority
This instrument is made under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
.
substitute:
Abatacept | Powder for I.V. infusion 250 mg | Injection | Orencia | BQ | MP | See Note 3 | See Note 3 | See Note 3 | See Note 3 |
| 1 |
| PB(100) |
insert:
Acamprosate | Tablet (enteric coated) containing acamprosate calcium 333 mg | Oral | ACAMPROSATE-WGR | WG | MP NP | C5366 |
| 180 | 1 |
| 180 |
|
|
insert:
Aciclovir | Tablet 200 mg | Oral | ACICLOVIR-WGR | WG | MP NP | C5942 |
| 90 | 5 |
| 90 |
|
|
insert:
Aciclovir | Tablet 800 mg | Oral | ACICLOVIR-WGR | WG | MP NP | C5959 C5967 |
| 35 | 0 |
| 35 |
|
|
substitute:
Aclidinium | Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses | Inhalation by mouth | Bretaris Genuair | FK | MP NP | C4516 | P4516 | 1 | 5 |
| 1 |
|
|
Aclidinium | Powder for oral inhalation in breath actuated device 322 micrograms (as bromide) per dose, 60 doses | Inhalation by mouth | Bretaris Genuair | FK | MP NP | C15634 | P15634 | 2 | 5 |
| 1 |
|
|
substitute:
Aclidinium with formoterol | Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | Brimica Genuair | FK | MP NP | C7798 | P7798 | 1 | 5 |
| 1 |
|
|
Aclidinium with formoterol | Powder for oral inhalation in breath actuated device containing aclidinium 340 micrograms (as bromide) with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | Brimica Genuair | FK | MP NP | C15691 | P15691 | 2 | 5 |
| 1 |
|
|
insert:
Alendronic acid | Tablet 70 mg (as alendronate sodium) | Oral | ALENDRONATE-WGR | WG | MP NP | C6310 C6323 C6327 | P6310 P6323 P6327 | 4 | 5 |
| 4 |
|
|
Alendronic acid | Tablet 70 mg (as alendronate sodium) | Oral | ALENDRONATE-WGR | WG | MP NP | C14242 C14291 C14309 | P14242 P14291 P14309 | 8 | 5 |
| 4 |
|
|
insert:
Allopurinol | Tablet 100 mg | Oral | ALLOPURINOL-WGR | WG | MP NP |
|
| 200 | 2 |
| 200 |
|
|
Allopurinol | Tablet 100 mg | Oral | ALLOPURINOL-WGR | WG | MP NP |
| P14238 | 400 | 2 |
| 200 |
|
|
insert:
Allopurinol | Tablet 300 mg | Oral | ALLOPURINOL-WGR | WG | MP NP |
|
| 60 | 2 |
| 60 |
|
|
Allopurinol | Tablet 300 mg | Oral | ALLOPURINOL-WGR | WG | MP NP |
| P14238 | 120 | 2 |
| 60 |
|
|
insert:
Allopurinol | Tablet 300 mg | Oral | APO-ALLOPURINOL | TX | MP NP |
|
| 60 | 2 |
| 60 |
|
|
Allopurinol | Tablet 300 mg | Oral | APO-ALLOPURINOL | TX | MP NP |
| P14238 | 120 | 2 |
| 60 |
|
|
substitute:
Amantadine | Capsule containing amantadine hydrochloride 100 mg | Oral | AMANTAMED | DZ | MP NP | C5132 | P5132 | 100 | 5 |
| 100 |
|
|
Amantadine | Capsule containing amantadine hydrochloride 100 mg | Oral | AMANTAMED | DZ | MP NP | C15711 | P15711 | 200 | 5 |
| 100 |
|
|
Amantadine | Capsule containing amantadine hydrochloride 100 mg | Oral | Symmetrel 100 | NV | MP NP | C5132 | P5132 | 100 | 5 |
| 100 |
|
|
Amantadine | Capsule containing amantadine hydrochloride 100 mg | Oral | Symmetrel 100 | NV | MP NP | C15711 | P15711 | 200 | 5 |
| 100 |
|
|
insert:
Amisulpride | Tablet 100 mg | Oral | AMISULPRIDE-WGR | WG | MP NP | C4246 |
| 30 | 5 |
| 30 |
|
|
insert:
Amisulpride | Tablet 200 mg | Oral | AMISULPRIDE-WGR | WG | MP NP | C4246 |
| 60 | 5 |
| 60 |
|
|
insert:
Amisulpride | Tablet 400 mg | Oral | AMISULPRIDE-WGR | WG | MP NP | C4246 |
| 60 | 5 |
| 60 |
|
|
insert:
Amitriptyline | Tablet containing amitriptyline hydrochloride 10 mg | Oral | AMITRIPTYLINE-WGR | WG | MP NP |
|
| 50 | 2 |
| 50 |
|
|
insert:
Amitriptyline | Tablet containing amitriptyline hydrochloride 25 mg | Oral | AMITRIPTYLINE-WGR | WG | MP NP |
|
| 50 | 2 |
| 50 |
|
|
insert:
Amlodipine | Tablet 5 mg (as besilate) | Oral | AMLODIPINE-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Amlodipine | Tablet 5 mg (as besilate) | Oral | AMLODIPINE-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Amlodipine | Tablet 5 mg (as besilate) | Oral | BTC Amlodipine | JB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Amlodipine | Tablet 5 mg (as besilate) | Oral | BTC Amlodipine | JB | MP NP |
| P14238 | 60 | 5 |
|
|
|
|
insert:
Amlodipine | Tablet 10 mg (as besilate) | Oral | AMLODIPINE-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Amlodipine | Tablet 10 mg (as besilate) | Oral | AMLODIPINE-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Amlodipine | Tablet 10 mg (as besilate) | Oral | BTC Amlodipine | JB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Amlodipine | Tablet 10 mg (as besilate) | Oral | BTC Amlodipine | JB |
|
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Amoxicillin | Capsule 500 mg (as trihydrate) | Oral | AMOXICILLIN-WGR | WG | PDP MP NP MW |
|
| 20 | 0 |
| 20 |
|
|
Amoxicillin | Capsule 500 mg (as trihydrate) | Oral | AMOXICILLIN-WGR | WG | MP NP |
| P10402 | 40 CN10402 | 0 CN10402 |
| 20 |
|
|
insert:
Amoxicillin | Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | Oral | AMOXICILLIN-WGR | WG | PDP |
|
| 1 | 0 |
| 1 |
|
|
Amoxicillin | Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | Oral | AMOXICILLIN-WGR | WG | MP NP |
|
| 1 | 1 |
| 1 |
|
|
insert:
Amoxicillin with clavulanic acid | Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 100 mL (S19A) | Oral | CLAVULIN-125F (GlaxoSmithKline, Canada) | DZ | PDP | C5833 C5894 | P5833 P5894 | 1 | 0 |
| 1 |
|
|
Amoxicillin with clavulanic acid | Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 100 mL (S19A) | Oral | CLAVULIN-125F (GlaxoSmithKline, Canada) | DZ | MP NP | C5832 C5893 | P5832 P5893 | 1 | 1 |
| 1 |
|
|
insert:
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMOXICILLIN/CLAVULANIC ACID-WGR 500/125 | WG | MP NP | C5832 C5893 | P5832 P5893 | 10 | 0 |
| 10 |
|
|
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMOXICILLIN/CLAVULANIC ACID-WGR 500/125 | WG | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 |
| 10 |
|
|
Amoxicillin with clavulanic acid | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMOXICILLIN/CLAVULANIC ACID-WGR 500/125 | WG | MP NP | C10405 | P10405 | 20 | 0 |
| 10 |
|
|
omit:
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AlphaClav Duo Forte | AF | MP NP | C5832 C5893 | P5832 P5893 | 10 | 0 |
| 10 |
|
|
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AlphaClav Duo Forte | AF | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 |
| 10 |
|
|
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AlphaClav Duo Forte | AF | MP NP | C10413 | P10413 | 20 | 0 |
| 10 |
|
|
insert:
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMOXICILLIN/CLAVULANIC ACID-WGR 875/125 | WG | MP NP | C5832 C5893 | P5832 P5893 | 10 | 0 |
| 10 |
|
|
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMOXICILLIN/CLAVULANIC ACID-WGR 875/125 | WG | PDP | C5833 C5894 | P5833 P5894 | 10 | 0 |
| 10 |
|
|
Amoxicillin with clavulanic acid | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMOXICILLIN/CLAVULANIC ACID-WGR 875/125 | WG | MP NP | C10413 | P10413 | 20 | 0 |
| 10 |
|
|
insert:
Anastrozole | Tablet 1 mg | Oral | ANASTROZOLE-WGR | WG | MP NP | C5464 | P5464 | 30 | 5 |
| 30 |
|
|
Anastrozole | Tablet 1 mg | Oral | ANASTROZOLE-WGR | WG | MP NP | C14943 | P14943 | 60 | 5 |
| 30 |
|
|
substitute:
Apomorphine | Injection containing apomorphine hydrochloride hemihydrate 50 mg in 5 mL | Injection | Movapo | TD | MP NP | C10844 | P10844 | 180 | 5 |
| 5 |
|
|
Apomorphine | Injection containing apomorphine hydrochloride hemihydrate 50 mg in 5 mL | Injection | Movapo | TD | MP | C11385 C11445 | P11385 P11445 | 180 | 5 |
| 5 |
| C(100) |
Apomorphine | Injection containing apomorphine hydrochloride hemihydrate 50 mg in 5 mL | Injection | Movapo | TD | MP NP | C15542 | P15542 | 360 | 5 |
| 5 |
|
|
Apomorphine | Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL | Injection | Apomine Solution for Infusion | IT | MP | C10830 C10863 | P10830 P10863 | 90 | 5 |
| 5 |
| C(100) |
Apomorphine | Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL | Injection | Apomine Solution for Infusion | IT | MP NP | C10844 | P10844 | 90 | 5 |
| 5 |
|
|
Apomorphine | Injection containing apomorphine hydrochloride hemihydrate 100 mg in 20 mL | Injection | Apomine Solution for Infusion | IT | MP NP | C15542 | P15542 | 180 | 5 |
| 5 |
|
|
Apomorphine | Solution for subcutaneous infusion containing apomorphine hydrochloride hemihydrate 50 mg in 10 mL pre‑filled syringe | Injection | Movapo PFS | TD | MP | C11385 C11445 | P11385 P11445 | 180 | 5 |
| 5 |
| C(100) |
Apomorphine | Solution for subcutaneous infusion containing apomorphine hydrochloride hemihydrate 50 mg in 10 mL pre‑filled syringe | Injection | Movapo PFS | TD | MP NP | C10844 | P10844 | 180 | 5 |
| 5 |
|
|
Apomorphine | Solution for subcutaneous infusion containing apomorphine hydrochloride hemihydrate 50 mg in 10 mL pre‑filled syringe | Injection | Movapo PFS | TD | MP NP | C15542 | P15542 | 360 | 5 |
| 5 |
|
|
Apomorphine | Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 mL pre‑filled pen | Injection | Apomine Intermittent | IT | MP | C10830 C10863 | P10830 P10863 | 100 | 5 |
| 5 |
| C(100) |
Apomorphine | Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 mL pre‑filled pen | Injection | Apomine Intermittent | IT | MP NP | C10844 | P10844 | 100 | 5 |
| 5 |
|
|
Apomorphine | Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 mL pre‑filled pen | Injection | Apomine Intermittent | IT | MP NP | C15542 | P15542 | 200 | 5 |
| 5 |
|
|
Apomorphine | Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 mL pre‑filled pen | Injection | Movapo Pen | TD | MP | C10830 C10863 | P10830 P10863 | 100 | 5 |
| 5 |
| C(100) |
Apomorphine | Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 mL pre‑filled pen | Injection | Movapo Pen | TD | MP NP | C10844 | P10844 | 100 | 5 |
| 5 |
|
|
Apomorphine | Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 mL pre‑filled pen | Injection | Movapo Pen | TD | MP NP | C15542 | P15542 | 200 | 5 |
| 5 |
|
|
insert:
Aripiprazole | Tablet 10 mg | Oral | ARIPIPRAZOLE-WGR | WG | MP NP | C4246 |
| 30 | 5 |
| 30 |
|
|
insert:
Aripiprazole | Tablet 15 mg | Oral | ARIPIPRAZOLE-WGR | WG | MP NP | C4246 |
| 30 | 5 |
| 30 |
|
|
insert:
Aripiprazole | Tablet 20 mg | Oral | ARIPIPRAZOLE-WGR | WG | MP NP | C4246 |
| 30 | 5 |
| 30 |
|
|
insert:
Aripiprazole | Tablet 30 mg | Oral | ARIPIPRAZOLE-WGR | WG | MP NP | C4246 |
| 30 | 5 |
| 30 |
|
|
insert:
Atenolol | Tablet 50 mg | Oral | ATENOLOL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Atenolol | Tablet 50 mg | Oral | ATENOLOL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Atezolizumab | Solution for subcutaneous injection 1875 mg in 15 mL | Injection | Tecentriq SC | RO | MP | C10917 | P10917 | 1 | 8 |
| 1 |
|
|
insert:
Atorvastatin | Tablet 10 mg (as calcium) | Oral | ATORVASTATIN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Atorvastatin | Tablet 10 mg (as calcium) | Oral | ATORVASTATIN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Atorvastatin | Tablet 10 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Atorvastatin | Tablet 10 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | IB | MP NP |
| P14238 | 60 | 5 |
| 60 |
|
|
insert:
Atorvastatin | Tablet 20 mg (as calcium) | Oral | ATORVASTATIN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Atorvastatin | Tablet 20 mg (as calcium) | Oral | ATORVASTATIN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Atorvastatin | Tablet 20 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Atorvastatin | Tablet 20 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | IB | MP NP |
| P14238 | 60 | 5 |
| 60 |
|
|
insert:
Atorvastatin | Tablet 40 mg (as calcium) | Oral | ATORVASTATIN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Atorvastatin | Tablet 40 mg (as calcium) | Oral | ATORVASTATIN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Atorvastatin | Tablet 40 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Atorvastatin | Tablet 40 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | IB | MP NP |
| P14238 | 60 | 5 |
| 60 |
|
|
insert:
Atorvastatin | Tablet 80 mg (as calcium) | Oral | ATORVASTATIN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Atorvastatin | Tablet 80 mg (as calcium) | Oral | ATORVASTATIN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Atorvastatin | Tablet 80 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Atorvastatin | Tablet 80 mg (as calcium) | Oral | Blooms the Chemist Atorvastatin | IB | MP NP |
| P14238 | 60 | 5 |
| 60 |
|
|
insert:
Azathioprine | Tablet 25 mg | Oral | AZATHIOPRINE-WGR | WG | MP NP |
|
| 100 | 5 |
| 100 |
|
|
insert:
Azathioprine | Tablet 50 mg | Oral | AZATHIOPRINE-WGR | WG | MP NP |
|
| 100 | 5 |
| 100 |
|
|
insert:
Azithromycin | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL (S19A) | Oral | Azithromycin (Zydus, USA) | DZ | MP NP | C5637 |
| 1 | 0 |
| 1 |
|
|
insert:
Azithromycin | Tablet 500 mg (as dihydrate) | Oral | AZITHROMYCIN-WGR | WG | MP NP | C5718 C5772 | P5718 P5772 | 2 | 0 |
| 2 |
|
|
Azithromycin | Tablet 500 mg (as dihydrate) | Oral | AZITHROMYCIN-WGR | WG | MP NP | C5637 | P5637 | 2 | 2 |
| 2 |
|
|
substitute:
Beclometasone | Pressurised inhalation containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | Qvar 50 | IL | MP NP |
|
| 1 | 5 |
| 1 |
|
|
Beclometasone | Pressurised inhalation containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | Qvar 50 | IL | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
Beclometasone | Pressurised inhalation containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | Qvar 100 | IL | MP NP |
|
| 1 | 5 |
| 1 |
|
|
Beclometasone | Pressurised inhalation containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | Qvar 100 | IL | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
Beclometasone | Pressurised inhalation in breath actuated device containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | Qvar 50 Autohaler | IL | MP NP | C6348 | P6348 | 1 | 5 |
| 1 |
|
|
Beclometasone | Pressurised inhalation in breath actuated device containing beclometasone dipropionate 50 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | Qvar 50 Autohaler | IL | MP NP | C15600 | P15600 | 2 | 5 |
| 1 |
|
|
Beclometasone | Pressurised inhalation in breath actuated device containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | Qvar 100 Autohaler | IL | MP NP | C6348 | P6348 | 1 | 5 |
| 1 |
|
|
Beclometasone | Pressurised inhalation in breath actuated device containing beclometasone dipropionate 100 micrograms per dose, 200 doses (CFC‑free formulation) | Inhalation by mouth | Qvar 100 Autohaler | IL | MP NP | C15600 | P15600 | 2 | 5 |
| 1 |
|
|
substitute:
Beclometasone with formoterol | Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose,120 dose | Inhalation by mouth | Fostair | EU | MP NP | C15469 | P15469 | 1 | 5 |
| 1 |
|
|
Beclometasone with formoterol | Pressurised inhalation containing beclometasone dipropionate 100 micrograms and formoterol fumarate dihydrate 6 micrograms per dose,120 dose | Inhalation by mouth | Fostair | EU | MP NP | C15599 | P15599 | 2 | 5 |
| 1 |
|
|
Beclometasone with formoterol | Pressurised inhalation containing beclometasone dipropionate 200 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Fostair 200/6 | EU | MP NP | C11057 | P11057 | 1 | 5 |
| 1 |
|
|
Beclometasone with formoterol | Pressurised inhalation containing beclometasone dipropionate 200 micrograms and formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Fostair 200/6 | EU | MP NP | C15656 | P15656 | 2 | 5 |
| 1 |
|
|
substitute:
Beclometasone with formoterol and glycopyrronium | Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses | Inhalation by mouth | Trimbow | EU | MP NP | C12349 | P12349 | 1 | 5 |
| 1 |
|
|
Beclometasone with formoterol and glycopyrronium | Pressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 doses | Inhalation by mouth | Trimbow | EU | MP NP | C15543 | P15543 | 2 | 5 |
| 1 |
|
|
insert:
Betaxolol | Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL | Application to the eye | Betoptic | NV | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Betaxolol | Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL | Application to the eye | BetoQuin | NM | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Bimatoprost | Eye drops 300 micrograms per mL, 3 mL | Application to the eye | Bimatoprost Sandoz | SZ | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
Bimatoprost | Eye drops 300 micrograms per mL, 3 mL | Application to the eye | BIMATOPROST-WGR | WG | MP AO |
|
| 1 | 5 |
| 1 |
|
|
Bimatoprost | Eye drops 300 micrograms per mL, 3 mL | Application to the eye | BIMATOPROST-WGR | WG | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Bimatoprost | Eye drops 300 micrograms per mL, 3 mL | Application to the eye | Bimprozt | TY | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Bimatoprost | Eye drops 300 micrograms per mL, 3 mL | Application to the eye | Bimtop | AF | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Bimatoprost | Eye drops 300 micrograms per mL, 3 mL | Application to the eye | Lumigan | VE | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Bimatoprost | Eye drops 300 micrograms per mL, single dose units 0.4 mL, 30 | Application to the eye | Lumigan PF | VE | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
substitute:
Bimatoprost with timolol | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL | Application to the eye | Ganfort 0.3/5 | VE | AO | C5038 | P5038 | 1 | 5 |
| 1 |
|
|
Bimatoprost with timolol | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL | Application to the eye | Ganfort 0.3/5 | VE | MP | C4343 | P4343 | 1 | 5 |
| 1 |
|
|
Bimatoprost with timolol | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, 3 mL | Application to the eye | Ganfort 0.3/5 | VE | MP AO | C15558 | P15558 | 2 | 5 |
| 1 |
|
|
Bimatoprost with timolol`` | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, single dose units 0.4 mL, 30 | Application to the eye | GANfort PF 0.3/5 | VE | MP | C4572 | P4572 | 1 | 5 |
| 1 |
|
|
Bimatoprost with timolol | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, single dose units 0.4 mL, 30 | Application to the eye | GANfort PF 0.3/5 | VE | AO | C5038 | P5038 | 1 | 5 |
| 1 |
|
|
Bimatoprost with timolol | Eye drops 300 micrograms bimatoprost with timolol 5 mg (as maleate) per mL, single dose units 0.4 mL, 30 | Application to the eye | GANfort PF 0.3/5 | VE | MP AO | C15558 | P15558 | 2 | 5 |
| 1 |
|
|
substitute:
Bisacodyl | Suppositories 10 mg, 10 | Rectal | Dulcolax | VZ | MP NP | C5640 C5775 C5819 C5823 C5851 C5866 C5879 | P5640 P5775 P5819 P5823 P5851 P5866 P5879 | 3 | 5 |
| 1 |
|
|
Bisacodyl | Suppositories 10 mg, 10 | Rectal | Petrus Bisacodyl Suppositories | PP | MP NP | C5640 C5775 C5819 C5823 C5851 C5866 C5879 | P5640 P5775 P5819 P5823 P5851 P5866 P5879 | 3 | 5 |
| 1 |
|
|
Bisacodyl | Suppositories 10 mg, 10 | Rectal | Dulcolax | VZ | MP NP | C15535 C15585 C15586 C15587 C15708 C15726 C15727 | P15535 P15585 P15586 P15587 P15708 P15726 P15727 | 6 | 5 |
| 1 |
|
|
Bisacodyl | Suppositories 10 mg, 10 | Rectal | Petrus Bisacodyl Suppositories | PP | MP NP | C15535 C15585 C15586 C15587 C15708 C15726 C15727 | P15535 P15585 P15586 P15587 P15708 P15726 P15727 | 6 | 5 |
| 1 |
|
|
Bisacodyl | Suppositories 10 mg, 12 | Rectal | Petrus Bisacodyl Suppositories | PP | MP NP | C5640 C5775 C5819 C5823 C5851 C5866 C5879 | P5640 P5775 P5819 P5823 P5851 P5866 P5879 | 3 | 4 |
| 1 |
|
|
Bisacodyl | Suppositories 10 mg, 12 | Rectal | Petrus Bisacodyl Suppositories | PP | MP NP | C15535 C15585 C15586 C15587 C15708 C15726 C15727 | P15535 P15585 P15586 P15587 P15708 P15726 P15727 | 6 | 4 |
| 1 |
|
|
Bisacodyl | Tablet 5 mg | Oral | Lax‑Tab | AE | MP NP | C5613 C5640 C5685 C5720 C5775 C5776 C5804 | P5613 P5640 P5685 P5720 P5775 P5776 P5804 | 200 | 2 |
| 200 |
|
|
Bisacodyl | Tablet 5 mg | Oral | Lax‑Tab | AE | MP NP | C15572 C15585 C15586 C15629 C15707 C15734 C15735 | P15572 P15585 P15586 P15629 P15707 P15734 P15735 | 400 | 2 |
| 200 |
|
|
insert:
Bisoprolol | Tablet containing bisoprolol fumarate 2.5 mg | Oral | BISOPROLOL-WGR | WG | MP NP | C5324 | P5324 | 28 | 5 |
| 28 |
|
|
Bisoprolol | Tablet containing bisoprolol fumarate 2.5 mg | Oral | BISOPROLOL-WGR | WG | MP NP | C14251 | P14251 | 56 | 5 |
| 28 |
|
|
insert:
Bisoprolol | Tablet containing bisoprolol fumarate 5 mg | Oral | BISOPROLOL-WGR | WG | MP NP | C5324 | P5324 | 28 | 5 |
| 28 |
|
|
Bisoprolol | Tablet containing bisoprolol fumarate 5 mg | Oral | BISOPROLOL-WGR | WG | MP NP | C14251 | P14251 | 56 | 5 |
| 28 |
|
|
insert:
Bisoprolol | Tablet containing bisoprolol fumarate 10 mg | Oral | BISOPROLOL-WGR | WG | MP NP | C5324 | P5324 | 28 | 5 |
| 28 |
|
|
Bisoprolol | Tablet containing bisoprolol fumarate 10 mg | Oral | BISOPROLOL-WGR | WG | MP NP | C14251 | P14251 | 56 | 5 |
| 28 |
|
|
omit from the column headed “Circumstances”: C10384 substitute:C15759
insert:
Brimonidine | Eye drops containing brimonidine tartrate 1.5 mg per mL, 5 mL | Application to the eye | Alphagan P 1.5 | VE | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Brimonidine | Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL | Application to the eye | Alphagan | VE | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Brimonidine | Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL | Application to the eye | Enidin | VB | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
substitute:
Brimonidine with timolol | Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Combigan | VE | AO | C5038 | P5038 | 1 | 5 |
| 1 |
|
|
Brimonidine with timolol | Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Combigan | VE | MP | C4343 | P4343 | 1 | 5 |
| 1 |
|
|
Brimonidine with timolol | Eye drops containing brimonidine tartrate 2 mg with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Combigan | VE | MP AO | C15558 | P15558 | 2 | 5 |
| 1 |
|
|
insert:
Brinzolamide | Eye drops 10 mg per mL, 5 mL | Application to the eye | Azopt | NV | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Brinzolamide | Eye drops 10 mg per mL, 5 mL | Application to the eye | BrinzoQuin | NM | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
substitute:
Brinzolamide with brimonidine | Eye drops 10 mg brinzolamide with 2 mg brimonidine tartrate per mL, 5 mL | Application to the eye | Simbrinza 1%/0.2% | NV | MP | C5630 | P5630 | 1 | 5 |
| 1 |
|
|
Brinzolamide with brimonidine | Eye drops 10 mg brinzolamide with 2 mg brimonidine tartrate per mL, 5 mL | Application to the eye | Simbrinza 1%/0.2% | NV | AO | C5038 | P5038 | 1 | 5 |
| 1 |
|
|
Brinzolamide with brimonidine | Eye drops 10 mg brinzolamide with 2 mg brimonidine tartrate per mL, 5 mL | Application to the eye | Simbrinza 1%/0.2% | NV | MP AO | C15558 | P15558 | 2 | 5 |
| 1 |
|
|
substitute:
Brinzolamide with timolol | Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Azarga | NV | MP | C4343 | P4343 | 1 | 5 |
| 1 |
|
|
Brinzolamide with timolol | Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Azarga | NV | AO | C5038 | P5038 | 1 | 5 |
| 1 |
|
|
Brinzolamide with timolol | Eye drops 10 mg brinzolamide with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Azarga | NV | MP AO | C15558 | P15558 | 2 | 5 |
| 1 |
|
|
insert:
Budesonide | Capsule (enteric) 3 mg | Oral | Budenofalk | FD | MP NP | C15772 |
| 100 | 1 |
| 50 |
|
|
substitute:
Budesonide | Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 | Inhalation | Pulmicort Respules | AP | MP NP | C6340 | P6340 | 1 | 5 |
| 1 |
|
|
Budesonide | Nebuliser suspension 500 micrograms in 2 mL single dose units, 30 | Inhalation | Pulmicort Respules | AP | MP NP | C15578 | P15578 | 2 | 5 |
| 1 |
|
|
substitute:
Budesonide | Nebuliser suspension 1 mg in 2 mL single dose units, 30 | Inhalation | Pulmicort Respules | AP | MP NP | C6340 | P6340 | 1 | 5 |
| 1 |
|
|
Budesonide | Nebuliser suspension 1 mg in 2 mL single dose units, 30 | Inhalation | Pulmicort Respules | AP | MP NP | C15578 | P15578 | 2 | 5 |
| 1 |
|
|
insert:
Budesonide | Powder for oral inhalation in breath actuated device 100 micrograms per dose, 200 doses | Inhalation by mouth | Pulmicort Turbuhaler | AP | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Budesonide | Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses | Inhalation by mouth | Pulmicort Turbuhaler | AP | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Budesonide | Powder for oral inhalation in breath actuated device 400 micrograms per dose, 200 doses | Inhalation by mouth | Pulmicort Turbuhaler | AP | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
substitute:
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Turbuhaler 100/6 | AP | MP | C10538 | P10538 | 1 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Turbuhaler 100/6 | AP | MP NP | C4380 | P4380 | 1 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Turbuhaler 100/6 | AP | MP | C15577 | P15577 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 100 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Turbuhaler 100/6 | AP | MP NP | C15755 | P15755 | 2 | 5 |
| 1 |
|
|
insert:
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | BiResp Spiromax | TB | MP NP | C15680 | P15680 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | BiResp Spiromax | TB | MP | C15577 | P15577 | 2 | 5 |
| 1 |
|
|
insert:
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | DuoResp Spiromax | EV | MP NP | C15680 | P15680 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | DuoResp Spiromax | EV | MP | C15577 | P15577 | 2 | 5 |
| 1 |
|
|
insert:
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Rilast TURBUHALER 200/6 | XT | MP NP | C15680 | P15680 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Rilast TURBUHALER 200/6 | XT | MP | C15577 | P15577 | 2 | 5 |
| 1 |
|
|
insert:
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Turbuhaler 200/6 | AP | MP NP | C15680 | P15680 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Turbuhaler 200/6 | AP | MP | C15577 | P15577 | 2 | 5 |
| 1 |
|
|
substitute:
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | BiResp Spiromax | TB | MP NP | C7979 C10121 | P7979 P10121 | 2 | 5 |
| 2 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | BiResp Spiromax | TB | MP NP | C15548 C15617 | P15548 P15617 | 4 | 5 |
| 2 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | Bufomix Easyhaler 400/12 | OX | MP NP | C7979 C10121 | P7979 P10121 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | Bufomix Easyhaler 400/12 | OX | MP NP | C15548 C15617 | P15548 P15617 | 4 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | DuoResp Spiromax | EV | MP NP | C7979 C10121 | P7979 P10121 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | DuoResp Spiromax | EV | MP NP | C7979 C10121 | P7979 P10121 | 2 | 5 |
| 2 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | DuoResp Spiromax | EV | MP NP | C15548 C15617 | P15548 P15617 | 4 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | DuoResp Spiromax | EV | MP NP | C15548 C15617 | P15548 P15617 | 4 | 5 |
| 2 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | Rilast TURBUHALER 400/12 | XT | MP NP | C7979 C10121 | P7979 P10121 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | Rilast TURBUHALER 400/12 | XT | MP NP | C15548 C15617 | P15548 P15617 | 4 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | Symbicort TURBUHALER 400/12 | AP | MP NP | C7979 C10121 | P7979 P10121 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | Symbicort TURBUHALER 400/12 | AP | MP NP | C15548 C15617 | P15548 P15617 | 4 | 5 |
| 1 |
|
|
omit:
Budesonide with formoterol | Pressurised inhalation containing budesonide 50 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Rapihaler 50/3 | AP | MP NP | C4397 |
| 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Pressurised inhalation containing budesonide 50 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Rapihaler 50/3 | AP | MP | C10538 |
| 2 | 5 |
| 1 |
|
|
insert:
Budesonide with formoterol | Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | Inhalation by mouth | Rilast RAPIHALER 100/3 | XT | MP NP | C15702 | P15702 | 4 | 5 |
| 1 |
|
|
Budesonide with formoterol | Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | Inhalation by mouth | Rilast RAPIHALER 100/3 | XT | MP | C15577 | P15577 | 4 | 5 |
| 1 |
|
|
insert:
Budesonide with formoterol | Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Rapihaler 100/3 | AP | MP NP | C15702 | P15702 | 4 | 5 |
| 1 |
|
|
Budesonide with formoterol | Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Rapihaler 100/3 | AP | MP | C15577 | P15577 | 4 | 5 |
| 1 |
|
|
substitute:
Budesonide with formoterol | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Rilast RAPIHALER 200/6 | XT | MP NP | C4404 C10121 | P4404 P10121 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Rilast RAPIHALER 200/6 | XT | MP | C10538 | P10538 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Rilast RAPIHALER 200/6 | XT | MP NP | C15548 C15615 | P15548 P15615 | 4 | 5 | 1 |
|
|
|
Budesonide with formoterol | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Rilast RAPIHALER 200/6 | XT | MP | C15577 | P15577 | 4 | 5 | 1 |
|
|
|
Budesonide with formoterol | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Rapihaler 200/6 | AP | MP NP | C4404 C10121 | P4404 P10121 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Rapihaler 200/6 | AP | MP | C10538 | P10538 | 2 | 5 |
| 1 |
|
|
Budesonide with formoterol | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Rapihaler 200/6 | AP | MP NP | C15548 C15615 | P15548 P15615 | 4 | 5 |
| 1 |
|
|
Budesonide with formoterol | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Rapihaler 200/6 | AP | MP | C15577 | P15577 | 4 | 5 |
| 1 |
|
|
substitute:
Budesonide with glycopyrronium and formoterol | Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | Inhalation by mouth | Breztri Aerosphere | AP | MP NP | C12349 | P12349 | 1 | 5 |
| 1 |
|
|
Budesonide with glycopyrronium and formoterol | Pressurised inhalation containing budesonide 160 micrograms with glycopyrronium 7.2 micrograms and formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | Inhalation by mouth | Breztri Aerosphere | AP | MP NP | C15543 | P15543 | 2 | 5 |
| 1 |
|
|
substitute:
Cabergoline | Tablet 1 mg | Oral | Cabaser | PF | MP NP | C5168 | P5168 | 30 | 5 |
| 30 |
|
|
Cabergoline | Tablet 1 mg | Oral | Cabaser | PF | MP NP | C15636 | P15636 | 60 | 5 |
| 30 |
|
|
substitute:
Cabergoline | Tablet 2 mg | Oral | Cabaser | PF | MP NP | C5168 | P5168 | 30 | 5 |
| 30 |
|
|
Cabergoline | Tablet 2 mg | Oral | Cabaser | PF | MP NP | C15636 | P15636 | 60 | 5 |
| 30 |
|
|
substitute:
Cabozantinib | Tablet 20 mg | Oral | Cabometyx | IS | MP | C15454 C15774 | P15454 P15774 | 30 | 2 |
| 30 |
|
|
Cabozantinib | Tablet 20 mg | Oral | Cabometyx | IS | MP | C15479 C15518 C15757 C15775 | P15479 P15518 P15757 P15775 | 30 | 5 |
| 30 |
|
|
Cabozantinib | Tablet 40 mg | Oral | Cabometyx | IS | MP | C15454 C15774 | P15454 P15774 | 30 | 2 |
| 30 |
|
|
Cabozantinib | Tablet 40 mg | Oral | Cabometyx | IS | MP | C15479 C15518 C15757 C15775 | C15479 C15518 C15757 C15775 | 30 | 5 |
| 30 |
|
|
Cabozantinib | Tablet 60 mg | Oral | Cabometyx | IS | MP | C15454 C15774 | P15454 P15774 | 30 | 2 |
| 30 |
|
|
Cabozantinib | Tablet 60 mg | Oral | Cabometyx | IS | MP | C15479 C15518 C15757 C15775 | C15479 C15518 C15757 C15775 | 30 | 5 |
| 30 |
|
|
omit:
Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | Blooms the Chemist Candesartan | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | Blooms the Chemist Candesartan | IB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | CANDESARTAN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Candesartan | Tablet containing candesartan cilexetil 4 mg | Oral | CANDESARTAN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | Blooms the Chemist Candesartan | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | Blooms the Chemist Candesartan | IB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | CANDESARTAN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Candesartan | Tablet containing candesartan cilexetil 8 mg | Oral | CANDESARTAN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Candesartan | Tablet containing candesartan cilexetil 16 mg | Oral | Blooms the Chemist Candesartan | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Candesartan | Tablet containing candesartan cilexetil 16 mg | Oral | Blooms the Chemist Candesartan | IB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Candesartan | Tablet containing candesartan cilexetil 16 mg | Oral | CANDESARTAN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Candesartan | Tablet containing candesartan cilexetil 16 mg | Oral | CANDESARTAN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Candesartan | Tablet containing candesartan cilexetil 32 mg | Oral | Blooms the Chemist Candesartan | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Candesartan | Tablet containing candesartan cilexetil 32 mg | Oral | Blooms the Chemist Candesartan | IB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Candesartan | Tablet containing candesartan cilexetil 32 mg | Oral | CANDESARTAN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Candesartan | Tablet containing candesartan cilexetil 32 mg | Oral | CANDESARTAN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg | Oral | CANDESARTAN HCTZ-WGR 16/12.5 | WG | MP NP | C4374 | P4374 | 30 | 5 |
| 30 |
|
|
Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg | Oral | CANDESARTAN HCTZ-WGR 16/12.5 | WG | MP NP | C14255 | P14255 | 60 | 5 |
| 30 |
|
|
omit:
Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | Oral | Blooms the Chemist Candesartan HCTZ 32/12.5 | IB | MP NP | C4374 | P4374 | 30 | 5 |
| 30 |
|
|
Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | Oral | Blooms the Chemist Candesartan HCTZ 32/12.5 | IB | MP NP | C14255 | P14255 | 60 | 5 |
| 30 |
|
|
insert:
Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | Oral | CANDESARTAN HCTZ-WGR 32/12.5 | WG | MP NP | C4374 | P4374 | 30 | 5 |
| 30 |
|
|
Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | Oral | CANDESARTAN HCTZ-WGR 32/12.5 | WG | MP NP | C14255 | P14255 | 60 | 5 |
| 30 |
|
|
omit:
Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | Oral | Blooms the Chemist Candesartan HCTZ 32/25 | IB | MP NP | C4374 | P4374 | 30 | 5 |
| 30 |
|
|
Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | Oral | Blooms the Chemist Candesartan HCTZ 32/25 | IB | MP NP | C14255 | P14255 | 60 | 5 |
| 30 |
|
|
insert:
Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | Oral | CANDESARTAN HCTZ-WGR 32/25 | WG | MP NP | C4374 | P4374 | 30 | 5 |
| 30 |
|
|
Candesartan with hydrochlorothiazide | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | Oral | CANDESARTAN HCTZ-WGR 32/25 | WG | MP NP | C14255 | P14255 | 60 | 5 |
| 30 |
|
|
omit:
Capecitabine | Tablet 500 mg | Oral | Capecitabine‑DRLA | RZ | MP |
|
| 120 | 2 |
| 120 |
|
|
insert:
Carbamazepine | Tablet 100 mg | Oral | Carbamazepine Sandoz | NM | MP NP |
| P14238 | 400 | 2 |
| 100 |
|
|
insert:
Carbamazepine | Tablet 100 mg | Oral | Tegretol 100 | NV | MP NP |
| P14238 | 400 | 2 |
| 100 |
|
|
insert:
Carbamazepine | Tablet 200 mg | Oral | Carbamazepine Sandoz | NM | MP NP |
| P14238 | 400 | 2 |
| 100 |
|
|
insert:
Carbamazepine | Tablet 200 mg | Oral | Tegretol 200 | NV | MP NP |
| P14238 | 400 | 2 |
| 100 |
|
|
substitute:
Carbomer | Eye gel 2 mg per g, 10 g | Application to the eye | Optifresh eye gel | PP | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Carbomer | Eye gel 2 mg per g, 10 g | Application to the eye | Optifresh eye gel | PP | MP NP AO | C15556 | P15556 | 2 | 5 |
| 1 |
|
|
Carbomer | Eye gel 2 mg per g, 10 g | Application to the eye | PAA | UL | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Carbomer | Eye gel 2 mg per g, 10 g | Application to the eye | PAA | UL | MP NP AO | C15556 | P15556 | 2 | 5 |
| 1 |
|
|
Carbomer | Eye gel 2 mg per g, 10 g | Application to the eye | Viscotears | UO | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Carbomer | Eye gel 2 mg per g, 10 g | Application to the eye | Viscotears | UO | MP NP AO | C15556 | P15556 | 2 | 5 |
| 1 |
|
|
Carbomer | Eye gel 2 mg per g, single dose units 0.6 mL, 30 | Application to the eye | Viscotears Gel PF | UO | MP NP AO | C6172 | P6172 | 3 | 5 |
| 1 |
|
|
Carbomer | Eye gel 2 mg per g, single dose units 0.6 mL, 30 | Application to the eye | Viscotears Gel PF | UO | MP NP AO | C15559 | P15559 | 6 | 5 |
| 1 |
|
|
substitute:
Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 10 mL | Application to the eye | Evolve Carmellose | CX | MP NP AO | C6172 | P6172 | 1 | 5 |
| 1 |
|
|
Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 10 mL | Application to the eye | Evolve Carmellose | CX | MP NP AO | C15559 | P15559 | 2 | 5 |
| 1 |
|
|
Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 15 mL | Application to the eye | Refresh Tears Plus | VE | AO NP |
|
| 1 | 5 |
| 1 |
|
|
Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 15 mL | Application to the eye | Refresh Tears Plus | VE | MP | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Carmellose | Eye drops containing carmellose sodium 5 mg per mL, 15 mL | Application to the eye | Refresh Tears Plus | VE | MP | C15640 | P15640 | 1 | 11 |
| 1 |
|
|
Carmellose | Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | Cellufresh | VE | MP NP AO | C6172 | P6172 | 3 | 5 |
| 1 |
|
|
Carmellose | Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 31 | Application to the eye | Cellufresh | VE | MP NP AO | C15559 | P15559 | 6 | 5 |
| 1 |
|
|
Carmellose | Eye drops containing carmellose sodium 10 mg per mL, 15 mL | Application to the eye | Refresh Liquigel | VE | AO NP |
|
| 1 | 5 |
| 1 |
|
|
Carmellose | Eye drops containing carmellose sodium 10 mg per mL, 15 mL | Application to the eye | Refresh Liquigel | VE | MP | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Carmellose | Eye drops containing carmellose sodium 10 mg per mL, 15 mL | Application to the eye | Refresh Liquigel | VE | MP | C15640 | P15640 | 1 | 11 |
| 1 |
|
|
Carmellose | Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | Celluvisc | VE | MP NP AO | C6172 | P6172 | 3 | 5 |
| 1 |
|
|
Carmellose | Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 31 | Application to the eye | Celluvisc | VE | MP NP AO | C15559 | P15559 | 6 | 5 |
| 1 |
|
|
insert:
Carvedilol | Tablet 6.25 mg | Oral | CARVEDILOL-WGR | WG | MP NP | C5324 C5394 | P5324 P5394 | 60 | 5 |
| 60 |
|
|
Carvedilol | Tablet 6.25 mg | Oral | CARVEDILOL-WGR | WG | MP NP | C14251 C14270 | P14251 P14270 | 120 | 5 |
| 60 |
|
|
insert:
Carvedilol | Tablet 12.5 mg | Oral | CARVEDILOL-WGR | WG | MP NP | C5324 C5394 | P5324 P5394 | 60 | 5 |
| 60 |
|
|
Carvedilol | Tablet 12.5 mg | Oral | CARVEDILOL-WGR | WG | MP NP | C14251 C14270 | P14251 P14270 | 120 | 5 |
| 60 |
|
|
insert:
Carvedilol | Tablet 25 mg | Oral | CARVEDILOL-WGR | WG | MP NP | C5324 C5394 | P5324 P5394 | 60 | 5 |
| 60 |
|
|
Carvedilol | Tablet 25 mg | Oral | CARVEDILOL-WGR | WG | MP NP | C14251 C14270 | P14251 P14270 | 120 | 5 |
| 60 |
|
|
insert:
Cefalexin | Capsule 500 mg (as monohydrate) | Oral | CEPHALEXIN-WGR | WG | MP NP MW PDP |
|
| 20 | 0 |
| 20 |
|
|
Cefalexin | Capsule 500 mg (as monohydrate) | Oral | CEPHALEXIN-WGR | WG | MP NP MW |
| P10410 | 40 CN10410 | 0 CN10410 |
| 20 |
|
|
Cefalexin | Capsule 500 mg (as monohydrate) | Oral | CEPHALEXIN-WGR | WG | MP |
| P6188 | 40 CN6188 | 1 CN6188 |
| 20 |
|
|
insert:
Celecoxib | Capsule 100 mg | Oral | CELECOXIB-WGR | WG | MP NP | C4907 C4962 |
| 60 | 3 |
| 60 |
|
|
insert:
Celecoxib | Capsule 200 mg | Oral | CELECOXIB-WGR | WG | MP NP | C4907 C4962 |
| 30 | 3 |
| 30 |
|
|
omit from the column headed “Circumstances”: C6732 C7369 substitute: C7346 C15759
insert:
Ciclesonide | Pressurised inhalation 80 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Alvesco 80 | EU | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Ciclesonide | Pressurised inhalation 160 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Alvesco 160 | EU | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Ciclosporin | Capsule 25 mg | Oral | CICLOSPORIN-WGR | WG | MP |
|
| 60 | 3 |
| 30 |
|
|
Ciclosporin | Capsule 25 mg | Oral | CICLOSPORIN-WGR | WG | MP |
| P14238 | 120 | 3 |
| 30 |
|
|
insert:
Ciclosporin | Capsule 50 mg | Oral | CICLOSPORIN-WGR | WG | MP |
|
| 60 | 3 |
| 30 |
|
|
Ciclosporin | Capsule 50 mg | Oral | CICLOSPORIN-WGR | WG | MP |
| P14238 | 120 | 3 |
| 30 |
|
|
insert:
Ciclosporin | Capsule 100 mg | Oral | CICLOSPORIN-WGR | WG | MP |
|
| 60 | 3 |
| 30 |
|
|
Ciclosporin | Capsule 100 mg | Oral | CICLOSPORIN-WGR | WG | MP |
| P14238 | 120 | 3 |
| 30 |
|
|
insert:
Ciprofloxacin | Tablet 250 mg (as hydrochloride) | Oral | CIPROFLOXACIN-WGR | WG | MP NP | C5614 C5615 C5666 C5687 C5688 C5689 C5722 C5780 |
| 14 | 0 |
| 14 |
|
|
insert:
Ciprofloxacin | Tablet 500 mg (as hydrochloride) | Oral | CIPROFLOXACIN-WGR | WG | MP NP | C5614 C5615 C5687 C5688 C5689 C5722 C5780 |
| 14 | 0 |
| 14 |
|
|
insert:
Ciprofloxacin | Tablet 750 mg (as hydrochloride) | Oral | CIPROFLOXACIN-WGR | WG | MP NP | C5614 C5615 C5687 C5688 C5689 C5722 C5780 |
| 14 | 0 |
| 14 |
|
|
substitute:
Citalopram | Tablet 10 mg (as hydrobromide) | Oral | Celapram | AF | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 10 mg (as hydrobromide) | Oral | Celapram | AF | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 10 mg (as hydrobromide) | Oral | Talam | RW | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 10 mg (as hydrobromide) | Oral | Talam | RW | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | APO‑Citalopram | TX | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | APO‑Citalopram | TX | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | APX‑Citalopram | TY | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | APX‑Citalopram | TY | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | Celapram | AF | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | Celapram | AF | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | Cipramil | LU | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | Cipramil | LU | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | Citalopram Sandoz | SZ | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | Citalopram Sandoz | SZ | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | NOUMED CITALOPRAM | VO | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | NOUMED CITALOPRAM | VO | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | Talam | RW | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 20 mg (as hydrobromide) | Oral | Talam | RW | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 40 mg (as hydrobromide) | Oral | APO‑Citalopram | TX | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 40 mg (as hydrobromide) | Oral | APO‑Citalopram | TX | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 40 mg (as hydrobromide) | Oral | Celapram | AF | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 40 mg (as hydrobromide) | Oral | Celapram | AF | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 40 mg (as hydrobromide) | Oral | Citalopram Sandoz | SZ | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 40 mg (as hydrobromide) | Oral | Citalopram Sandoz | SZ | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 40 mg (as hydrobromide) | Oral | NOUMED CITALOPRAM | VO | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 40 mg (as hydrobromide) | Oral | NOUMED CITALOPRAM | VO | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Citalopram | Tablet 40 mg (as hydrobromide) | Oral | Talam | RW | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Citalopram | Tablet 40 mg (as hydrobromide) | Oral | Talam | RW | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
insert:
Clindamycin | Capsule 150 mg (as hydrochloride) | Oral | CLINDAMYCIN-WGR | WG | PDP | C5487 | P5487 | 24 | 0 |
| 24 |
|
|
|
Clindamycin | Capsule 150 mg (as hydrochloride) | Oral | CLINDAMYCIN-WGR | WG | MP NP MW | C5470 | P5470 | 48 | 1 |
| 24 |
|
|
|
insert:
Clomipramine | Tablet containing clomipramine hydrochloride 25 mg | Oral | CLOMIPRAMINE-WGR | WG | MP NP | C6250 C6251 C6299 |
| 50 | 2 |
| 50 |
|
|
omit:
Clopidogrel | Tablet 75 mg (as besilate) | Oral | BTC Clopidogrel | JB | MP NP |
|
| 28 | 5 |
| 28 |
|
|
Clopidogrel | Tablet 75 mg (as besilate) | Oral | BTC Clopidogrel | JB | MP NP |
| P14238 | 56 | 5 |
| 28 |
|
|
insert:
Clopidogrel | Tablet 75 mg (as besilate) | Oral | CLOPIDOGREL-WGR | WG | MP NP |
|
| 28 | 5 |
| 28 |
|
|
Clopidogrel | Tablet 75 mg (as besilate) | Oral | CLOPIDOGREL-WGR | WG | MP NP |
| P14238 | 56 | 5 |
| 28 |
|
|
substitute:
Colestyramine | Sachets containing 4.7 g oral powder (equivalent to 4 g colestyramine), 50 | Oral | Questran Lite | GO | MP NP |
|
| 2 | 5 |
| 1 |
|
|
Colestyramine | Sachets containing 4.7 g oral powder (equivalent to 4 g colestyramine), 50 | Oral | Questran Lite | GO | MP NP |
| P14238 | 4 | 5 |
| 1 |
|
|
substitute:
Crizotinib | Capsule 200 mg | Oral | Xalkori | PF | MP | C13186 C15776 C15803 |
| 60 | 3 |
| 60 |
|
|
Crizotinib | Capsule 250 mg | Oral | Xalkori | PF | MP | C13186 C15776 C15803 |
| 60 | 3 |
| 60 |
|
|
substitute:
Desvenlafaxine | Tablet (extended release) 50 mg (as succinate) | Oral | Pristiq | PF | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (extended release) 50 mg (as succinate) | Oral | Pristiq | PF | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (extended release) 100 mg (as succinate) | Oral | Pristiq | PF | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (extended release) 100 mg (as succinate) | Oral | Pristiq | PF | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg | Oral | BTC Desvenlafaxine | BG | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg | Oral | BTC Desvenlafaxine | BG | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg | Oral | Desfax | AF | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg | Oral | Desfax | AF | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg | Oral | DESVEN | RW | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg | Oral | DESVEN | RW | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg | Oral | Desvenlafaxine Sandoz | SZ | MP NP | C5650 |
| 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg | Oral | Desvenlafaxine Sandoz | SZ | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg | Oral | DESVENLAFAXINE-WGR XR | WG | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg | Oral | DESVENLAFAXINE-WGR XR | WG | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg (as benzoate) | Oral | APO-Desvenlafaxine MR | TX | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg (as benzoate) | Oral | APO-Desvenlafaxine MR | TX | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg (as benzoate) | Oral | Desvenlafaxine GH XR | GQ | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 50 mg (as benzoate) | Oral | Desvenlafaxine GH XR | GQ | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg | Oral | BTC Desvenlafaxine | BG | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg | Oral | BTC Desvenlafaxine | BG | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg | Oral | Desfax | AF | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg | Oral | Desfax | AF | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg | Oral | DESVEN | RW | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg | Oral | DESVEN | RW | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg | Oral | Desvenlafaxine Sandoz | SZ | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg | Oral | Desvenlafaxine Sandoz | SZ | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg | Oral | DESVENLAFAXINE-WGR XR | WG | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg | Oral | DESVENLAFAXINE-WGR XR | WG | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg (as benzoate) | Oral | APO-Desvenlafaxine MR | TX | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg (as benzoate) | Oral | APO-Desvenlafaxine MR | TX | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg (as benzoate) | Oral | Desvenlafaxine GH XR | GQ | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Desvenlafaxine | Tablet (modified release) 100 mg (as benzoate) | Oral | Desvenlafaxine GH XR | GQ | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
substitute:
Diazepam | Oral liquid 10 mg per 10 mL, 100 mL | Oral | Diazepam Elixir | ON | MP NP | C4244 |
| 1 | 0 |
| 1 |
|
|
Diazepam | Tablet 2 mg | Oral | Antenex 2 | AF | MP NP PDP |
|
| 50 | 0 |
| 50 |
|
|
Diazepam | Tablet 2 mg | Oral | Antenex 2 | AF | MP NP |
| P6176 | 50 | 3 |
| 50 |
|
|
Diazepam | Tablet 2 mg | Oral | APO-Diazepam | TX | MP NP PDP |
|
| 50 | 0 |
| 50 |
|
|
Diazepam | Tablet 2 mg | Oral | APO-Diazepam | TX | MP NP |
| P6176 | 50 | 3 |
| 50 |
|
|
Diazepam | Tablet 2 mg | Oral | APX-Diazepam | TY | MP NP PDP |
|
| 50 | 0 |
| 50 |
|
|
Diazepam | Tablet 2 mg | Oral | APX-Diazepam | TY | MP NP |
| P6176 | 50 | 3 |
| 50 |
|
|
Diazepam | Tablet 2 mg | Oral | DIAZEPAM-WGR | WG | MP NP PDP |
|
| 50 | 0 |
| 50 |
|
|
Diazepam | Tablet 2 mg | Oral | DIAZEPAM-WGR | WG | MP NP |
| P6176 | 50 CN6176 | 3 CN6176 |
| 50 |
|
|
Diazepam | Tablet 2 mg | Oral | Valpam 2 | RW | MP NP PDP |
|
| 50 | 0 |
| 50 |
|
|
Diazepam | Tablet 2 mg | Oral | Valpam 2 | RW | MP NP |
| P6176 | 50 | 3 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | Antenex 5 | AF | MP NP PDP |
|
| 50 | 0 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | Antenex 5 | AF | MP NP |
| P6176 | 50 | 3 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | APO-Diazepam | TX | MP NP PDP |
|
| 50 | 0 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | APO-Diazepam | TX | MP NP |
| P6176 | 50 | 3 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | APX-Diazepam | TY | MP NP PDP |
|
| 50 | 0 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | APX-Diazepam | TY | MP NP |
| P6176 | 50 | 3 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | DIAZEPAM-WGR | WG | MP NP PDP |
|
| 50 | 0 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | DIAZEPAM-WGR | WG | MP NP |
| P6176 | 50 CN6176 | 3 CN6176 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | NOUMED DIAZEPAM | VO | MP NP PDP |
|
| 50 | 0 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | NOUMED DIAZEPAM | VO | MP NP |
| P6176 | 50 | 3 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | Valium | IX | MP NP PDP |
|
| 50 | 0 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | Valium | IX | MP NP |
| P6176 | 50 | 3 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | Valpam 5 | RW | MP NP PDP |
|
| 50 | 0 |
| 50 |
|
|
Diazepam | Tablet 5 mg | Oral | Valpam 5 | RW | MP NP |
| P6176 | 50 | 3 |
| 50 |
|
|
insert:
Diclofenac | Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | DICLOFENAC-WGR | WG | PDP |
|
| 100 | 0 |
| 50 |
|
|
Diclofenac | Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | DICLOFENAC-WGR | WG | MP NP |
|
| 100 | 3 |
| 50 |
|
|
insert:
Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | DICLOFENAC-WGR | WG | PDP |
|
| 50 | 0 |
| 50 |
|
|
Diclofenac | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | DICLOFENAC-WGR | WG | MP NP |
|
| 50 | 3 |
| 50 |
|
|
substitute:
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | Oral | Cardizem CD | SW | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | Oral | Cardizem CD | SW | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | Oral | Diltiazem Sandoz CD | SZ | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | Oral | Diltiazem Sandoz CD | SZ | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | Oral | Vasocardol CD | AV | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | Oral | Vasocardol CD | AV | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | Oral | Cardizem CD | SW | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | Oral | Cardizem CD | SW | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | Oral | Diltiazem Sandoz CD | SZ | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | Oral | Diltiazem Sandoz CD | SZ | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | Oral | Vasocardol CD | AV | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | Oral | Vasocardol CD | AV | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | Oral | Cardizem CD | SW | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | Oral | Cardizem CD | SW | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | Oral | Diltiazem Sandoz CD | SZ | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | Oral | Diltiazem Sandoz CD | SZ | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | Oral | Vasocardol CD | AV | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Diltiazem | Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | Oral | Vasocardol CD | AV | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Diltiazem | Tablet containing diltiazem hydrochloride 60 mg | Oral | Cardizem | SW | MP NP |
|
| 90 | 5 |
| 90 |
|
|
Diltiazem | Tablet containing diltiazem hydrochloride 60 mg | Oral | Cardizem | SW | MP NP |
| P14238 | 180 | 5 |
| 90 |
|
|
Diltiazem | Tablet containing diltiazem hydrochloride 60 mg | Oral | Vasocardol | AV | MP NP |
|
| 90 | 5 |
| 90 |
|
|
Diltiazem | Tablet containing diltiazem hydrochloride 60 mg | Oral | Vasocardol | AV | MP NP |
| P14238 | 180 | 5 |
| 90 |
|
|
insert:
Donepezil | Tablet containing donepezil hydrochloride 5 mg | Oral | DONEPEZIL-WGR | WG | MP NP | C13938 |
| 28 | 5 |
| 28 |
|
|
Donepezil | Tablet containing donepezil hydrochloride 5 mg | Oral | DONEPEZIL-WGR | WG | MP | C13938 C13940 C13941 |
| 28 | 5 |
| 28 |
|
|
insert:
Donepezil | Tablet containing donepezil hydrochloride 10 mg | Oral | DONEPEZIL-WGR | WG | MP NP | C13938 |
| 28 | 5 |
| 28 |
|
|
Donepezil | Tablet containing donepezil hydrochloride 10 mg | Oral | DONEPEZIL-WGR | WG | MP | C13940 C13941 |
| 28 | 5 |
| 28 |
|
|
substitute:
Dorzolamide | Eye drops 20 mg (as hydrochloride) per mL, 5 mL | Application to the eye | Trusamide | AF | AO MP |
|
| 1 | 5 |
| 1 |
|
|
Dorzolamide | Eye drops 20 mg (as hydrochloride) per mL, 5 mL | Application to the eye | Trusamide | AF | AO MP |
| P14238 | 2 | 5 |
| 1 |
|
|
Dorzolamide | Eye drops 20 mg (as hydrochloride) per mL, 5 mL | Application to the eye | Trusopt | MF | AO MP |
|
| 1 | 5 |
| 1 |
|
|
Dorzolamide | Eye drops 20 mg (as hydrochloride) per mL, 5 mL | Application to the eye | Trusopt | MF | AO MP |
| P14238 | 2 | 5 |
| 1 |
|
|
substitute:
Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Cosdor | AF | MP | C4343 | P4343 | 1 | 5 |
| 1 |
|
|
Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Cosdor | AF | AO | C5038 | P5038 | 1 | 5 |
| 1 |
|
|
Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Cosdor | AF | AO MP | C15558 | P15558 | 2 | 5 |
| 1 |
|
|
Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Cosopt | MF | MP | C4343 | P4343 | 1 | 5 |
| 1 |
|
|
Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Cosopt | MF | AO | C5038 | P5038 | 1 | 5 |
| 1 |
|
|
Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Cosopt | MF | AO MP | C15558 | P15558 | 2 | 5 |
| 1 |
|
|
Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Vizo-PF Dorzolatim | AE | MP | C4343 | P4343 | 1 | 5 |
| 1 |
|
|
Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Vizo-PF Dorzolatim | AE | AO | C5038 | P5038 | 1 | 5 |
| 1 |
|
|
Dorzolamide with timolol | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Vizo-PF Dorzolatim | AE | AO MP | C15558 | P15558 | 2 | 5 |
| 1 |
|
|
substitute:
Doxycycline | Capsule 50 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | YN | MP NP | C4475 C4529 C4539 | P4475 P4529 P4539 | 25 | 5 |
| 25 |
|
|
Doxycycline | Capsule 50 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | YN | MP NP | C15596 C15659 C15686 | P15596 P15659 P15686 | 50 | 2 |
| 25 |
|
|
Doxycycline | Capsule 50 mg (as hyclate) (containing enteric coated pellets) | Oral | Mayne Pharma Doxycycline | YT | MP NP | C4475 C4529 C4539 | P4475 P4529 P4539 | 25 | 5 |
| 25 |
|
|
Doxycycline | Capsule 50 mg (as hyclate) (containing enteric coated pellets) | Oral | Mayne Pharma Doxycycline | YT | MP NP | C15596 C15659 C15686 | P15596 P15659 P15686 | 50 | 2 |
| 25 |
|
|
Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | YN | PDP |
|
| 7 | 0 |
| 7 |
|
|
Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | YN | MP NP |
|
| 7 | 1 |
| 7 |
|
|
Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | YN | MP NP |
| P4514 | 28 | 0 |
| 7 |
|
|
Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | YN | MP |
| P6200 | 28 | 5 |
| 7 |
|
|
Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx | YN | MP |
| P15625 | 56 | 2 |
| 7 |
|
|
Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Mayne Pharma Doxycycline | YT | PDP |
|
| 7 | 0 |
| 7 |
|
|
Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Mayne Pharma Doxycycline | YT | MP NP |
|
| 7 | 1 |
| 7 |
|
|
Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Mayne Pharma Doxycycline | YT | MP NP |
| P4485 | 21 | 0 |
| 21 |
|
|
Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Mayne Pharma Doxycycline | YT | MP NP |
| P4514 | 28 | 0 |
| 7 |
|
|
Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Mayne Pharma Doxycycline | YT | MP |
| P6200 | 28 | 5 |
| 7 |
|
|
Doxycycline | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Mayne Pharma Doxycycline | YT | MP |
| P15625 | 56 | 2 |
| 7 |
|
|
Doxycycline | Tablet 50 mg (as hyclate) | Oral | APX-Doxycycline | TX | MP NP | C4475 C4529 C4539 | P4475 P4529 P4539 | 25 | 5 |
| 25 |
|
|
Doxycycline | Tablet 50 mg (as hyclate) | Oral | APX-Doxycycline | TX | MP NP | C15596 C15659 C15686 | P15596 P15659 P15686 | 50 | 2 |
| 25 |
|
|
Doxycycline | Tablet 50 mg (as hyclate) | Oral | Doxsig | RW | MP NP | C4475 C4529 C4539 | P4475 P4529 P4539 | 25 | 5 |
| 25 |
|
|
Doxycycline | Tablet 50 mg (as hyclate) | Oral | Doxsig | RW | MP NP | C15596 C15659 C15686 | P15596 P15659 P15686 | 50 | 2 |
| 25 |
|
|
Doxycycline | Tablet 50 mg (as hyclate) | Oral | DOXYCYCLINE-WGR | WG | MP NP | C4475 C4529 C4539 | P4475 P4529 P4539 | 25 | 5 |
| 25 |
|
|
Doxycycline | Tablet 50 mg (as hyclate) | Oral | DOXYCYCLINE-WGR | WG | MP NP | C15596 C15659 C15686 | P15596 P15659 P15686 | 50 | 2 |
| 25 |
|
|
Doxycycline | Tablet 50 mg (as hyclate) | Oral | Doxylin 50 | AF | MP NP | C4475 C4529 C4539 | P4475 P4529 P4539 | 25 | 5 |
| 25 |
|
|
Doxycycline | Tablet 50 mg (as hyclate) | Oral | Doxylin 50 | AF | MP NP | C15596 C15659 C15686 | P15596 P15659 P15686 | 50 | 2 |
| 25 |
|
|
Doxycycline | Tablet 50 mg (as monohydrate) | Oral | Doxycycline Sandoz | HX | MP NP | C4475 C4529 C4539 | P4475 P4529 P4539 | 25 | 5 |
| 25 |
|
|
Doxycycline | Tablet 50 mg (as monohydrate) | Oral | Doxycycline Sandoz | HX | MP NP | C15596 C15659 C15686 | P15596 P15659 P15686 | 50 | 2 |
| 25 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX-Doxycycline | TX | PDP |
|
| 7 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX-Doxycycline | TX | MP NP |
|
| 7 | 1 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX-Doxycycline | TX | MP NP |
| P4485 | 21 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX-Doxycycline | TX | MP NP |
| P4485 | 21 | 0 |
| 21 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX-Doxycycline | TX | MP NP |
| P4514 | 28 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX-Doxycycline | TX | MP |
| P6200 | 28 | 5 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | APX-Doxycycline | TX | MP |
| P15625 | 56 | 2 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxsig | RW | PDP |
|
| 7 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxsig | RW | MP NP |
|
| 7 | 1 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxsig | RW | MP NP |
| P4485 | 21 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxsig | RW | MP NP |
| P4485 | 21 | 0 |
| 21 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxsig | RW | MP NP |
| P4514 | 28 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxsig | RW | MP |
| P6200 | 28 | 5 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxsig | RW | MP |
| P15625 | 56 | 2 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | DOXYCYCLINE-WGR | WG | PDP |
|
| 7 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | DOXYCYCLINE-WGR | WG | MP NP |
|
| 7 | 1 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | DOXYCYCLINE-WGR | WG | MP NP |
| P4485 | 21 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | DOXYCYCLINE-WGR | WG | MP NP |
| P4514 | 28 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | DOXYCYCLINE-WGR | WG | MP |
| P6200 | 28 | 5 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | DOXYCYCLINE-WGR | WG | MP |
| P15625 | 56 | 2 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxylin 100 | AF | PDP |
|
| 7 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxylin 100 | AF | MP NP |
|
| 7 | 1 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxylin 100 | AF | MP NP |
| P4485 | 21 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxylin 100 | AF | MP NP |
| P4485 | 21 | 0 |
| 21 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxylin 100 | AF | MP NP |
| P4514 | 28 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxylin 100 | AF | MP |
| P6200 | 28 | 5 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as hyclate) | Oral | Doxylin 100 | AF | MP |
| P15625 | 56 | 2 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as monohydrate) | Oral | Doxycycline Sandoz | HX | PDP |
|
| 7 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as monohydrate) | Oral | Doxycycline Sandoz | HX | MP NP |
|
| 7 | 1 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as monohydrate) | Oral | Doxycycline Sandoz | HX | MP NP |
| P4485 | 21 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as monohydrate) | Oral | Doxycycline Sandoz | HX | MP NP |
| P4514 | 28 | 0 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as monohydrate) | Oral | Doxycycline Sandoz | HX | MP |
| P6200 | 28 | 5 |
| 7 |
|
|
Doxycycline | Tablet 100 mg (as monohydrate) | Oral | Doxycycline Sandoz | HX | MP |
| P15625 | 56 | 2 |
| 7 |
|
|
insert:
Enalapril | Tablet containing enalapril maleate 5 mg | Oral | ENALAPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Enalapril | Tablet containing enalapril maleate 5 mg | Oral | ENALAPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Enalapril | Tablet containing enalapril maleate 10 mg | Oral | ENALAPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Enalapril | Tablet containing enalapril maleate 10 mg | Oral | ENALAPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Enalapril | Tablet containing enalapril maleate 20 mg | Oral | ENALAPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Enalapril | Tablet containing enalapril maleate 20 mg | Oral | ENALAPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
substitute:
Entacapone | Tablet 200 mg | Oral | Comtan | SZ | MP NP | C5133 | P5133 | 200 | 4 |
| 100 |
|
|
Entacapone | Tablet 200 mg | Oral | Comtan | SZ | MP NP | C15602 | P15602 | 400 | 4 |
| 100 |
|
|
insert:
Entecavir | Tablet 0.5 mg (as monohydrate) | Oral | ENTECAVIR-WGR | WG | MP NP | C4993 C5036 |
| 60 | 5 |
| 30 |
| D(100) |
insert:
Entecavir | Tablet 1 mg (as monohydrate) | Oral | ENTECAVIR-WGR | WG | MP NP | C5037 C5044 |
| 60 | 5 |
| 30 |
| D(100) |
omit from the column headed “Circumstances”: C13184 C1327 subsitute: C13186 C15776
substitute:
Eprosartan with hydrochlorothiazide | Tablet 600 mg eprosartan (as mesilate) with 12.5 mg hydrochlorothiazide | Oral | Teveten Plus 600/12.5 | GO | MP NP | C4374 | P4374 | 28 | 5 |
| 28 |
|
|
Eprosartan with hydrochlorothiazide | Tablet 600 mg eprosartan (as mesilate) with 12.5 mg hydrochlorothiazide | Oral | Teveten Plus 600/12.5 | GO | MP NP | C15624 | P15624 | 56 | 5 |
| 28 |
|
|
insert:
Erythromycin | Capsule 250 mg (containing enteric coated pellets) | Oral | Mayne Pharma Erythromycin | YT | MP |
| P15710 | 100 CN15710 | 2 CN15710 |
| 25 |
|
|
substitute:
Escitalopram | Oral solution 20 mg (as oxalate) per mL, 15 mL | Oral | Lexapro | LU | MP NP | C4680 C4681 C4707 C4721 C4747 | P4680 P4681 P4707 P4721 P4747 | 1 | 5 |
| 1 |
|
|
Escitalopram | Oral solution 20 mg (as oxalate) per mL, 15 mL | Oral | Lexapro | LU | MP NP | C15606 C15639 C15670 C15698 C15751 | P15606 P15639 P15670 P15698 P15751 | 2 | 2 |
| 1 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | APO-Escitalopram | TX | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | APO-Escitalopram | TX | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | APX-Escitalopram | TY | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | APX-Escitalopram | TY | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Blooms Escitalopram | BG | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Blooms Escitalopram | BG | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Cilopam-S | ZS | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Cilopam-S | ZS | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Escitalopram GH | HQ | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Escitalopram GH | HQ | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Escitalopram Sandoz | HX | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Escitalopram Sandoz | HX | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Esipram | CF | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Esipram | CF | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Lexam 10 | RW | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Lexam 10 | RW | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Lexapro | LU | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | Lexapro | LU | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | LoxaLate | AF | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | LoxaLate | AF | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | NOUMED ESCITALOPRAM | VO | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 10 mg (as oxalate) | Oral | NOUMED ESCITALOPRAM | VO | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | APO-Escitalopram | TX | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | APO-Escitalopram | TX | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | APX-Escitalopram | TY | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | APX-Escitalopram | TY | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Blooms Escitalopram | BG | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Blooms Escitalopram | BG | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Cilopam-S | ZS | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Cilopam-S | ZS | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Escitalopram GH | HQ | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Escitalopram GH | HQ | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Escitalopram Sandoz | HX | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Escitalopram Sandoz | HX | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Esipram | CF | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Esipram | CF | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Lexam 20 | RW | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Lexam 20 | RW | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Lexapro | LU | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | Lexapro | LU | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | LoxaLate | AF | MP NP | C4755 | P4755 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | LoxaLate | AF | MP NP | C15666 | P15666 | 56 | 2 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | NOUMED ESCITALOPRAM | VO | MP NP | C4690 C4703 C4755 C4756 C4757 | P4690 P4703 P4755 P4756 P4757 | 28 | 5 |
| 28 |
|
|
Escitalopram | Tablet 20 mg (as oxalate) | Oral | NOUMED ESCITALOPRAM | VO | MP NP | C15550 C15551 C15666 C15669 C15696 | P15550 P15551 P15666 P15669 P15696 | 56 | 2 |
| 28 |
|
|
substitute:
Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | Oral | Noxicid Caps | AL | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | Oral | Noxicid Caps | AL | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | Oral | Noxicid Caps | AL | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | Oral | Noxicid Caps | AL | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Capsule (enteric) 20 mg (as magnesium) | Oral | Noxicid Caps | AL | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Capsule (enteric) 40 mg (as magnesium) | Oral | Noxicid Caps | AL | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Capsule (enteric) 40 mg (as magnesium) | Oral | Noxicid Caps | AL | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Capsule (enteric) 40 mg (as magnesium) | Oral | Noxicid Caps | AL | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Capsule (enteric) 40 mg (as magnesium) | Oral | Noxicid Caps | AL | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Capsule (enteric) 40 mg (as magnesium) | Oral | Noxicid Caps | AL | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | APO-Esomeprazole | TY | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | APO-Esomeprazole | TY | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | APO-Esomeprazole | TY | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | APO-Esomeprazole | TY | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | APO-Esomeprazole | TY | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole GH | GQ | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole GH | GQ | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole GH | GQ | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole GH | GQ | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole GH | GQ | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole GxP | AF | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole GxP | AF | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole GxP | AF | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole GxP | AF | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole GxP | AF | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Mylan | AL | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Mylan | AL | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Mylan | AL | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Mylan | AL | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Mylan | AL | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole RBX | RA | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole RBX | RA | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole RBX | RA | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole RBX | RA | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole RBX | RA | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | MQ | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | MQ | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | MQ | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | MQ | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | MQ | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | ESOMEPRAZOLE-WGR | WG | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | ESOMEPRAZOLE-WGR | WG | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | ESOMEPRAZOLE-WGR | WG | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | ESOMEPRAZOLE-WGR | WG | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | ESOMEPRAZOLE-WGR | WG | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esopreze | BG | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esopreze | BG | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esopreze | BG | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esopreze | BG | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Esopreze | BG | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexazole | RW | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexazole | RW | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexazole | RW | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexazole | RW | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexazole | RW | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexium | AP | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexium | AP | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexium | AP | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexium | AP | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexium | AP | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexole | RF | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexole | RF | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexole | RF | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexole | RF | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | Nexole | RF | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | VO | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | VO | MP NP | C8776 C8780 C8827 | P8776 P8780 P8827 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | VO | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | VO | MP NP | C15530 C15658 C15682 | P15530 P15658 P15682 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | VO | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | APO-Esomeprazole | TY | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | APO-Esomeprazole | TY | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | APO-Esomeprazole | TY | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | APO-Esomeprazole | TY | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | APO-Esomeprazole | TY | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole GH | GQ | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole GH | GQ | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole GH | GQ | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole GH | GQ | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole GH | GQ | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole GxP | AF | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole GxP | AF | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole GxP | AF | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole GxP | AF | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole GxP | AF | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Mylan | AL | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Mylan | AL | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Mylan | AL | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Mylan | AL | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Mylan | AL | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole RBX | RA | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole RBX | RA | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole RBX | RA | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole RBX | RA | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole RBX | RA | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | MQ | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | MQ | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | MQ | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | MQ | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esomeprazole Viatris | MQ | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | ESOMEPRAZOLE-WGR | WG | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | ESOMEPRAZOLE-WGR | WG | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | ESOMEPRAZOLE-WGR | WG | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | ESOMEPRAZOLE-WGR | WG | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | ESOMEPRAZOLE-WGR | WG | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esopreze | BG | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esopreze | BG | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esopreze | BG | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esopreze | BG | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Esopreze | BG | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexazole | RW | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexazole | RW | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexazole | RW | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexazole | RW | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexazole | RW | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexium | AP | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexium | AP | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexium | AP | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexium | AP | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexium | AP | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexole | RF | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexole | RF | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexole | RF | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexole | RF | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | Nexole | RF | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | VO | MP NP | C8902 | P8902 | 30 | 1 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | VO | MP NP | C8777 C8778 | P8777 P8778 | 30 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | VO | MP | C11370 | P11370 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | VO | MP NP | C15655 C15704 | P15655 P15704 | 60 | 5 |
| 30 |
|
|
Esomeprazole | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | NOUMED ESOMEPRAZOLE | VO | MP | C15705 | P15705 | 120 | 5 |
| 30 |
|
|
insert:
Estradiol with norethisterone | Transdermal patches containing 510 micrograms estradiol (as hemihydrate) with 4.8 mg norethisterone acetate, 8 | Transdermal | Estalis continuous 50/250 | SZ | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Exemestane | Tablet 25 mg | Oral | EXEMESTANE-WGR | WG | MP | C4796 | P4796 | 30 | 5 |
| 30 |
|
|
Exemestane | Tablet 25 mg | Oral | EXEMESTANE-WGR | WG | MP NP | C5522 | P5522 | 30 | 5 |
| 30 |
|
|
Exemestane | Tablet 25 mg | Oral | EXEMESTANE-WGR | WG | MP | C15031 | P15031 | 60 | 5 |
| 30 |
|
|
Exemestane | Tablet 25 mg | Oral | EXEMESTANE-WGR | WG | MP NP | C14992 | P14992 | 60 | 5 |
| 30 |
|
|
insert:
Ezetimibe | Tablet 10 mg | Oral | EZETIMIBE-WGR | WG | MP NP | C7966 C7990 C7996 | P7966 P7990 P7996 | 30 | 5 |
| 30 |
|
|
Ezetimibe | Tablet 10 mg | Oral | EZETIMIBE-WGR | WG | MP NP | C14249 C14283 C14310 | P14249 P14283 P14310 | 60 | 5 |
| 30 |
|
|
insert:
Ezetimibe with simvastatin | Tablet 10 mg-10 mg | Oral | EZETIMIBE/SIMVASTATIN-WGR 10/10 | WG | MP NP | C7958 | P7958 | 30 | 5 |
| 30 |
|
|
Ezetimibe with simvastatin | Tablet 10 mg-10 mg | Oral | EZETIMIBE/SIMVASTATIN-WGR 10/10 | WG | MP NP | C14269 | P14269 | 60 | 5 |
| 30 |
|
|
insert:
Ezetimibe with simvastatin | Tablet 10 mg-20 mg | Oral | EZETIMIBE/SIMVASTATIN-WGR 10/20 | WG | MP NP | C7958 | P7958 | 30 | 5 |
| 30 |
|
|
Ezetimibe with simvastatin | Tablet 10 mg-20 mg | Oral | EZETIMIBE/SIMVASTATIN-WGR 10/20 | WG | MP NP | C14269 | P14269 | 60 | 5 |
| 30 |
|
|
insert:
Ezetimibe with simvastatin | Tablet 10 mg-40 mg | Oral | EZETIMIBE/SIMVASTATIN-WGR 10/40 | WG | MP NP | C7957 | P7957 | 30 | 5 |
| 30 |
|
|
Ezetimibe with simvastatin | Tablet 10 mg-40 mg | Oral | EZETIMIBE/SIMVASTATIN-WGR 10/40 | WG | MP NP | C14284 | P14284 | 60 | 5 |
| 30 |
|
|
insert:
Ezetimibe with simvastatin | Tablet 10 mg-80 mg | Oral | EZETIMIBE/SIMVASTATIN-WGR 10/80 | WG | MP NP | C7957 | P7957 | 30 | 5 |
| 30 |
|
|
Ezetimibe with simvastatin | Tablet 10 mg-80 mg | Oral | EZETIMIBE/SIMVASTATIN-WGR 10/80 | WG | MP NP | C14284 | P14284 | 60 | 5 |
| 30 |
|
|
insert:
Famciclovir | Tablet 250 mg | Oral | FAMCICLOVIR-WGR | WG | MP NP | C5937 | P5937 | 20 | 1 |
| 20 |
|
|
Famciclovir | Tablet 250 mg | Oral | FAMCICLOVIR-WGR | WG | MP NP | C5951 | P5951 | 21 | 0 |
| 21 |
|
|
Famciclovir | Tablet 250 mg | Oral | FAMCICLOVIR-WGR | WG | MP NP | C5971 | P5971 | 56 | 5 |
| 56 |
|
|
insert:
Famciclovir | Tablet 500 mg | Oral | FAMCICLOVIR-WGR | WG | MP NP | C5943 | P5943 | 30 | 0 |
| 30 |
|
|
Famciclovir | Tablet 500 mg | Oral | FAMCICLOVIR-WGR | WG | MP NP | C5947 C5948 C5949 C5954 | P5947 P5948 P5949 P5954 | 56 | 5 |
| 56 |
|
|
insert:
Fenofibrate | Tablet 48 mg | Oral | FENOFIBRATE-WGR | WG | MP NP |
|
| 60 | 5 |
| 60 |
|
|
Fenofibrate | Tablet 48 mg | Oral | FENOFIBRATE-WGR | WG | MP NP |
| P14238 | 120 | 5 |
| 60 |
|
|
omit:
Fenofibrate | Tablet 145 mg | Oral | Blooms the Chemist Fenofibrate | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Fenofibrate | Tablet 145 mg | Oral | Blooms the Chemist Fenofibrate | IB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Fenofibrate | Tablet 145 mg | Oral | FENOFIBRATE-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Fenofibrate | Tablet 145 mg | Oral | FENOFIBRATE-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
substitute:
Fluoxetine | Capsule 10 mg (Medreich) (S19A) | Oral | Fluoxetine Capsules 10 mg (Medreich, UK) | LM | MP NP | C14828 C14832 |
| 30 | 5 |
| 30 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | APO-Fluoxetine | TX | MP NP | C4755 C6277 | P4755 P6277 | 28 | 5 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | APO-Fluoxetine | TX | MP NP | C15582 C15666 | C15582 C15666 | 56 | 2 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Blooms the Chemist Fluoxetine | BG | MP NP | C4755 C6277 | P4755 P6277 | 28 | 5 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Blooms the Chemist Fluoxetine | BG | MP NP | C15582 C15666 | C15582 C15666 | 56 | 2 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | FLUOTEX | RF | MP NP | C4755 C6277 | P4755 P6277 | 28 | 5 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | FLUOTEX | RF | MP NP | C15582 C15666 | C15582 C15666 | 56 | 2 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Fluoxetine APOTEX | TY | MP NP | C4755 C6277 | P4755 P6277 | 28 | 5 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Fluoxetine APOTEX | TY | MP NP | C15582 C15666 | C15582 C15666 | 56 | 2 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Fluoxetine generichealth | GQ | MP NP | C4755 C6277 | P4755 P6277 | 28 | 5 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Fluoxetine generichealth | GQ | MP NP | C15582 C15666 | C15582 C15666 | 56 | 2 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Fluoxetine Sandoz | SZ | MP NP | C4755 C6277 | P4755 P6277 | 28 | 5 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Fluoxetine Sandoz | SZ | MP NP | C15582 C15666 | C15582 C15666 | 56 | 2 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | NOUMED FLUOXETINE | VO | MP NP | C4755 C6277 | P4755 P6277 | 28 | 5 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | NOUMED FLUOXETINE | VO | MP NP | C15582 C15666 | C15582 C15666 | 56 | 2 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Prozac 20 | LY | MP NP | C4755 C6277 | P4755 P6277 | 28 | 5 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Prozac 20 | LY | MP NP | C15582 C15666 | C15582 C15666 | 56 | 2 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Zactin | AF | MP NP | C4755 C6277 | P4755 P6277 | 28 | 5 |
| 28 |
|
|
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Zactin | AF | MP NP | C15582 C15666 | C15582 C15666 | 56 | 2 |
| 28 |
|
|
Fluoxetine | Tablet, dispersible, 20 mg (as hydrochloride) | Oral | Zactin Tablet | AF | MP NP | C4755 C6277 |
| 28 | 5 |
| 28 |
|
|
insert:
Fluticasone furoate | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms per dose, 30 doses | Inhalation by mouth | Arnuity Ellipta | GK | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Fluticasone furoate | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms per dose, 30 doses | Inhalation by mouth | Arnuity Ellipta | GK | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone furoate with umeclidinium and vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | Trelegy Ellipta 100/62.5/25 | GK | MP NP | C12349 | P12349 | 1 | 5 |
| 1 |
|
|
Fluticasone furoate with umeclidinium and vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | Trelegy Ellipta 100/62.5/25 | GK | MP NP | C15543 | P15543 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone furoate with umeclidinium and vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | Trelegy Ellipta 200/62.5/25 | GK | MP NP | C12603 | P12603 | 1 | 5 |
| 1 |
|
|
Fluticasone furoate with umeclidinium and vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | Trelegy Ellipta 200/62.5/25 | GK | MP NP | C15601 | P15601 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone furoate with vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | Breo Ellipta 100/25 | GK | MP NP | C4711 C10121 | P4711 P10121 | 1 | 5 |
| 1 |
|
|
Fluticasone furoate with vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | Breo Ellipta 100/25 | GK | MP NP | C15546 C15548 | P15546 P15548 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone furoate with vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | Breo Ellipta 200/25 | GK | MP NP | C4731 | P4731 | 1 | 5 |
| 1 |
|
|
Fluticasone furoate with vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 200 micrograms with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | Breo Ellipta 200/25 | GK | MP NP | C15692 | P15692 | 2 | 5 |
| 1 |
|
|
insert:
Fluticasone propionate | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses | Inhalation by mouth | Axotide Junior Accuhaler | TX | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Fluticasone propionate | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses | Inhalation by mouth | Flixotide Junior Accuhaler | GK | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Fluticasone propionate | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses | Inhalation by mouth | Axotide Accuhaler | TX | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Fluticasone propionate | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses | Inhalation by mouth | Flixotide Accuhaler | GK | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Axotide Junior | TX | MP NP | C14180 | P14180 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Axotide Junior | TX | MP NP | C14238 | P14238 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Flixotide Junior | GK | MP NP | C14180 | P14180 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Flixotide Junior | GK | MP NP | C14238 | P14238 | 2 | 5 |
| 1 |
|
|
insert:
Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Axotide | TX | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Flixotide | GK | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Fluticasone Cipla Inhaler | LR | MP NP |
| P14238 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 50 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | Inhalation by mouth | flutiform 50/5 | MF | MP NP | C4395 | P4395 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 50 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | Inhalation by mouth | flutiform 50/5 | MF | MP NP | C15635 | P15635 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | Inhalation by mouth | flutiform 125/5 | MF | MP NP | C4395 | P4395 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with formoterol fumarate dihydrate 5 micrograms per dose, 120 doses | Inhalation by mouth | flutiform 125/5 | MF | MP NP | C15635 | P15635 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with formoterol fumarate dihydrate 10 micrograms per dose, 120 doses | Inhalation by mouth | flutiform 250/10 | MF | MP NP | C4395 | P4395 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with formoterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with formoterol fumarate dihydrate 10 micrograms per dose, 120 doses | Inhalation by mouth | flutiform 250/10 | MF | MP NP | C15635 | P15635 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | PAVTIDE ACCUHALER 100/50 | TX | MP NP | C4930 | P4930 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | PAVTIDE ACCUHALER 100/50 | TX | MP NP | C15604 | P15604 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Seretide Accuhaler 100/50 | GK | MP NP | C4930 | P4930 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Seretide Accuhaler 100/50 | GK | MP NP | C15604 | P15604 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Fluticasone Salmeterol Ciphaler 250/50 | LR | MP NP | C15138 | P15138 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Fluticasone Salmeterol Ciphaler 250/50 | LR | MP NP | C15693 | P15693 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | PAVTIDE ACCUHALER 250/50 | TX | MP NP | C15138 | P15138 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | PAVTIDE ACCUHALER 250/50 | TX | MP NP | C15693 | P15693 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Salflumix Easyhaler 250/50 | OX | MP NP | C15138 | P15138 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Salflumix Easyhaler 250/50 | OX | MP NP | C15693 | P15693 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | SalplusF DPI 250/50 | SZ | MP NP | C15138 | P15138 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | SalplusF DPI 250/50 | SZ | MP NP | C15693 | P15693 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Seretide Accuhaler 250/50 | GK | MP NP | C15138 | P15138 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Seretide Accuhaler 250/50 | GK | MP NP | C15693 | P15693 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Fluticasone Salmeterol Ciphaler 500/50 | LR | MP NP | C10121 C15118 | P10121 P15118 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Fluticasone Salmeterol Ciphaler 500/50 | LR | MP NP | C15548 C15714 | P15548 P15714 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | PAVTIDE ACCUHALER 500/50 | TX | MP NP | C10121 C15118 | P10121 P15118 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | PAVTIDE ACCUHALER 500/50 | TX | MP NP | C15548 C15714 | P15548 P15714 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Salflumix Easyhaler 500/50 | OX | MP NP | C10121 C15118 | P10121 P15118 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Salflumix Easyhaler 500/50 | OX | MP NP | C15548 C15714 | P15548 P15714 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | SalplusF DPI 500/50 | SZ | MP NP | C10121 C15118 | P10121 P15118 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | SalplusF DPI 500/50 | SZ | MP NP | C15548 C15714 | P15548 P15714 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Seretide Accuhaler 500/50 | GK | MP NP | C10121 C15118 | P10121 P15118 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Seretide Accuhaler 500/50 | GK | MP NP | C15548 C15714 | P15548 P15714 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | PAVTIDE MDI 50/25 | TX | MP NP | C4930 | P4930 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | PAVTIDE MDI 50/25 | TX | MP NP | C15604 | P15604 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Seretide MDI 50/25 | GK | MP NP | C4930 | P4930 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Seretide MDI 50/25 | GK | MP NP | C15604 | P15604 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Evocair MDI | AF | MP NP | C4930 | P4930 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Evocair MDI | AF | MP NP | C15604 | P15604 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Fluticasone + Salmeterol Cipla 125/25 | LR | MP NP | C4930 | P4930 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Fluticasone + Salmeterol Cipla 125/25 | LR | MP NP | C15604 | P15604 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Pavtide | TX | MP NP | C4930 | P4930 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Pavtide | TX | MP NP | C15604 | P15604 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | SalplusF Inhaler 125/25 | SZ | MP NP | C4930 | P4930 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | SalplusF Inhaler 125/25 | SZ | MP NP | C15604 | P15604 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Seretide MDI 125/25 | GK | MP NP | C4930 | P4930 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Seretide MDI 125/25 | GK | MP NP | C15604 | P15604 | 2 | 5 |
| 1 |
|
|
substitute:
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Evocair MDI | AF | MP NP | C4930 C10121 | P4930 P10121 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Evocair MDI | AF | MP NP | C15548 C15715 | P15548 P15715 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Fluticasone + Salmeterol Cipla 250/25 | LR | MP NP | C4930 C10121 | P4930 P10121 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Fluticasone + Salmeterol Cipla 250/25 | LR | MP NP | C15548 C15715 | P15548 P15715 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Pavtide | TX | MP NP | C4930 C10121 | P4930 P10121 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Pavtide | TX | MP NP | C15548 C15715 | P15548 P15715 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | SalplusF Inhaler 250/25 | SZ | MP NP | C4930 C10121 | P4930 P10121 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | SalplusF Inhaler 250/25 | SZ | MP NP | C15548 C15715 | P15548 P15715 | 2 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Seretide MDI 250/25 | GK | MP NP | C4930 C10121 | P4930 P10121 | 1 | 5 |
| 1 |
|
|
Fluticasone propionate with salmeterol | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Seretide MDI 250/25 | GK | MP NP | C15548 C15715 | P15548 P15715 | 2 | 5 |
| 1 |
|
|
substitute:
Fluvoxamine | Tablet containing fluvoxamine maleate 50 mg | Oral | APO-Fluvoxamine | TX | MP NP | C4755 C6277 | P4755 P6277 | 30 | 5 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 50 mg | Oral | APO-Fluvoxamine | TX | MP NP | C15582 C15666 | P15582 P15666 | 60 | 2 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 50 mg | Oral | Faverin 50 | RW | MP NP | C4755 C6277 | P4755 P6277 | 30 | 5 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 50 mg | Oral | Faverin 50 | RW | MP NP | C15582 C15666 | P15582 P15666 | 60 | 2 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 50 mg | Oral | FLUVOXAMINE-WGR | WG | MP NP | C4755 C6277 | P4755 P6277 | 30 | 5 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 50 mg | Oral | FLUVOXAMINE-WGR | WG | MP NP | C15582 C15666 | P15582 P15666 | 60 | 2 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 50 mg | Oral | Luvox | GO | MP NP | C4755 C6277 | P4755 P6277 | 30 | 5 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 50 mg | Oral | Luvox | GO | MP NP | C15582 C15666 | P15582 P15666 | 60 | 2 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 50 mg | Oral | Movox 50 | AL | MP NP | C4755 C6277 | P4755 P6277 | 30 | 5 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 50 mg | Oral | Movox 50 | AL | MP NP | C15582 C15666 | P15582 P15666 | 60 | 2 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 100 mg | Oral | APO-Fluvoxamine | TX | MP NP | C4755 C6277 | P4755 P6277 | 30 | 5 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 100 mg | Oral | APO-Fluvoxamine | TX | MP NP | C15582 C15666 | P15582 P15666 | 60 | 2 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 100 mg | Oral | Faverin 100 | RW | MP NP | C4755 C6277 | P4755 P6277 | 30 | 5 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 100 mg | Oral | Faverin 100 | RW | MP NP | C15582 C15666 | P15582 P15666 | 60 | 2 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 100 mg | Oral | FLUVOXAMINE-WGR | WG | MP NP | C4755 C6277 | P4755 P6277 | 30 | 5 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 100 mg | Oral | FLUVOXAMINE-WGR | WG | MP NP | C15582 C15666 | P15582 P15666 | 60 | 2 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 100 mg | Oral | Luvox | GO | MP NP | C4755 C6277 | P4755 P6277 | 30 | 5 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 100 mg | Oral | Luvox | GO | MP NP | C15582 C15666 | P15582 P15666 | 60 | 2 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 100 mg | Oral | Movox 100 | AF | MP NP | C4755 C6277 | P4755 P6277 | 30 | 5 |
| 30 |
|
|
Fluvoxamine | Tablet containing fluvoxamine maleate 100 mg | Oral | Movox 100 | AF | MP NP | C15582 C15666 | P15582 P15666 | 60 | 2 |
| 30 |
|
|
substitute:
Folinic acid | Injection containing calcium folinate equivalent to 50 mg folinic acid in 5 mL | Injection | Leucovorin Calcium (Pfizer Australia Pty Ltd) | PF | MP |
|
| 10 | 2 |
| 10 |
|
|
Folinic acid | Tablet containing calcium folinate equivalent to 15 mg folinic acid | Oral | Leucovorin Calcium (Hospira Pty Limited) | PF | MP | C5938 |
| 10 | 0 |
| 10 |
|
|
Folinic acid | Tablet containing calcium folinate equivalent to 15 mg folinic acid | Oral | Leucovorin Calcium (Hospira Pty Limited) | PF | MP | C5973 |
| 10 | 0 |
| 10 |
| C(100) |
substitute:
Formoterol | Capsule containing powder for oral inhalation containing formoterol fumarate dihydrate 12 micrograms (for use in Foradile Aerolizer) | Inhalation by mouth | Foradile | SZ | MP NP | C6355 | P6355 | 60 | 5 |
| 60 |
|
|
Formoterol | Capsule containing powder for oral inhalation containing formoterol fumarate dihydrate 12 micrograms (for use in Foradile Aerolizer) | Inhalation by mouth | Foradile | SZ | MP NP | C15607 | P15607 | 120 | 5 |
| 60 |
|
|
Formoterol | Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 6 micrograms per dose, 60 doses | Inhalation by mouth | Oxis Turbuhaler | AP | MP NP | C6355 | P6355 | 1 | 5 |
| 1 |
|
|
Formoterol | Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 6 micrograms per dose, 60 doses | Inhalation by mouth | Oxis Turbuhaler | AP | MP NP | C15607 | P15607 | 2 | 5 |
| 1 |
|
|
Formoterol | Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | Oxis Turbuhaler | AP | MP NP | C6355 | P6355 | 1 | 5 |
| 1 |
|
|
Formoterol | Powder for oral inhalation in breath actuated device containing formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | Oxis Turbuhaler | AP | MP NP | C15607 | P15607 | 2 | 5 |
| 1 |
|
|
insert:
Furosemide | Tablet 20 mg | Oral | FUROSEMIDE-WGR | WG | MP NP |
|
| 100 | 1 |
| 100 |
|
|
Furosemide | Tablet 20 mg | Oral | FUROSEMIDE-WGR | WG | MP NP |
| P14238 | 200 | 1 |
| 100 |
|
|
insert:
Furosemide | Tablet 40 mg | Oral | FUROSEMIDE-WGR | WG | MP NP |
|
| 100 | 1 |
| 100 |
|
|
Furosemide | Tablet 40 mg | Oral | FUROSEMIDE-WGR | WG | MP NP |
| P14238 | 200 | 1 |
| 100 |
|
|
insert:
Gabapentin | Capsule 300 mg | Oral | GABAPENTIN-WGR | WG | MP NP | C4928 |
| 100 | 5 |
| 100 |
|
|
insert:
Gabapentin | Capsule 400 mg | Oral | GABAPENTIN-WGR | WG | MP NP | C4928 |
| 100 | 5 |
| 100 |
|
|
omit:
Glimepiride | Tablet 1 mg | Oral | Amaryl | SW | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Glimepiride | Tablet 1 mg | Oral | Amaryl | SW | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Glimepiride | Tablet 1 mg | Oral | GLIMEPIRIDE-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Glimepiride | Tablet 1 mg | Oral | GLIMEPIRIDE-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Glimepiride | Tablet 2 mg | Oral | GLIMEPIRIDE-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Glimepiride | Tablet 2 mg | Oral | GLIMEPIRIDE-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Glimepiride | Tablet 3 mg | Oral | GLIMEPIRIDE-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Glimepiride | Tablet 3 mg | Oral | GLIMEPIRIDE-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Glimepiride | Tablet 4 mg | Oral | GLIMEPIRIDE-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Glimepiride | Tablet 4 mg | Oral | GLIMEPIRIDE-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Glyceryl trinitrate | Transdermal patch 18 mg | Transdermal | Minitran 5 | IL | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Glyceryl trinitrate | Transdermal patch 36 mg | Transdermal | Minitran 10 | IL | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Glyceryl trinitrate | Transdermal patch 54 mg | Transdermal | Minitran 15 | IL | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
substitute:
Glycopyrronium | Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler) | Inhalation by mouth | seebri breezhaler | NV | MP NP | C4516 | P4516 | 30 | 5 |
| 30 |
|
|
Glycopyrronium | Capsule containing powder for oral inhalation 50 micrograms (as bromide) (for use in Breezhaler) | Inhalation by mouth | seebri breezhaler | NV | MP NP | C15634 | P15634 | 60 | 5 |
| 30 |
|
|
omit:
Granisetron | Concentrated injection 3 mg (as hydrochloride) in 3 mL | Injection | Granisetron Kabi | PK | MP NP | C4077 C4092 |
| 1 | 0 | V4077 | 1 |
|
|
Granisetron | Concentrated injection 3 mg (as hydrochloride) in 3 mL | Injection | Granisetron Kabi | PK | MP | C4139 |
| 1 | 0 | V4139 | 1 |
| C(100) |
omit from the column headed “Responsible Person”: JC substitute: IX
substitute:
Hyaluronic acid | Eye drops containing sodium hyaluronate 1 mg per mL, 10 mL | Application to the eye | Hylo-Fresh | AE | MP NP AO | C4105 | P4105 | 1 | 5 |
| 1 |
|
|
Hyaluronic acid | Eye drops containing sodium hyaluronate 1 mg per mL, 10 mL | Application to the eye | Hylo-Fresh | AE | MP NP AO | C15559 | P15559 | 2 | 5 |
| 1 |
|
|
Hyaluronic acid | Eye drops containing sodium hyaluronate 2 mg per mL, 10 mL | Application to the eye | Hylo-Forte | AE | MP NP AO | C4105 | P4105 | 1 | 5 |
| 1 |
|
|
Hyaluronic acid | Eye drops containing sodium hyaluronate 2 mg per mL, 10 mL | Application to the eye | Hylo-Forte | AE | MP NP AO | C15559 | P15559 | 2 | 5 |
| 1 |
|
|
insert:
Hydrocortisone | Tablet 20 mg | Oral | Hydrocortisone Viatris 20 | AL | MP NP |
| P14238 | 120 | 4 |
| 60 |
|
|
insert:
Hydrocortisone | Tablet 20 mg | Oral | Hysone 20 | AF | MP NP |
| P14238 | 120 | 4 |
| 60 |
|
|
substitute:
Hypromellose | 0.3% w/v eye drops, 10 mL (preservative free) | Application to the eye | Evolve Hypromellose | CX | MP NP AO | C6172 | P6172 | 1 | 5 |
| 1 |
|
|
Hypromellose | 0.3% w/v eye drops, 10 mL (preservative free) | Application to the eye | Evolve Hypromellose | CX | MP NP AO | C15559 | P15559 | 2 | 5 |
| 1 |
|
|
Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the eye | Genteal | AQ | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the eye | Genteal | AQ | MP NP AO | C15556 | P15556 | 2 | 5 |
| 1 |
|
|
Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the eye | In a Wink Moisturising | IQ | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the eye | In a Wink Moisturising | IQ | MP NP AO | C15556 | P15556 | 2 | 5 |
| 1 |
|
|
Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the eye | Revive Tears | PP | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Hypromellose | Eye drops 3 mg per mL, 10 mL | Application to the eye | Revive Tears | PP | MP NP AO | C15556 | P15556 | 2 | 5 |
| 1 |
|
|
Hypromellose | Eye drops 5 mg per mL, 15 mL | Application to the eye | Methopt | AF | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Hypromellose | Eye drops 5 mg per mL, 15 mL | Application to the eye | Methopt | AF | MP NP AO | C15556 | P15556 | 2 | 5 |
| 1 |
|
|
substitute:
Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg-2 mg per g, 10 g | Application to the eye | Genteal gel | AQ | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg-2 mg per g, 10 g | Application to the eye | Genteal gel | AQ | MP | C15640 | P15640 | 1 | 11 |
| 1 |
|
|
Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg-2 mg per g, 10 g | Application to the eye | HPMC PAA | IQ | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Hypromellose with carbomer 980 | Ocular lubricating gel 3 mg-2 mg per g, 10 g | Application to the eye | HPMC PAA | IQ | MP | C15640 | P15640 | 1 | 11 |
| 1 |
|
|
substitute:
Hypromellose with dextran | Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL | Application to the eye | Poly-Tears | IQ | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Hypromellose with dextran | Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL | Application to the eye | Poly-Tears | IQ | MP NP AO | C15556 | P15556 | 2 | 5 |
| 1 |
|
|
Hypromellose with dextran | Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL | Application to the eye | Tears Naturale | AQ | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Hypromellose with dextran | Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL | Application to the eye | Tears Naturale | AQ | MP NP AO | C15556 | P15556 | 2 | 5 |
| 1 |
|
|
substitute:
Ibuprofen | Tablet 400 mg | Oral | APO-Ibuprofen 400 | TX | MP NP MW PDP |
|
| 30 | 0 |
| 30 |
|
|
Ibuprofen | Tablet 400 mg | Oral | APO-Ibuprofen 400 | TX | PDP |
| P6256 P6282 | 90 | 0 |
| 30 |
|
|
Ibuprofen | Tablet 400 mg | Oral | APO-Ibuprofen 400 | TX | MP NP |
| P6149 P6214 P6283 | 90 | 3 |
| 30 |
|
|
Ibuprofen | Tablet 400 mg | Oral | Brufen | GO | MP NP MW PDP |
|
| 30 | 0 |
| 30 |
|
|
Ibuprofen | Tablet 400 mg | Oral | Brufen | GO | PDP |
| P6256 P6282 | 90 | 0 |
| 30 |
|
|
Ibuprofen | Tablet 400 mg | Oral | Brufen | GO | MP NP |
| P6149 P6214 P6283 | 90 | 3 |
| 30 |
|
|
Ibuprofen | Tablet 400 mg | Oral | MEDICHOICE Ibuprofen 400 mg | NB | MP NP MW PDP |
|
| 30 | 0 |
| 30 |
|
|
Ibuprofen | Tablet 400 mg | Oral | MEDICHOICE Ibuprofen 400 mg | NB | PDP |
| P6256 P6282 | 90 | 0 |
| 30 |
|
|
Ibuprofen | Tablet 400 mg | Oral | MEDICHOICE Ibuprofen 400 mg | NB | MP NP |
| P6149 P6214 P6283 | 90 | 3 |
| 30 |
|
|
substitute:
Imatinib | Capsule 100 mg (as mesilate) | Oral | ARX-IMATINIB | XT | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 60 | 2 |
| 60 |
|
|
Imatinib | Capsule 100 mg (as mesilate) | Oral | ARX-IMATINIB | XT | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 60 | 5 |
| 60 |
|
|
Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib-APOTEX | TX | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 60 | 2 |
| 60 |
|
|
Imatinib | Capsule 100 mg (as mesilate) | Oral | Imatinib-APOTEX | TX | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 60 | 5 |
| 60 |
|
|
Imatinib | Capsule 100 mg (as mesilate) | Oral | IMATINIB-DRLA | RZ | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 60 | 2 |
| 60 |
|
|
Imatinib | Capsule 100 mg (as mesilate) | Oral | IMATINIB-DRLA | RZ | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 60 | 5 |
| 60 |
|
|
Imatinib | Capsule 400 mg (as mesilate) | Oral | Imatinib GH | GQ | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 30 | 2 |
| 30 |
|
|
Imatinib | Capsule 400 mg (as mesilate) | Oral | Imatinib GH | GQ | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 30 | 5 |
| 30 |
|
|
Imatinib | Capsule 400 mg (as mesilate) | Oral | Imatinib-APOTEX | TX | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 30 | 2 |
| 30 |
|
|
Imatinib | Capsule 400 mg (as mesilate) | Oral | Imatinib-APOTEX | TX | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 30 | 5 |
| 30 |
|
|
Imatinib | Capsule 400 mg (as mesilate) | Oral | IMATINIB-DRLA | RZ | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 30 | 2 |
| 30 |
|
|
Imatinib | Capsule 400 mg (as mesilate) | Oral | IMATINIB-DRLA | RZ | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 30 | 5 |
| 30 |
|
|
Imatinib | Tablet 100 mg (as mesilate) | Oral | Gilmat | CR | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 60 | 2 |
| 60 |
|
|
Imatinib | Tablet 100 mg (as mesilate) | Oral | Gilmat | CR | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 60 | 5 |
| 60 |
|
|
Imatinib | Tablet 100 mg (as mesilate) | Oral | Glivec | NV | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 60 | 2 |
| 60 |
|
|
Imatinib | Tablet 100 mg (as mesilate) | Oral | Glivec | NV | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 60 | 5 |
| 60 |
|
|
Imatinib | Tablet 100 mg (as mesilate) | Oral | IMATINIB RBX | RA | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 60 | 2 |
| 60 |
|
|
Imatinib | Tablet 100 mg (as mesilate) | Oral | IMATINIB RBX | RA | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 60 | 5 |
| 60 |
|
|
Imatinib | Tablet 100 mg (as mesilate) | Oral | Imatinib Sandoz | SZ | MP | C9203 C9207 C12525 C12527 C12542 C12543 | P9203 P9207 P12525 P12527 P12542 P12543 | 60 | 2 |
| 60 |
|
|
Imatinib | Tablet 100 mg (as mesilate) | Oral | Imatinib Sandoz | SZ | MP | C9204 C9206 C9209 C9240 C9243 C9274 C9276 C9296 C12536 C12541 | P9204 P9206 P9209 P9240 P9243 P9274 P9276 P9296 P12536 P12541 | 60 | 5 |
| 60 |
|
|
Imatinib | Tablet 100 mg (as mesilate) | Oral | Imatinib-Teva | TB | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 60 | 2 |
| 60 |
|
|
Imatinib | Tablet 100 mg (as mesilate) | Oral | Imatinib-Teva | TB | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 60 | 5 |
| 60 |
|
|
Imatinib | Tablet 400 mg (as mesilate) | Oral | Gilmat | CR | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 30 | 2 |
| 30 |
|
|
Imatinib | Tablet 400 mg (as mesilate) | Oral | Gilmat | CR | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 30 | 5 |
| 30 |
|
|
Imatinib | Tablet 400 mg (as mesilate) | Oral | Glivec | NV | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 30 | 2 |
| 30 |
|
|
Imatinib | Tablet 400 mg (as mesilate) | Oral | Glivec | NV | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 30 | 5 |
| 30 |
|
|
Imatinib | Tablet 400 mg (as mesilate) | Oral | IMATINIB RBX | RA | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 30 | 2 |
| 30 |
|
|
Imatinib | Tablet 400 mg (as mesilate) | Oral | IMATINIB RBX | RA | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 30 | 5 |
| 30 |
|
|
Imatinib | Tablet 400 mg (as mesilate) | Oral | Imatinib Sandoz | SZ | MP | C9203 C9207 C12525 C12527 C12542 C12543 | P9203 P9207 P12525 P12527 P12542 P12543 | 30 | 2 |
| 30 |
|
|
Imatinib | Tablet 400 mg (as mesilate) | Oral | Imatinib Sandoz | SZ | MP | C9204 C9206 C9209 C9240 C9243 C9274 C9276 C9296 C12536 C12541 | P9204 P9206 P9209 P9240 P9243 P9274 P9276 P9296 P12536 P12541 | 30 | 5 |
| 30 |
|
|
Imatinib | Tablet 400 mg (as mesilate) | Oral | Imatinib-Teva | TB | MP | C9203 C9207 C9319 C12525 C12527 C12542 C12543 C13132 | P9203 P9207 P9319 P12525 P12527 P12542 P12543 P13132 | 30 | 2 |
| 30 |
|
|
Imatinib | Tablet 400 mg (as mesilate) | Oral | Imatinib-Teva | TB | MP | C9204 C9206 C9209 C9238 C9240 C9243 C9274 C9276 C9278 C9296 C12536 C12541 | P9204 P9206 P9209 P9238 P9240 P9243 P9274 P9276 P9278 P9296 P12536 P12541 | 30 | 5 |
| 30 |
|
|
Imatinib | Tablet 600 mg (as mesilate) | Oral | Imatab | JU | MP | C9203 C9207 C12525 C12527 C12542 C12543 C12685 C13132 | P9203 P9207 P12525 P12527 P12542 P12543 P12685 P13132 | 30 | 2 |
| 30 |
|
|
Imatinib | Tablet 600 mg (as mesilate) | Oral | Imatab | JU | MP | C9209 C9240 C12536 C12541 | P9209 P9240 P12536 P12541 | 30 | 5 |
| 30 |
|
|
substitute:
Indacaterol | Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler) | Inhalation by mouth | Onbrez | NV | MP NP | C6366 | P6366 | 30 | 5 |
| 30 |
|
|
Indacaterol | Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler) | Inhalation by mouth | Onbrez | NV | MP NP | C15736 | P15736 | 60 | 5 |
| 30 |
|
|
Indacaterol | Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler) | Inhalation by mouth | Onbrez | NV | MP NP | C6366 | P6366 | 30 | 5 |
| 30 |
|
|
Indacaterol | Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler) | Inhalation by mouth | Onbrez | NV | MP NP | C15736 | P15736 | 60 | 5 |
| 30 |
|
|
substitute:
Indacaterol with glycopyrronium | Capsule containing powder for oral inhalation indacaterol 110 micrograms (as maleate) with glycopyrronium 50 micrograms (as bromide) (for use in Breezhaler) | Inhalation by mouth | ultibro breezhaler 110/50 | NV | MP NP | C7798 | P7798 | 30 | 5 |
| 30 |
|
|
Indacaterol with glycopyrronium | Capsule containing powder for oral inhalation indacaterol 110 micrograms (as maleate) with glycopyrronium 5 micrograms (as bromide) (for use in Breezhaler) | Inhalation by mouth | ultibro breezhaler 110/50 | NV | MP NP | C15691 | P15691 | 60 | 5 |
| 30 |
|
|
substitute:
Indacaterol with glycopyrronium and mometasone | Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 136 micrograms (for use in Breezhaler) | Inhalation by mouth | Enerzair Breezhaler | NV | MP NP | C12603 | P12603 | 30 | 5 |
| 30 |
|
|
Indacaterol with glycopyrronium and mometasone | Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 136 micrograms (for use in Breezhaler) | Inhalation by mouth | Enerzair Breezhaler | NV | MP NP | C15601 | P15601 | 60 | 5 |
| 30 |
|
|
Indacaterol with glycopyrronium and mometasone | Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 68 micrograms (for use in Breezhaler) | Inhalation by mouth | Enerzair Breezhaler | NV | MP NP | C12603 | P12603 | 30 | 5 |
| 30 |
|
|
Indacaterol with glycopyrronium and mometasone | Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 68 micrograms (for use in Breezhaler) | Inhalation by mouth | Enerzair Breezhaler | NV | MP NP | C15601 | P15601 | 60 | 5 |
| 30 |
|
|
substitute:
Indacaterol with mometasone | Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 127.5 micrograms (for use in Breezhaler) | Inhalation by mouth | Atectura Breezhaler | NV | MP NP | C11360 | P11360 | 30 | 5 |
| 30 |
|
|
Indacaterol with mometasone | Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 127.5 micrograms (for use in Breezhaler) | Inhalation by mouth | Atectura Breezhaler | NV | MP NP | C15653 | P15653 | 60 | 5 |
| 30 |
|
|
Indacaterol with mometasone | Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 260 micrograms (for use in Breezhaler) | Inhalation by mouth | Atectura Breezhaler | NV | MP NP | C11360 | P11360 | 30 | 5 |
| 30 |
|
|
Indacaterol with mometasone | Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 260 micrograms (for use in Breezhaler) | Inhalation by mouth | Atectura Breezhaler | NV | MP NP | C15653 | P15653 | 60 | 5 |
| 30 |
|
|
Indacaterol with mometasone | Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 62.5 micrograms (for use in Breezhaler) | Inhalation by mouth | Atectura Breezhaler | NV | MP NP | C11360 | P11360 | 30 | 5 |
| 30 |
|
|
Indacaterol with mometasone | Capsule containing powder for oral inhalation indacaterol 125 micrograms (as acetate) with mometasone furoate 62.5 micrograms (for use in Breezhaler) | Inhalation by mouth | Atectura Breezhaler | NV | MP NP | C15653 | P15653 | 60 | 5 |
| 30 |
|
|
Irbesartan | Tablet 75 mg | Oral | Avapro | AV | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Irbesartan | Tablet 75 mg | Oral | Avapro | AV | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Irbesartan | Tablet 75 mg | Oral | Blooms the Chemist Irbesartan | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Irbesartan | Tablet 75 mg | Oral | Blooms the Chemist Irbesartan | IB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Irbesartan | Tablet 75 mg | Oral | IRBESARTAN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Irbesartan | Tablet 75 mg | Oral | IRBESARTAN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Irbesartan | Tablet 150 mg | Oral | Blooms the Chemist Irbesartan | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Irbesartan | Tablet 150 mg | Oral | Blooms the Chemist Irbesartan | IB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Irbesartan | Tablet 150 mg | Oral | IRBESARTAN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Irbesartan | Tablet 150 mg | Oral | IRBESARTAN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Irbesartan | Tablet 300 mg | Oral | IRBESARTAN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Irbesartan | Tablet 300 mg | Oral | IRBESARTAN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Irbesartan with hydrochlorothiazide | Tablet 150 mg-12.5 mg | Oral | IRBESARTAN HCTZ-WGR 150/12.5 | WG | MP NP | C4374 | P4374 | 30 | 5 |
| 30 |
|
|
Irbesartan with hydrochlorothiazide | Tablet 150 mg-12.5 mg | Oral | IRBESARTAN HCTZ-WGR 150/12.5 | WG | MP NP | C14255 | P14255 | 60 | 5 |
| 30 |
|
|
insert:
Irbesartan with hydrochlorothiazide | Tablet 300 mg-12.5 mg | Oral | IRBESARTAN HCTZ-WGR 300/12.5 | WG | MP NP | C4374 | P4374 | 30 | 5 |
| 30 |
|
|
Irbesartan with hydrochlorothiazide | Tablet 300 mg-12.5 mg | Oral | IRBESARTAN HCTZ-WGR 300/12.5 | WG | MP NP | C14255 | P14255 | 60 | 5 |
| 30 |
|
|
insert:
Irbesartan with hydrochlorothiazide | Tablet 300 mg-25 mg | Oral | IRBESARTAN HCTZ-WGR 300/25 | WG | MP NP | C4374 | P4374 | 30 | 5 |
| 30 |
|
|
Irbesartan with hydrochlorothiazide | Tablet 300 mg-25 mg | Oral | IRBESARTAN HCTZ-WGR 300/25 | WG | MP NP | C14255 | P14255 | 60 | 5 |
| 30 |
|
|
insert:
Isosorbide mononitrate | Tablet 60 mg (sustained release) | Oral | ISOSORBIDE MR-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Isosorbide mononitrate | Tablet 60 mg (sustained release) | Oral | ISOSORBIDE MR-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Isotretinoin | Capsule 10 mg | Oral | ISOTRETINOIN-WGR | WG | MP | C5224 |
| 60 | 3 |
| 60 |
|
|
insert:
Isotretinoin | Capsule 20 mg | Oral | ISOTRETINOIN-WGR | WG | MP | C5224 |
| 60 | 3 |
| 60 |
|
|
insert:
Ivabradine | Tablet 5 mg (as hydrochloride) | Oral | IVABRADINE-WGR | WG | MP NP | C4979 |
| 56 | 5 |
| 56 |
|
|
insert:
Lamotrigine | Tablet 25 mg | Oral | LAMOTRIGINE-WGR | WG | MP NP | C11081 | P11081 | 56 | 5 |
| 56 |
|
|
Lamotrigine | Tablet 25 mg | Oral | LAMOTRIGINE-WGR | WG | MP NP | C14855 | P14855 | 112 | 5 |
| 56 |
|
|
insert:
Lamotrigine | Tablet 50 mg | Oral | LAMOTRIGINE-WGR | WG | MP NP | C11081 | P11081 | 56 | 5 |
| 56 |
|
|
Lamotrigine | Tablet 50 mg | Oral | LAMOTRIGINE-WGR | WG | MP NP | C14855 | P14855 | 112 | 5 |
| 56 |
|
|
insert:
Lamotrigine | Tablet 100 mg | Oral | LAMOTRIGINE-WGR | WG | MP NP | C11081 | P11081 | 56 | 5 |
| 56 |
|
|
Lamotrigine | Tablet 100 mg | Oral | LAMOTRIGINE-WGR | WG | MP NP | C14855 | P14855 | 112 | 5 |
| 56 |
|
|
insert:
Lamotrigine | Tablet 200 mg | Oral | LAMOTRIGINE-WGR | WG | MP NP | C11081 | P11081 | 56 | 5 |
| 56 |
|
|
Lamotrigine | Tablet 200 mg | Oral | LAMOTRIGINE-WGR | WG | MP NP | C14855 | P14855 | 112 | 5 |
| 56 |
|
|
substitute:
Lansoprazole | Capsule 15 mg | Oral | Zopral | AF | MP NP | C5444 C5512 | P5444 P5512 | 30 | 5 |
| 30 |
|
|
Lansoprazole | Capsule 15 mg | Oral | Zopral | AF | MP NP | C15574 C15633 | P15574 P15633 | 60 | 5 |
| 30 |
|
|
Lansoprazole | Capsule 30 mg | Oral | APO-Lansoprazole | TX | MP NP | C8774 C8775 | P8774 P8775 | 28 | 1 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | APO-Lansoprazole | TX | MP NP | C8776 C8780 | P8776 P8780 | 28 | 5 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | APO-Lansoprazole | TX | MP NP | C11310 C15530 C15658 | P11310 P15530 P15658 | 56 | 5 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | APO-Lansoprazole | TX | MP | C15531 | P15531 | 112 | 5 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | Lanzopran | RA | MP NP | C8774 C8775 | P8774 P8775 | 28 | 1 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | Lanzopran | RA | MP NP | C8776 C8780 | P8776 P8780 | 28 | 5 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | Lanzopran | RA | MP NP | C11310 C15530 C15658 | P11310 P15530 P15658 | 56 | 5 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | Lanzopran | RA | MP | C15531 | P15531 | 112 | 5 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | NOUMED LANSOPRAZOLE | VO | MP NP | C8774 C8775 | P8774 P8775 | 28 | 1 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | NOUMED LANSOPRAZOLE | VO | MP NP | C8776 C8780 | P8776 P8780 | 28 | 5 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | NOUMED LANSOPRAZOLE | VO | MP NP | C11310 C15530 C15658 | P11310 P15530 P15658 | 56 | 5 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | NOUMED LANSOPRAZOLE | VO | MP | C15531 | P15531 | 112 | 5 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | Zopral | AF | MP NP | C8774 C8775 | P8774 P8775 | 28 | 1 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | Zopral | AF | MP NP | C8776 C8780 | P8776 P8780 | 28 | 5 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | Zopral | AF | MP NP | C11310 C15530 C15658 | P11310 P15530 P15658 | 56 | 5 |
| 28 |
|
|
Lansoprazole | Capsule 30 mg | Oral | Zopral | AF | MP | C15531 | P15531 | 112 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | APO-Lansoprazole ODT | TX | MP NP | C5444 C5512 | P5444 P5512 | 28 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | APO-Lansoprazole ODT | TX | MP NP | C15574 C15633 | P15574 P15633 | 56 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | Lansoprazole ODT GH | GQ | MP NP | C5444 C5512 | P5444 P5512 | 28 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | Lansoprazole ODT GH | GQ | MP NP | C15574 C15633 | P15574 P15633 | 56 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | Zopral ODT | AF | MP NP | C5444 C5512 | P5444 P5512 | 28 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | Zopral ODT | AF | MP NP | C15574 C15633 | P15574 P15633 | 56 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | Zoton FasTabs | PF | MP NP | C5444 C5512 | P5444 P5512 | 28 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | Zoton FasTabs | PF | MP NP | C15574 C15633 | P15574 P15633 | 56 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | APO-Lansoprazole ODT | TX | MP NP | C8774 C8775 | P8774 P8775 | 28 | 1 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | APO-Lansoprazole ODT | TX | MP NP | C8776 C8780 | P8776 P8780 | 28 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | APO-Lansoprazole ODT | TX | MP NP | C11310 C15530 C15658 | P11310 P15530 P15658 | 56 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | APO-Lansoprazole ODT | TX | MP | C15531 | P15531 | 112 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | Lansoprazole ODT GH | GQ | MP NP | C8774 C8775 | P8774 P8775 | 28 | 1 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | Lansoprazole ODT GH | GQ | MP NP | C8776 C8780 | P8776 P8780 | 28 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | Lansoprazole ODT GH | GQ | MP NP | C11310 C15530 C15658 | P11310 P15530 P15658 | 56 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | Lansoprazole ODT GH | GQ | MP | C15531 | P15531 | 112 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | Zopral ODT | AF | MP NP | C8774 C8775 | P8774 P8775 | 28 | 1 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | Zopral ODT | AF | MP NP | C8776 C8780 | P8776 P8780 | 28 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | Zopral ODT | AF | MP NP | C11310 C15530 C15658 | P11310 P15530 P15658 | 56 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | Zopral ODT | AF | MP | C15531 | P15531 | 112 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | Zoton FasTabs | PF | MP NP | C8774 C8775 | P8774 P8775 | 28 | 1 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | Zoton FasTabs | PF | MP NP | C8776 C8780 | P8776 P8780 | 28 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | Zoton FasTabs | PF | MP NP | C11310 C15530 C15658 | P11310 P15530 P15658 | 56 | 5 |
| 28 |
|
|
Lansoprazole | Tablet 30 mg (orally disintegrating) | Oral | Zoton FasTabs | PF | MP | C15531 | P15531 | 112 | 5 |
| 28 |
|
|
substitute:
Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | APO-Latanoprost | TX | MP AO |
|
| 1 | 5 |
| 1 |
|
|
Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | APO-Latanoprost | TX | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | Latanoprost Sandoz | SZ | MP AO |
|
| 1 | 5 |
| 1 |
|
|
Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | Latanoprost Sandoz | SZ | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | LATANOPROST-WGR | WG | MP AO |
|
| 1 | 5 |
| 1 |
|
|
Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | LATANOPROST-WGR | WG | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | Xalaprost | AF | MP AO |
|
| 1 | 5 |
| 1 |
|
|
Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | Xalaprost | AF | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | Xalatan | AS | MP AO |
|
| 1 | 5 |
| 1 |
|
|
Latanoprost | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | Xalatan | AS | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
substitute:
Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | APO-Latanoprost/Timolol 0.05/5 | TX | AO | C5038 | P5038 | 1 | 5 |
| 1 |
|
|
Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | APO-Latanoprost/Timolol 0.05/5 | TX | MP | C4343 | P4343 | 1 | 5 |
| 1 |
|
|
Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | APO-Latanoprost/Timolol 0.05/5 | TX | MP AO | C15558 | P15558 | 2 | 5 |
| 1 |
|
|
Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Xalacom | AS | AO | C5038 | P5038 | 1 | 5 |
| 1 |
|
|
Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Xalacom | AS | MP | C4343 | P4343 | 1 | 5 |
| 1 |
|
|
Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Xalacom | AS | MP AO | C15558 | P15558 | 2 | 5 |
| 1 |
|
|
Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Xalamol 50/5 | AF | AO | C5038 | P5038 | 1 | 5 |
| 1 |
|
|
Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Xalamol 50/5 | AF | MP | C4343 | P4343 | 1 | 5 |
| 1 |
|
|
Latanoprost with timolol | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Xalamol 50/5 | AF | MP AO | C15558 | P15558 | 2 | 5 |
| 1 |
|
|
omit:
Leflunomide | Tablet 10 mg | Oral | Arabloc | AV | MP | C13753 C13771 | P13753 P13771 | 30 | 5 |
| 30 |
|
|
Leflunomide | Tablet 10 mg | Oral | Arabloc | AV | MP | C14941 C14942 | P14941 P14942 | 60 | 5 |
| 30 |
|
|
insert:
Leflunomide | Tablet 10 mg | Oral | LEFLUNOMIDE-WGR | WG | MP | C13753 C13771 | P13753 P13771 | 30 | 5 |
| 30 |
|
|
Leflunomide | Tablet 10 mg | Oral | LEFLUNOMIDE-WGR | WG | MP | C14941 C14942 | P14941 P14942 | 60 | 5 |
| 30 |
|
|
insert:
Leflunomide | Tablet 20 mg | Oral | LEFLUNOMIDE-WGR | WG | MP | C13753 C13771 | P13753 P13771 | 30 | 5 |
| 30 |
|
|
Leflunomide | Tablet 20 mg | Oral | LEFLUNOMIDE-WGR | WG | MP | C14941 C14942 | P14941 P14942 | 60 | 5 |
| 30 |
|
|
omit:
Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | BTC Lercanidipine | JB | MP NP |
|
| 28 | 5 |
| 28 |
|
|
Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | BTC Lercanidipine | JB | MP NP |
| P14238 | 56 | 5 |
| 28 |
|
|
insert:
Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | LERCANIDIPINE-WGR | WG | MP NP |
|
| 28 | 5 |
| 28 |
|
|
Lercanidipine | Tablet containing lercanidipine hydrochloride 10 mg | Oral | LERCANIDIPINE-WGR | WG | MP NP |
| P14238 | 56 | 5 |
| 28 |
|
|
omit:
Lercanidipine | Tablet containing lercanidipine hydrochloride 20 mg | Oral | BTC Lercanidipine | JB | MP NP |
|
| 28 | 5 |
| 28 |
|
|
Lercanidipine | Tablet containing lercanidipine hydrochloride 20 mg | Oral | BTC Lercanidipine | JB | MP NP |
| P14238 | 56 | 5 |
| 28 |
|
|
insert:
Lercanidipine | Tablet containing lercanidipine hydrochloride 20 mg | Oral | LERCANIDIPINE-WGR | WG | MP NP |
|
| 28 | 5 |
| 28 |
|
|
Lercanidipine | Tablet containing lercanidipine hydrochloride 20 mg | Oral | LERCANIDIPINE-WGR | WG | MP NP |
| P14238 | 56 | 5 |
| 28 |
|
|
insert:
Letrozole | Tablet 2.5 mg | Oral | LETROZOLE-WGR | WG | MP NP | C5464 | P5464 | 30 | 5 |
| 30 |
|
|
Letrozole | Tablet 2.5 mg | Oral | LETROZOLE-WGR | WG | MP NP | C14943 | P14943 | 60 | 5 |
| 30 |
|
|
insert:
Levetiracetam | Tablet 250 mg | Oral | LEVETIRACETAM-WGR | WG | MP NP | C11116 | P11116 | 60 | 5 |
| 60 |
|
|
Levetiracetam | Tablet 250 mg | Oral | LEVETIRACETAM-WGR | WG | MP NP | C14964 | P14964 | 120 | 5 |
| 60 |
|
|
insert:
Levetiracetam | Tablet 500 mg | Oral | LEVETIRACETAM-WGR | WG | MP NP | C11116 | P11116 | 60 | 5 |
| 60 |
|
|
Levetiracetam | Tablet 500 mg | Oral | LEVETIRACETAM-WGR | WG | MP NP | C14964 | P14964 | 120 | 5 |
| 60 |
|
|
insert:
Levetiracetam | Tablet 1 g | Oral | LEVETIRACETAM-WGR | WG | MP NP | C11116 | P11116 | 60 | 5 |
| 60 |
|
|
Levetiracetam | Tablet 1 g | Oral | LEVETIRACETAM-WGR | WG | MP NP | C14964 | P14964 | 120 | 5 |
| 60 |
|
|
substitute:
Levodopa with benserazide | Capsule containing levodopa 50 mg with 12.5 mg benserazide (as hydrochloride) | Oral | Madopar 62.5 | RO | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with benserazide | Capsule containing levodopa 50 mg with 12.5 mg benserazide (as hydrochloride) | Oral | Madopar 62.5 | RO | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with benserazide | Capsule containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) | Oral | Madopar 125 | RO | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with benserazide | Capsule containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) | Oral | Madopar 125 | RO | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with benserazide | Capsule containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) (sustained release) | Oral | Madopar HBS | RO | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with benserazide | Capsule containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) (sustained release) | Oral | Madopar HBS | RO | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with benserazide | Capsule containing levodopa 200 mg with 50 mg benserazide (as hydrochloride) | Oral | Madopar | RO | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with benserazide | Capsule containing levodopa 200 mg with 50 mg benserazide (as hydrochloride) | Oral | Madopar | RO | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with benserazide | Dispersible tablet containing levodopa 50 mg with 12.5 mg benserazide (as hydrochloride) | Oral | Madopar Rapid 62.5 | RO | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with benserazide | Dispersible tablet containing levodopa 50 mg with 12.5 mg benserazide (as hydrochloride) | Oral | Madopar Rapid 62.5 | RO | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with benserazide | Dispersible tablet containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) | Oral | Madopar Rapid 125 | RO | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with benserazide | Dispersible tablet containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) | Oral | Madopar Rapid 125 | RO | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with benserazide | Tablet containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) | Oral | Madopar 125 | RO | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with benserazide | Tablet containing levodopa 100 mg with 25 mg benserazide (as hydrochloride) | Oral | Madopar 125 | RO | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with benserazide | Tablet containing levodopa 200 mg with 50 mg benserazide (as hydrochloride) | Oral | Madopar | RO | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with benserazide | Tablet containing levodopa 200 mg with 50 mg benserazide (as hydrochloride) | Oral | Madopar | RO | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
substitute:
Levodopa with carbidopa | Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg per mL, 100 mL | Intra intestinal | Duodopa | VE | MP | C10138 C10161 | P10138 P10161 | 28 | 5 |
| 7 |
| C(100) |
Levodopa with carbidopa | Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg per mL, 100 mL | Intra intestinal | Duodopa | VE | MP NP | C10197 | P10197 | 28 | 5 |
| 7 |
|
|
Levodopa with carbidopa | Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg per mL, 100 mL | Intra intestinal | Duodopa | VE | MP | C10363 C10375 | P10363 P10375 | 56 | 5 |
| 7 |
| C(100) |
Levodopa with carbidopa | Intestinal gel containing levodopa 20 mg with carbidopa monohydrate 5 mg per mL, 100 mL | Intra intestinal | Duodopa | VE | MP NP | C10386 | P10386 | 56 | 5 |
| 7 |
|
|
Levodopa with carbidopa | Tablet 100 mg-25 mg (as monohydrate) | Oral | APO-Levodopa/Carbidopa | TX | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 100 mg-25 mg (as monohydrate) | Oral | APO-Levodopa/Carbidopa | TX | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 100 mg-25 mg (as monohydrate) | Oral | Kinson | AF | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 100 mg-25 mg (as monohydrate) | Oral | Kinson | AF | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 100 mg-25 mg (as monohydrate) | Oral | SINADOPA 100/25 | RW | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 100 mg-25 mg (as monohydrate) | Oral | SINADOPA 100/25 | RW | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 100 mg-25 mg (as monohydrate) | Oral | Sinemet 100/25 | AL | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 100 mg-25 mg (as monohydrate) | Oral | Sinemet 100/25 | AL | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 250 mg-25 mg (as monohydrate) | Oral | APO-Levodopa/Carbidopa | TX | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 250 mg-25 mg (as monohydrate) | Oral | APO-Levodopa/Carbidopa | TX | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 250 mg-25 mg (as monohydrate) | Oral | SINADOPA 250/25 | RW | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 250 mg-25 mg (as monohydrate) | Oral | SINADOPA 250/25 | RW | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 250 mg-25 mg (as monohydrate) | Oral | Sinemet | AL | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet 250 mg-25 mg (as monohydrate) | Oral | Sinemet | AL | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet (modified release) 200 mg-50 mg (as monohydrate) | Oral | Sinemet CR | AL | MP NP | C5253 | P5253 | 100 | 5 |
| 100 |
|
|
Levodopa with carbidopa | Tablet (modified release) 200 mg-50 mg (as monohydrate) | Oral | Sinemet CR | AL | MP NP | C15608 | P15608 | 200 | 5 |
| 100 |
|
|
substitute:
Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Carlevent | TX | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Carlevent | TX | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | L.C.E. Sandoz | HX | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | L.C.E. Sandoz | HX | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Lecteva | TB | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Lecteva | TB | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Stalevo 50/12.5/200mg | SZ | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Stalevo 50/12.5/200mg | SZ | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Carlevent | TX | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Carlevent | TX | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | L.C.E. Sandoz | HX | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | L.C.E. Sandoz | HX | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Lecteva | TB | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Lecteva | TB | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Stalevo 75/18.75/200mg | SZ | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Stalevo 75/18.75/200mg | SZ | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Carlevent | TX | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Carlevent | TX | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | L.C.E. Sandoz | HX | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | L.C.E. Sandoz | HX | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Lecteva | TB | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Lecteva | TB | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Stalevo 100/25/200mg | SZ | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Stalevo 100/25/200mg | SZ | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Carlevent | TX | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Carlevent | TX | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | L.C.E. Sandoz | HX | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | L.C.E. Sandoz | HX | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Lecteva | TB | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Lecteva | TB | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Stalevo 125/31.25/200mg | SZ | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Stalevo 125/31.25/200mg | SZ | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Carlevent | TX | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Carlevent | TX | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | L.C.E. Sandoz | HX | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | L.C.E. Sandoz | HX | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Lecteva | TB | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Lecteva | TB | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Stalevo 150/37.5/200mg | SZ | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Stalevo 150/37.5/200mg | SZ | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Carlevent | TX | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Carlevent | TX | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | L.C.E. Sandoz | HX | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | L.C.E. Sandoz | HX | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Lecteva | TB | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Lecteva | TB | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Stalevo 200/50/200mg | SZ | MP NP | C5212 C5288 | P5212 P5288 | 200 | 4 |
| 100 |
|
|
Levodopa with carbidopa and entacapone | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Stalevo 200/50/200mg | SZ | MP NP | C15564 C15565 | P15564 P15565 | 400 | 4 |
| 100 |
|
|
insert:
Levonorgestrel with ethinylestradiol | Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets | Oral | LEVETH 150/30 ED | WG | MP NP |
|
| 4 | 2 |
| 4 |
|
|
insert:
Lisinopril | Tablet 5 mg | Oral | LISINOPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Lisinopril | Tablet 5 mg | Oral | LISINOPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Lisinopril | Tablet 10 mg | Oral | LISINOPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Lisinopril | Tablet 10 mg | Oral | LISINOPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Lisinopril | Tablet 20 mg | Oral | LISINOPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Lisinopril | Tablet 20 mg | Oral | LISINOPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Lurasidone | Tablet containing lurasidone hydrochloride 40 mg | Oral | LURASIDONE-WGR | WG | MP NP | C4246 |
| 30 | 5 |
| 30 |
|
|
insert:
Lurasidone | Tablet containing lurasidone hydrochloride 80 mg | Oral | LURASIDONE-WGR | WG | MP NP | C4246 |
| 30 | 5 |
| 30 |
|
|
insert:
Macrogol 3350 | Powder for oral solution 510 g | Oral | OsmoLax | KY | MP NP | C15539 C15593 C15661 C15709 C15729 | P15539 P15593 P15661 P15709 P15729 | 2 | 5 |
| 1 |
|
|
insert:
Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | APO-MACROGOL plus ELECTROLYTES | TX | MP NP | C15688 C15730 C15745 C15746 C15747 | P15688 P15730 P15745 P15746 P15747 | 2 | 5 |
| 1 |
|
|
insert:
Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | APOHEALTH Macrogol with Electrolytes | GX | MP NP | C15688 C15730 C15745 C15746 C15747 | P15688 P15730 P15745 P15746 P15747 | 2 | 5 |
| 1 |
|
|
insert:
Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | Chemists' Own Macrogol with Electrolytes | RW | MP NP | C15688 C15730 C15745 C15746 C15747 | P15688 P15730 P15745 P15746 P15747 | 2 | 5 |
| 1 |
|
|
insert:
Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | Macrovic | RF | MP NP | C15688 C15730 C15745 C15746 C15747 | P15688 P15730 P15745 P15746 P15747 | 2 | 5 |
| 1 |
|
|
insert:
Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | Molaxole | GO | MP NP | C15688 C15730 C15745 C15746 C15747 | P15688 P15730 P15745 P15746 P15747 | 2 | 5 |
| 1 |
|
|
insert:
Macrogol 3350 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | Movicol | NE | MP NP | C15688 C15730 C15745 C15746 C15747 | P15688 P15730 P15745 P15746 P15747 | 2 | 5 |
| 1 |
|
|
insert:
Meloxicam | Capsule 7.5 mg | Oral | MELOXICAM-WGR | WG | MP NP | C4907 C4962 |
| 30 | 3 |
| 30 |
|
|
insert:
Meloxicam | Capsule 15 mg | Oral | MELOXICAM-WGR | WG | MP NP | C4907 C4962 |
| 30 | 3 |
| 30 |
|
|
insert:
Meloxicam | Tablet 7.5 mg | Oral | MELOXICAM-WGR | WG | MP NP | C4907 C4962 |
| 30 | 3 |
| 30 |
|
|
insert:
Meloxicam | Tablet 15 mg | Oral | MELOXICAM-WGR | WG | MP NP | C4907 C4962 |
| 30 | 3 |
| 30 |
|
|
substitute:
Mesna | Solution for I.V. injection 400 mg in 4 mL ampoule | Injection | Uromitexan | BX | MP | C5106 |
| 15 | 5 |
| 15 |
|
|
Mesna | Solution for I.V. injection 400 mg in 4 mL ampoule | Injection | Uromitexan | BX | MP | C5130 |
| 15 | 5 |
| 15 |
| C(100) |
Mesna | Solution for I.V. injection 1 g in 10 mL ampoule | Injection | Uromitexan | BX | MP | C5106 |
| 15 | 5 |
| 15 |
|
|
Mesna | Solution for I.V. injection 1 g in 10 mL ampoule | Injection | Uromitexan | BX | MP | C5130 |
| 15 | 5 |
| 15 |
| C(100) |
insert:
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | METFORMIN-WGR XR | WG | MP NP |
|
| 120 | 5 |
| 120 |
|
|
Metformin | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | METFORMIN-WGR XR | WG | MP NP |
| P14238 | 240 | 5 |
| 120 |
|
|
insert:
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | METFORMIN-WGR XR | WG | MP NP |
|
| 60 | 5 |
| 60 |
|
|
Metformin | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | METFORMIN-WGR XR | WG | MP NP |
| P14238 | 120 | 5 |
| 60 |
|
|
insert:
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | METFORMIN-WGR | WG | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Metformin | Tablet containing metformin hydrochloride 500 mg | Oral | METFORMIN-WGR | WG | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
insert:
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Diaformin Viatris | MQ | MP NP |
|
| 60 | 5 |
| 60 |
|
|
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | Diaformin Viatris | MQ | MP NP |
| P14238 | 120 | 5 |
| 60 |
|
|
insert:
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | METFORMIN-WGR | WG | MP NP |
|
| 60 | 5 |
| 60 |
|
|
Metformin | Tablet containing metformin hydrochloride 850 mg | Oral | METFORMIN-WGR | WG | MP NP |
| P14238 | 120 | 5 |
| 60 |
|
|
insert:
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Diaformin Viatris | MQ | MP NP |
|
| 90 | 5 |
| 90 |
|
|
Metformin | Tablet containing metformin hydrochloride 1 g | Oral | Diaformin Viatris | MQ | MP NP |
| P14238 | 180 | 5 |
| 90 |
|
|
omit:
Methylprednisolone | Powder for injection 40 mg (as sodium succinate) (S19A) | Injection | Solu-Medrone | LM | MP NP |
|
| 5 | 0 |
| 1 |
|
|
substitute:
Metoclopramide | Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | APO-Metoclopramide | TX | MP NP MW PDP |
|
| 25 | 0 |
| 25 |
|
|
Metoclopramide | Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | APO-Metoclopramide | TX | MP NP |
| P11683 | 100 | 5 |
| 25 |
|
|
Metoclopramide | Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | EMEXLON | RW | MP NP MW PDP |
|
| 25 | 0 |
| 25 |
|
|
Metoclopramide | Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | EMEXLON | RW | MP NP |
| P11683 | 100 | 5 |
| 25 |
|
|
Metoclopramide | Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | Maxolon | IL | MP NP MW PDP |
|
| 25 | 0 |
| 25 |
|
|
Metoclopramide | Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | Maxolon | IL | MP NP |
| P11683 | 100 | 5 |
| 25 |
|
|
Metoclopramide | Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | METOCLOPRAMIDE-WGR | WG | MP NP MW PDP |
|
| 25 | 0 |
| 25 |
|
|
Metoclopramide | Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | METOCLOPRAMIDE-WGR | WG | MP NP |
| P11683 | 100 | 5 |
| 25 |
|
|
Metoclopramide | Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | Pramin | AF | MP NP MW PDP |
|
| 25 | 0 |
| 25 |
|
|
Metoclopramide | Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | Pramin | AF | MP NP |
| P11683 | 100 | 5 |
| 25 |
|
|
insert:
Metoprolol | Tablet containing metoprolol tartrate 50 mg | Oral | METOPROLOL-WGR | WG | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Metoprolol | Tablet containing metoprolol tartrate 50 mg | Oral | METOPROLOL-WGR | WG | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
insert:
Metoprolol | Tablet containing metoprolol tartrate 100 mg | Oral | METOPROLOL-WGR | WG | MP NP |
|
| 60 | 5 |
| 60 |
|
|
Metoprolol | Tablet containing metoprolol tartrate 100 mg | Oral | METOPROLOL-WGR | WG | MP NP |
| P14238 | 120 | 5 |
| 60 |
|
|
substitute:
Mianserin | Tablet containing mianserin hydrochloride 10 mg | Oral | Lumin 10 | AF | MP NP | C6278 | P6278 | 50 | 5 |
| 50 |
|
|
Mianserin | Tablet containing mianserin hydrochloride 10 mg | Oral | Lumin 10 | AF | MP NP | C15580 | P15580 | 100 | 2 |
| 50 |
|
|
Mianserin | Tablet containing mianserin hydrochloride 20 mg | Oral | Lumin 20 | AF | MP NP | C6278 | P6278 | 50 | 5 |
| 50 |
|
|
Mianserin | Tablet containing mianserin hydrochloride 20 mg | Oral | Lumin 20 | AF | MP NP | C15580 | P15580 | 100 | 2 |
| 50 |
|
|
insert:
Migalastat | Capsule containing 150 mg migalastat hydrochloride (equivalent to 123 mg migalastat) | Oral | Galafold | FT | MP | C15787 C15801 C15808 |
| 14 | 5 |
| 14 |
|
|
substitute:
Minocycline | Tablet 50 mg (as hydrochloride) | Oral | Akamin 50 | AF | MP NP | C5995 | P5995 | 60 | 5 |
| 60 |
|
|
Minocycline | Tablet 50 mg (as hydrochloride) | Oral | Akamin 50 | AF | MP NP | C15657 | P15657 | 120 | 2 |
| 60 |
|
|
Minocycline | Tablet 50 mg (as hydrochloride) | Oral | Minomycin-50 | AS | MP NP | C5995 | P5995 | 60 | 5 |
| 60 |
|
|
Minocycline | Tablet 50 mg (as hydrochloride) | Oral | Minomycin-50 | AS | MP NP | C15657 | P15657 | 120 | 2 |
| 60 |
|
|
substitute:
Mirtazapine | Tablet 15 mg | Oral | APX-Mirtazapine | TY | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg | Oral | APX-Mirtazapine | TY | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg | Oral | Axit 15 | AF | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg | Oral | Axit 15 | AF | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg | Oral | Blooms The Chemist Mirtazapine | BG | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg | Oral | Blooms The Chemist Mirtazapine | BG | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg | Oral | MIRTANZA | RF | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg | Oral | MIRTANZA | RF | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg | Oral | Mirtazapine Sandoz | SZ | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg | Oral | Mirtazapine Sandoz | SZ | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg | Oral | MIRTAZAPINE-WGR | WG | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg | Oral | MIRTAZAPINE-WGR | WG | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg (orally disintegrating) | Oral | MIRTANZA ODT | RF | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 15 mg (orally disintegrating) | Oral | MIRTANZA ODT | RF | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | APX-Mirtazapine | TY | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | APX-Mirtazapine | TY | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | Avanza | AL | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | Avanza | AL | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | Axit 30 | AF | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | Axit 30 | AF | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | Blooms The Chemist Mirtazapine | BG | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | Blooms The Chemist Mirtazapine | BG | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | MIRTANZA | RF | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | MIRTANZA | RF | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | Mirtazapine Sandoz | SZ | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | Mirtazapine Sandoz | SZ | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | MIRTAZAPINE-WGR | WG | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | MIRTAZAPINE-WGR | WG | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | NOUMED MIRTAZAPINE | VO | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg | Oral | NOUMED MIRTAZAPINE | VO | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg (orally disintegrating) | Oral | MIRTANZA ODT | RF | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 30 mg (orally disintegrating) | Oral | MIRTANZA ODT | RF | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | APX-Mirtazapine | TY | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | APX-Mirtazapine | TY | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | Axit 45 | AF | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | Axit 45 | AF | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | Blooms The Chemist Mirtazapine | BG | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | Blooms The Chemist Mirtazapine | BG | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | MIRTANZA | RF | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | MIRTANZA | RF | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | Mirtazapine Sandoz | SZ | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | Mirtazapine Sandoz | SZ | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | MIRTAZAPINE-WGR | WG | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | MIRTAZAPINE-WGR | WG | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | NOUMED MIRTAZAPINE | VO | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg | Oral | NOUMED MIRTAZAPINE | VO | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg (orally disintegrating) | Oral | MIRTANZA ODT | RF | MP NP | C5650 | P5650 | 30 | 5 |
| 30 |
|
|
Mirtazapine | Tablet 45 mg (orally disintegrating) | Oral | MIRTANZA ODT | RF | MP NP | C15553 | P15553 | 60 | 2 |
| 30 |
|
|
substitute:
Moclobemide | Tablet 150 mg | Oral | Amira 150 | AF | MP NP | C5650 | P5650 | 60 | 5 |
| 60 |
|
|
Moclobemide | Tablet 150 mg | Oral | Amira 150 | AF | MP NP | C15553 | P15553 | 120 | 2 |
| 60 |
|
|
Moclobemide | Tablet 150 mg | Oral | Aurorix | GO | MP NP | C5650 | P5650 | 60 | 5 |
| 60 |
|
|
Moclobemide | Tablet 150 mg | Oral | Aurorix | GO | MP NP | C15553 | P15553 | 120 | 2 |
| 60 |
|
|
Moclobemide | Tablet 150 mg | Oral | Clobemix | XT | MP NP | C5650 | P5650 | 60 | 5 |
| 60 |
|
|
Moclobemide | Tablet 150 mg | Oral | Clobemix | XT | MP NP | C15553 | P15553 | 120 | 2 |
| 60 |
|
|
Moclobemide | Tablet 150 mg | Oral | Moclobemide Sandoz | SZ | MP NP | C5650 | P5650 | 60 | 5 |
| 60 |
|
|
Moclobemide | Tablet 150 mg | Oral | Moclobemide Sandoz | SZ | MP NP | C15553 | P15553 | 120 | 2 |
| 60 |
|
|
Moclobemide | Tablet 150 mg | Oral | MOCLOBEMIDE-WGR | WG | MP NP | C5650 | P5650 | 60 | 5 |
| 60 |
|
|
Moclobemide | Tablet 150 mg | Oral | MOCLOBEMIDE-WGR | WG | MP NP | C15553 | P15553 | 120 | 2 |
| 60 |
|
|
Moclobemide | Tablet 300 mg | Oral | Amira 300 | AF | MP NP | C5650 | P5650 | 60 | 5 |
| 60 |
|
|
Moclobemide | Tablet 300 mg | Oral | Amira 300 | AF | MP NP | C15553 | P15553 | 120 | 2 |
| 60 |
|
|
Moclobemide | Tablet 300 mg | Oral | Aurorix 300 mg | GO | MP NP | C5650 | P5650 | 60 | 5 |
| 60 |
|
|
Moclobemide | Tablet 300 mg | Oral | Aurorix 300 mg | GO | MP NP | C15553 | P15553 | 120 | 2 |
| 60 |
|
|
Moclobemide | Tablet 300 mg | Oral | Clobemix | XT | MP NP | C5650 | P5650 | 60 | 5 |
| 60 |
|
|
Moclobemide | Tablet 300 mg | Oral | Clobemix | XT | MP NP | C15553 | P15553 | 120 | 2 |
| 60 |
|
|
Moclobemide | Tablet 300 mg | Oral | Moclobemide Sandoz | SZ | MP NP | C5650 | P5650 | 60 | 5 |
| 60 |
|
|
Moclobemide | Tablet 300 mg | Oral | Moclobemide Sandoz | SZ | MP NP | C15553 | P15553 | 120 | 2 |
| 60 |
|
|
Moclobemide | Tablet 300 mg | Oral | MOCLOBEMIDE-WGR | WG | MP NP | C5650 | P5650 | 60 | 5 |
| 60 |
|
|
Moclobemide | Tablet 300 mg | Oral | MOCLOBEMIDE-WGR | WG | MP NP | C15553 | P15553 | 120 | 2 |
| 60 |
|
|
insert:
Modafinil | Tablet 100 mg | Oral | MODAFINIL-WGR | WG | MP | C10935 C10968 C10970 |
| 120 | 5 |
| 60 |
|
|
substitute:
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | MONTELAIR 4 | RF | MP NP | C6666 | P6666 | 28 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | MONTELAIR 4 | RF | MP NP | C15642 | P15642 | 56 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Montelukast APOTEX | GX | MP NP | C6666 | P6666 | 28 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Montelukast APOTEX | GX | MP NP | C15642 | P15642 | 56 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Montelukast Lupin | HQ | MP NP | C6666 | P6666 | 28 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Montelukast Lupin | HQ | MP NP | C15642 | P15642 | 56 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Montelukast Mylan | AF | MP NP | C6666 | P6666 | 28 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Montelukast Mylan | AF | MP NP | C15642 | P15642 | 56 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Montelukast Sandoz 4 | SZ | MP NP | C6666 | P6666 | 28 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Montelukast Sandoz 4 | SZ | MP NP | C15642 | P15642 | 56 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Montelukast Viatris | AL | MP NP | C6666 | P6666 | 28 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 4 mg (as sodium) | Oral | Montelukast Viatris | AL | MP NP | C15642 | P15642 | 56 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | MONTELAIR 5 | RF | MP NP | C6674 C7781 | P6674 P7781 | 28 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | MONTELAIR 5 | RF | MP NP | C15643 C15644 | P15643 P15644 | 56 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Montelukast APOTEX | GX | MP NP | C6674 C7781 | P6674 P7781 | 28 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Montelukast APOTEX | GX | MP NP | C15643 C15644 | P15643 P15644 | 56 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Montelukast Lupin | HQ | MP NP | C6674 C7781 | P6674 P7781 | 28 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Montelukast Lupin | HQ | MP NP | C15643 C15644 | P15643 P15644 | 56 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Montelukast Mylan | AF | MP NP | C6674 C7781 | P6674 P7781 | 28 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Montelukast Mylan | AF | MP NP | C15643 C15644 | P15643 P15644 | 56 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Montelukast Sandoz 5 | SZ | MP NP | C6674 C7781 | P6674 P7781 | 28 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Montelukast Sandoz 5 | SZ | MP NP | C15643 C15644 | P15643 P15644 | 56 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Montelukast Viatris | AL | MP NP | C6674 C7781 | P6674 P7781 | 28 | 5 |
| 28 |
|
|
Montelukast | Tablet, chewable, 5 mg (as sodium) | Oral | Montelukast Viatris | AL | MP NP | C15643 C15644 | P15643 P15644 | 56 | 5 |
| 28 |
|
|
insert:
Moxonidine | Tablet 200 micrograms | Oral | MOXONIDINE-WGR | WG | MP NP | C4944 | P4944 | 30 | 5 |
| 30 |
|
|
Moxonidine | Tablet 200 micrograms | Oral | MOXONIDINE-WGR | WG | MP NP | C14289 | P14289 | 60 | 5 |
| 30 |
|
|
insert:
Moxonidine | Tablet 400 micrograms | Oral | MOXONIDINE-WGR | WG | MP NP | C4944 | P4944 | 30 | 5 |
| 30 |
|
|
Moxonidine | Tablet 400 micrograms | Oral | MOXONIDINE-WGR | WG | MP NP | C14289 | P14289 | 60 | 5 |
| 30 |
|
|
substitute:
Nitrazepam | Tablet 5 mg | Oral | Alodorm | AF | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Nitrazepam | Tablet 5 mg | Oral | Alodorm | AF | MP NP |
| P6175 | 50 | 3 |
| 25 |
|
|
Nitrazepam | Tablet 5 mg | Oral | Alodorm | AF | MP NP |
| P5661 P5771 P5941 P5950 | 50 | 5 |
| 25 |
|
|
Nitrazepam | Tablet 5 mg | Oral | Mogadon | IL | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Nitrazepam | Tablet 5 mg | Oral | Mogadon | IL | MP NP |
| P6175 | 50 | 3 |
| 25 |
|
|
Nitrazepam | Tablet 5 mg | Oral | Mogadon | IL | MP NP |
| P5661 P5771 P5941 P5950 | 50 | 5 |
| 25 |
|
|
substitute:
Nizatidine | Capsule 150 mg | Oral | Nizac | RF | MP NP |
|
| 60 | 5 |
| 60 |
|
|
Nizatidine | Capsule 150 mg | Oral | Nizac | RF | MP NP |
| P14238 | 120 | 5 |
| 60 |
|
|
Nizatidine | Capsule 150 mg | Oral | Tacidine | AF | MP NP |
|
| 60 | 5 |
| 60 |
|
|
Nizatidine | Capsule 150 mg | Oral | Tacidine | AF | MP NP |
| P14238 | 120 | 5 |
| 60 |
|
|
Nizatidine | Capsule 150 mg | Oral | Tazac | RW | MP NP |
|
| 60 | 5 |
| 60 |
|
|
Nizatidine | Capsule 150 mg | Oral | Tazac | RW | MP NP |
| P14238 | 120 | 5 |
| 60 |
|
|
Nizatidine | Capsule 300 mg | Oral | Nizac | RF | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Nizatidine | Capsule 300 mg | Oral | Nizac | RF | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Nizatidine | Capsule 300 mg | Oral | Tacidine | AF | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Nizatidine | Capsule 300 mg | Oral | Tacidine | AF | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Nizatidine | Capsule 300 mg | Oral | Tazac | RW | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Nizatidine | Capsule 300 mg | Oral | Tazac | RW | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
substitute:
Octreotide | Injection 500 micrograms (as acetate) in 1 mL | Injection | Octreotide Acetate Omega (Canada) | GQ | MP | C6369 C6390 C8165 C9232 C9233 C9289 |
| 90 | 11 |
| 5 |
| D(100) |
Octreotide | Injection 500 micrograms (as acetate) in 1 mL | Injection | Octreotide GH | HQ | MP | C6369 C6390 C8165 C9232 C9233 C9289 |
| 90 | 11 |
| 5 |
| D(100) |
Octreotide | Injection 500 micrograms (as acetate) in 1 mL | Injection | Octreotide (SUN) | RA | MP | C6369 C6390 C8165 C9232 C9233 C9289 |
| 90 | 11 |
| 5 |
| D(100) |
Octreotide | Injection 500 micrograms (as acetate) in 1 mL | Injection | Sandostatin 0.5 | NV | MP | C6369 C6390 C8165 C9232 C9233 C9289 |
| 90 | 11 |
| 5 |
| D(100) |
omit:
Olanzapine | Tablet 2.5 mg | Oral | NOUMED OLANZAPINE | VO | MP NP | C5856 C5869 |
| 28 | 5 |
| 28 |
|
|
omit:
Olanzapine | Tablet 5 mg | Oral | NOUMED OLANZAPINE | VO | MP NP | C5856 C5869 |
| 28 | 5 |
| 28 |
|
|
insert:
Olanzapine | Tablet 5 mg (orally disintegrating) | Oral | OLANZAPINE ODT-WGR | WG | MP NP | C5856 C5869 |
| 28 | 5 |
| 28 |
|
|
omit:
Olanzapine | Tablet 7.5 mg | Oral | NOUMED OLANZAPINE | VO | MP NP | C5856 C5869 |
| 28 | 5 |
| 28 |
|
|
omit:
Olanzapine | Tablet 10 mg | Oral | NOUMED OLANZAPINE | VO | MP NP | C5856 C5869 |
| 28 | 5 |
| 28 |
|
|
insert:
Olanzapine | Tablet 10 mg (orally disintegrating) | Oral | OLANZAPINE ODT-WGR | WG | MP NP | C5856 C5869 |
| 28 | 5 |
| 28 |
|
|
insert:
Olanzapine | Tablet 15 mg (orally disintegrating) | Oral | OLANZAPINE ODT-WGR | WG | MP NP | C5856 C5869 |
| 28 | 5 |
| 28 |
|
|
insert:
Olanzapine | Tablet 20 mg (orally disintegrating) | Oral | OLANZAPINE ODT-WGR | WG | MP NP | C5856 C5869 |
| 28 | 5 |
| 28 |
|
|
insert:
Olmesartan | Tablet containing olmesartan medoxomil 20 mg | Oral | OLMESARTAN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Olmesartan | Tablet containing olmesartan medoxomil 20 mg | Oral | OLMESARTAN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Olmesartan | Tablet containing olmesartan medoxomil 40 mg | Oral | OLMESARTAN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Olmesartan | Tablet containing olmesartan medoxomil 40 mg | Oral | OLMESARTAN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | Oral | APO-OLMESARTAN/AMLODIPINE 20/5 | TY | MP NP | C4373 | P4373 | 30 | 5 |
| 30 |
|
|
Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | Oral | APO-OLMESARTAN/AMLODIPINE 20/5 | TY | MP NP | C14257 | P14257 | 60 | 5 |
| 30 |
|
|
insert:
Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | Oral | OLMESARTAN AMLODIPINE-WGR 20/5 | WG | MP NP | C4373 | P4373 | 30 | 5 |
| 30 |
|
|
Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | Oral | OLMESARTAN AMLODIPINE-WGR 20/5 | WG | MP NP | C14257 | P14257 | 60 | 5 |
| 30 |
|
|
insert:
Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | OLMESARTAN AMLODIPINE-WGR 40/10 | WG | MP NP | C4373 | P4373 | 30 | 5 |
| 30 |
|
|
Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | OLMESARTAN AMLODIPINE-WGR 40/10 | WG | MP NP | C14839 | P14839 | 60 | 5 |
| 30 |
|
|
insert:
Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | OLMESARTAN AMLODIPINE-WGR 40/5 | WG | MP NP | C4373 | P4373 | 30 | 5 |
| 30 |
|
|
Olmesartan with amlodipine | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | OLMESARTAN AMLODIPINE-WGR 40/5 | WG | MP NP | C14839 | P14839 | 60 | 5 |
| 30 |
|
|
insert:
Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | OLMESARTAN HCTZ-WGR 20/12.5 | WG | MP NP | C4374 | P4374 | 30 | 5 |
| 30 |
|
|
Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | OLMESARTAN HCTZ-WGR 20/12.5 | WG | MP NP | C14255 | P14255 | 60 | 5 |
| 30 |
|
|
insert:
Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | OLMESARTAN HCTZ-WGR 40/12.5 | WG | MP NP | C4374 | P4374 | 30 | 5 |
| 30 |
|
|
Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | OLMESARTAN HCTZ-WGR 40/12.5 | WG | MP NP | C14255 | P14255 | 60 | 5 |
| 30 |
|
|
insert:
Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | OLMESARTAN HCTZ-WGR 40/25 | WG | MP NP | C4374 | P4374 | 30 | 5 |
| 30 |
|
|
Olmesartan with hydrochlorothiazide | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | OLMESARTAN HCTZ-WGR 40/25 | WG | MP NP | C14255 | P14255 | 60 | 5 |
| 30 |
|
|
substitute:
Omeprazole | Capsule 20 mg | Oral | APO-Omeprazole | TX | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | APO-Omeprazole | TX | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | APO-Omeprazole | TX | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | APO-Omeprazole | TX | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | APO-Omeprazole | TX | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Maxor | AF | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Maxor | AF | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Maxor | AF | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Maxor | AF | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Maxor | AF | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Omeprazole Sandoz | HX | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Omeprazole Sandoz | HX | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Omeprazole Sandoz | HX | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Omeprazole Sandoz | HX | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Omeprazole Sandoz | HX | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Pemzo | RW | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Pemzo | RW | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Pemzo | RW | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Pemzo | RW | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Pemzo | RW | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Pharmacor Omeprazole 20 | CR | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Pharmacor Omeprazole 20 | CR | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Pharmacor Omeprazole 20 | CR | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Pharmacor Omeprazole 20 | CR | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Pharmacor Omeprazole 20 | CR | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Probitor | SZ | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Probitor | SZ | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Probitor | SZ | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Probitor | SZ | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Capsule 20 mg | Oral | Probitor | SZ | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Omeprazole | Tablet 10 mg (as magnesium) | Oral | Losec Tablets | PB | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Omeprazole | Tablet 10 mg (as magnesium) | Oral | Losec Tablets | PB | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | APO-Omeprazole | TX | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | APO-Omeprazole | TX | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | APO-Omeprazole | TX | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | APO-Omeprazole | TX | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | APO-Omeprazole | TX | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | Maxor EC Tabs | AF | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | Maxor EC Tabs | AF | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | Maxor EC Tabs | AF | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | Maxor EC Tabs | AF | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | Maxor EC Tabs | AF | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | Ozmep | RW | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | Ozmep | RW | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | Ozmep | RW | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | Ozmep | RW | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg | Oral | Ozmep | RW | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Acimax Tablets | FJ | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Acimax Tablets | FJ | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Acimax Tablets | FJ | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Acimax Tablets | FJ | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Acimax Tablets | FJ | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | PB | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | PB | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | PB | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | PB | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | PB | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omepral | FQ | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omepral | FQ | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omepral | FQ | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omepral | FQ | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omepral | FQ | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omeprazole Sandoz | SZ | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omeprazole Sandoz | SZ | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omeprazole Sandoz | SZ | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omeprazole Sandoz | SZ | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Omeprazole | Tablet 20 mg (as magnesium) | Oral | Omeprazole Sandoz | SZ | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
insert:
Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | ONDANSETRON-WGR | WG | MP NP | C4118 | P4118 | 4 | 0 | V4118 | 4 |
|
|
Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | ONDANSETRON-WGR | WG | MP | C5778 | P5778 | 4 | 0 | V5778 | 4 |
| C(100) |
Ondansetron | Tablet 4 mg (as hydrochloride dihydrate) | Oral | ONDANSETRON-WGR | WG | MP NP | C15193 | P15193 | 10 | 1 |
| 10 |
|
|
insert:
Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | ONDANSETRON ODT-WGR | WG | MP NP | C5618 | P5618 | 4 | 0 | V5618 | 4 |
|
|
Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | ONDANSETRON ODT-WGR | WG | MP | C5743 | P5743 | 4 | 0 | V5743 | 4 |
| C(100) |
Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | ONDANSETRON ODT-WGR | WG | MP NP | C15193 | P15193 | 10 | 1 |
| 10 |
|
|
insert:
Ondansetron | Tablet 8 mg (as hydrochloride dihydrate) | Oral | ONDANSETRON-WGR | WG | MP NP | C4118 | P4118 | 4 | 0 | V4118 | 4 |
|
|
Ondansetron | Tablet 8 mg (as hydrochloride dihydrate) | Oral | ONDANSETRON-WGR | WG | MP | C5778 | P5778 | 4 | 0 | V5778 | 4 |
| C(100) |
Ondansetron | Tablet 8 mg (as hydrochloride dihydrate) | Oral | ONDANSETRON-WGR | WG | MP NP | C15193 | P15193 | 10 | 1 |
| 10 |
|
|
insert:
Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | ONDANSETRON ODT-WGR | WG | MP NP | C5618 | P5618 | 4 | 0 | V5618 | 4 |
|
|
Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | ONDANSETRON ODT-WGR | WG | MP | C5778 | P5778 | 4 | 0 | V5778 | 4 |
| C(100) |
Ondansetron | Tablet (orally disintegrating) 8 mg | Oral | ONDANSETRON ODT-WGR | WG | MP NP | C15193 | P15193 | 10 | 1 |
| 10 |
|
|
insert:
Oxazepam | Tablet 30 mg | Oral | OXAZEPAM-WGR | WG | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Oxazepam | Tablet 30 mg | Oral | OXAZEPAM-WGR | WG | MP NP |
| P6176 | 50 CN6176 | 3 CN6176 |
| 25 |
|
|
Oxazepam | Tablet 30 mg | Oral | OXAZEPAM-WGR | WG | MP NP |
| P6217 P6230 P6262 | 50 CN6217 CN6230 CN6262 | 5 CN6217 CN6230 CN6262 |
| 25 |
|
|
substitute:
Oxcarbazepine | Tablet 150 mg | Oral | Trileptal | NV | MP NP | C5183 | P5183 | 100 | 5 |
| 100 |
|
|
Oxcarbazepine | Tablet 150 mg | Oral | Trileptal | NV | MP NP | C14932 | P14932 | 200 | 5 |
| 100 |
|
|
omit from the column headed “Responsible Person” (all instances): YN substitute (all instances): SZ
substitute:
Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral | Somac | NQ | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral | Somac | NQ | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral | Somac | NQ | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral | Somac | NQ | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Sachet containing granules 40 mg (as sodium sesquihydrate) | Oral | Somac | NQ | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APO-Pantoprazole | TX | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APO-Pantoprazole | TX | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | BTC Pantoprazole | BG | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | BTC Pantoprazole | BG | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | NOUMED PANTOPRAZOLE | VO | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | NOUMED PANTOPRAZOLE | VO | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Ozpan | RA | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Ozpan | RA | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Panthron | ZS | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Panthron | ZS | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | TY | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | TY | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Pantoprazole generichealth | HQ | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Pantoprazole generichealth | HQ | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Pantoprazole Sandoz | SZ | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Pantoprazole Sandoz | SZ | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | PANTOPRAZOLE-WGR | WG | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | PANTOPRAZOLE-WGR | WG | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Salpraz | AF | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Salpraz | AF | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Somac | NQ | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Somac | NQ | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Sozol | RW | MP NP | C5444 C5512 C5529 | P5444 P5512 P5529 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | Sozol | RW | MP NP | C15574 C15575 C15633 | P15574 P15575 P15633 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | APO-Pantoprazole | TX | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | APO-Pantoprazole | TX | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | APO-Pantoprazole | TX | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | APO-Pantoprazole | TX | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | APO-Pantoprazole | TX | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | BTC Pantoprazole | BG | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | BTC Pantoprazole | BG | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | BTC Pantoprazole | BG | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | BTC Pantoprazole | BG | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | BTC Pantoprazole | BG | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | I-Pantoprazole | CR | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | I-Pantoprazole | CR | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | I-Pantoprazole | CR | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | I-Pantoprazole | CR | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | I-Pantoprazole | CR | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | NOUMED PANTOPRAZOLE | VO | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | NOUMED PANTOPRAZOLE | VO | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | NOUMED PANTOPRAZOLE | VO | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | NOUMED PANTOPRAZOLE | VO | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | NOUMED PANTOPRAZOLE | VO | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Ozpan | RA | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Ozpan | RA | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Ozpan | RA | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Ozpan | RA | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Ozpan | RA | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Panthron | ZS | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Panthron | ZS | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Panthron | ZS | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Panthron | ZS | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Panthron | ZS | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | TY | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | TY | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | TY | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | TY | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole APOTEX | TY | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole generichealth | HQ | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole generichealth | HQ | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole generichealth | HQ | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole generichealth | HQ | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole generichealth | HQ | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole Sandoz | SZ | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole Sandoz | SZ | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole Sandoz | SZ | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole Sandoz | SZ | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Pantoprazole Sandoz | SZ | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | PANTOPRAZOLE-WGR | WG | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | PANTOPRAZOLE-WGR | WG | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | PANTOPRAZOLE-WGR | WG | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | PANTOPRAZOLE-WGR | WG | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | PANTOPRAZOLE-WGR | WG | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Salpraz | AF | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Salpraz | AF | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Salpraz | AF | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Salpraz | AF | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Salpraz | AF | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Somac | NQ | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Somac | NQ | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Somac | NQ | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Somac | NQ | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Somac | NQ | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | RW | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | RW | MP NP | C8776 C8780 C8866 | P8776 P8780 P8866 | 30 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | RW | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | RW | MP NP | C15530 C15658 C15678 | P15530 P15658 P15678 | 60 | 5 |
| 30 |
|
|
Pantoprazole | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | Sozol | RW | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
substitute:
Paraffin | Eye drops containing liquid paraffin, glycerol, tyloxapol, poloxamer-188, trometamol hydrochloride, trometamol, cetalkonium chloride, 10 mL (preservative free) | Application to the eye | Cationorm | CS | MP NP AO | C6172 | P6172 | 1 | 5 |
| 1 |
|
|
Paraffin | Eye drops containing liquid paraffin, glycerol, tyloxapol, poloxamer-188, trometamol hydrochloride, trometamol, cetalkonium chloride, 10 mL (preservative free) | Application to the eye | Cationorm | CS | MP NP AO | C15559 | P15559 | 2 | 5 |
| 1 |
|
|
Paraffin | Eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Poly Visc | IQ | MP NP AO |
|
| 2 | 5 |
| 1 |
|
|
Paraffin | Eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Poly Visc | IQ | MP NP AO |
| P14238 | 4 | 5 |
| 1 |
|
|
Paraffin | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Poly Visc | IQ | MP NP AO |
|
| 1 | 5 |
| 1 |
|
|
Paraffin | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Poly Visc | IQ | MP NP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
Paraffin | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Refresh Night Time | VE | MP NP AO |
|
| 1 | 5 |
| 1 |
|
|
Paraffin | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Refresh Night Time | VE | MP NP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
substitute:
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | APO-Paroxetine | TX | MP NP | C4755 C6277 C6636 | P4755 P6277 P6636 | 30 | 5 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | APO-Paroxetine | TX | MP NP | C15582 C15666 C15722 | P15582 P15666 P15722 | 60 | 2 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | APX-Paroxetine | TY | MP NP | C4755 C6277 C6636 | P4755 P6277 P6636 | 30 | 5 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | APX-Paroxetine | TY | MP NP | C15582 C15666 C15722 | P15582 P15666 P15722 | 60 | 2 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Aropax | AS | MP NP | C4755 C6277 C6636 | P4755 P6277 P6636 | 30 | 5 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Aropax | AS | MP NP | C15582 C15666 C15722 | P15582 P15666 P15722 | 60 | 2 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Blooms The Chemist Paroxetine | BG | MP NP | C4755 C6277 C6636 | P4755 P6277 P6636 | 30 | 5 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Blooms The Chemist Paroxetine | BG | MP NP | C15582 C15666 C15722 | P15582 P15666 P15722 | 60 | 2 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Extine 20 | RW | MP NP | C4755 C6277 C6636 | P4755 P6277 P6636 | 30 | 5 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Extine 20 | RW | MP NP | C15582 C15666 C15722 | P15582 P15666 P15722 | 60 | 2 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Noumed Paroxetine | VO | MP NP | C4755 C6277 C6636 | P4755 P6277 P6636 | 30 | 5 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Noumed Paroxetine | VO | MP NP | C15582 C15666 C15722 | P15582 P15666 P15722 | 60 | 2 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Paroxetine GH | GQ | MP NP | C4755 C6277 C6636 | P4755 P6277 P6636 | 30 | 5 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Paroxetine GH | GQ | MP NP | C15582 C15666 C15722 | P15582 P15666 P15722 | 60 | 2 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Paroxetine Sandoz | SZ | MP NP | C4755 C6277 C6636 | P4755 P6277 P6636 | 30 | 5 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Paroxetine Sandoz | SZ | MP NP | C15582 C15666 C15722 | P15582 P15666 P15722 | 60 | 2 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | PAROXETINE-WGR | WG | MP NP | C4755 C6277 C6636 | P4755 P6277 P6636 | 30 | 5 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | PAROXETINE-WGR | WG | MP NP | C15582 C15666 C15722 | P15582 P15666 P15722 | 60 | 2 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Paxtine | AF | MP NP | C4755 C6277 C6636 | P4755 P6277 P6636 | 30 | 5 |
| 30 |
|
|
Paroxetine | Tablet 20 mg (as hydrochloride) | Oral | Paxtine | AF | MP NP | C15582 C15666 C15722 | P15582 P15666 P15722 | 60 | 2 |
| 30 |
|
|
substitute:
Perfluorohexyloctane | Eye drops, 3 mL | Application to the eye | Novatears | AE | MP NP AO | C6172 | P6172 | 1 | 5 |
| 1 |
|
|
Perfluorohexyloctane | Eye drops, 3 mL | Application to the eye | Novatears | AE | MP NP AO | C15559 | P15559 | 2 | 5 |
| 1 |
|
|
insert:
Perindopril | Tablet containing perindopril arginine 2.5 mg | Oral | Perindopril Arginine-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Perindopril | Tablet containing perindopril arginine 2.5 mg | Oral | Perindopril Arginine-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Perindopril | Tablet containing perindopril arginine 5 mg | Oral | Perindopril Arginine-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Perindopril | Tablet containing perindopril arginine 5 mg | Oral | Perindopril Arginine-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Perindopril | Tablet containing perindopril arginine 10 mg | Oral | Perindopril Arginine-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Perindopril | Tablet containing perindopril arginine 10 mg | Oral | Perindopril Arginine-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | BTC Perindopril | JB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | BTC Perindopril | JB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | PERINDOPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Perindopril | Tablet containing perindopril erbumine 2 mg | Oral | PERINDOPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | BTC Perindopril | JB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | BTC Perindopril | JB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | PERINDOPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Perindopril | Tablet containing perindopril erbumine 4 mg | Oral | PERINDOPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Perindopril | Tablet containing perindopril erbumine 8 mg | Oral | BTC Perindopril | JB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Perindopril | Tablet containing perindopril erbumine 8 mg | Oral | BTC Perindopril | JB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Perindopril | Tablet containing perindopril erbumine 8 mg | Oral | PERINDOPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Perindopril | Tablet containing perindopril erbumine 8 mg | Oral | PERINDOPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | PERINDOPRIL/INDAPAMIDE-WGR 4/1.25 | WG | MP NP | C4375 | P4375 | 30 | 5 |
| 30 |
|
|
Perindopril with indapamide | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | PERINDOPRIL/INDAPAMIDE-WGR 4/1.25 | WG | MP NP | C14267 | P14267 | 60 | 5 |
| 30 |
|
|
substitute:
Pilocarpine | Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL | Application to the eye | Isopto Carpine | NV | MP AO |
|
| 1 | 5 |
| 1 |
|
|
Pilocarpine | Eye drops containing pilocarpine hydrochloride 10 mg per mL, 15 mL | Application to the eye | Isopto Carpine | NV | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
Pilocarpine | Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL | Application to the eye | Isopto Carpine | NV | MP AO |
|
| 1 | 5 |
| 1 |
|
|
Pilocarpine | Eye drops containing pilocarpine hydrochloride 20 mg per mL, 15 mL | Application to the eye | Isopto Carpine | NV | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
Pilocarpine | Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL | Application to the eye | Isopto Carpine | NV | MP AO |
|
| 1 | 5 |
| 1 |
|
|
Pilocarpine | Eye drops containing pilocarpine hydrochloride 40 mg per mL, 15 mL | Application to the eye | Isopto Carpine | NV | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
insert:
Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | ARX-PIOGLITAZONE | XT | MP NP | C15321 | P15321 | 28 | 5 |
| 28 |
|
|
Pioglitazone | Tablet 15 mg (as hydrochloride) | Oral | ARX-PIOGLITAZONE | XT | MP NP | C15290 | P15290 | 56 | 5 |
| 28 |
|
|
substitute:
Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg-3 mg per mL, 15 mL | Application to the eye | Optix | PP | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg-3 mg per mL, 15 mL | Application to the eye | Optix | PP | MP NP AO | C15556 | P15556 | 2 | 5 |
| 1 |
|
|
Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg-3 mg per mL, 15 mL | Application to the eye | Systane | AQ | MP NP AO | C15560 | P15560 | 1 | 5 |
| 1 |
|
|
Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg-3 mg per mL, 15 mL | Application to the eye | Systane | AQ | MP NP AO | C15556 | P15556 | 2 | 5 |
| 1 |
|
|
Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg-3 mg per mL, single dose units 0.8 mL, 30 | Application to the eye | Systane | AQ | MP NP AO | C6172 | P6172 | 2 | 5 |
| 1 |
|
|
Polyethylene glycol 400 with propylene glycol | Eye drops 4 mg-3 mg per mL, single dose units 0.8 mL, 30 | Application to the eye | Systane | AQ | MP NP AO | C15559 | P15559 | 4 | 5 |
| 1 |
|
|
insert:
Posaconazole | Tablet (modified release) 100 mg | Oral | POSACONAZOLE-WGR | WG | MP NP | C5169 C5395 C5396 |
| 24 | 0 |
| 24 |
|
|
substitute:
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 375 micrograms | Oral | APO-Pramipexole ER | TX | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 375 micrograms | Oral | APO-Pramipexole ER | TX | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 375 micrograms | Oral | Sifrol ER | BY | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 375 micrograms | Oral | Sifrol ER | BY | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 375 micrograms | Oral | SIMIPEX XR | RW | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 375 micrograms | Oral | SIMIPEX XR | RW | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 750 micrograms | Oral | APO-Pramipexole ER | TX | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 750 micrograms | Oral | APO-Pramipexole ER | TX | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 750 micrograms | Oral | Sifrol ER | BY | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 750 micrograms | Oral | Sifrol ER | BY | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 750 micrograms | Oral | SIMIPEX XR | RW | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 750 micrograms | Oral | SIMIPEX XR | RW | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg | Oral | APO-Pramipexole ER | TX | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg | Oral | APO-Pramipexole ER | TX | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg | Oral | Sifrol ER | BY | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg | Oral | Sifrol ER | BY | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg | Oral | SIMIPEX XR | RW | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg | Oral | SIMIPEX XR | RW | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 2.25 mg | Oral | APO-Pramipexole ER | TX | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 2.25 mg | Oral | APO-Pramipexole ER | TX | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 2.25 mg | Oral | Sifrol ER | BY | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 2.25 mg | Oral | Sifrol ER | BY | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 2.25 mg | Oral | SIMIPEX XR | RW | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 2.25 mg | Oral | SIMIPEX XR | RW | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg | Oral | APO-Pramipexole ER | TX | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg | Oral | APO-Pramipexole ER | TX | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg | Oral | Sifrol ER | BY | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg | Oral | Sifrol ER | BY | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg | Oral | SIMIPEX XR | RW | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg | Oral | SIMIPEX XR | RW | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg | Oral | APO-Pramipexole ER | TX | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg | Oral | APO-Pramipexole ER | TX | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg | Oral | Sifrol ER | BY | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg | Oral | Sifrol ER | BY | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg | Oral | SIMIPEX XR | RW | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg | Oral | SIMIPEX XR | RW | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg | Oral | APO-Pramipexole ER | TX | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg | Oral | APO-Pramipexole ER | TX | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg | Oral | Sifrol ER | BY | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg | Oral | Sifrol ER | BY | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg | Oral | SIMIPEX XR | RW | MP NP | C5131 | P5131 | 30 | 5 |
| 30 |
|
|
Pramipexole | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg | Oral | SIMIPEX XR | RW | MP NP | C15568 | P15568 | 60 | 5 |
| 30 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 125 micrograms | Oral | APO-Pramipexole | TX | MP NP | C5363 | P5363 | 30 | 0 |
| 30 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 125 micrograms | Oral | APO-Pramipexole | TX | MP NP | C5411 | P5411 | 30 | 2 |
| 30 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 125 micrograms | Oral | Sifrol | BY | MP NP | C5363 | P5363 | 30 | 0 |
| 30 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 125 micrograms | Oral | Sifrol | BY | MP NP | C5411 | P5411 | 30 | 2 |
| 30 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 125 micrograms | Oral | Simipex 0.125 | RW | MP NP | C5363 | P5363 | 30 | 0 |
| 30 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 125 micrograms | Oral | Simipex 0.125 | RW | MP NP | C5411 | P5411 | 30 | 2 |
| 30 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 125 micrograms | Oral | Simpral | AF | MP NP | C5363 | P5363 | 30 | 0 |
| 30 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 125 micrograms | Oral | Simpral | AF | MP NP | C5411 | P5411 | 30 | 2 |
| 30 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | APO-Pramipexole | TX | MP NP | C5411 | P5411 | 100 | 2 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | APO-Pramipexole | TX | MP NP | C5363 | P5363 | 100 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | APO-Pramipexole | TX | MP NP | C15570 | P15570 | 200 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | Sifrol | BY | MP NP | C5411 | P5411 | 100 | 2 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | Sifrol | BY | MP NP | C5363 | P5363 | 100 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | Sifrol | BY | MP NP | C15570 | P15570 | 200 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | Simipex 0.25 | RW | MP NP | C5411 | P5411 | 100 | 2 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | Simipex 0.25 | RW | MP NP | C5363 | P5363 | 100 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | Simipex 0.25 | RW | MP NP | C15570 | P15570 | 200 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | Simpral | AF | MP NP | C5411 | P5411 | 100 | 2 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | Simpral | AF | MP NP | C5363 | P5363 | 100 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | Simpral | AF | MP NP | C15570 | P15570 | 200 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 1 mg | Oral | APO-Pramipexole | TX | MP NP | C5363 | P5363 | 100 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 1 mg | Oral | APO-Pramipexole | TX | MP NP | C15570 | P15570 | 200 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 1 mg | Oral | Sifrol | BY | MP NP | C5363 | P5363 | 100 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 1 mg | Oral | Sifrol | BY | MP NP | C15570 | P15570 | 200 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 1 mg | Oral | Simipex 1 | RW | MP NP | C5363 | P5363 | 100 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 1 mg | Oral | Simipex 1 | RW | MP NP | C15570 | P15570 | 200 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 1 mg | Oral | Simpral | AF | MP NP | C5363 | P5363 | 100 | 5 |
| 100 |
|
|
Pramipexole | Tablet containing pramipexole dihydrochloride monohydrate 1 mg | Oral | Simpral | AF | MP NP | C15570 | P15570 | 200 | 5 |
| 100 |
|
|
insert:
Pravastatin | Tablet containing pravastatin sodium 10 mg | Oral | PRAVASTATIN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Pravastatin | Tablet containing pravastatin sodium 10 mg | Oral | PRAVASTATIN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Pravastatin | Tablet containing pravastatin sodium 20 mg | Oral | PRAVASTATIN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Pravastatin | Tablet containing pravastatin sodium 20 mg | Oral | PRAVASTATIN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Pravastatin | Tablet containing pravastatin sodium 40 mg | Oral | PRAVASTATIN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Pravastatin | Tablet containing pravastatin sodium 40 mg | Oral | PRAVASTATIN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
substitute:
Pregabalin | Capsule 25 mg | Oral | APO-Pregabalin | TX | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 25 mg | Oral | Blooms The Chemist Pregabalin | IB | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 25 mg | Oral | BTC Pregabalin | BG | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 25 mg | Oral | Lyrica | UJ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 25 mg | Oral | Lyzalon | AF | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 25 mg | Oral | Neuroccord | CR | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 25 mg | Oral | NOUMED PREGABALIN | VO | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 25 mg | Oral | Prebalin | RF | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 25 mg | Oral | PREGABALIN-DRLA | RZ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 25 mg | Oral | Pregabalin Lupin | HQ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 25 mg | Oral | Pregabalin Sandoz | SZ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 25 mg | Oral | PREGABALIN-WGR | WG | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 75 mg | Oral | APO-Pregabalin | TX | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 75 mg | Oral | BTC Pregabalin | BG | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 75 mg | Oral | Lyrica | UJ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 75 mg | Oral | Lyzalon | AF | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 75 mg | Oral | Neuroccord | CR | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 75 mg | Oral | NOUMED PREGABALIN | VO | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 75 mg | Oral | Prebalin | RF | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 75 mg | Oral | PREGABALIN-DRLA | RZ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 75 mg | Oral | Pregabalin Lupin | HQ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 75 mg | Oral | Pregabalin Sandoz | SZ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 75 mg | Oral | PREGABALIN-WGR | WG | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | APO-Pregabalin | TX | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | Blooms The Chemist Pregabalin | IB | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | BTC Pregabalin | BG | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | Cipla Pregabalin | LR | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | Lyrica | UJ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | Lyzalon | AF | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | Neuroccord | CR | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | NOUMED PREGABALIN | VO | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | Prebalin | RF | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | PREGABALIN-DRLA | RZ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | Pregabalin Lupin | HQ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | Pregabalin Sandoz | SZ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 150 mg | Oral | PREGABALIN-WGR | WG | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 300 mg | Oral | APO-Pregabalin | TX | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 300 mg | Oral | Blooms The Chemist Pregabalin | IB | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 300 mg | Oral | BTC Pregabalin | BG | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 300 mg | Oral | Lyrica | UJ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 300 mg | Oral | Lyzalon | AF | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 300 mg | Oral | Neuroccord | CR | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 300 mg | Oral | NOUMED PREGABALIN | VO | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 300 mg | Oral | Prebalin | RF | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 300 mg | Oral | PREGABALIN-DRLA | RZ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 300 mg | Oral | Pregabalin Lupin | HQ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 300 mg | Oral | Pregabalin Sandoz | SZ | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
Pregabalin | Capsule 300 mg | Oral | PREGABALIN-WGR | WG | MP NP | C4172 |
| 56 | 5 |
| 56 |
|
|
substitute:
Prochlorperazine | Injection containing prochlorperazine mesilate 12.5 mg in 1 mL | Injection | Stemetil | SW | MP NP PDP |
|
| 10 | 0 |
| 10 |
|
|
Prochlorperazine | Tablet containing prochlorperazine maleate 5 mg | Oral | APO-Prochlorperazine | TX | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Prochlorperazine | Tablet containing prochlorperazine maleate 5 mg | Oral | ProCalm | RW | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Prochlorperazine | Tablet containing prochlorperazine maleate 5 mg | Oral | Prochlorperazine GH | GQ | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Prochlorperazine | Tablet containing prochlorperazine maleate 5 mg | Oral | PROCHLORPERAZINE-WGR | WG | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Prochlorperazine | Tablet containing prochlorperazine maleate 5 mg | Oral | Stemetil | SW | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Prochlorperazine | Tablet containing prochlorperazine maleate 5 mg (S19A) | Oral | Stemetil (Ireland) | OJ | MP NP PDP |
|
| 25 | 0 |
| 250 |
|
|
insert:
Propranolol | Tablet containing propranolol hydrochloride 10 mg | Oral | PROPRANOLOL-WGR | WG | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Propranolol | Tablet containing propranolol hydrochloride 10 mg | Oral | PROPRANOLOL-WGR | WG | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
insert:
Propranolol | Tablet containing propranolol hydrochloride 40 mg | Oral | PROPRANOLOL-WGR | WG | MP NP |
|
| 100 | 5 |
| 100 |
|
|
Propranolol | Tablet containing propranolol hydrochloride 40 mg | Oral | PROPRANOLOL-WGR | WG | MP NP |
| P14238 | 200 | 5 |
| 100 |
|
|
insert:
Pyridostigmine | Tablet containing pyridostigmine bromide 10 mg | Oral | Mestinon | IL | MP |
| P14238 | 200 | 5 |
| 50 |
|
|
insert:
Pyridostigmine | Tablet containing pyridostigmine bromide 60 mg | Oral | Mestinon | IL | MP |
| P14238 | 300 | 5 |
| 150 |
|
|
insert:
Pyridostigmine | Tablet containing pyridostigmine bromide 180 mg (modified release) | Oral | Mestinon Timespan | IL | MP |
| P14238 | 200 | 5 |
| 50 |
|
|
substitute:
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | APO-Rabeprazole | TX | MP NP | C5444 C5512 | P5444 P5512 | 28 | 5 |
| 28 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | APO-Rabeprazole | TX | MP NP | C15574 C15633 | P15574 P15633 | 56 | 5 |
| 28 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Parbezol | RW | MP NP | C5444 C5512 | P5444 P5512 | 28 | 5 |
| 28 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Parbezol | RW | MP NP | C15574 C15633 | P15574 P15633 | 56 | 5 |
| 28 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Pariet | JC | MP NP | C5444 C5512 | P5444 P5512 | 28 | 5 |
| 28 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Pariet | JC | MP NP | C15574 C15633 | P15574 P15633 | 56 | 5 |
| 28 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Rabeprazole Sandoz | SZ | MP NP | C5444 C5512 | P5444 P5512 | 28 | 5 |
| 28 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Rabeprazole Sandoz | SZ | MP NP | C15574 C15633 | P15574 P15633 | 56 | 5 |
| 28 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | RABEPRAZOLE-WGR | WG | MP NP | C5444 C5512 | P5444 P5512 | 28 | 5 |
| 28 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | RABEPRAZOLE-WGR | WG | MP NP | C15574 C15633 | P15574 P15633 | 56 | 5 |
| 28 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | APO-Rabeprazole | TX | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | APO-Rabeprazole | TX | MP NP | C8776 C8780 | P8776 P8780 | 30 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | APO-Rabeprazole | TX | MP NP | C15530 C15658 | P15530 P15658 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | APO-Rabeprazole | TX | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | APO-Rabeprazole | TX | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Noumed Rabeprazole | VO | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Noumed Rabeprazole | VO | MP NP | C8776 C8780 | P8776 P8780 | 30 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Noumed Rabeprazole | VO | MP NP | C15530 C15658 | P15530 P15658 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Noumed Rabeprazole | VO | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Noumed Rabeprazole | VO | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Parbezol | RW | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Parbezol | RW | MP NP | C8776 C8780 | P8776 P8780 | 30 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Parbezol | RW | MP NP | C15530 C15658 | P15530 P15658 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Parbezol | RW | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Parbezol | RW | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Pariet | JC | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Pariet | JC | MP NP | C8776 C8780 | P8776 P8780 | 30 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Pariet | JC | MP NP | C15530 C15658 | P15530 P15658 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Pariet | JC | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Pariet | JC | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole Mylan | AF | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole Mylan | AF | MP NP | C8776 C8780 | P8776 P8780 | 30 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole Mylan | AF | MP NP | C15530 C15658 | P15530 P15658 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole Mylan | AF | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole Mylan | AF | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole Sandoz | SZ | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole Sandoz | SZ | MP NP | C8776 C8780 | P8776 P8780 | 30 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole Sandoz | SZ | MP NP | C15530 C15658 | P15530 P15658 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole Sandoz | SZ | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole Sandoz | SZ | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole SUN | RN | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole SUN | RN | MP NP | C8776 C8780 | P8776 P8780 | 30 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole SUN | RN | MP NP | C15530 C15658 | P15530 P15658 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole SUN | RN | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Rabeprazole SUN | RN | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | RABEPRAZOLE-WGR | WG | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | RABEPRAZOLE-WGR | WG | MP NP | C8776 C8780 | P8776 P8780 | 30 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | RABEPRAZOLE-WGR | WG | MP NP | C15530 C15658 | P15530 P15658 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | RABEPRAZOLE-WGR | WG | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | RABEPRAZOLE-WGR | WG | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Zabep | AL | MP NP | C8774 C8775 | P8774 P8775 | 30 | 1 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Zabep | AL | MP NP | C8776 C8780 | P8776 P8780 | 30 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Zabep | AL | MP NP | C15530 C15658 | P15530 P15658 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Zabep | AL | MP | C11310 | P11310 | 60 | 5 |
| 30 |
|
|
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Zabep | AL | MP | C15531 | P15531 | 120 | 5 |
| 30 |
|
|
insert:
Ramipril | Capsule 10 mg | Oral | RAMIPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Ramipril | Capsule 10 mg | Oral | RAMIPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Ramipril | Tablet 1.25 mg | Oral | RAMIPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Ramipril | Tablet 1.25 mg | Oral | RAMIPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Ramipril | Tablet 2.5 mg | Oral | RAMIPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Ramipril | Tablet 2.5 mg | Oral | RAMIPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Ramipril | Tablet 5 mg | Oral | Ramipril Viatris | AL | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Ramipril | Tablet 5 mg | Oral | Ramipril Viatris | AL | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
Ramipril | Tablet 5 mg | Oral | RAMIPRIL-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Ramipril | Tablet 5 mg | Oral | RAMIPRIL-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Ramipril | Tablet 10 mg | Oral | RAMIPRIL TABS-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Ramipril | Tablet 10 mg | Oral | RAMIPRIL TABS-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
substitute:
Rasagiline | Tablet 1 mg (as mesilate) | Oral | Alziras | RW | MP NP | C5339 | P5339 | 30 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | Alziras | RW | MP NP | C15648 | P15648 | 60 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | Azilect | TB | MP NP | C5339 | P5339 | 30 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | Azilect | TB | MP NP | C15648 | P15648 | 60 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | Pharmacor Rasagiline | CR | MP NP | C5339 | P5339 | 30 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | Pharmacor Rasagiline | CR | MP NP | C15648 | P15648 | 60 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | Rasagiline Lupin | HQ | MP NP | C5339 | P5339 | 30 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | Rasagiline Lupin | HQ | MP NP | C15648 | P15648 | 60 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | Rasagiline Sandoz | SZ | MP NP | C5339 | P5339 | 30 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | Rasagiline Sandoz | SZ | MP NP | C15648 | P15648 | 60 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | Rasagiline-Teva | EV | MP NP | C5339 | P5339 | 30 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | Rasagiline-Teva | EV | MP NP | C15648 | P15648 | 60 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | RASAGILINE-WGR | WG | MP NP | C5339 | P5339 | 30 | 5 |
| 30 |
|
|
Rasagiline | Tablet 1 mg (as mesilate) | Oral | RASAGILINE-WGR | WG | MP NP | C15648 | P15648 | 60 | 5 |
| 30 |
|
|
substitute:
Ravulizumab | Solution concentrate for I.V. infusion 1,100 mg in 11 mL | Injection | Ultomiris | XI | MP | See Note 3 | See Note 3 | See Note 3 | See Note 3 |
| 1 |
| D(100) |
Ravulizumab | Solution concentrate for I.V. infusion 300 mg in 3 mL | Injection | Ultomiris | XI | MP | See Note 3 | See Note 3 | See Note 3 | See Note 3 |
| 1 |
| D(100) |
substitute:
Reboxetine | Tablet 4 mg (as mesilate) | Oral | Edronax | PF | MP NP | C5650 | C5650 | 60 | 5 |
| 60 |
|
|
Reboxetine | Tablet 4 mg (as mesilate) | Oral | Edronax | PF | MP NP | C15553 | P15553 | 120 | 2 |
| 60 |
|
|
substitute:
Rifabutin | Capsule 150 mg | Oral | Mycobutin | PF | MP NP | C6350 C6356 C9560 C9622 |
| 120 | 5 |
| 30 |
| D(100) |
substitute:
Riluzole | Oral suspension 50 mg per 10 mL, 300 mL | Oral | Teglutik | CS | MP NP | C5341 C8738 | C5341 C8738 | 2 | 5 |
| 1 |
|
|
Riluzole | Oral suspension 50 mg per 10 mL, 300 mL | Oral | Teglutik | CS | MP NP | C15719 | P15719 | 4 | 5 |
| 1 |
|
|
Riluzole | Tablet 50 mg | Oral | APO-Riluzole | TX | MP NP | C5341 C8738 | C5341 C8738 | 56 | 5 |
| 56 |
|
|
Riluzole | Tablet 50 mg | Oral | APO-Riluzole | TX | MP NP | C15719 | P15719 | 112 | 5 |
| 56 |
|
|
Riluzole | Tablet 50 mg | Oral | Pharmacor Riluzole | CR | MP NP | C5341 C8738 | C5341 C8738 | 56 | 5 |
| 56 |
|
|
Riluzole | Tablet 50 mg | Oral | Pharmacor Riluzole | CR | MP NP | C15719 | P15719 | 112 | 5 |
| 56 |
|
|
Riluzole | Tablet 50 mg | Oral | Rilutek | SW | MP NP | C5341 C8738 | C5341 C8738 | 56 | 5 |
| 56 |
|
|
Riluzole | Tablet 50 mg | Oral | Rilutek | SW | MP NP | C15719 | P15719 | 112 | 5 |
| 56 |
|
|
Riluzole | Tablet 50 mg | Oral | Riluzole Sandoz | SZ | MP NP | C5341 C8738 | C5341 C8738 | 56 | 5 |
| 56 |
|
|
Riluzole | Tablet 50 mg | Oral | Riluzole Sandoz | SZ | MP NP | C15719 | P15719 | 112 | 5 |
| 56 |
|
|
substitute:
Risdiplam | Powder for oral solution 750 micrograms per mL, 80 mL | Oral | Evrysdi | RO | MP | See Note 3 | See Note 3 | See Note 3 | See Note 3 |
| 1 |
| D(100) |
insert:
Risedronic acid | Tablet containing risedronate sodium 35 mg | Oral | RISEDRONATE-WGR | WG | MP NP | C6310 C6323 C6327 | P6310 P6323 P6327 | 4 | 5 |
| 4 |
|
|
Risedronic acid | Tablet containing risedronate sodium 35 mg | Oral | RISEDRONATE-WGR | WG | MP NP | C14234 C14235 C14263 | P14234 P14235 P14263 | 8 | 5 |
| 4 |
|
|
insert:
Risperidone | Oral solution 1 mg per mL, 100 mL | Oral | Risperidone Lupin | GQ | MP NP | C6898 C6899 C10020 C10021 | P6898 P6899 P10020 P10021 | 1 | 2 |
| 1 |
|
|
Risperidone | Oral solution 1 mg per mL, 100 mL | Oral | Risperidone Lupin | GQ | MP NP | C4246 C5907 | P4246 P5907 | 1 | 5 |
| 1 |
|
|
substitute:
Rituximab | Solution for I.V. infusion 100 mg in 10 mL | Injection | Riximyo | SZ | MP |
|
| 6 | 0 |
| 2 |
| D(100) |
Rituximab | Solution for I.V. infusion 100 mg in 10 mL | Injection | Riximyo | SZ | MP |
|
| See Note 3 | See Note 3 |
| 2 |
| D(100) |
Rituximab | Solution for I.V. infusion 100 mg in 10 mL | Injection | Ruxience | PF | MP |
|
| 6 | 0 |
| 1 |
| D(100) |
Rituximab | Solution for I.V. infusion 100 mg in 10 mL | Injection | Ruxience | PF | MP |
|
| See Note 3 | See Note 3 |
| 1 |
| D(100) |
Rituximab | Solution for I.V. infusion 100 mg in 10 mL | Injection | Truxima | EW | MP |
|
| 6 | 0 |
| 2 |
| D(100) |
Rituximab | Solution for I.V. infusion 100 mg in 10 mL | Injection | Truxima | EW | MP |
|
| See Note 3 | See Note 3 |
| 2 |
| D(100) |
Rituximab | Solution for I.V. infusion 500 mg in 50 mL | Injection | Riximyo | SZ | MP |
|
| 2 | 1 |
| 1 |
| D(100) |
Rituximab | Solution for I.V. infusion 500 mg in 50 mL | Injection | Riximyo | SZ | MP |
|
| See Note 3 | See Note 3 |
| 1 |
| D(100) |
Rituximab | Solution for I.V. infusion 500 mg in 50 mL | Injection | Ruxience | PF | MP |
|
| 2 | 1 |
| 1 |
| D(100) |
Rituximab | Solution for I.V. infusion 500 mg in 50 mL | Injection | Ruxience | PF | MP |
|
| See Note 3 | See Note 3 |
| 1 |
| D(100) |
Rituximab | Solution for I.V. infusion 500 mg in 50 mL | Injection | Truxima | EW | MP |
|
| 2 | 1 |
| 1 |
| D(100) |
Rituximab | Solution for I.V. infusion 500 mg in 50 mL | Injection | Truxima | EW | MP |
|
| See Note 3 | See Note 3 |
| 1 |
| D(100) |
insert:
Rizatriptan | Tablet (orally disintegrating) 10 mg (as benzoate) | Oral | RIZATRIPTAN ODT-WGR | WG | MP NP | C5708 |
| 4 | 5 |
| 2 |
|
|
insert:
Rosuvastatin | Tablet 5 mg (as calcium) | Oral | APO-ROSUVASTATIN | TX | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Rosuvastatin | Tablet 5 mg (as calcium) | Oral | APO-ROSUVASTATIN | TX | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Rosuvastatin | Tablet 5 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | IB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Rosuvastatin | Tablet 5 mg (as calcium) | Oral | ROSUVASTATIN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Rosuvastatin | Tablet 5 mg (as calcium) | Oral | ROSUVASTATIN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Rosuvastatin | Tablet 10 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Rosuvastatin | Tablet 10 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | IB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Rosuvastatin | Tablet 10 mg (as calcium) | Oral | ROSUVASTATIN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Rosuvastatin | Tablet 10 mg (as calcium) | Oral | ROSUVASTATIN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Rosuvastatin | Tablet 20 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Rosuvastatin | Tablet 20 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | IB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Rosuvastatin | Tablet 20 mg (as calcium) | Oral | ROSUVASTATIN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Rosuvastatin | Tablet 20 mg (as calcium) | Oral | ROSUVASTATIN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
omit:
Rosuvastatin | Tablet 40 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | IB | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Rosuvastatin | Tablet 40 mg (as calcium) | Oral | Blooms the Chemist Rosuvastatin | IB | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
insert:
Rosuvastatin | Tablet 40 mg (as calcium) | Oral | ROSUVASTATIN-WGR | WG | MP NP |
|
| 30 | 5 |
| 30 |
|
|
Rosuvastatin | Tablet 40 mg (as calcium) | Oral | ROSUVASTATIN-WGR | WG | MP NP |
| P14238 | 60 | 5 |
| 30 |
|
|
substitute:
Rotigotine | Transdermal patch 4.5 mg | Transdermal | Neupro | UC | MP | C4190 | P4190 | 28 | 5 |
| 28 |
|
|
Rotigotine | Transdermal patch 4.5 mg | Transdermal | Neupro | UC | MP | C15675 | P15675 | 56 | 5 |
| 28 |
|
|
Rotigotine | Transdermal patch 9 mg | Transdermal | Neupro | UC | MP | C4204 | P4204 | 28 | 5 |
| 28 |
|
|
Rotigotine | Transdermal patch 9 mg | Transdermal | Neupro | UC | MP | C15649 | P15649 | 56 | 5 |
| 28 |
|
|
Rotigotine | Transdermal patch 13.5 mg | Transdermal | Neupro | UC | MP | C4204 | P4204 | 28 | 5 |
| 28 |
|
|
Rotigotine | Transdermal patch 13.5 mg | Transdermal | Neupro | UC | MP | C15649 | P15649 | 56 | 5 |
| 28 |
|
|
Rotigotine | Transdermal patch 18 mg | Transdermal | Neupro | UC | MP | C4204 | P4204 | 28 | 5 |
| 28 |
|
|
Rotigotine | Transdermal patch 18 mg | Transdermal | Neupro | UC | MP | C15649 | P15649 | 56 | 5 |
| 28 |
|
|
insert:
Roxithromycin | Tablet 150 mg | Oral | ROXITHROMYCIN-WGR | WG | MP NP PDP |
|
| 10 | 0 |
| 10 |
|
|
Roxithromycin | Tablet 150 mg | Oral | ROXITHROMYCIN-WGR | WG | MP NP |
| P10404 | 20 CN10404 | 0 CN10404 |
| 10 |
|
|
insert:
Roxithromycin | Tablet 300 mg | Oral | ROXITHROMYCIN-WGR | WG | MP NP PDP |
|
| 5 | 0 |
| 5 |
|
|
Roxithromycin | Tablet 300 mg | Oral | ROXITHROMYCIN-WGR | WG | MP NP |
| P10404 | 10 CN10404 | 0 CN10404 |
| 5 |
|
|
substitute:
Sacituzumab govitecan | Powder for injection 180 mg | Injection | Trodelvy | GI | MP | C12656 |
| See Note 3 | See Note 3 |
| 1 |
| D(100) |
Sacituzumab govitecan | Powder for injection 180 mg | Injection | Trodelvy | GI | MP | C12669 |
| See Note 3 | See Note 3 |
| 1 |
| D(100) |
substitute:
Safinamide | Tablet 50 mg | Oral | Xadago | CS | MP NP | C8624 | P8624 | 30 | 5 |
| 30 |
|
|
Safinamide | Tablet 50 mg | Oral | Xadago | CS | MP NP | C15699 | P15699 | 60 | 5 |
| 30 |
|
|
Safinamide | Tablet 100 mg | Oral | Xadago | CS | MP NP | C8624 | P8624 | 30 | 5 |
| 30 |
|
|
Safinamide | Tablet 100 mg | Oral | Xadago | CS | MP NP | C15699 | P15699 | 60 | 5 |
| 30 |
|
|
substitute:
Salmeterol | Powder for oral inhalation in breath actuated device 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Serevent Accuhaler | GK | MP NP | C6355 | P6355 | 1 | 5 |
| 1 |
|
|
Salmeterol | Powder for oral inhalation in breath actuated device 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Serevent Accuhaler | GK | MP NP | C15607 | P15607 | 2 | 5 |
| 1 |
|
|
substitute:
Secukinumab | Injection 150 mg in 1 mL pre-filled pen | Injection | Cosentyx | NV | MP | C15799 C15806 C15807 C15810 | P15799 P15806 P15807 P15810 | 2 | 3 |
| 2 |
|
|
substitute:
Secukinumab | Injection 150 mg in 1 mL pre-filled pen | Injection | Cosentyx | NV | MP | C6696 C8830 C8892 C9063 C9105 C15767 C15779 | P6696 P8830 P8892 P9063 P9105 P15767 P15779 | 2 | 5 |
| 2 |
|
|
substitute:
Secukinumab | Injection 150 mg in 1 mL pre-filled pen | Injection | Cosentyx | NV | MP | C9069 C9078 C9155 C11089 C11096 C11138 C11154 C14430 C14462 C15280 C15296 C15307 C15768 C15805 C15812 | P9069 P9078 P9155 P11089 P11096 P11138 P11154 P14430 P14462 P15280 P15296 P15307 P15768 P15805 P15812 | 8 | 0 |
| 2 |
|
|
substitute:
Selegiline | Tablet containing selegiline hydrochloride 5 mg | Oral | Eldepryl | OX | MP NP | C5338 | P5338 | 100 | 5 |
| 100 |
|
|
Selegiline | Tablet containing selegiline hydrochloride 5 mg | Oral | Eldepryl | OX | MP NP | C15700 | P15700 | 200 | 5 |
| 100 |
|
|
substitute:
Selexipag | Tablet 800 micrograms | Oral | Uptravi | JC | MP | See Note 3 | See Note 3 | See Note 3 | See Note 3 |
| 60 |
| D(100) |
substitute:
Selinexor | Tablet 20 mg | Oral | Xpovio | TG | MP | C14021 C14045 | P14021 P14045 | 16 | 2 |
| 16 |
| D(100) |
Selinexor | Tablet 20 mg | Oral | Xpovio | TG | MP | C14023 C14024 | P14023 P14024 | 20 | 2 |
| 20 |
| D(100) |
Selinexor | Tablet 20 mg | Oral | Xpovio | TG | MP | C14031 C14039 | P14031 P14039 | 32 | 2 |
| 32 |
| D(100) |
substitute:
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | APO-Sertraline | TX | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | APO-Sertraline | TX | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Blooms The Chemist Sertraline | BG | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Blooms The Chemist Sertraline | BG | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Eleva 50 | AF | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Eleva 50 | AF | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | NOUMED SERTRALINE | VO | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | NOUMED SERTRALINE | VO | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Sertra 50 | RW | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Sertra 50 | RW | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Sertraline generichealth | GQ | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Sertraline generichealth | GQ | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Sertraline Sandoz | SZ | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Sertraline Sandoz | SZ | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | SERTRALINE-WGR | WG | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | SERTRALINE-WGR | WG | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Setrona | RA | MP NP | C4755 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Setrona | RA | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Zoloft | UJ | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 50 mg (as hydrochloride) | Oral | Zoloft | UJ | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | APO-Sertraline | TX | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | APO-Sertraline | TX | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Blooms The Chemist Sertraline | BG | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Blooms The Chemist Sertraline | BG | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Eleva 100 | AF | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Eleva 100 | AF | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | NOUMED SERTRALINE | VO | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | NOUMED SERTRALINE | VO | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Sertra 100 | RW | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Sertra 100 | RW | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Sertraline generichealth | GQ | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Sertraline generichealth | GQ | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Sertraline Sandoz | SZ | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Sertraline Sandoz | SZ | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | SERTRALINE-WGR | WG | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | SERTRALINE-WGR | WG | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Setrona | RA | MP NP | C4755 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Setrona | RA | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Zoloft | UJ | MP NP | C4755 C6277 C6289 | P4755 P6277 P6289 | 30 | 5 |
| 30 |
|
|
Sertraline | Tablet 100 mg (as hydrochloride) | Oral | Zoloft | UJ | MP NP | C15582 C15583 C15666 | P15582 P15583 P15666 | 60 | 2 |
| 30 |
|
|
omit:
Sofosbuvir with velpatasvir and voxilaprevir | Tablet containing 400 mg sofosbuvir with 100 mg velpatasvir and 100 mg voxilaprevir | Oral | Vosevi | GI | MP NP | C10248 |
| 28 | 2 |
| 28 |
| C(100) |
insert:
Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Enemas 3.125 g-450 mg-45 mg in 5 mL, 12 | Rectal | Micolette | AE | MP NP | C15572 C15585 C15586 C15629 C15707 C15734 C15735 | P15572 P15585 P15586 P15629 P15707 P15734 P15735 | 4 | 2 |
| 1 |
|
|
insert:
Sotalol | Tablet containing sotalol hydrochloride 80 mg | Oral | SOTALOL-WGR | WG | MP NP | C5664 |
| 60 | 5 |
| 60 |
|
|
insert:
Sotalol | Tablet containing sotalol hydrochloride 160 mg | Oral | SOTALOL-WGR | WG | MP NP | C5664 |
| 60 | 5 |
| 60 |
|
|
substitute:
Soy lecithin | Eye spray 10 mg per mL, 10 mL | Application | tearsagain | RB | MP NP AO | C6172 | P6172 | 2 | 5 |
| 1 |
|
|
Soy lecithin | Eye spray 10 mg per mL, 10 mL | Application | tearsagain | RB | MP NP AO | C15559 | P15559 | 4 | 5 |
| 1 |
|
|
insert:
Sumatriptan | Tablet 50 mg (as succinate) | Oral | SUMATRIPTAN-WGR | WG | MP NP | C5259 |
| 4 | 5 |
| 4 |
|
|
insert:
Telmisartan | Tablet 40 mg | Oral | TELMISARTAN-WGR | WG | MP NP |
|
| 28 | 5 |
| 28 |
|
|
Telmisartan | Tablet 40 mg | Oral | TELMISARTAN-WGR | WG | MP NP |
| P14238 | 56 | 5 |
| 28 |
|
|
insert:
Telmisartan | Tablet 80 mg | Oral | TELMISARTAN-WGR | WG | MP NP |
|
| 28 | 5 |
| 28 |
|
|
Telmisartan | Tablet 80 mg | Oral | TELMISARTAN-WGR | WG | MP NP |
| P14238 | 56 | 5 |
| 28 |
|
|
insert:
Telmisartan with hydrochlorothiazide | Tablet 40 mg-12.5 mg | Oral | TELMISARTAN HCTZ-WGR 40/12.5 | WG | MP NP | C4374 | P4374 | 28 | 5 |
| 28 |
|
|
Telmisartan with hydrochlorothiazide | Tablet 40 mg-12.5 mg | Oral | TELMISARTAN HCTZ-WGR 40/12.5 | WG | MP NP | C14255 | P14255 | 56 | 5 |
| 28 |
|
|
insert:
Telmisartan with hydrochlorothiazide | Tablet 80 mg-12.5 mg | Oral | TELMISARTAN HCTZ-WGR 80/12.5 | WG | MP NP | C4374 | P4374 | 28 | 5 |
| 28 |
|
|
Telmisartan with hydrochlorothiazide | Tablet 80 mg-12.5 mg | Oral | TELMISARTAN HCTZ-WGR 80/12.5 | WG | MP NP | C14255 | P14255 | 56 | 5 |
| 28 |
|
|
insert:
Telmisartan with hydrochlorothiazide | Tablet 80 mg-25 mg | Oral | TELMISARTAN HCTZ-WGR 80/25 | WG | MP NP | C4374 | P4374 | 28 | 5 |
| 28 |
|
|
Telmisartan with hydrochlorothiazide | Tablet 80 mg-25 mg | Oral | TELMISARTAN HCTZ-WGR 80/25 | WG | MP NP | C14255 | P14255 | 56 | 5 |
| 28 |
|
|
substitute:
Temazepam | Tablet 10 mg | Oral | APO-Temazepam | TX | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | APO-Temazepam | TX | MP NP |
| P6175 | 50 | 3 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | APO-Temazepam | TX | MP NP |
| P5661 P5941 P5950 | 50 | 5 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | Normison | AS | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | Normison | AS | MP NP |
| P6175 | 50 | 3 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | Normison | AS | MP NP |
| P5661 P5941 P5950 | 50 | 5 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | Temaze | AF | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | Temaze | AF | MP NP |
| P6175 | 50 | 3 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | Temaze | AF | MP NP |
| P5661 P5941 P5950 | 50 | 5 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | TEMAZEPAM-WGR | WG | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | TEMAZEPAM-WGR | WG | MP NP |
| P6175 | 50 | 3 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | TEMAZEPAM-WGR | WG | MP NP |
| P5661 P5941 P5950 | 50 | 5 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | Temtabs | LN | MP NP PDP |
|
| 25 | 0 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | Temtabs | LN | MP NP |
| P6175 | 50 | 3 |
| 25 |
|
|
Temazepam | Tablet 10 mg | Oral | Temtabs | LN | MP NP |
| P5661 P5941 P5950 | 50 | 5 |
| 25 |
|
|
substitute:
Terbinafine | Cream containing terbinafine hydrochloride 10 mg per g, 15 g | Application | Lamisil | NP | MP NP | C6412 C6434 |
| 2 | 3 |
| 1 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | APO-Terbinafine | TX | MP NP | C6404 C6453 | P6404 P6453 | 42 | 0 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | APO-Terbinafine | TX | MP NP | C6395 | P6395 | 42 | 1 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | Lamisil (Novartis Pharmaceuticals Australia Pty Limited) | NV | MP NP | C6404 C6453 | P6404 P6453 | 42 | 0 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | Lamisil (Novartis Pharmaceuticals Australia Pty Limited) | NV | MP NP | C6395 | P6395 | 42 | 1 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | NOUMED TERBINAFINE | VO | MP NP | C6404 C6453 | P6404 P6453 | 42 | 0 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | NOUMED TERBINAFINE | VO | MP NP | C6395 | P6395 | 42 | 1 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | Tamsil | RW | MP NP | C6404 C6453 | P6404 P6453 | 42 | 0 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | Tamsil | RW | MP NP | C6395 | P6395 | 42 | 1 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | Terbinafine-DRLA | RZ | MP NP | C6404 C6453 | P6404 P6453 | 42 | 0 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | Terbinafine-DRLA | RZ | MP NP | C6395 | P6395 | 42 | 1 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | Terbinafine Sandoz | SZ | MP NP | C6404 C6453 | P6404 P6453 | 42 | 0 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | Terbinafine Sandoz | SZ | MP NP | C6395 | P6395 | 42 | 1 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | TERBINAFINE-WGR | WG | MP NP | C6404 C6453 | P6404 P6453 | 42 | 0 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | TERBINAFINE-WGR | WG | MP NP | C6395 | P6395 | 42 | 1 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | Tinasil | AF | MP NP | C6404 C6453 | P6404 P6453 | 42 | 0 |
| 42 |
|
|
Terbinafine | Tablet 250 mg (as hydrochloride) | Oral | Tinasil | AF | MP NP | C6395 | P6395 | 42 | 1 |
| 42 |
|
|
substitute:
Teriparatide | Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen | Injection | Teriparatide Lupin | GQ | MP | C12270 C12492 | P12270 P12492 | 1 | 5 |
| 1 |
|
|
Teriparatide | Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen | Injection | Teriparatide Lupin | GQ | MP | C15536 | P15536 | 2 | 2 |
| 1 |
|
|
Teriparatide | Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen | Injection | Terrosa | FX | MP | C12270 C12492 | P12270 P12492 | 1 | 5 |
| 1 |
|
|
Teriparatide | Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen | Injection | Terrosa | FX | MP | C15536 | P15536 | 2 | 2 |
| 1 |
|
|
substitute:
Testosterone | Transdermal cream 50 mg per mL, 50 mL | Transdermal | AndroForte 5 | LX | MP | C11838 C11891 C11947 C11962 C11963 | P11838 P11891 P11947 P11962 P11963 | 1 | 1 |
| 1 |
|
|
Testosterone | Transdermal cream 50 mg per mL, 50 mL | Transdermal | AndroForte 5 | LX | MP | C15622 C15623 C15654 C15739 C15756 | P15622 P15623 P15654 P15739 P15756 | 2 | 1 |
| 1 |
|
|
substitute:
Tetrabenazine | Tablet 25 mg | Oral | iNova Pharmaceuticals (Australia) Pty Ltd | IL | MP NP | C5340 | P5340 | 112 | 5 |
| 112 |
|
|
Tetrabenazine | Tablet 25 mg | Oral | iNova Pharmaceuticals (Australia) Pty Ltd | IL | MP NP | C15673 | P15673 | 224 | 5 |
| 112 |
|
|
Tetrabenazine | Tablet 25 mg | Oral | Tetrabenazine SUN | RA | MP NP | C5340 | P5340 | 112 | 5 |
| 112 |
|
|
Tetrabenazine | Tablet 25 mg | Oral | Tetrabenazine SUN | RA | MP NP | C15673 | P15673 | 224 | 5 |
| 112 |
|
|
substitute:
Thalidomide | Capsule 50 mg | Oral | Thalomid | CJ | MP | C5914 C9290 |
| 112 | 0 |
| 28 |
| D(100) |
Thalidomide | Capsule 100 mg | Oral | Thalomid | CJ | MP | C5914 C9290 |
| 56 | 0 |
| 28 |
| D(100) |
substitute:
Tiotropium | Capsule containing powder for oral inhalation 13 micrograms (as bromide) (for use in Zonda device) | Inhalation by mouth | Braltus | TB | MP NP | C6352 | P6352 | 30 | 5 |
| 30 |
|
|
Tiotropium | Capsule containing powder for oral inhalation 13 micrograms (as bromide) (for use in Zonda device) | Inhalation by mouth | Braltus | TB | MP NP | C15611 | P15611 | 60 | 5 |
| 30 |
|
|
Tiotropium | Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in HandiHaler) | Inhalation by mouth | Spiriva | BY | MP NP | C6352 | P6352 | 30 | 5 |
| 30 |
|
|
Tiotropium | Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in HandiHaler) | Inhalation by mouth | Spiriva | BY | MP NP | C15611 | P15611 | 60 | 5 |
| 30 |
|
|
Tiotropium | Capsule containing powder for oral inhalation 1 micrograms (as bromide monohydrate) (for use in LupinHaler) | Inhalation by mouth | Tiotropium Lupin | GQ | MP NP | C6352 | P6352 | 30 | 5 |
| 30 |
|
|
Tiotropium | Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in LupinHaler) | Inhalation by mouth | Tiotropium Lupin | GQ | MP NP | C15611 | P15611 | 60 | 5 |
| 30 |
|
|
Tiotropium | Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations) | Inhalation by mouth | Spiriva Respimat | BY | MP NP | C5509 C8606 C12599 | P5509 P8606 P12599 | 1 | 5 |
| 1 |
|
|
Tiotropium | Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations) | Inhalation by mouth | Spiriva Respimat | BY | MP NP | C15566 C15753 C15754 | P15566 P15753 P15754 | 2 | 5 |
| 1 |
|
|
substitute:
Tiotropium with olodaterol | Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses | Inhalation by mouth | Spiolto Respimat | BY | MP NP | C7798 | P7798 | 1 | 5 |
| 1 |
|
|
Tiotropium with olodaterol | Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses | Inhalation by mouth | Spiolto Respimat | BY | MP NP | C15691 | P15691 | 2 | 5 |
| 1 |
|
|
substitute:
Tocilizumab | Concentrate for injection 80 mg in 4 mL | Injection | Actemra | RO | MP | See Note 3 | See Note 3 | See Note 3 | See Note 3 |
| 1 |
| PB(100) |
substitute:
Tocilizumab | Concentrate for injection 200 mg in 10 mL | Injection | Actemra | RO | MP | See Note 3 | See Note 3 | See Note 3 | See Note 3 |
| 1 |
| PB(100) |
substitute:
Tocilizumab | Concentrate for injection 400 mg in 20 mL | Injection | Actemra | RO | MP | See Note 3 | See Note 3 | See Note 3 | See Note 3 |
| 1 |
| PB(100) |
insert:
Topiramate | Tablet 25 mg | Oral | TOPIRAMATE-WGR | WG | MP NP | C5325 C5516 | P5325 P5516 | 60 | 5 |
| 60 |
|
|
Topiramate | Tablet 25 mg | Oral | TOPIRAMATE-WGR | WG | MP NP | C14901 C14973 | P14901 P14973 | 120 | 5 |
| 60 |
|
|
insert:
Topiramate | Tablet 50 mg | Oral | TOPIRAMATE-WGR | WG | MP NP | C5325 C5516 | P5325 P5516 | 60 | 5 |
| 60 |
|
|
Topiramate | Tablet 50 mg | Oral | TOPIRAMATE-WGR | WG | MP NP | C14901 C14973 | P14901 P14973 | 120 | 5 |
| 60 |
|
|
insert:
Topiramate | Tablet 100 mg | Oral | TOPIRAMATE-WGR | WG | MP NP | C5325 C5516 | P5325 P5516 | 60 | 5 |
| 60 |
|
|
Topiramate | Tablet 100 mg | Oral | TOPIRAMATE-WGR | WG | MP NP | C14901 C14973 | P14901 P14973 | 120 | 5 |
| 60 |
|
|
insert:
Topiramate | Tablet 200 mg | Oral | TOPIRAMATE-WGR | WG | MP NP | C5516 | P5516 | 60 | 5 |
| 60 |
|
|
Topiramate | Tablet 200 mg | Oral | TOPIRAMATE-WGR | WG | MP NP | C14973 | P14973 | 120 | 5 |
| 60 |
|
|
substitute:
Trabectedin | Powder for I.V. infusion 1 mg | Injection | Yondelis | ZL | MP | C14196 | P14196 | See Note 3 | See Note 3 |
| 1 |
| D(100) |
Trabectedin | Powder for I.V. infusion 1 mg | Injection | Yondelis | ZL | MP | C14197 | P14197 | See Note 3 | See Note 3 |
| 1 |
| D(100) |
substitute:
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | APO-Tramadol | TX | MP NP PDP | C10766 | P10766 | 10 | 0 |
| 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | APO-Tramadol | TX | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | APO-Tramadol | TX | PDP | C10768 | P10768 | 20 | 0 |
| 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramadol Sandoz | SZ | MP NP PDP | C10766 | P10766 | 10 | 0 |
| 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramadol Sandoz | SZ | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramadol Sandoz | SZ | PDP | C10768 | P10768 | 20 | 0 |
| 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | TRAMADOL-WGR | WG | MP NP PDP | C10766 | P10766 | 10 | 0 |
| 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | TRAMADOL-WGR | WG | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | TRAMADOL-WGR | WG | PDP | C10768 | P10768 | 20 | 0 |
| 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramal | CS | MP NP PDP | C10766 | P10766 | 10 | 0 |
| 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramal | CS | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramal | CS | PDP | C10768 | P10768 | 20 | 0 |
| 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramedo | AF | MP NP PDP | C10766 | P10766 | 10 | 0 |
| 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramedo | AF | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Tramedo | AF | PDP | C10768 | P10768 | 20 | 0 |
| 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Zydol | RW | MP NP PDP | C10766 | P10766 | 10 | 0 |
| 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Zydol | RW | MP NP | C10764 C10771 C10772 | P10764 P10771 P10772 | 20 | 0 | V10764 V10771 V10772 | 20 |
|
|
Tramadol | Capsule containing tramadol hydrochloride 50 mg | Oral | Zydol | RW | PDP | C10768 | P10768 | 20 | 0 |
| 20 |
|
|
insert:
Tramadol | Tablet (sustained release) containing tramadol hydrochloride 100 mg | Oral | TRAMADOL-WGR SR | WG | MP NP | C10748 C10752 C10755 |
| 20 | 0 | V10748 V10752 V10755 | 20 |
|
|
insert:
Tramadol | Tablet (sustained release) containing tramadol hydrochloride 150 mg | Oral | TRAMADOL-WGR SR | WG | MP NP | C10748 C10752 C10755 |
| 20 | 0 | V10748 V10752 V10755 | 20 |
|
|
insert:
Tramadol | Tablet (sustained release) containing tramadol hydrochloride 200 mg | Oral | TRAMADOL-WGR SR | WG | MP NP | C10748 C10752 C10755 |
| 20 | 0 | V10748 V10752 V10755 | 20 |
|
|
insert:
Tranylcypromine | Tablet 10 mg (as sulfate) | Oral | Parnate | GH | MP |
| P14238 | 100 | 1 |
| 50 |
|
|
substitute:
Trastuzumab | Powder for I.V. infusion 60 mg | Injection | Trazimera | PF | MP | C9349 C9353 C9571 C9573 C10213 C10294 C15820 C15831 |
| See Note 3 | See Note 3 | V15820 V15831 | 1 |
| PB(100) |
Trastuzumab | Powder for I.V. infusion 150 mg | Injection | Herzuma | EW | MP | C9349 C9353 C9571 C9573 C10213 C10294 C15820 C15831 |
| See Note 3 | See Note 3 | V15820 V15831 | 1 |
| PB(100) |
Trastuzumab | Powder for I.V. infusion 150 mg | Injection | Kanjinti | JU | MP | C9349 C9353 C9571 C9573 C10213 C10294 C15820 C15831 |
| See Note 3 | See Note 3 | V15820 V15831 | 1 |
| PB(100) |
Trastuzumab | Powder for I.V. infusion 150 mg | Injection | Ogivri | SZ | MP | C9349 C9353 C9571 C9573 C10213 C10294 C15820 C15831 |
| See Note 3 | See Note 3 | V15820 V15831 | 1 |
| PB(100) |
Trastuzumab | Powder for I.V. infusion 150 mg | Injection | Trazimera | PF | MP | C9349 C9353 C9571 C9573 C10213 C10294 C15820 C15831 |
| See Note 3 | See Note 3 | V15820 V15831 | 1 |
| PB(100) |
Trastuzumab | Powder for I.V. infusion 420 mg | Injection | Kanjinti | JU | MP | C9349 C9353 C9571 C9573 C10213 C10294 C15820 C15831 |
| See Note 3 | See Note 3 | V15820 V15831 | 1 |
| PB(100) |
Trastuzumab | Powder for I.V. infusion 440 mg with diluent | Injection | Herzuma | EW | MP | C9349 C9353 C9571 C9573 C10213 C10294 C15820 C15831 |
| See Note 3 | See Note 3 | V15820 V15831 | 1 |
| PB(100) |
Trastuzumab | Solution for subcutaneous injection containing trastuzumab 600 mg in 5 mL | Injection | Herceptin SC | RO | MP | C9353 | P9353 | 1 | 0 |
| 1 |
|
|
Trastuzumab | Solution for subcutaneous injection containing trastuzumab 600 mg in 5 mL | Injection | Herceptin SC | RO | MP | C9462 C10212 | P9462 P10212 | 1 | 3 |
| 1 |
|
|
substitute:
Trastuzumab deruxtecan | Powder for I.V. infusion 100 mg | Injection | Enhertu | AP | MP | C15826 C15832 |
| See Note 3 | See Note 3 | V15826 V15832 | 1 |
| D(100) |
substitute:
Trastuzumab emtansine | Powder for I.V. infusion 100 mg | Injection | Kadcyla | RO | MP | C15818 C15819 C15827 C15828 |
| See Note 3 | See Note 3 | V15818 V15819 V15827 V15828 | 1 |
| D(100) |
Trastuzumab emtansine | Powder for I.V. infusion 160 mg | Injection | Kadcyla | RO | MP | C15818 C15819 C15827 C15828 |
| See Note 3 | See Note 3 | V15818 V15819 V15827 V15828 | 1 |
| D(100) |
substitute:
Travoprost | Eye drops 40 micrograms per mL, 2.5 mL | Application to the eye | Travatan | NV | MP AO |
|
| 1 | 5 |
| 1 |
|
|
Travoprost | Eye drops 40 micrograms per mL, 2.5 mL | Application to the eye | Travatan | NV | MP AO |
| P14238 | 2 | 5 |
| 1 |
|
|
substitute:
Travoprost with timolol | Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Duotrav | NV | AO | C5038 | P5038 | 1 | 5 |
| 1 |
|
|
Travoprost with timolol | Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Duotrav | NV | MP | C4343 | P4343 | 1 | 5 |
| 1 |
|
|
Travoprost with timolol | Eye drops 40 micrograms travoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Duotrav | NV | MP AO | C15558 | P15558 | 2 | 5 |
| 1 |
|
|
omit:
Triglycerides, long chain with glucose polymer | Oral liquid 250 mL, 18 (ProZero) | Oral | ProZero | VF | MP NP | C4438 |
| 6 | 5 |
| 1 |
|
|
insert:
Trimethoprim | Tablet 300 mg | Oral | TRIMETHOPRIM-WGR | WG | MP NP |
|
| 7 | 1 |
| 7 |
|
|
Trimethoprim | Tablet 300 mg | Oral | TRIMETHOPRIM-WGR | WG | MP |
| P4243 | 14 | 2 |
| 7 |
|
|
Trimethoprim | Tablet 300 mg | Oral | TRIMETHOPRIM-WGR | WG | MP |
| P6163 | 28 | 0 |
| 7 |
|
|
substitute:
Umeclidinium | Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses | Inhalation by mouth | Incruse Ellipta | GK | MP NP | C4516 | P4516 | 1 | 5 |
| 1 |
|
|
Umeclidinium | Powder for oral inhalation in breath actuated device 62.5 micrograms (as bromide) per dose, 30 doses | Inhalation by mouth | Incruse Ellipta | GK | MP NP | C15634 | P15634 | 2 | 5 |
| 1 |
|
|
substitute:
Umeclidinium with vilanterol | Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | Anoro Ellipta 62.5/25 | GK | MP NP | C7798 | P7798 | 1 | 5 |
| 1 |
|
|
Umeclidinium with vilanterol | Powder for oral inhalation in breath actuated device containing umeclidinium 62.5 micrograms (as bromide) with vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | Inhalation by mouth | Anoro Ellipta 62.5/25 | GK | MP NP | C15691 | P15691 | 2 | 5 |
| 1 |
|
|
insert:
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | VALACICLOVIR-WGR | WG | MP NP | C5960 | P5960 | 20 | 0 |
| 10 |
|
|
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | VALACICLOVIR-WGR | WG | MP NP | C5940 C5961 | P5940 P5961 | 30 | 5 |
| 30 |
|
|
Valaciclovir | Tablet 500 mg (as hydrochloride) | Oral | VALACICLOVIR-WGR | WG | MP NP | C5962 C5968 | P5962 P5968 | 42 | 0 |
| 42 |
|
|
omit from the column headed “Circumstances”: C4989 C9316 substitute: C15782 C15784 C15800 C15814
omit from the column headed “Circumstances”: C4989 C9316 substitute: C15782 C15784 C15800 C15814
omit from the column headed “Circumstances”: C4989 C9316 substitute: C15782 C15784 C15800 C15814
insert:
Venlafaxine | Capsule (modified release) 37.5 mg (as hydrochloride) | Oral | VENLAFAXINE XR-WGR | WG | MP NP | C5650 |
| 28 | 0 |
| 28 |
|
|
substitute:
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | APO-Venlafaxine XR | TX | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | APO-Venlafaxine XR | TX | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Efexor-XR | UJ | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Efexor-XR | UJ | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Elaxine SR 75 | RW | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Elaxine SR 75 | RW | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Enlafax-XR | AF | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Enlafax-XR | AF | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Sandoz Venlafaxine XR | HX | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Sandoz Venlafaxine XR | HX | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Venlafaxine generichealth XR | GQ | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | Venlafaxine generichealth XR | GQ | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | VENLAFAXINE XR-WGR | WG | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 75 mg (as hydrochloride) | Oral | VENLAFAXINE XR-WGR | WG | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
substitute:
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | APO-Venlafaxine XR | TX | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | APO-Venlafaxine XR | TX | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | Efexor-XR | UJ | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | Efexor-XR | UJ | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | Elaxine SR 150 | RW | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | Elaxine SR 150 | RW | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | Enlafax-XR | AF | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | Enlafax-XR | AF | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | Sandoz Venlafaxine XR | HX | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | Sandoz Venlafaxine XR | HX | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | Venlafaxine generichealth XR | GQ | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | Venlafaxine generichealth XR | GQ | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | VENLAFAXINE XR-WGR | WG | MP NP | C5650 | P5650 | 28 | 5 |
| 28 |
|
|
Venlafaxine | Capsule (modified release) 150 mg (as hydrochloride) | Oral | VENLAFAXINE XR-WGR | WG | MP NP | C15553 | P15553 | 56 | 2 |
| 28 |
|
|
Budesonide with formoterol | Pressurised inhalation containing budesonide 50 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | Inhalation by mouth | Symbicort Rapihaler 50/3 | AP | 1 |
|
|
Triglycerides, long chain with glucose polymer | Oral liquid 250 mL, 18 (ProZero) | Oral | ProZero | VF | 1 |
|
|
FT | AMICUS THERAPEUTICS PTY LTD | 87 621 776 476 |
JB | Apotex Pty Ltd | 52 096 916 148 |
WG | WAGNER PHARMACEUTICALS PTY LTD | 48 670 339 867 |
ZP | Medis Pharma Pty Ltd | 67 109 225 747 |
omit from the column headed “Listed Drug”: Fosinopril with hydrochlorothiazide
insert in alphabetical order in the column headed “Listed Drug”: Ceritinib
insert in alphabetical order in the column headed “Listed Drug”: Entrectinib
omit entry for Circumstances Code “C14238” and substitute:
C14238 | P14238 | CN14238 | Acarbose Allopurinol Amlodipine Amlodipine with atorvastatin Atenolol Atorvastatin Baclofen Beclometasone Betaxolol Bimatoprost Brimonidine Brinzolamide Budesonide Candesartan Carbamazepine Carbimazole Chlortalidone Ciclesonide Ciclosporin Clonidine Clopidogrel Clopidogrel with aspirin Colestyramine Cortisone Cyproterone Dexamethasone Diltiazem Dorzolamide Enalapril Eprosartan Estradiol Estradiol and estradiol with dydrogesterone Estradiol and estradiol with norethisterone Estradiol with norethisterone Estriol Ethosuximide Everolimus Felodipine Fenofibrate Fluticasone furoate Fluticasone propionate Fluvastatin Furosemide Gemfibrozil Glibenclamide Gliclazide Glimepiride Glipizide Glyceryl trinitrate Hydrochlorothiazide Hydrochlorothiazide with amiloride Hydrocortisone Indapamide Irbesartan Isosorbide dinitrate Isosorbide mononitrate Labetalol Latanoprost Lercanidipine Levodopa with benserazide Levodopa with carbidopa Lisinopril Medroxyprogesterone Metformin Methenamine Methotrexate Metoprolol Mycophenolic acid Nicorandil Nifedipine Nizatidine Norethisterone Olmesartan Pancreatic extract Paraffin Penicillamine Perindopril Perindopril with indapamide Phenytoin Pilocarpine Pizotifen Potassium chloride Potassium chloride with potassium bicarbonate Pravastatin Prazosin Prednisolone Prednisone Probenecid Propranolol Propylthiouracil Pyridostigmine Ramipril Rosuvastatin Simvastatin Sirolimus Sodium bicarbonate Spironolactone Sulfasalazine Sulthiame Tacrolimus Telmisartan Toremifene Trandolapril Tranylcypromine Travoprost Valproic acid Valsartan Verapamil | The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
omit entry for Circumstances Code “C15261” and substitute:
C15261 | P15261 | CN15261 | Alogliptin Linagliptin Saxagliptin Sitagliptin Vildagliptin | Diabetes mellitus type 2 The treatment must be used in combination with at least one of: metformin, a sulfonylurea, insulin; AND The condition must be inadequately responsive to at least one of: metformin, a sulfonylurea, insulin. Patient must not be undergoing concomitant PBS-subsidised treatment with any of: a GLP-1 receptor agonist, another DPP4 inhibitor. | Compliance with Authority Required procedures - Streamlined Authority Code 15261 |
C15530 | P15530 | CN15530 | Esomeprazole Lansoprazole Omeprazole Pantoprazole Rabeprazole | Gastro-oesophageal reflux disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The treatment must be for long-term maintenance of gastro-oesophageal reflux disease in a patient with symptoms inadequately controlled using a low dose proton pump inhibitor. | Compliance with Authority Required procedures - Streamlined Authority Code 15530 |
C15531 | P15531 | CN15531 | Esomeprazole Lansoprazole Omeprazole Pantoprazole Rabeprazole | Complex gastro-oesophageal reflux disease (GORD) One of: (1) establishment of symptom control, (2) maintenance treatment, (3) re-establishment of symptom control The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Must be treated by a gastroenterologist; OR Must be treated by a surgeon with expertise in the upper gastrointestinal tract; OR Must be treated by a medical practitioner who has consulted at least one of the above mentioned specialists in relation to this current PBS benefit being sought, with the specialist's name documented in the patient's medical records for auditing purposes; OR Must be treated by a medical practitioner who has not consulted a specialist, but only if treatment continues therapy initiated under this restriction with involvement by a specialist (i.e. continuing treatment initiated for non-complex GORD does not meet this criterion), with the specialist's name documented in the patient's medical records for auditing purposes. The treatment must be: (i) the sole PBS-subsidised proton pump inhibitor (PPI) for this condition, (ii) the sole strength of this PPI, (iii) the sole form of PPI; AND Patient must must have symptoms inadequately controlled with each of: (i) a standard dose proton pump inhibitor (PPI) administered once daily, (ii) a low dose PPI administered twice daily; treatment is for: (1) establishment of symptom control; OR Patient must be assessed for the risks/benefits of a step-down in dosing from standard dose PPI administered twice daily, with the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-establishment of symptom control; OR Patient must have trialled a step-down in dosing, with symptoms adequately managed with once daily dosing; treatment is for: (2) maintenance treatment, but with the quantity sought in this authority application being up to 1 pack per dispensing. Check patient adherence to any preceding PPI treatment regimen. Exclude non-adherence as a cause of inadequate control before accessing treatment under this restriction. | Compliance with Authority Required procedures |
C15535 | P15535 | CN15535 | Bisacodyl | Terminal malignant neoplasia The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Patient must identify as Aboriginal or Torres Strait Islander. |
|
C15536 | P15536 | CN15536 | Teriparatide | Severe established osteoporosis Continuing treatment The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously been issued with an authority prescription for this drug; AND The treatment must not exceed a lifetime maximum of 18 months therapy. Must be treated by a specialist; OR Must be treated by a consultant physician. | Compliance with Authority Required procedures - Streamlined Authority Code 15536 |
C15539 | P15539 | CN15539 | Macrogol 3350 | Chronic constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be inadequately controlled with first line interventions such as bulk-forming agents. |
|
C15542 | P15542 | CN15542 | Apomorphine | Parkinson disease Maintenance therapy The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have experienced severely disabling motor fluctuations which have not responded to other therapy; AND Patient must have been commenced on treatment in a specialist unit in a hospital setting. | Compliance with Authority Required procedures - Streamlined Authority Code 15542 |
C15543 | P15543 | CN15543 | Beclometasone with formoterol and glycopyrronium Budesonide with glycopyrronium and formoterol Fluticasone furoate with umeclidinium and vilanterol | Chronic obstructive pulmonary disease (COPD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have experienced at least one severe COPD exacerbation, which required hospitalisation, or two or more moderate exacerbations in the previous 12 months, with significant symptoms despite regular bronchodilator therapy with a long acting muscarinic antagonist (LAMA) and a long acting beta-2 agonist (LABA) or an inhaled corticosteroid (ICS) and a LABA; OR Patient must have been stabilised on a combination of a LAMA, LABA and an ICS for this condition. Patient must not be undergoing treatment with this product in each of the following circumstances: (i) treatment of asthma in the absence of a COPD diagnosis, (ii) initiation of bronchodilator therapy in COPD, (iii) use as reliever therapy for asthma, (iv) dosed at an interval/frequency that differs to that recommended in the approved Product Information. | Compliance with Authority Required procedures - Streamlined Authority Code 15543 |
C15546 | P15546 | CN15546 | Fluticasone furoate with vilanterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids. Patient must be aged 12 years or over. | Compliance with Authority Required procedures - Streamlined Authority Code 15546 |
C15548 | P15548 | CN15548 | Budesonide with formoterol Fluticasone furoate with vilanterol Fluticasone propionate with salmeterol | Chronic obstructive pulmonary disease (COPD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have significant symptoms despite regular beta-2 agonist bronchodilator therapy; AND Patient must have experienced at least one severe COPD exacerbation, which required hospitalisation, or two or more moderate exacerbations in the previous 12 months. | Compliance with Authority Required procedures - Streamlined Authority Code 15548 |
C15550 | P15550 | CN15550 | Escitalopram | Moderate to severe generalised anxiety disorder (GAD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND Patient must not have responded to non-pharmacological therapy; AND Patient must have been assessed by a psychiatrist. |
|
C15551 | P15551 | CN15551 | Escitalopram | Moderate to severe social anxiety disorder (social phobia, SAD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND Patient must not have responded to non-pharmacological therapy; AND Patient must be one for whom a GP Mental Health Care Plan, as described under items 2715 or 2717 of the Medicare Benefits Schedule, has been prepared. |
|
C15553 | P15553 | CN15553 | Desvenlafaxine Mirtazapine Moclobemide Reboxetine Venlafaxine | Major depressive disorders The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15556 | P15556 | CN15556 | Carbomer Hypromellose Hypromellose with dextran Polyethylene glycol 400 with propylene glycol | Severe dry eye syndrome The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15558 | P15558 | CN15558 | Bimatoprost with timolol Brimonidine with timolol Brinzolamide with brimonidine Brinzolamide with timolol Dorzolamide with timolol Latanoprost with timolol Travoprost with timolol | Elevated intra-ocular pressure The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must have been inadequately controlled with monotherapy; AND Patient must have open-angle glaucoma; OR Patient must have ocular hypertension. |
|
C15559 | P15559 | CN15559 | Carbomer Carmellose Hyaluronic acid Hypromellose Paraffin Perfluorohexyloctane Polyethylene glycol 400 with propylene glycol Soy lecithin | Severe dry eye syndrome The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be sensitive to preservatives in multi-dose eye drops. | Compliance with Authority Required procedures - Streamlined Authority Code 15559 |
C15560 | P15560 | CN15560 | Carbomer Carmellose Carmellose with glycerin Hypromellose Hypromellose with carbomer 980 Hypromellose with dextran Polyethylene glycol 400 with propylene glycol | Severe dry eye syndrome |
|
C15564 | P15564 | CN15564 | Levodopa with carbidopa and entacapone | Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be being treated with levodopa decarboxylase inhibitor combinations; AND Patient must be experiencing fluctuations in motor function due to end-of-dose effect. |
|
C15565 | P15565 | CN15565 | Levodopa with carbidopa and entacapone | Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be stabilised on concomitant treatment with levodopa decarboxylase inhibitor combinations and entacapone. |
|
C15566 | P15566 | CN15566 | Tiotropium | Severe asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have experienced at least one severe asthma exacerbation in the 12 months prior to having first commenced treatment for severe asthma, which required systemic corticosteroid treatment despite each of: (i) receiving optimised asthma therapy, (ii) being assessed for adherence to therapy, (iii) being assessed for correct inhaler technique; AND The treatment must be used in combination with a maintenance combination of an inhaled corticosteroid (ICS) and a long acting beta-2 agonist (LABA) unless a LABA is contraindicated. Patient must be at least 18 years of age. Optimised asthma therapy includes adherence to the maintenance combination of an inhaled corticosteroid (at least 800 micrograms budesonide per day or equivalent) and a long acting beta-2 agonist. |
|
C15568 | P15568 | CN15568 | Pramipexole | Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15570 | P15570 | CN15570 | Pramipexole | Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15572 | P15572 | CN15572 | Bisacodyl Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Terminal malignant neoplasia The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15574 | P15574 | CN15574 | Lansoprazole Omeprazole Pantoprazole Rabeprazole | Gastro-oesophageal reflux disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15575 | P15575 | CN15575 | Omeprazole Pantoprazole | Zollinger-Ellison syndrome The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15577 | P15577 | CN15577 | Budesonide with formoterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have failed PBS-subsidised fluticasone proprionate and salmeterol as a fixed dose combination for this condition. Must be treated by a respiratory physician; OR Must be treated by a paediatrician. | Compliance with Authority Required procedures - Streamlined Authority Code 15577 |
C15578 | P15578 | CN15578 | Budesonide | Severe chronic asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must require long-term steroid therapy; AND Patient must not be able to use other forms of inhaled steroid therapy. | Compliance with Authority Required procedures - Streamlined Authority Code 15578 |
C15580 | P15580 | CN15580 | Mianserin | Severe depression The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15582 | P15582 | CN15582 | Fluoxetine Fluvoxamine Paroxetine Sertraline | Obsessive-compulsive disorder The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15583 | P15583 | CN15583 | Sertraline | Panic disorder The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The treatment must be for use when other treatments have failed; OR The treatment must be for use when other treatments are inappropriate. |
|
C15585 | P15585 | CN15585 | Bisacodyl Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be paraplegic or quadriplegic or have severe neurogenic impairment of bowel function. |
|
C15586 | P15586 | CN15586 | Bisacodyl Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be receiving palliative care. |
|
C15587 | P15587 | CN15587 | Bisacodyl | Constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult. Patient must identify as Aboriginal or Torres Strait Islander. |
|
C15593 | P15593 | CN15593 | Macrogol 3350 | Constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be receiving palliative care. |
|
C15596 | P15596 | CN15596 | Doxycycline | Bronchiectasis The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Patient must be aged 8 years or older. |
|
C15599 | P15599 | CN15599 | Beclometasone with formoterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids; OR Patient must have experienced frequent asthma symptoms while receiving treatment with oral or inhaled corticosteroids and require single maintenance and reliever therapy; OR Patient must have experienced frequent asthma symptoms while receiving treatment with a combination of an inhaled corticosteroid and long acting beta-2 agonist and require single maintenance and reliever therapy. Patient must be at least 18 years of age. | Compliance with Authority Required procedures - Streamlined Authority Code 15599 |
C15600 | P15600 | CN15600 | Beclometasone | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be unable to achieve co-ordinated use of other metered dose inhalers containing this drug |
|
C15601 | P15601 | CN15601 | Fluticasone furoate with umeclidinium and vilanterol Indacaterol with glycopyrronium and mometasone | Severe asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have experienced at least one severe asthma exacerbation in the 12 months prior to having first commenced treatment for severe asthma, which required systemic corticosteroid treatment despite each of: (i) receiving optimised asthma therapy, (ii) being assessed for adherence to therapy, (iii) being assessed for correct inhaler technique. Patient must be at least 18 years of age. Optimised asthma therapy includes adherence to the maintenance combination of an inhaled corticosteroid (at least 800 micrograms budesonide per day or equivalent) and a long acting beta-2 agonist. | Compliance with Authority Required procedures - Streamlined Authority Code 15601 |
C15602 | P15602 | CN15602 | Entacapone | Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The treatment must be as adjunctive therapy to a levodopa-decarboxylase inhibitor combination; AND Patient must be experiencing fluctuations in motor function due to end-of-dose effect. |
|
C15604 | P15604 | CN15604 | Fluticasone propionate with salmeterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids. Patient must be aged 4 years or older. | Compliance with Authority Required procedures - Streamlined Authority Code 15604 |
C15606 | P15606 | CN15606 | Escitalopram | Moderate to severe generalised anxiety disorder (GAD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND Patient must not have responded to non-pharmacological therapy; AND Patient must be one for whom a GP Mental Health Care Plan, as described under items 2715 or 2717 of the Medicare Benefits Schedule, has been prepared. |
|
C15607 | P15607 | CN15607 | Formoterol Salmeterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must experience frequent episodes of the condition; AND Patient must be currently receiving treatment with oral corticosteroids; OR Patient must be currently receiving treatment with optimal doses of inhaled corticosteroids. |
|
C15608 | P15608 | CN15608 | Levodopa with carbidopa | Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be one in which fluctuations in motor function are not adequately controlled by frequent dosing with conventional formulations of levodopa with decarboxylase inhibitor. |
|
C15611 | P15611 | CN15611 | Tiotropium | Chronic obstructive pulmonary disease (COPD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15615 | P15615 | CN15615 | Budesonide with formoterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids. Patient must be aged 12 years or over. | Compliance with Authority Required procedures - Streamlined Authority Code 15615 |
C15617 | P15617 | CN15617 | Budesonide with formoterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids. | Compliance with Authority Required procedures - Streamlined Authority Code 15617 |
C15622 | P15622 | CN15622 | Testosterone | Androgen deficiency The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have an established pituitary or testicular disorder. Must be treated by a specialist general paediatrician, specialist paediatric endocrinologist, specialist urologist, specialist endocrinologist or a Fellow of the Australasian Chapter of Sexual Health Medicine; or in consultation with one of these specialists; or have an appointment to be assessed by one of these specialists. The treatment must be applied to the scrotum area. The name of the specialist must be included in the authority application. | Compliance with Authority Required procedures |
C15623 | P15623 | CN15623 | Testosterone | Pubertal induction The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Patient must be under 18 years of age. Must be treated by a specialist general paediatrician, specialist paediatric endocrinologist, specialist urologist, specialist endocrinologist or a Fellow of the Australasian Chapter of Sexual Health Medicine; or in consultation with one of these specialists; or have an appointment to be assessed by one of these specialists. The treatment must be applied to the scrotum area. The name of the specialist must be included in the authority application. | Compliance with Authority Required procedures |
C15624 | P15624 | CN15624 | Eprosartan with hydrochlorothiazide | Hypertension The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The treatment must not be for the initiation of anti-hypertensive therapy; AND The condition must be inadequately controlled with an angiotensin II antagonist; OR The condition must be inadequately controlled with a thiazide diuretic. |
|
C15625 | P15625 | CN15625 | Doxycycline | Severe acne The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15629 | P15629 | CN15629 | Bisacodyl Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be receiving long-term nursing care and in respect of whom a Carer Allowance is payable as a disabled adult. |
|
C15633 | P15633 | CN15633 | Lansoprazole Omeprazole Pantoprazole Rabeprazole | Scleroderma oesophagus The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15634 | P15634 | CN15634 | Aclidinium Glycopyrronium Umeclidinium | Chronic obstructive pulmonary disease (COPD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15635 | P15635 | CN15635 | Fluticasone propionate with formoterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids. Patient must be aged 12 years or over. | Compliance with Authority Required procedures - Streamlined Authority Code 15635 |
C15636 | P15636 | CN15636 | Cabergoline | Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15639 | P15639 | CN15639 | Escitalopram | Major depressive disorders The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15640 | P15640 | CN15640 | Carmellose Carmellose with glycerin Hypromellose with carbomer 980 | Severe dry eye syndrome Patient must be receiving treatment under a GP Management Plan or Team Care Arrangements where Medicare benefits were or are payable for the preparation of the Plan or coordination of the Arrangements. |
|
C15642 | P15642 | CN15642 | Montelukast | Asthma First-line prevention The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Patient must be aged 2 to 5 years inclusive. The condition must be frequent intermittent; OR The condition must be mild persistent; AND The treatment must be the single preventer agent; AND The treatment must be an alternative to sodium cromoglycate; OR The treatment must be an alternative to nedocromil sodium. | Compliance with Authority Required procedures - Streamlined Authority Code 15642 |
C15643 | P15643 | CN15643 | Montelukast | Asthma First-line prevention The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be frequent intermittent; OR The condition must be mild persistent; AND The treatment must be the single preventer agent; AND The treatment must be an alternative to sodium cromoglycate; OR The treatment must be an alternative to nedocromil sodium. Patient must be aged 6 to 14 years inclusive. | Compliance with Authority Required procedures - Streamlined Authority Code 15643 |
C15644 | P15644 | CN15644 | Montelukast | Asthma Prevention of condition The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be exercise-induced; AND The treatment must be as an alternative to adding salmeterol xinafoate; OR The treatment must be an alternative to adding formoterol fumarate; AND The condition must be otherwise well controlled while receiving optimal dose inhaled corticosteroid; AND Patient must require short-acting beta-2 agonist 3 or more times per week for prevention or relief of residual exercise-related symptoms. Patient must be aged 6 to 14 years inclusive. | Compliance with Authority Required procedures - Streamlined Authority Code 15644 |
C15648 | C15648 | CN15648 | Rasagiline | Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15649 | P15649 | CN15649 | Rotigotine | Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The treatment must be as adjunctive therapy to a levodopa-decarboxylase inhibitor combination. |
|
C15653 | P15653 | CN15653 | Indacaterol with mometasone | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids. Patient must be aged 12 years or over. | Compliance with Authority Required procedures - Streamlined Authority Code 15653 |
C15654 | P15654 | CN15654 | Testosterone | Micropenis The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Patient must be under 18 years of age. Must be treated by a specialist general paediatrician, specialist paediatric endocrinologist, specialist urologist, specialist endocrinologist or a Fellow of the Australasian Chapter of Sexual Health Medicine; or in consultation with one of these specialists; or have an appointment to be assessed by one of these specialists. The treatment must be applied to the scrotum area. The name of the specialist must be included in the authority application. | Compliance with Authority Required procedures |
C15655 | P15655 | CN15655 | Esomeprazole | Scleroderma oesophagus The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have symptoms which are inadequately controlled using a standard dose proton pump inhibitor. | Compliance with Authority Required procedures |
C15656 | P15656 | CN15656 | Beclometasone with formoterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids. Patient must be aged 18 years or older. | Compliance with Authority Required procedures - Streamlined Authority Code 15656 |
C15657 | P15657 | CN15657 | Minocycline | Severe acne The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must not be responding to other tetracyclines. |
|
C15658 | P15658 | CN15658 | Esomeprazole Lansoprazole Omeprazole Pantoprazole Rabeprazole | Scleroderma oesophagus The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. | Compliance with Authority Required procedures - Streamlined Authority Code 15658 |
C15659 | P15659 | CN15659 | Doxycycline | Chronic bronchitis The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Patient must be aged 8 years or older. |
|
C15661 | P15661 | CN15661 | Macrogol 3350 | Constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be paraplegic, quadriplegic or have severe neurogenic impairment of bowel function; AND The condition must be unresponsive to other oral therapies. |
|
C15666 | P15666 | CN15666 | Citalopram Escitalopram Fluoxetine Fluvoxamine Paroxetine Sertraline | Major depressive disorders The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15669 | P15669 | CN15669 | Escitalopram | Moderate to severe generalised anxiety disorder (GAD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND Patient must not have responded to non-pharmacological therapy; AND Patient must be one for whom a GP Mental Health Care Plan, as described under items 2715 or 2717 of the Medicare Benefits Schedule, has been prepared. |
|
C15670 | P15670 | CN15670 | Escitalopram | Moderate to severe generalised anxiety disorder (GAD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND Patient must not have responded to non-pharmacological therapy; AND Patient must have been assessed by a psychiatrist. |
|
C15673 | P15673 | CN15673 | Tetrabenazine | Hyperkinetic extrapyramidal disorders The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. | Compliance with Authority Required procedures - Streamlined Authority Code 15673 |
C15675 | P15675 | CN15675 | Rotigotine | Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The treatment must be as adjunctive therapy to a levodopa-decarboxylase inhibitor combination. |
|
C15678 | P15678 | CN15678 | Omeprazole Pantoprazole | Zollinger-Ellison syndrome The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. | Compliance with Authority Required procedures - Streamlined Authority Code 15678 |
C15680 | P15680 | CN15680 | Budesonide with formoterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids; OR Patient must have experienced frequent asthma symptoms while receiving treatment with oral or inhaled corticosteroids and require single maintenance and reliever therapy; OR Patient must have experienced frequent asthma symptoms while receiving treatment with a combination of an inhaled corticosteroid and long acting beta-2 agonist and require single maintenance and reliever therapy. | Compliance with Authority Required procedures - Streamlined Authority Code 15680 |
C15682 | P15682 | CN15682 | Esomeprazole | Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. | Compliance with Authority Required procedures - Streamlined Authority Code 15682 |
C15686 | P15686 | CN15686 | Doxycycline | Severe acne The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15688 | P15688 | PN15688 | Macrogol 3350 | Constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be receiving palliative care. |
|
C15691 | P15691 | CN15691 | Aclidinium with formoterol Indacaterol with glycopyrronium Tiotropium with olodaterol Umeclidinium with vilanterol | Chronic obstructive pulmonary disease (COPD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have COPD symptoms that persist despite regular bronchodilator treatment with a long acting muscarinic antagonist (LAMA); OR Patient must have COPD symptoms that persist despite regular bronchodilator treatment with a long acting beta 2 agonist (LABA); OR Patient must have been stabilised on a combination of a LAMA and a LABA. | Compliance with Authority Required procedures - Streamlined Authority Code 15691 |
C15692 | P15692 | CN15692 | Fluticasone furoate with vilanterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids. Patient must be aged 12 years or over. | Compliance with Authority Required procedures - Streamlined Authority Code 15692 |
C15693 | P15693 | CN15693 | Fluticasone propionate with salmeterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids. | Compliance with Authority Required procedures - Streamlined Authority Code 15693 |
C15696 | P15696 | CN15696 | Escitalopram | Moderate to severe social anxiety disorder (social phobia, SAD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND Patient must not have responded to non-pharmacological therapy; AND Patient must have been assessed by a psychiatrist. |
|
C15698 | P15698 | CN15698 | Escitalopram | Moderate to severe social anxiety disorder (social phobia, SAD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND Patient must not have responded to non-pharmacological therapy; AND Patient must have been assessed by a psychiatrist. |
|
C15699 | P15699 | CN15699 | Safinamide | Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The treatment must be as adjunctive therapy to a levodopa-decarboxylase inhibitor combination. |
|
C15700 | P15700 | CN15700 | Selegiline | Late stage Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The treatment must be as adjunctive therapy to a levodopa-decarboxylase inhibitor combination. |
|
C15702 | P15702 | CN15702 | Budesonide with formoterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids; OR Patient must have experienced frequent asthma symptoms while receiving treatment with oral or inhaled corticosteroids and require single maintenance and reliever therapy; OR Patient must have experienced frequent asthma symptoms while receiving treatment with a combination of an inhaled corticosteroid and long acting beta-2 agonist. Patient must be aged 12 years or over. | Compliance with Authority Required procedures - Streamlined Authority Code 15702 |
C15704 | P15704 | CN15704 | Esomeprazole | Pathological hypersecretory conditions including Zollinger-Ellison syndrome and idiopathic hypersecretion The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have symptoms which are inadequately controlled using a standard dose proton pump inhibitor. | Compliance with Authority Required procedures |
C15705 | P15705 | CN15705 | Esomeprazole | Complex gastro-oesophageal reflux disease (GORD) One of: (1) establishment of symptom control, (2) maintenance treatment, (3) re-establishment of symptom control The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Must be treated by a gastroenterologist; OR Must be treated by a surgeon with expertise in the upper gastrointestinal tract. The treatment must be: (i) the sole PBS-subsidised proton pump inhibitor (PPI) for this condition, (ii) the sole strength of this PPI, (iii) the sole form of PPI; AND Patient must have symptoms inadequately controlled with each of: (i) a high dose proton pump inhibitor (PPI) administered once daily, (ii) a standard dose PPI administered twice daily; treatment is for: (1) establishment of symptom control; OR Patient must be assessed for the risks/benefits of a step-down in dosing from a high dose PPI administered twice daily, with the determination being that the risks outweigh the benefits; treatment is for: (2) maintenance treatment; OR Patient must have trialled a step-down in dosing, yet symptoms have re-emerged/worsened; treatment is for: (3) re-establishment of symptom control; OR Patient must have trialled a step-down in dosing, with symptoms adequately managed with once daily dosing; treatment is for: (2) maintenance treatment, but with the quantity sought in this authority application being up to 1 pack per dispensing. Check patient adherence to any preceding PPI treatment regimen. Exclude non-adherence as a cause of inadequate control before accessing treatment under this restriction. | Compliance with Authority Required procedures |
C15707 | P15707 | CN15707 | Bisacodyl Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Anorectal congenital abnormalities The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15708 | P15708 | CN15708 | Bisacodyl | Constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be receiving long-term nursing care on account of age, infirmity or other condition in a hospital, nursing home or residential facility. Patient must identify as Aboriginal or Torres Strait Islander. |
|
C15709 | P15709 | CN15709 | Macrogol 3350 | Faecal impaction The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be inadequately controlled with first line interventions such as bulk-forming agents. |
|
C15710 | P15710 | CN15710 | Erythromycin | Severe acne The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be one in which tetracycline therapy is inappropriate. | Compliance with Authority Required procedures - Streamlined Authority Code 15710 |
C15711 | P15711 | CN15711 | Amantadine | Parkinson disease The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must not be drug induced. |
|
C15714 | P15714 | CN15714 | Fluticasone propionate with salmeterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids. | Compliance with Authority Required procedures - Streamlined Authority Code 15714 |
C15715 | P15715 | CN15715 | Fluticasone propionate with salmeterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids. Patient must be aged 4 years or older. | Compliance with Authority Required procedures - Streamlined Authority Code 15715 |
C15719 | P15719 | CN15719 | Riluzole | Amyotrophic lateral sclerosis Continuing treatment The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must be ambulatory; OR Patient must not be ambulatory, and must be able to either use upper limbs or to swallow; AND Patient must not have undergone a tracheostomy; AND Patient must not have experienced respiratory failure. | Compliance with Authority Required procedures |
C15722 | P15722 | CN15722 | Paroxetine | Panic disorder The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15726 | P15726 | CN15726 | Bisacodyl | Anorectal congenital abnormalities The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Patient must identify as Aboriginal or Torres Strait Islander. |
|
C15727 | P15727 | CN15727 | Bisacodyl | Megacolon The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Patient must identify as Aboriginal or Torres Strait Islander. |
|
C15729 | P15729 | CN15729 | Macrogol 3350 | Constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have malignant neoplasia. |
|
C15730 | P15730 | CN15730 | Macrogol 3350 | Constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be paraplegic, quadriplegic or have severe neurogenic impairment of bowel function; AND The condition must be unresponsive to other oral therapies. |
|
C15734 | P15734 | CN15734 | Bisacodyl Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must be receiving long-term nursing care on account of age, infirmity or other condition in a hospital, nursing home or residential facility. |
|
C15735 | P15735 | CN15735 | Bisacodyl Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate | Megacolon The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15736 | P15736 | CN15736 | Indacaterol | Chronic obstructive pulmonary disease (COPD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15739 | P15739 | CN15739 | Testosterone | Androgen deficiency The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must not have an established pituitary or testicular disorder; AND The condition must not be due to age, obesity, cardiovascular diseases, infertility or drugs. Patient must be aged 40 years or older. Must be treated by a specialist urologist, specialist endocrinologist or a Fellow of the Australasian Chapter of Sexual Health Medicine; or in consultation with one of these specialists; or have an appointment to be assessed by one of these specialists. The treatment must be applied to the scrotum area. Androgen deficiency is defined as: (i) testosterone level of less than 6 nmol per litre; OR (ii) testosterone level between 6 and 15 nmol per litre with high luteinising hormone (LH) (greater than 1.5 times the upper limit of the eugonodal reference range for young men, or greater than 14 IU per litre, whichever is higher). Androgen deficiency must be confirmed by at least two morning blood samples taken on different mornings. The dates and levels of the qualifying testosterone and LH measurements must be, or must have been provided in the authority application when treatment with this drug is or was initiated. The name of the specialist must be included in the authority application. | Compliance with Authority Required procedures |
C15745 | P15745 | CN15745 | Macrogol 3350 | Constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have malignant neoplasia. |
|
C15746 | P15746 | CN15746 | Macrogol 3350 | Chronic constipation The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be inadequately controlled with first line interventions such as bulk-forming agents. |
|
C15747 | P15747 | CN15747 | Macrogol 3350 | Faecal impaction The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be inadequately controlled with first line interventions such as bulk-forming agents. |
|
C15751 | P15751 | CN15751 | Escitalopram | Moderate to severe social anxiety disorder (social phobia, SAD) The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The condition must be defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria; AND Patient must not have responded to non-pharmacological therapy; AND Patient must be one for whom a GP Mental Health Care Plan, as described under items 2715 or 2717 of the Medicare Benefits Schedule, has been prepared. |
|
C15753 | P15753 | CN15753 | Tiotropium | Bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease Long-term maintenance treatment The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
|
C15754 | P15754 | CN15754 | Tiotropium | Severe asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Must be treated by a respiratory physician, paediatric respiratory physician, clinical immunologist, allergist, paediatrician or general physician experienced in the management of patients with severe asthma; or in consultation with one of these specialists. Patient must have failed to achieve adequate control with optimised asthma therapy, despite formal assessment of and adherence to correct inhaler technique, which has been documented; AND Patient must have experienced at least one severe exacerbation prior to receiving PBS-subsidised treatment with this drug for this condition, which has required documented use of systemic corticosteroids in the previous 12 months while receiving optimised asthma therapy; OR Patient must have experienced frequent episodes of moderate asthma exacerbations prior to receiving PBS-subsidised treatment with this drug for this condition; AND The treatment must be used in combination with a maintenance combination of an inhaled corticosteroid (ICS) and a long acting beta-2 agonist (LABA) unless a LABA is contraindicated. Patient must be aged 6 to 17 years inclusive. Optimised asthma therapy includes adherence to the maintenance combination of a medium to high dose ICS and a LABA. If LABA therapy is contraindicated, not tolerated or not effective, montelukast, cromoglycate or nedocromil may be used as an alternative | Compliance with Authority Required procedures - Streamlined Authority Code 15754 |
C15755 | P15755 | CN15755 | Budesonide with formoterol | Asthma The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND Patient must have previously had frequent episodes of asthma while receiving treatment with oral corticosteroids or optimal doses of inhaled corticosteroids; OR Patient must have experienced frequent asthma symptoms while receiving treatment with oral or inhaled corticosteroids and require single maintenance and reliever therapy; OR Patient must have experienced frequent asthma symptoms while receiving treatment with a combination of an inhaled corticosteroid and long acting beta-2 agonist and require single maintenance and reliever therapy. Patient must be aged 12 years or over. | Compliance with Authority Required procedures - Streamlined Authority Code 15755 |
C15756 | P15756 | CN15756 | Testosterone | Constitutional delay of growth or puberty The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Patient must be under 18 years of age. Must be treated by a specialist general paediatrician, specialist paediatric endocrinologist, specialist urologist, specialist endocrinologist or a Fellow of the Australasian Chapter of Sexual Health Medicine; or in consultation with one of these specialists; or have an appointment to be assessed by one of these specialists. The treatment must be applied to the scrotum area. The name of the specialist must be included in the authority application. | Compliance with Authority Required procedures |
C15757 | P15757 | CN15757 | Cabozantinib | Stage IV renal cell carcinoma (RCC) Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements for maintenance treatment Patient must have previously received non-PBS-subsidised treatment with this drug for this condition prior to 1 September 2024; AND Patient must have had a prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk classification score at treatment initiation with this drug of either: (i) 1 to 2 (intermediate risk), (ii) 3 to 6 (poor risk); document the IMDC risk classification score in the patient's medical records if not already documented; AND Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST); AND The treatment must be the sole PBS-subsidised therapy for this condition; AND Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug. | Compliance with Authority Required procedures - Streamlined Authority Code 15757 |
C15759 | P15759 | CN15759 | Alectinib Brigatinib Ceritinib | Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) Initial treatment The treatment must be as monotherapy; AND The condition must be non-squamous type non-small cell lung cancer (NSCLC) or not otherwise specified type NSCLC; AND Patient must have a WHO performance status of 2 or less; AND Patient must have evidence of an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material, defined as either: (i) 15% (or greater) positive cells by fluorescence in situ hybridisation (FISH) testing, (ii) positive next generation sequencing (NGS) testing. | Compliance with Authority Required procedures |
C15764 | P15764 | CN15764 | Adalimumab | Moderate to severe hidradenitis suppurativa Initial treatment - Initial 1 (new patient) Patient must have, at the time of application, a Hurley stage II or III grading with an abscess and inflammatory nodule (AN) count greater than or equal to 3; AND Patient must have failed to achieve an adequate response to 2 courses of different antibiotics each for 3 months prior to initiation of PBS subsidised treatment with this drug for this condition; OR Patient must have had an adverse reaction to an antibiotic of a severity necessitating permanent treatment withdrawal resulting in the patient being unable to complete treatment with 2 different courses of antibiotics each for 3 months prior to initiation of PBS-subsidised treatment with this drug for this condition; OR Patient must be contraindicated to treatment with an antibiotic due to an allergic reaction of a severity necessitating permanent treatment withdrawal resulting in the patient being unable to complete treatment with 2 different courses of antibiotics each for 3 months prior to initiation of PBS-subsidised treatment with this drug for this condition; AND Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must not receive more than 16 weeks of treatment under this restriction. Must be treated by a dermatologist. Assessment of disease severity must be no more than 4 weeks old at the time of application. An assessment of a patient's response to this initial course of treatment must be conducted following a minimum of 12 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. At the time of authority application the prescriber must request the first 4 weeks of treatment under this restriction; and weeks 5 to 16 of treatment under Initial 1 (new patient) or Initial 2 (recommencement of treatment) - balance of supply The authority application must be made in writing and must include: (1) details of the proposed prescription; and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes: (i) the Hurley stage grading; and (ii) the AN count; and (iii) the name of the antibiotic/s received for two separate courses each of three months; or (iv) confirmation that the adverse reaction or allergy to an antibiotic necessitated permanent treatment withdrawal resulting in the patient being unable to complete a three month course of antibiotics. The name of the one course of antibiotics of three months duration must be provided. Where the patient is unable to be treated with any courses of antibiotics the prescriber must confirm that the patient has a history of adverse reaction or allergy necessitating permanent treatment withdrawal to two different antibiotics. | Compliance with Written Authority Required procedures |
C15765 | P15765 | CN15765 | Adalimumab | Moderate to severe hidradenitis suppurativa Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) Patient must have, at the time of application, a Hurley stage II or III grading with an abscess and inflammatory nodule (AN) count greater than or equal to 3; AND Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND Patient must not receive more than 16 weeks of treatment under this restriction. Must be treated by a dermatologist. Assessment of disease severity must be no more than 4 weeks old at the time of application. A response to treatment is defined as: Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae. To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. At the time of authority application the prescriber must request the first 4 weeks of treatment under this restriction; and weeks 5 to 16 of treatment under Initial 1 (new patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply. The authority application must be made in writing and must include: (1) details of the proposed prescription; and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes: (i) the Hurley stage grading; and (ii) the AN count. | Compliance with Written Authority Required procedures |
C15767 | P15767 | C15767 | Secukinumab | Moderate to severe hidradenitis suppurativa Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must have demonstrated a response to treatment with this drug for this condition. Must be treated by a dermatologist. A response to treatment is defined as: Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae. An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 16 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. A maximum of 24 weeks treatment will be authorised under this restriction per continuing treatment. The authority application must be made in writing and must include: (1) details of the proposed prescription; and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes the Hidradenitis Suppurativa Clinical Response (HiSCR) result. | Compliance with Written Authority Required procedures |
C15768 | P15768 | C15768 | Secukinumab | Moderate to severe hidradenitis suppurativa Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have had 3 treatment failures within this treatment cycle to PBS-subsidised biological medicines for this condition; AND Patient must not receive more than 20 weeks of treatment under this restriction. Must be treated by a dermatologist. Assessment of disease severity must be no more than 4 weeks old at the time of application. A response to treatment is defined as: Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae. An application for a patient who has received PBS-subsidised treatment with this drug, has not experienced treatment failure, and wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below. To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 16 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. The authority application must be made in writing and must include: (1) details of the proposed prescription(s); and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes: (i) the Hurley stage grading; and (ii) the AN count. Details of two completed prescriptions should be submitted with every initial application for this drug. One prescription should be for the induction doses, containing a quantity of 8 doses of 150 mg and no repeats and the second prescription should be for 2 doses of 150 mg and 3 repeats. This restriction is intended for induction dosing only. | Compliance with Written Authority Required procedures |
C15772 | P15772 | CN15772 | Budesonide | Mild to moderate Crohn disease The condition must affect the ileum; OR The condition must affect the ascending colon; OR The condition must affect the ileum and ascending colon. The total duration of therapy should be no more than 10 weeks in any single course. | Compliance with Authority Required procedures - Streamlined Authority Code 15772 |
C15774 | P15774 | CN15774 | Cabozantinib | Stage IV renal cell carcinoma (RCC) Initial treatment The condition must be each of: (i) classified as having an intermediate to poor survival risk score according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), (ii) untreated with a tyrosine kinase inhibitor; OR Patient must have progressive disease according to the Response Evaluation Criteria in Solid Tumours (RECIST) despite treatment with a tyrosine kinase inhibitor, irrespective of the current IMDC survival risk score; AND Patient must have a WHO performance status of 2 or less; AND The treatment must be the sole PBS-subsidised therapy for this condition. Patient must be undergoing treatment with this drug for the first time at the time of the first PBS prescription. | Compliance with Authority Required procedures - Streamlined Authority Code 15774 |
C15775 | P15775 | CN15775 | Cabozantinib | Stage IV renal cell carcinoma (RCC) Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST); AND The treatment must be the sole PBS-subsidised therapy for this condition; AND Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug. | Compliance with Authority Required procedures - Streamlined Authority Code 15775 |
C15776 | C15776 | CN15776 | Crizotinib Entrectinib | Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) Initial treatment The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition; AND The condition must be non-squamous type non-small cell lung cancer (NSCLC) or not otherwise specified type NSCLC; AND Patient must have a WHO performance status of 2 or less; AND Patient must have evidence of c-ROS proto-oncogene 1 (ROS1) gene rearrangement in tumour material, defined as either: (i) 15% (or greater) positive cells by fluorescence in situ hybridisation (FISH) testing, (ii) positive next generation sequencing (NGS) testing; AND Patient must not have received prior treatment with a c-ROS proto-oncogene 1 (ROS1) receptor tyrosine kinase inhibitor for this condition; OR Patient must have developed intolerance to a c-ROS proto-oncogene 1 (ROS1) receptor tyrosine kinase inhibitor necessitating permanent treatment withdrawal. Applications for authorisation of initial treatment must be made via the Online PBS Authorities System (real time assessment) or in writing via HPOS form upload or mail. If the application is submitted through HPOS form upload or mail, it must include: (a) details of the proposed prescription; and (b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). The following must be documented in the patient's medical records: (a) evidence of c-ROS proto-oncogene 1 (ROS1) gene rearrangement in tumour material. | Compliance with Written Authority Required procedures |
C15777 | P15777 | CN15777 | Adalimumab | Moderate to severe hidradenitis suppurativa First continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must have demonstrated a response to treatment with this drug for this condition. Must be treated by a dermatologist. A response to treatment is defined as: Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae. An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. A maximum of 24 weeks treatment will be authorised under this restriction per continuing treatment. The authority application must be made in writing and must include: (1) details of the proposed prescription; and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes the Hidradenitis Suppurativa Clinical Response (HiSCR) result. | Compliance with Written Authority Required procedures |
C15779 | P15779 | CN15779 | Secukinumab | Moderate to severe hidradenitis suppurativa Transitioning from non-PBS to PBS-subsidised supply - Grandfather arrangements Patient must have received non-PBS-subsidised treatment with this drug for this PBS indication prior to 1 June 2024; AND Patient must have had a Hurley stage II or III with an abscess and inflammatory nodule (AN) count greater than or equal to 3 prior to starting treatment with this drug for this condition; AND Patient must have demonstrated a response to treatment by achieving Hidradenitis Suppurativa Clinical Response (HiSCR) after 16 weeks of treatment if the patient has been treated with this drug for this condition for 16 weeks or longer; AND Patient must have failed to achieve an adequate response to 2 courses of different antibiotics each for 3 months prior to initiation of non-PBS-subsidised treatment with this drug for this condition; OR Patient must have had an adverse reaction to an antibiotic of a severity necessitating permanent treatment withdrawal resulting in the patient being unable to complete treatment with 2 different courses of antibiotics each for 3 months prior to initiation of non-PBS-subsidised treatment with this drug for this condition; OR Patient must be contraindicated to treatment with an antibiotic due to an allergic reaction of a severity necessitating permanent treatment withdrawal resulting in the patient being unable to complete treatment with 2 different courses of antibiotics each for 3 months prior to initiation of non-PBS-subsidised treatment with this drug for this condition; AND Patient must not receive more than 24 weeks of treatment under this restriction. Must be treated by a dermatologist. A response to treatment is defined as: Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae. An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 16 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. Assessment of disease severity must not have been more than 4 weeks old at the time treatment with this drug was initiated. The authority application must be made in writing and must include: (a) details of the proposed prescription; and (b) completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes: (i) the Hurley stage grading; and (ii) the AN count; and (iii) the name of the antibiotic/s received for two separate courses each of three months; or (iv) confirmation that the adverse reaction or allergy to an antibiotic necessitated permanent treatment withdrawal resulting in the patient being unable to complete a three month course of antibiotics. The name of the one course of antibiotics of three months duration must be provided. Where the patient is unable to be treated with any courses of antibiotics the prescriber must confirm that the patient has a history of adverse reaction or allergy necessitating permanent treatment withdrawal to two different antibiotics (v) the Hidradenitis Suppurativa Clinical Response (HiSCR) result if the patient has received 16 weeks or more of treatment. A patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria. | Compliance with Written Authority Required procedures |
C15781 | C15781 | CN15781 | Larotrectinib | Solid tumours with confirmed neurotrophic tropomyosin receptor kinase (NTRK) gene fusion Continuing treatment Patient must be undergoing continuing PBS-subsidised treatment commenced through an 'Initial treatment' listing for solid tumours (of any type) with confirmed NTRK gene fusion where treatment with this drug is/was initiated in a child; OR Patient must be undergoing continuing PBS-subsidised treatment commenced through an 'Initial treatment' listing for solid tumours (of certain specified types) with confirmed NTRK gene fusion which either includes: (i) mammary analogue secretory carcinoma of the salivary gland, (ii) secretory breast carcinoma. The treatment must cease to be a PBS benefit upon radiographic progression; AND The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition. Where radiographic progression is observed, mark any remaining repeat prescriptions with the word 'cancelled'. | Compliance with Authority Required procedures |
C15782 | P15782 | CN15782 | Ganciclovir Valganciclovir | Cytomegalovirus infection and disease Patient must be a solid organ transplant recipient at risk of cytomegalovirus disease. | Compliance with Authority Required procedures - Streamlined Authority Code 15782 |
C15784 | P15784 | CN15784 | Ganciclovir Valganciclovir | Cytomegalovirus infection and disease Patient must be a bone marrow transplant recipient at risk of cytomegalovirus disease. | Compliance with Authority Required procedures - Streamlined Authority Code 15784 |
C15787 | P15787 | CN15787 | Migalastat | Fabry disease Grandfather arrangement (transition from LSDP-funded Fabry disease therapy) Patient must have previously received treatment with this drug for this condition funded under the Australian Government's Life Saving Drugs Program (LSDP) prior to 1 September 2024; OR Patient must have previously received treatment with Enzyme Replacement Therapy for this condition funded under the Australian Government's Life Saving Drugs Program (LSDP) prior to 1 September 2024; AND Patient must have a documented migalastat amenable galactosidase alpha (GLA) gene variant prior to commencing treatment with this drug; AND Patient must have/have had an estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m2prior to commencing treatment with this drug. Must be treated by a physician with expertise in the management of Fabry disease. Patient must be at least 12 years of age. A patient may qualify for PBS-subsidised treatment under this restriction once only. For continuing PBS-subsidised treatment, a Grandfathered patient must qualify under the Continuing treatment criteria. Confirmation of eligibility for treatment with diagnostic reports including the confirmed mutations must be documented in the patient's medical records. The authority application must be made in writing and must include: (1) details of the proposed prescription; and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). | Compliance with Written Authority Required procedures |
C15788 | P15788 | CN15788 | Adalimumab | Moderate to severe hidradenitis suppurativa Initial 1 (new patient), Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years), or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 16 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 16 weeks treatment. Must be treated by a dermatologist. A maximum of 12 weeks of treatment will be authorised under this restriction. | Compliance with Authority Required procedures |
C15795 | P15795 | CN15795 | Adalimumab | Moderate to severe hidradenitis suppurativa Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have had 3 treatment failures within this treatment cycle to PBS-subsidised biological medicines for this condition; AND Patient must not receive more than 16 weeks of treatment under this restriction. Must be treated by a dermatologist. Assessment of disease severity must be no more than 4 weeks old at the time of application. A response to treatment is defined as: Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae. An application for a patient who has received PBS-subsidised treatment with this drug, has not experienced treatment failure, and wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below. To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. At the time of authority application the prescriber must request the first 4 weeks of treatment under this restriction; and weeks 5 to 16 of treatment under Initial 1 (new patient), Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply. The authority application must be made in writing and must include: (1) details of the proposed prescription; and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes: (i) the Hurley stage grading; and (ii) the AN count. | Compliance with Written Authority Required procedures |
C15796 | P15796 | CN15796 | Adalimumab | Moderate to severe hidradenitis suppurativa Subsequent continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition under the First continuing treatment restriction; AND Patient must have demonstrated a response to treatment with this drug for this condition. Must be treated by a dermatologist. A response to treatment is defined as: Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae. An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. A maximum of 24 weeks treatment will be authorised under this restriction per continuing treatment. The authority application must be made in writing and must include: (1) details of the proposed prescription; and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes the Hidradenitis Suppurativa Clinical Response (HiSCR) result. | Compliance with Written Authority Required procedures |
C15797 | P15797 | CN15797 | Adalimumab | Moderate to severe hidradenitis suppurativa Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must have demonstrated a response to treatment with this drug for this condition. Must be treated by a dermatologist. A response to treatment is defined as: Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae. An application for the continuing treatment must be accompanied with the assessment of response conducted following a minimum of 12 weeks of therapy and no later than 4 weeks from cessation of the most recent course of treatment. This will enable ongoing treatment for those who meet the continuing restriction for PBS-subsidised treatment. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. A maximum of 24 weeks treatment will be authorised under this restriction per continuing treatment. The authority application must be made in writing and must include: (1) details of the proposed prescription; and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes the Hidradenitis Suppurativa Clinical Response (HiSCR) result. | Compliance with Written Authority Required procedures |
C15799 | P15799 | CN15799 | Secukinumab | Moderate to severe hidradenitis suppurativa Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) Patient must have, at the time of application, a Hurley stage II or III grading with an abscess and inflammatory nodule (AN) count greater than or equal to 3; AND Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND Patient must not receive more than 20 weeks of treatment under this restriction. Must be treated by a dermatologist. Assessment of disease severity must be no more than 4 weeks old at the time of application. A response to treatment is defined as: Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae. To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 16 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. The authority application must be made in writing and must include: (1) details of the proposed prescription(s); and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes: (i) the Hurley stage grading; and (ii) the AN count. Details of two completed prescriptions should be submitted with every initial application for this drug. One prescription should be for the induction doses, containing a quantity of 8 doses of 150 mg and no repeats and the second prescription should be for 2 doses of 150 mg and 3 repeats. | Compliance with Written Authority Required procedures |
C15800 | P15800 | CN15800 | Ganciclovir Valganciclovir | Cytomegalovirus infection and disease Patient must be a bone marrow transplant recipient at risk of cytomegalovirus disease. | Compliance with Authority Required procedures - Streamlined Authority Code 15800 |
C15801 | P15801 | CN15801 | Migalastat | Fabry disease Continuing treatment Patient must have received prior PBS-subsidised treatment with this drug for this condition; AND Patient must have demonstrated clinical improvement or stabilisation of condition, the details of which must be kept with the patient's record; AND Patient must not have developed another life threatening/severe disease where long term prognosis is unlikely to be influenced by migalastat. Must be treated by a physician with expertise in the management of Fabry disease. | Compliance with Authority Required procedures |
C15803 | P15803 | CN15803 | Crizotinib | Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) Initial treatment The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this condition; AND The condition must be non-squamous type non-small cell lung cancer (NSCLC) or not otherwise specified type NSCLC; AND Patient must have a WHO performance status of 2 or less; AND Patient must have evidence of an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material, defined as either: (i) 15% (or greater) positive cells by fluorescence in situ hybridisation (FISH) testing, (ii) positive next generation sequencing (NGS) testing. Applications for authorisation of initial treatment must be made via the Online PBS Authorities System (real time assessment) or in writing via HPOS form upload or mail. If the application is submitted through HPOS form upload or mail, it must include: (a) details of the proposed prescription; and (b) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). The following must be documented in the patient's medical records: (a) evidence of an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material. | Compliance with Written Authority Required procedures |
C15804 | P15804 | CN15804 | Lorlatinib | Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC) Initial treatment The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; AND The condition must be non-squamous type non-small cell lung cancer (NSCLC) or not otherwise specified type NSCLC; AND Patient must have a WHO performance status of 2 or less; AND Patient must have evidence of an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material, defined as either: (i) 15% (or greater) positive cells by fluorescence in situ hybridisation (FISH) testing, (ii) positive next generation sequencing (NGS) testing. | Compliance with Authority Required procedures |
C15805 | P15805 | CN15805 | Secukinumab | Moderate to severe hidradenitis suppurativa Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) Patient must have, at the time of application, a Hurley stage II or III grading with an abscess and inflammatory nodule (AN) count greater than or equal to 3; AND Patient must have previously received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must have a break in treatment of 5 years or more from the most recently approved PBS-subsidised biological medicine for this condition; AND Patient must not receive more than 20 weeks of treatment under this restriction. Must be treated by a dermatologist. Assessment of disease severity must be no more than 4 weeks old at the time of application. A response to treatment is defined as: Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae. To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 16 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. The authority application must be made in writing and must include: (1) details of the proposed prescription(s); and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes: (i) the Hurley stage grading; and (ii) the AN count. Details of two completed prescriptions should be submitted with every initial application for this drug. One prescription should be for the induction doses, containing a quantity of 8 doses of 150 mg and no repeats and the second prescription should be for 2 doses of 150 mg and 3 repeats. This restriction is intended for induction dosing only. | Compliance with Written Authority Required procedures |
C15806 | P15806 | CN15806 | Secukinumab | Moderate to severe hidradenitis suppurativa Initial treatment - Initial 2 (Change or recommencement of treatment after a break in biological medicine of less than 5 years) Patient must have received prior PBS-subsidised treatment with a biological medicine for this condition in this treatment cycle; AND Patient must not have had 3 treatment failures within this treatment cycle to PBS-subsidised biological medicines for this condition; AND Patient must not receive more than 20 weeks of treatment under this restriction. Must be treated by a dermatologist. Assessment of disease severity must be no more than 4 weeks old at the time of application. A response to treatment is defined as: Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) of a 50% reduction in AN count compared to baseline with no increase in abscesses or draining fistulae. An application for a patient who has received PBS-subsidised treatment with this drug, has not experienced treatment failure, and wishes to recommence therapy with this drug, must be accompanied by evidence of a response to the patient's most recent course of PBS-subsidised treatment with this drug, within the timeframes specified below. To demonstrate a response to treatment the application must be accompanied with the assessment of response, conducted following a minimum of 16 weeks of therapy and no later than 4 weeks from cessation of the most recent course of biological medicine. It is recommended that an application for the continuing treatment be submitted no later than 4 weeks from the date of completion of the most recent course of treatment. This is to ensure treatment continuity for those who meet the continuing restriction. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. The authority application must be made in writing and must include: (1) details of the proposed prescription(s); and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes: (i) the Hurley stage grading; and (ii) the AN count. Details of two completed prescriptions should be submitted with every initial application for this drug. One prescription should be for the induction doses, containing a quantity of 8 doses of 150 mg and no repeats and the second prescription should be for 2 doses of 150 mg and 3 repeats. | Compliance with Written Authority Required procedures |
C15807 | P15807 | CN15807 | Secukinumab | Moderate to severe hidradenitis suppurativa Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) - balance of supply Patient must have received insufficient therapy with this drug for this condition under the Initial 1 (new patient) restriction to complete 20 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 20 weeks treatment; OR Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 20 weeks treatment; AND The treatment must provide no more than the balance of up to 20 weeks treatment. Must be treated by a dermatologist. | Compliance with Authority Required procedures |
C15808 | P15808 | CN15808 | Migalastat | Fabry disease Initial treatment Patient must have at least one of: (i) documented deficiency of alpha-galactosidase enzyme activity in blood, (ii) presence of genetic mutations known to result in deficiency of alpha-galactosidase enzyme activity; AND Patient must have a documented migalastat amenable galactosidase alpha (GLA) gene variant; AND Patient must have an estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m2; AND Patient must be male with Fabry-related renal disease confirmed by at least one of the following: (i) abnormal albuminuria of more than 20 mcg/min, as determined by 2 separate samples at least 24 hours apart, (ii) abnormal proteinuria of more than 150 mg/24 hours, (iii) albumin:creatinine ratio greater than upper limit of normal in 2 separate samples at least 24 hours apart, (iv) renal disease due to long-term accumulation of glycosphingolipids in the kidneys; OR Patient must be female with Fabry-related renal disease confirmed by at least one of the following: (i) proteinuria of more than 300 mg/24 hours with clinical evidence of progression, (ii) renal disease due to long-term accumulation of glycosphingolipids in the kidneys; OR Patient must have Fabry-related cardiac disease confirmed by at least one of the following: (i) left ventricular hypertrophy, as evidenced by cardiac magnetic resonance imagining (MRI) or echocardiogram data, in the absence of hypertension, (ii) significant life-threatening arrhythmia or conduction defect, (iii) Late gadolinium enhancement or a low T1 on cardiac MRI; OR Patient must have Fabry-related either: (i) ischaemic disease, (ii) cerebrovascular disease as shown on objective testing with no other cause or risk factors identified; OR Patient must have Fabry-related uncontrolled chronic pain despite the use of recommended doses of appropriate analgesia and antiepileptic medications for peripheral neuropathy; OR Patient must have significant Fabry-related gastrointestinal symptoms despite the use of the recommended doses of appropriate pharmacological therapies. Must be treated by a physician with expertise in the management of Fabry disease. Patient must be at least 12 years of age. If hypertension is present in patients relying their eligibility on Fabry-related cardiac disease, the prescriber must treat it optimally for at least 6 months prior to submitting the first PBS authority application. Confirmation of eligibility for treatment with diagnostic reports including the confirmed mutations must be documented in the patient's medical records. The authority application must be made in writing and must include: (1) details of the proposed prescription; and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). | Compliance with Written Authority Required procedures |
C15810 | P15810 | CN15810 | Secukinumab | Moderate to severe hidradenitis suppurativa Initial treatment - Initial 1 (new patient) Patient must have, at the time of application, a Hurley stage II or III grading with an abscess and inflammatory nodule (AN) count greater than or equal to 3; AND Patient must have failed to achieve an adequate response to 2 courses of different antibiotics each for 3 months prior to initiation of PBS subsidised treatment with this drug for this condition; OR Patient must have had an adverse reaction to an antibiotic of a severity necessitating permanent treatment withdrawal resulting in the patient being unable to complete treatment with 2 different courses of antibiotics each for 3 months prior to initiation of PBS-subsidised treatment with this drug for this condition; OR Patient must be contraindicated to treatment with an antibiotic due to an allergic reaction of a severity necessitating permanent treatment withdrawal resulting in the patient being unable to complete treatment with 2 different courses of antibiotics each for 3 months prior to initiation of PBS-subsidised treatment with this drug for this condition; AND Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must not receive more than 20 weeks of treatment under this restriction. Must be treated by a dermatologist. Assessment of disease severity must be no more than 4 weeks old at the time of application. An assessment of a patient's response to this initial course of treatment must be conducted following a minimum of 16 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. The authority application must be made in writing and must include: (1) details of the proposed prescription(s); and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes: (i) the Hurley stage grading; and (ii) the AN count; and (iii) the name of the antibiotic/s received for two separate courses each of three months; or (iv) confirmation that the adverse reaction or allergy to an antibiotic necessitated permanent treatment withdrawal resulting in the patient being unable to complete a three month course of antibiotics. The name of the one course of antibiotics of three months duration must be provided. Where the patient is unable to be treated with any courses of antibiotics the prescriber must confirm that the patient has a history of adverse reaction or allergy necessitating permanent treatment withdrawal to two different antibiotics. Details of two completed prescriptions should be submitted with every initial application for this drug. One prescription should be for the induction doses, containing a quantity of 8 doses of 150 mg and no repeats and the second prescription should be for 2 doses of 150 mg and 3 repeats. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
C15812 | P15812 | CN15812 | Secukinumab | Moderate to severe hidradenitis suppurativa Initial treatment - Initial 1 (new patient) Patient must have, at the time of application, a Hurley stage II or III grading with an abscess and inflammatory nodule (AN) count greater than or equal to 3; AND Patient must have failed to achieve an adequate response to 2 courses of different antibiotics each for 3 months prior to initiation of PBS subsidised treatment with this drug for this condition; OR Patient must have had an adverse reaction to an antibiotic of a severity necessitating permanent treatment withdrawal resulting in the patient being unable to complete treatment with 2 different courses of antibiotics each for 3 months prior to initiation of PBS-subsidised treatment with this drug for this condition; OR Patient must be contraindicated to treatment with an antibiotic due to an allergic reaction of a severity necessitating permanent treatment withdrawal resulting in the patient being unable to complete treatment with 2 different courses of antibiotics each for 3 months prior to initiation of PBS-subsidised treatment with this drug for this condition; AND Patient must not have received PBS-subsidised treatment with a biological medicine for this condition; AND Patient must not receive more than 20 weeks of treatment under this restriction. Must be treated by a dermatologist. Assessment of disease severity must be no more than 4 weeks old at the time of application. An assessment of a patient's response to this initial course of treatment must be conducted following a minimum of 16 weeks of therapy and no later than 4 weeks prior the completion of this course of treatment. Where a response assessment is not conducted within the required timeframe, the patient will be deemed to have failed to respond to treatment with this drug, unless the patient has experienced a serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment. The authority application must be made in writing and must include: (1) details of the proposed prescription(s); and (2) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice) which includes: (i) the Hurley stage grading; and (ii) the AN count; and (iii) the name of the antibiotic/s received for two separate courses each of three months; or (iv) confirmation that the adverse reaction or allergy to an antibiotic necessitated permanent treatment withdrawal resulting in the patient being unable to complete a three month course of antibiotics. The name of the one course of antibiotics of three months duration must be provided. Where the patient is unable to be treated with any courses of antibiotics the prescriber must confirm that the patient has a history of adverse reaction or allergy necessitating permanent treatment withdrawal to two different antibiotics. This restriction is intended for induction dosing only. Details of two completed prescriptions should be submitted with every initial application for this drug. One prescription should be for the induction doses, containing a quantity of 8 doses of 150 mg and no repeats and the second prescription should be for 2 doses of 150 mg and 3 repeats. Serious adverse reaction of a severity resulting in the necessity for permanent withdrawal of treatment is not considered as a treatment failure. | Compliance with Written Authority Required procedures |
C15814 | P15814 | CN15814 | Ganciclovir Valganciclovir | Cytomegalovirus infection and disease Patient must be a solid organ transplant recipient at risk of cytomegalovirus disease. | Compliance with Authority Required procedures - Streamlined Authority Code 15814 |
C15818 | P15818 | P15818 | Trastuzumab emtansine | Early HER2 positive breast cancer Initial adjuvant treatment The treatment must be prescribed within 12 weeks after surgery; AND Patient must have, prior to commencing treatment with this drug, evidence of residual invasive cancer in the breast and/or axillary lymph nodes following completion of surgery, as demonstrated by a pathology report; AND Patient must have completed systemic neoadjuvant therapy that included trastuzumab and taxane-based chemotherapy prior to surgery; AND The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure; AND The treatment must not extend beyond 42 weeks (14 cycles) duration under the initial and the continuing treatment restrictions combined. Authority applications for initial treatment must be made via the Online PBS Authorities System (real time assessment), or in writing via HPOS form upload or mail and must include: (a) details (date, unique identifying number/code or provider number) of the pathology report from an Approved Pathology Authority demonstrating evidence of residual invasive carcinoma in the breast and/or axillary lymph nodes following completion of surgery. The pathology report must be documented in the patient's medical records. If the application is submitted through HPOS form upload or mail, it must include: (i) details of the proposed prescription; and (ii) a completed authority application form relevant to the indication and treatment phase (the latest version is located on the website specified in the Administrative Advice). Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg. | Compliance with Written Authority Required procedures |
C15819 | P15819 | P15819 | Trastuzumab emtansine | Early HER2 positive breast cancer Continuing adjuvant treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND Patient must not have developed disease progression while being treated with this drug for this condition; AND The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure; AND The treatment must not extend beyond 42 weeks (14 cycles) duration under the initial and the continuing treatment restrictions combined. Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg. | Compliance with Authority Required procedures |
C15820 | P15820 | CN15820 | Trastuzumab | Early HER2 positive breast cancer Initial treatment (3 weekly regimen) Patient must have undergone surgery (adjuvant) or be preparing for surgery (neoadjuvant); AND The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure; AND Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy; OR Patient must not receive more than 52 weeks of combined trastuzumab and trastuzumab emtansine therapy if adjuvant trastuzumab emtansine therapy has been discontinued due to intolerance. HER2 positivity must be demonstrated by in situ hybridisation (ISH). Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to initiating treatment with this drug for this condition. Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg. | Compliance with Authority Required procedures - Streamlined Authority Code 15820 |
C15826 | P15826 | CN15826 | Trastuzumab deruxtecan | Metastatic (Stage IV) HER2 positive breast cancer Patient must have evidence of human epidermal growth factor (HER2) gene amplification as demonstrated by in situ hybridisation (ISH) in either the primary tumour/a metastatic lesion - establish this finding once only with the first PBS prescription; AND The condition must have progressed following treatment with at least one prior HER2 directed regimen for metastatic breast cancer; OR The condition must have, at the time of treatment initiation with this drug, progressed during/within 6 months following adjuvant treatment with a HER2 directed therapy; AND Patient must have, at the time of initiating treatment with this drug, a WHO performance status no higher than 1; AND The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; AND The treatment must not be prescribed where any of the following is present: (i) left ventricular ejection fraction of less than 50%, (ii) symptomatic heart failure; confirm cardiac function testing for the first PBS prescription only. Patient must be undergoing initial treatment with this drug - the following are true: (i) this is the first prescription for this drug, (ii) this prescription seeks no more than 3 repeat prescriptions; OR Patient must be undergoing continuing treatment with drug - the following are true: (i) there has been an absence of further disease progression whilst on active treatment with this drug, (ii) this prescription does not seek to re-treat after disease progression, (iii) this prescription seeks no more than 8 repeat prescriptions. Confirm that the following information is documented/retained in the patient's medical records once only with the first PBS prescription: 1) Evidence of HER2 gene amplification (evidence obtained in relation to past PBS treatment is acceptable). 2) Details of prior HER2 directed drug regimens prescribed for the patient. 3) Cardiac function test results (evidence obtained in relation to past PBS treatment is acceptable). Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg. | Compliance with Authority Required procedures |
C15827 | P15827 | CN15827 | Trastuzumab emtansine | Metastatic (Stage IV) HER2 positive breast cancer Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for metastatic (Stage IV) HER2 positive breast cancer; AND Patient must not receive PBS-subsidised treatment with this drug if progressive disease develops while on this drug; AND The treatment must be the sole PBS-subsidised therapy for this condition; AND The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure. A patient who has progressive disease when treated with this drug is no longer eligible for PBS-subsidised treatment with this drug. The treatment must not exceed a lifetime total of one continuous course for this PBS indication. Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg. | Compliance with Authority Required procedures |
C15828 | P15828 | CN15828 | Trastuzumab emtansine | Metastatic (Stage IV) HER2 positive breast cancer Initial treatment Patient must have evidence of human epidermal growth factor receptor 2 (HER2) gene amplification as demonstrated by in situ hybridisation (ISH) either in the primary tumour or a metastatic lesion, confirmed through a pathology report from an Approved Pathology Authority; AND The condition must have progressed following treatment with pertuzumab and trastuzumab in combination; OR The condition must have progressed during or within 6 months of completing adjuvant therapy with trastuzumab; AND Patient must have a WHO performance status of 0 or 1; AND The treatment must be the sole PBS-subsidised therapy for this condition; AND The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure. The following information must be provided by the prescriber at the time of application: (a) details (date, unique identifying number/code or provider number) of the pathology report from an Approved Pathology Authority confirming evidence of HER2 gene amplification in the primary tumour or a metastatic lesion by in situ hybridisation (ISH). (b) dates of treatment with trastuzumab and pertuzumab; (c) date of demonstration of progression following treatment with trastuzumab and pertuzumab; or (d) date of demonstration of progression and date of completion of adjuvant trastuzumab treatment. If intolerance to treatment develops during the relevant period of use, which is of a severity necessitating permanent treatment withdrawal, please provide details of the degree of this toxicity at the time of application. All reports must be documented in the patient's medical records. Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to seeking the initial authority approval. Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg. | Compliance with Authority Required procedures |
C15831 | P15831 | CN15831 | Trastuzumab | Early HER2 positive breast cancer Initial treatment (weekly regimen) Patient must have undergone surgery (adjuvant) or be preparing for surgery (neoadjuvant); AND The treatment must not be used in a patient with a left ventricular ejection fraction (LVEF) of less than 45% and/or with symptomatic heart failure; AND Patient must not receive more than 52 weeks of combined PBS-subsidised and non-PBS-subsidised therapy; OR Patient must not receive more than 52 weeks of combined trastuzumab and trastuzumab emtansine therapy if adjuvant trastuzumab emtansine therapy has been discontinued due to intolerance. HER2 positivity must be demonstrated by in situ hybridisation (ISH). Cardiac function must be tested by echocardiography (ECHO) or multigated acquisition (MUGA), prior to initiating treatment with this drug for this condition. Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg. | Compliance with Authority Required procedures - Streamlined Authority Code 15831 |
C15832 | P15832 | CN15832 | Trastuzumab deruxtecan | Unresectable and/or metastatic HER2-low breast cancer Patient must have evidence of human epidermal growth factor receptor 2 (HER2)-low disease; AND Patient must have received prior chemotherapy in the metastatic setting; OR Patient must have developed disease recurrence during or within 6 months of completing adjuvant chemotherapy; AND Patient must have received or be ineligible for endocrine therapy in the metastatic setting, if hormone receptor positive; AND Patient must have, at the time of initiating treatment with this drug, a WHO performance status no higher than 1; AND The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication; AND The treatment must not be prescribed where any of the following is present: (i) left ventricular ejection fraction of less than 50%, (ii) symptomatic heart failure; confirm cardiac function testing for the first PBS prescription only. Patient must be undergoing initial treatment with this drug - the following are true: (i) this is the first prescription for this drug, (ii) this prescription seeks no more than 3 repeat prescriptions; OR Patient must be undergoing continuing treatment with drug - the following are true: (i) there has been an absence of further disease progression whilst on active treatment with this drug, (ii) this prescription does not seek to re-treat after disease progression, (iii) this prescription seeks no more than 8 repeat prescriptions. HER2-low is defined as an immunohistochemical (IHC) score of 1+ or an IHC score of 2+ and a negative result on in situ hybridization (ISH). Confirm that the following information is documented/retained in the patient's medical records once only with the first PBS prescription: 1) Evidence of HER2-low status 2) Details of prior drug regimens prescribed for the patient 3) Cardiac function test results Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg. | Compliance with Authority Required procedures |
V15818 | Trastuzumab emtansine | Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg |
V15819 | Trastuzumab emtansine | Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg |
V15820 | Trastuzumab | Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg |
V15826 | Trastuzumab deruxtecan | Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg |
V15827 | Trastuzumab emtansine | Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg |
V15828 | Trastuzumab emtansine | Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg |
V15831 | Trastuzumab | Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg |
V15832 | Trastuzumab deruxtecan | Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg |
V15818 | Trastuzumab emtansine | Increased maximum amounts may only be authorised where a patient's weight is greater than 125 kg |
omit table and substitute:
Listed Drug | Schedule Equivalent Group | Form | Manner of Administration | Brand |
Abacavir with lamivudine | GRP-21981 | Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg | Oral | ABACAVIR/LAMIVUDINE 600/300 SUN |
Acalabrutinib | GRP-27509 | Capsule 100 mg | Oral | Calquence |
Acalabrutinib | GRP-27509 | Tablet 100 mg | Oral | CALQUENCE |
Acamprosate | GRP-22403 | Tablet (enteric coated) containing acamprosate calcium 333 mg | Oral | ACAMPROSATE VIATRIS |
Acarbose | GRP-20709 | Tablet 100 mg | Oral | Acarbose Viatris |
Acarbose | GRP-20718 | Tablet 50 mg | Oral | Acarbose Viatris |
Aciclovir | GRP-22959 | Eye ointment 30 mg per g, 4.5 g | Application to the eye | ViruPOS |
Aciclovir | GRP-15446 | Tablet 200 mg | Oral | ACICLOVIR-WGR |
Aciclovir | GRP-19838 | Tablet 800 mg | Oral | ACICLOVIR-WGR |
Acitretin | GRP-19579 | Capsule 10 mg | Oral | Neotigason |
Acitretin | GRP-19580 | Capsule 25 mg | Oral | Neotigason |
Adalimumab | GRP-25059 | Injection 20 mg in 0.2 mL pre-filled syringe | Injection | Humira |
Adalimumab | GRP-25059 | Injection 20 mg in 0.4 mL pre-filled syringe | Injection | Abrilada |
Adalimumab | GRP- 25060 | Injection 40 mg in 0.4 mL pre-filled pen | Injection | Adalicip |
Adalimumab | GRP- 25060 | Injection 40 mg in 0.8 mL pre-filled pen | Injection | Abrilada |
Adalimumab | GRP- 25058 | Injection 40 mg in 0.4 mL pre-filled syringe | Injection | Adalicip |
Adalimumab | GRP- 25058 | Injection 40 mg in 0.8 mL pre-filled syringe | Injection | Abrilada |
Adefovir | GRP-28116 | Tablet containing adefovir dipivoxil 10 mg | Oral | APO-Adefovir |
Adefovir | GRP-28116 | Tablet containing adefovir dipivoxil 10 mg (S19A) | Oral | Adefovir Dipivoxil Tablets 10 mg (SigmaPharm Laboratories) |
Adrenaline (epinephrine) | GRP-22361 | I.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injector | Injection | Adrenaline Viatris |
Adrenaline (epinephrine) | GRP-22391 | I.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injector | Injection | Adrenaline Jr Viatris |
Aflibercept | GRP-24277 | Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL) | Injection | Eylea |
Aflibercept | GRP-24277 | Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe | Injection | Eylea |
Alendronic acid | GRP-19660 | Tablet 70 mg (as alendronate sodium) | Oral | ALENDRONATE-WGR |
Allopurinol | GRP-15579 | Tablet 100 mg | Oral | ALLOPURINOL-WGR |
Allopurinol | GRP-19808 | Tablet 300 mg | Oral | ALLOPURINOL-WGR |
Alprazolam | GRP-21739 | Tablet 500 micrograms | Oral | Alprax 0.5 |
Alprazolam | GRP-21744 | Tablet 1 mg | Oral | Alprax 1 |
Amantadine | GRP-28296 | Capsule containing amantadine hydrochloride 100 mg | Oral | AMANTAMED |
Ambrisentan | GRP-24436 | Tablet 5 mg | Oral | Ambrisentan Viatris |
Ambrisentan | GRP-24438 | Tablet 10 mg | Oral | Ambrisentan Viatris |
Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides | GRP-27823 | Oral powder 400 g (Alfamino) | Oral | Alfamino |
Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides | GRP-27823 | Oral powder with 2'-fucosyllactose and lacto-N-neotetraose, 400 g (Alfamino) | Oral | Alfamino |
Amiodarone | GRP-19644 | Tablet containing amiodarone hydrochloride 100 mg | Oral | Aratac 100 |
Amiodarone | GRP-19926 | Tablet containing amiodarone hydrochloride 200 mg | Oral | APO-Amiodarone |
Amisulpride | GRP-19672 | Tablet 200 mg | Oral | AMISULPRIDE-WGR |
Amisulpride | GRP-19732 | Tablet 400 mg | Oral | AMISULPRIDE-WGR |
Amisulpride | GRP-19930 | Tablet 100 mg | Oral | AMISULPRIDE-WGR |
Amitriptyline | GRP-19959 | Tablet containing amitriptyline hydrochloride 25 mg | Oral | AMITRIPTYLINE-WGR |
Amitriptyline | GRP-19960 | Tablet containing amitriptyline hydrochloride 10 mg | Oral | AMITRIPTYLINE-WGR |
Amitriptyline | GRP-19962 | Tablet containing amitriptyline hydrochloride 50 mg | Oral | APO-Amitriptyline 50 |
Amlodipine | GRP-19712 | Tablet 5 mg (as besilate) | Oral | AMLODIPINE-WGR |
Amlodipine | GRP-19809 | Tablet 10 mg (as besilate) | Oral | AMLODIPINE-WGR |
Amlodipine with atorvastatin | GRP-19632 | Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | Oral | Cadivast 5/80 |
Amlodipine with atorvastatin | GRP-19666 | Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) | Oral | Cadivast 10/20 |
Amlodipine with atorvastatin | GRP-19713 | Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) | Oral | Cadivast 10/10 |
Amlodipine with atorvastatin | GRP-19788 | Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | Oral | Cadivast 5/40 |
Amlodipine with atorvastatin | GRP-19849 | Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) | Oral | Cadivast 10/40 |
Amlodipine with atorvastatin | GRP-19927 | Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) | Oral | Cadivast 10/80 |
Amlodipine with valsartan | GRP-19839 | Tablet 5 mg (as besilate)-80 mg | Oral | Amlodipine/Valsartan Novartis 5/80 |
Amlodipine with valsartan | GRP-22201 | Tablet 10 mg (as besilate)-160 mg | Oral | Amlodipine/Valsartan Novartis 10/160 |
Amlodipine with valsartan | GRP-22208 | Tablet 5 mg (as besilate)-320 mg | Oral | Amlodipine/Valsartan Novartis 5/320 |
Amlodipine with valsartan | GRP-22209 | Tablet 5 mg (as besilate)-160 mg | Oral | Amlodipine/Valsartan Novartis 5/160 |
Amlodipine with valsartan | GRP-22211 | Tablet 10 mg (as besilate)-320 mg | Oral | Amlodipine/Valsartan Novartis 10/320 |
Amlodipine with valsartan and hydrochlorothiazide | GRP-19956 | Tablet 5 mg (as besilate)-160 mg-12.5 mg | Oral | Amlodipine/Valsartan/HCT Novartis 5/160/12.5 |
Amlodipine with valsartan and hydrochlorothiazide | GRP-22202 | Tablet 10 mg (as besilate)-160 mg-25 mg | Oral | Amlodipine/Valsartan/HCT Novartis 10/160/25 |
Amlodipine with valsartan and hydrochlorothiazide | GRP-22203 | Tablet 10 mg (as besilate)-160 mg-12.5 mg | Oral | Amlodipine/Valsartan/HCT Novartis 10/160/12.5 |
Amlodipine with valsartan and hydrochlorothiazide | GRP-22204 | Tablet 5 mg (as besilate)-160 mg-25 mg | Oral | Amlodipine/Valsartan/HCT Novartis 5/160/25 |
Amlodipine with valsartan and hydrochlorothiazide | GRP-22207 | Tablet 10 mg (as besilate)-320 mg-25 mg | Oral | Amlodipine/Valsartan/HCT Novartis 10/320/25 |
Amoxicillin | GRP-19635 | Tablet 1 g (as trihydrate) | Oral | Amoxycillin Sandoz |
Amoxicillin | GRP-20061 | Powder for oral suspension 125 mg (as trihydrate) per 5 mL, 100 mL | Oral | APO-Amoxycillin |
Amoxicillin | GRP-20029 | Capsule 250 mg (as trihydrate) | Oral | AMILOXYN |
Amoxicillin | GRP-20241 | Capsule 500 mg (as trihydrate) | Oral | AMILOXYN |
Amoxicillin | GRP-26767 | Powder for oral suspension 250 mg (as trihydrate) per 5 mL, 100 mL | Oral | AMOXICILLIN-WGR |
Amoxicillin with clavulanic acid | GRP-20135 | Tablet containing 500 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMCLAVOX DUO 500/125 |
Amoxicillin with clavulanic acid | GRP-26768 | Tablet containing 875 mg amoxicillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate) | Oral | AMCLAVOX DUO FORTE 875/125 |
Amoxicillin with clavulanic acid | GRP-28006 | Powder for oral suspension containing 400 mg amoxicillin (as trihydrate) with 57 mg clavulanic acid (as potassium clavulanate) per 5 mL, 60 mL | Oral | Augmentin Duo 400 |
Amoxicillin with clavulanic acid | GRP-29087 | Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 100 mL (S19A) | Oral | CLAVULIN-125F (GlaxoSmithKline, Canada) |
Amoxicillin with clavulanic acid | GRP-29087 | Powder for oral suspension containing 125 mg amoxicillin (as trihydrate) with 31.25 mg clavulanic acid (as potassium clavulanate) per 5 mL, 75 mL | Oral | Curam |
Anastrozole | GRP-19931 | Tablet 1 mg | Oral | ANASTROZOLE-WGR |
Apomorphine | GRP-22998 | Solution for subcutaneous injection containing apomorphine hydrochloride 30 mg in 3 mL pre-filled pen | Injection | Apomine Intermittent |
Aprepitant | GRP-23389 | Capsule 165 mg | Oral | APREPITANT SCP |
Aripiprazole | GRP-20893 | Tablet 10 mg | Oral | APO-Aripiprazole |
Aripiprazole | GRP-20895 | Tablet 15 mg | Oral | APO-Aripiprazole |
Aripiprazole | GRP-20908 | Tablet 30 mg | Oral | APO-Aripiprazole |
Aripiprazole | GRP-20910 | Tablet 20 mg | Oral | APO-Aripiprazole |
Atenolol | GRP-19895 | Tablet 50 mg | Oral | APO-Atenolol |
Atomoxetine | GRP-20889 | Capsule 25 mg (as hydrochloride) | Oral | APO-Atomoxetine |
Atomoxetine | GRP-20897 | Capsule 10 mg (as hydrochloride) | Oral | APO-Atomoxetine |
Atomoxetine | GRP-20900 | Capsule 40 mg (as hydrochloride) | Oral | APO-Atomoxetine |
Atomoxetine | GRP-20901 | Capsule 80 mg (as hydrochloride) | Oral | APO-Atomoxetine |
Atomoxetine | GRP-20902 | Capsule 100 mg (as hydrochloride) | Oral | APO-Atomoxetine |
Atomoxetine | GRP-20903 | Capsule 60 mg (as hydrochloride) | Oral | APO-Atomoxetine |
Atomoxetine | GRP-20905 | Capsule 18 mg (as hydrochloride) | Oral | APO-Atomoxetine |
Atorvastatin | GRP-19975 | Tablet 20 mg (as calcium) | Oral | APO-Atorvastatin |
Atorvastatin | GRP-19978 | Tablet 10 mg (as calcium) | Oral | APO-Atorvastatin |
Atorvastatin | GRP-20048 | Tablet 40 mg (as calcium) | Oral | APO-Atorvastatin |
Atorvastatin | GRP-20251 | Tablet 80 mg (as calcium) | Oral | APO-Atorvastatin |
Atovaquone with proguanil | GRP-27571 | Tablet containing atovaquone 250 mg with proguanil hydrochloride 100 mg | Oral | AtovaquoPro Lupin 250/100 |
Azacitidine | GRP-20703 | Powder for injection 100 mg | Injection | AZACITIDINE EUGIA |
Azathioprine | GRP-19674 | Tablet 50 mg | Oral | APO-Azathioprine |
Azathioprine | GRP-19937 | Tablet 25 mg | Oral | APO-Azathioprine |
Azithromycin | GRP-19990 | Tablet 500 mg (as dihydrate) | Oral | APO-Azithromycin |
Azithromycin | GRP-29088 | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL | Oral | Zithromax |
Azithromycin | GRP-29088 | Powder for oral suspension 200 mg (as dihydrate) per 5 mL, 15 mL (S19A) | Oral | Azithromycin (Zydus, USA) |
Baclofen | GRP-21530 | Intrathecal injection 10 mg in 5 mL | Injection | Bacthecal |
Baclofen | GRP-19905 | Tablet 25 mg | Oral | APO-Baclofen |
Baclofen | GRP-19941 | Tablet 10 mg | Oral | APO-Baclofen |
Benzathine benzylpenicillin | GRP-28213 | Powder for injection 1,200,000 units with diluent 5 mL (S19A) | Injection | Extencilline Benzathine Benzylpenicillin (France) |
Benzathine benzylpenicillin | GRP-28213 | Injection containing 1,200,000 units benzathine benzylpenicillin tetrahydrate in 2.3 mL single use pre-filled syringe | Injection | Bicillin L-A |
Betamethasone | GRP-19733 | Cream 500 micrograms (as valerate) per g, 15 g | Application | Betnovate 1/2 |
Betamethasone | GRP-19946 | Cream 200 micrograms (as valerate) per g, 100 g | Application | Betnovate 1/5 |
Betamethasone | GRP-19782 | Cream 200 micrograms (as valerate) per g, 100 g | Application | Antroquoril |
Betamethasone | GRP-19864 | Cream 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone |
Betamethasone | GRP-19903 | Ointment 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone |
Betaxolol | GRP-20098 | Eye drops, solution, 5 mg (as hydrochloride) per mL, 5 mL | Application to the eye | BetoQuin |
Bicalutamide | GRP-19638 | Tablet 50 mg | Oral | APO-Bicalutamide |
Bimatoprost | GRP-21740 | Eye drops 300 micrograms per mL, 3 mL | Application to the eye | BIMATOPROST-WGR |
Bisacodyl | GRP-20157 | Suppositories 10 mg, 10 | Rectal | Dulcolax |
Bisoprolol | GRP-19779 | Tablet containing bisoprolol fumarate 2.5 mg | Oral | APO-Bisoprolol |
Bisoprolol | GRP-19812 | Tablet containing bisoprolol fumarate 5 mg | Oral | APO-Bisoprolol |
Bisoprolol | GRP-19813 | Tablet containing bisoprolol fumarate 10 mg | Oral | APO-Bisoprolol |
Bivalirudin | GRP-21165 | Powder for I.V. injection 250 mg (as trifluoroacetate) | Injection | BIVALIRUDIN ARX |
Bosentan | GRP-21629 | Tablet 125 mg (as monohydrate) | Oral | BOSENTAN DR.REDDY'S |
Bosentan | GRP-21635 | Tablet 62.5 mg (as monohydrate) | Oral | BOSENTAN DR.REDDY'S |
Brimonidine | GRP-20314 | Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL | Application to the eye | Alphagan |
Brinzolamide | GRP-20064 | Eye drops 10 mg per mL, 5 mL | Application to the eye | Azopt |
Budesonide with formoterol | GRP-22143 | Powder for oral inhalation in breath actuated device containing budesonide 400 micrograms with formoterol fumarate dihydrate 12 micrograms per dose, 60 doses | Inhalation by mouth | BiResp Spiromax |
Budesonide with formoterol | GRP-22141 | Powder for oral inhalation in breath actuated device containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | BiResp Spiromax |
Budesonide with formoterol | GRP-27568 | Pressurised inhalation containing budesonide 100 micrograms with formoterol fumarate dihydrate 3 micrograms per dose, 120 doses | Inhalation by mouth | Rilast RAPIHALER 100/3 |
Budesonide with formoterol | GRP-27583 | Pressurised inhalation containing budesonide 200 micrograms with formoterol fumarate dihydrate 6 micrograms per dose, 120 doses | Inhalation by mouth | Rilast RAPIHALER 200/6 |
Buprenorphine | GRP-22372 | Transdermal patch 20 mg | Transdermal | B-Patch |
Buprenorphine | GRP-22373 | Transdermal patch 10 mg | Transdermal | B-Patch |
Buprenorphine | GRP-22384 | Transdermal patch 5 mg | Transdermal | B-Patch |
Buprenorphine | GRP-22459 | Transdermal patch 15 mg | Transdermal | B-Patch |
Buprenorphine | GRP-24286 | Transdermal patch 25 mg | Transdermal | Bupredermal |
Buprenorphine | GRP-24274 | Transdermal patch 30 mg | Transdermal | Bupredermal |
Buprenorphine | GRP-24293 | Transdermal patch 40 mg | Transdermal | Bupredermal |
Calcipotriol with betamethasone | GRP-21266 | Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g | Application | Calcipotriol/Betamethasone Sandoz 50/500 |
Calcitriol | GRP-19708 | Capsule 0.25 microgram | Oral | APO-Calcitriol |
Candesartan | GRP-19554 | Tablet containing candesartan cilexetil 8 mg | Oral | APO-Candesartan |
Candesartan | GRP-19564 | Tablet containing candesartan cilexetil 32 mg | Oral | APO-Candesartan |
Candesartan | GRP-19566 | Tablet containing candesartan cilexetil 4 mg | Oral | APO-Candesartan |
Candesartan | GRP-19568 | Tablet containing candesartan cilexetil 16 mg | Oral | APO-Candesartan |
Candesartan with hydrochlorothiazide | GRP-19559 | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg | Oral | APO-Candesartan HCTZ 32/25 |
Candesartan with hydrochlorothiazide | GRP-19563 | Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg | Oral | APO-Candesartan HCTZ 32/12.5 |
Candesartan with hydrochlorothiazide | GRP-19567 | Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg | Oral | APO-Candesartan HCTZ 16/12.5 |
Capecitabine | GRP-19591 | Tablet 500 mg | Oral | Capecitabine Alphapharm |
Carbamazepine | GRP-14653 | Tablet 200 mg | Oral | Carbamazepine Sandoz |
Carbamazepine | GRP-19583 | Tablet 100 mg | Oral | Carbamazepine Sandoz |
Carbimazole | GRP-24069 | Tablet 5 mg | Oral | Neo-Mercazole |
Carbomer | GRP-20037 | Eye gel 2 mg per g, 10 g | Application to the eye | Optifresh eye gel |
Carvedilol | GRP-19636 | Tablet 12.5 mg | Oral | APO-Carvedilol |
Carvedilol | GRP-19677 | Tablet 25 mg | Oral | APO-Carvedilol |
Carvedilol | GRP-19703 | Tablet 3.125 mg | Oral | APO-Carvedilol |
Carvedilol | GRP-19799 | Tablet 6.25 mg | Oral | APO-Carvedilol |
Cefaclor | GRP-19974 | Tablet (sustained release) 375 mg (as monohydrate) | Oral | Ceclor CD |
Cefaclor | GRP-20159 | Powder for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL | Oral | Aclor 125 |
Cefaclor | GRP-20181 | Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL | Oral | Aclor 250 |
Cefalexin | GRP-20166 | Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL | Oral | Cefalexin Sandoz |
Cefalexin | GRP-20033 | Capsule 250 mg (as monohydrate) | Oral | APO-Cephalexin |
Cefalexin | GRP-20298 | Capsule 500 mg (as monohydrate) | Oral | APO-Cephalexin |
Cefalexin | GRP-27406 | Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL | Oral | Cefalexin Sandoz |
Cefuroxime | GRP-22638 | Tablet 250 mg (as axetil) | Oral | Pharmacor Cefuroxime |
Celecoxib | GRP-19618 | Capsule 100 mg | Oral | APX-Celecoxib |
Celecoxib | GRP-19623 | Capsule 200 mg | Oral | APX-Celecoxib |
Ciclosporin | GRP-20026 | Capsule 100 mg | Oral | APO-Ciclosporin |
Ciclosporin | GRP-20143 | Capsule 50 mg | Oral | APO-Ciclosporin |
Ciclosporin | GRP-20032 | Capsule 25 mg | Oral | APO-Ciclosporin |
Cinacalcet | GRP-24882 | Tablet 30 mg (as hydrochloride) | Oral | Cinacalcet Viatris |
Cinacalcet | GRP-24888 | Tablet 60 mg (as hydrochloride) | Oral | Cinacalcet Viatris |
Cinacalcet | GRP-24892 | Tablet 90 mg (as hydrochloride) | Oral | Cinacalcet Viatris |
Ciprofloxacin | GRP-19988 | Eye drops 3 mg (as hydrochloride) per mL, 5 mL | Application to the eye | CiloQuin |
Ciprofloxacin | GRP-19723 | Tablet 750 mg (as hydrochloride) | Oral | APO-Ciprofloxacin |
Ciprofloxacin | GRP-19859 | Tablet 500 mg (as hydrochloride) | Oral | APO-Ciprofloxacin |
Ciprofloxacin | GRP-19910 | Tablet 250 mg (as hydrochloride) | Oral | APO-Ciprofloxacin |
Citalopram | GRP-19656 | Tablet 40 mg (as hydrobromide) | Oral | APO-Citalopram |
Citalopram | GRP-19940 | Tablet 20 mg (as hydrobromide) | Oral | APO-Citalopram |
Citalopram | GRP-19953 | Tablet 10 mg (as hydrobromide) | Oral | Celapram |
Clarithromycin | GRP-19649 | Tablet 250 mg | Oral | Clarithro 250 |
Clindamycin | GRP-19995 | Capsule 150 mg (as hydrochloride) | Oral | APO-Clindamycin |
Clomipramine | GRP-19890 | Tablet containing clomipramine hydrochloride 25 mg | Oral | APO-Clomipramine |
Clonazepam | GRP-22717 | Tablet 500 micrograms | Oral | Paxam 0.5 |
Clonidine | GRP-21381 | Tablet containing clonidine hydrochloride 100 micrograms | Oral | APO-Clonidine |
Clopidogrel | GRP-17110 | Tablet 75 mg (as besilate) | Oral | CLOPIDOGREL-WGR |
Clopidogrel | GRP-17110 | Tablet 75 mg (as hydrogen sulfate) | Oral | Blooms Clopidogrel |
Clopidogrel with aspirin | GRP-19773 | Tablet 75 mg (as hydrogen sulfate)-100 mg | Oral | APX-Clopidogrel/Aspirin 75/100 |
Codeine with paracetamol | GRP-20169 | Tablet containing codeine phosphate hemihydrate 30 mg with paracetamol 500 mg | Oral | APO- Paracetamol/Codeine 500/30 |
Colchicine | GRP-19820 | Tablet 500 micrograms | Oral | Colcine |
Cyproterone | GRP-19722 | Tablet containing cyproterone acetate 50 mg | Oral | ANTERONE 50 |
Cyproterone | GRP-19842 | Tablet containing cyproterone acetate 100 mg | Oral | ANTERONE 100 |
Dabigatran etexilate | GRP-28121 | Capsule 110 mg (as mesilate) | Oral | ARX-Dabigatran |
Dabigatran etexilate | GRP-28118 | Capsule 150 mg (as mesilate) | Oral | ARX-Dabigatran |
Dabigatran etexilate | GRP-28127 | Capsule 75 mg (as mesilate) | Oral | ARX-Dabigatran |
Darunavir | GRP-24212 | Tablet 600 mg | Oral | Darunavir Juno |
Darunavir | GRP-24212 | Tablet 600 mg (as ethanolate) | Oral | Prezista |
Darunavir | GRP-25566 | Tablet 800 mg | Oral | Darunavir Juno |
Darunavir | GRP-25566 | Tablet 800 mg (as ethanolate) | Oral | Prezista |
Dasatinib | GRP-25848 | Tablet 70 mg | Oral | DASATINIB-TEVA |
Dasatinib | GRP-25853 | Tablet 50 mg | Oral | DASATINIB-TEVA |
Dasatinib | GRP-25849 | Tablet 20 mg | Oral | DASATINIB-TEVA |
Dasatinib | GRP-25880 | Tablet 100 mg | Oral | DASATINIB-TEVA |
Deferasirox | GRP-25387 | Tablet 180 mg | Oral | DEFERASIROX-TEVA |
Deferasirox | GRP-25385 | Tablet 90 mg | Oral | DEFERASIROX-TEVA |
Deferasirox | GRP-25395 | Tablet 360 mg | Oral | DEFERASIROX-TEVA |
Deferasirox | GRP-28209 | Tablet, dispersible, 125 mg | Oral | Deferasirox Juno |
Deferasirox | GRP-28219 | Tablet, dispersible, 500 mg | Oral | Deferasirox Juno |
Deferasirox | GRP-28210 | Tablet, dispersible, 250 mg | Oral | Deferasirox Juno |
Desmopressin | GRP-24629 | Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 50 actuations, 5 mL, USP (Apotex) | Nasal | Desmopressin Nasal Spray USP (Apotex) |
Desmopressin | GRP-24629 | Nasal spray (pump pack) containing desmopressin acetate 10 micrograms per actuation, 60 actuations, 6 mL | Nasal | Minirin Nasal Spray |
Desvenlafaxine | GRP-16219 | Tablet (extended release) 100 mg (as succinate) | Oral | Pristiq |
Desvenlafaxine | GRP-16219 | Tablet (modified release) 100 mg | Oral | BTC Desvenlafaxine |
Desvenlafaxine | GRP-16219 | Tablet (modified release) 100 mg (as benzoate) | Oral | APO-Desvenlafaxine MR |
Desvenlafaxine | GRP-16220 | Tablet (extended release) 50 mg (as succinate) | Oral | Pristiq |
Desvenlafaxine | GRP-16220 | Tablet (modified release) 50 mg | Oral | BTC Desvenlafaxine |
Desvenlafaxine | GRP-16220 | Tablet (modified release) 50 mg (as benzoate) | Oral | APO-Desvenlafaxine MR |
Dexamethasone with framycetin and gramicidin | GRP-19777 | Ear drops containing dexamethasone 500 micrograms (as sodium metasulfobenzoate), framycetin sulfate 5 mg and gramicidin 50 micrograms per mL, 8 mL | Application to the ear | Otodex |
Diazepam | GRP-20001 | Tablet 5 mg | Oral | APO-Diazepam |
Diazepam | GRP-20081 | Tablet 2 mg | Oral | APO-Diazepam |
Diclofenac | GRP-20116 | Tablet (enteric coated) containing diclofenac sodium 50 mg | Oral | APO-Diclofenac |
Diclofenac | GRP-20112 | Tablet (enteric coated) containing diclofenac sodium 25 mg | Oral | APO-Diclofenac |
Dicloxacillin | GRP-20360 | Capsule 500 mg (as sodium) | Oral | DICLOXACILLIN VIATRIS 500 |
Dicloxacillin | GRP-22402 | Capsule 250 mg (as sodium) | Oral | DICLOXACILLIN VIATRIS 250 |
Digoxin | GRP-19717 | Tablet 250 micrograms | Oral | Lanoxin |
Digoxin | GRP-19774 | Tablet 62.5 micrograms | Oral | Lanoxin-PG |
Diltiazem | GRP-19652 | Capsule (controlled delivery) containing diltiazem hydrochloride 180 mg | Oral | Cardizem CD |
Diltiazem | GRP-19869 | Tablet containing diltiazem hydrochloride 60 mg | Oral | Cardizem |
Diltiazem | GRP-19894 | Capsule (controlled delivery) containing diltiazem hydrochloride 240 mg | Oral | Cardizem CD |
Diltiazem | GRP-19934 | Capsule (controlled delivery) containing diltiazem hydrochloride 360 mg | Oral | Cardizem CD |
Dimethyl fumarate | GRP-26010 | Capsule (modified release) 120 mg | Oral | APO-DIMETHYL FUMARATE |
Dimethyl fumarate | GRP-26012 | Capsule (modified release) 240 mg | Oral | APO-DIMETHYL FUMARATE |
Diphenoxylate with atropine | GRP-19655 | Tablet containing diphenoxylate hydrochloride 2.5 mg with atropine sulfate monohydrate 25 micrograms | Oral | Lofenoxal |
Disopyramide | GRP-27397 | Capsule 100 mg | Oral | Rythmodan |
Disopyramide | GRP-27397 | Capsule 100 mg (s19A) | Oral | Rythmodan (Canada) |
Domperidone | GRP-26945 | Tablet 10 mg | Oral | APO-DOMPERIDONE |
Donepezil | GRP-20245 | Tablet containing donepezil hydrochloride 10 mg | Oral | APO-Donepezil |
Donepezil | GRP-20096 | Tablet containing donepezil hydrochloride 5 mg | Oral | APO-Donepezil |
Dorzolamide | GRP-19989 | Eye drops 20 mg (as hydrochloride) per mL, 5 mL | Application to the eye | Trusamide |
Dorzolamide with timolol | GRP-19979 | Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL | Application to the eye | Cosdor |
Dosulepin | GRP-22377 | Capsule containing dosulepin hydrochloride 25 mg | Oral | Dosulepin Viatris |
Dosulepin | GRP-22392 | Tablet containing dosulepin hydrochloride 75 mg | Oral | Dosulepin Viatris 75 |
Doxorubicin - pegylated liposomal | GRP-19578 | Suspension for I.V. infusion containing pegylated liposomal doxorubicin hydrochloride 20 mg in 10 mL | Injection | Caelyx |
Doxycycline | GRP-14639 | Capsule 100 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx |
Doxycycline | GRP-14639 | Tablet 100 mg (as hyclate) | Oral | APX-Doxycycline |
Doxycycline | GRP-14639 | Tablet 100 mg (as monohydrate) | Oral | Doxycycline Sandoz |
Doxycycline | GRP-15635 | Capsule 50 mg (as hyclate) (containing enteric coated pellets) | Oral | Doryx |
Doxycycline | GRP-15635 | Tablet 50 mg (as hyclate) | Oral | APX-Doxycycline |
Doxycycline | GRP-15635 | Tablet 50 mg (as monohydrate) | Oral | Doxycycline Sandoz |
Duloxetine | GRP-19918 | Capsule 30 mg (as hydrochloride) | Oral | APO-Duloxetine |
Duloxetine | GRP-19957 | Capsule 60 mg (as hydrochloride) | Oral | APO-Duloxetine |
Dutasteride | GRP-21860 | Capsule 500 micrograms | Oral | APO-Dutasteride |
Dutasteride with tamsulosin | GRP-24027 | Capsule containing dutasteride 500 micrograms with tamsulosin hydrochloride 400 micrograms | Oral | Doubluts |
Enalapril | GRP-19633 | Tablet containing enalapril maleate 20 mg | Oral | APO-Enalapril |
Enalapril | GRP-19752 | Tablet containing enalapril maleate 5 mg | Oral | APO-Enalapril |
Enalapril | GRP-19843 | Tablet containing enalapril maleate 10 mg | Oral | APO-Enalapril |
Enalapril with hydrochlorothiazide | GRP-19645 | Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg | Oral | Enalapril/HCT Sandoz |
Enoxaparin | GRP-22367 | Injection containing enoxaparin sodium 40 mg (4,000 I.U. anti-Xa) in 0.4 mL pre-filled syringe | Injection | Clexane Safety-Lock |
Enoxaparin | GRP-22371 | Injection containing enoxaparin sodium 60 mg (6,000 I.U. anti-Xa) in 0.6 mL pre-filled syringe | Injection | Clexane Safety-Lock |
Enoxaparin | GRP-22357 | Injection containing enoxaparin sodium 100 mg (10,000 I.U. anti-Xa) in 1 mL pre-filled syringe | Injection | Clexane Safety-Lock |
Enoxaparin | GRP-22378 | Injection containing enoxaparin sodium 80 mg (8,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Injection | Clexane Safety-Lock |
Enoxaparin | GRP-22387 | Injection containing enoxaparin sodium 20 mg (2,000 I.U. anti-Xa) in 0.2 mL pre-filled syringe | Injection | Clexane Safety-Lock |
Enoxaparin | GRP-28012 | Injection containing enoxaparin sodium 120 mg (12,000 I.U. anti-Xa) in 0.8 mL pre-filled syringe | Injection | Clexane Forte Safety-Lock |
Enoxaparin | GRP-28013 | Injection containing enoxaparin sodium 150 mg (15,000 I.U. anti-Xa) in 1 mL pre-filled syringe | Injection | Clexane Forte Safety-Lock |
Entecavir | GRP-21166 | Tablet 0.5 mg (as monohydrate) | Oral | ENTAC |
Entecavir | GRP-21170 | Tablet 1 mg (as monohydrate) | Oral | ENTECAVIR APO |
Eplerenone | GRP-20704 | Tablet 50 mg | Oral | APO-Eplerenone |
Eplerenone | GRP-20711 | Tablet 25 mg | Oral | APO-Eplerenone |
Epoprostenol | GRP-28614 | Powder for I.V. infusion 1.5 mg (as sodium) | Injection | Veletri |
Epoprostenol | GRP-28614 | Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL | Injection | Flolan |
Epoprostenol | GRP-28616 | Powder for I.V. infusion 500 micrograms (as sodium) | Injection | Veletri |
Epoprostenol | GRP-28616 | Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL | Injection | Flolan |
Erlotinib | GRP-24881 | Tablet 100 mg (as hydrochloride) | Oral | Erlotinib APOTEX |
Erlotinib | GRP-24895 | Tablet 25 mg (as hydrochloride) | Oral | Erlotinib APOTEX |
Erlotinib | GRP-24897 | Tablet 150 mg (as hydrochloride) | Oral | Erlotinib APOTEX |
Escitalopram | GRP-19665 | Tablet 20 mg (as oxalate) | Oral | APO-Escitalopram |
Escitalopram | GRP-19817 | Tablet 10 mg (as oxalate) | Oral | APO-Escitalopram |
Esomeprazole | GRP-17061 | Capsule (enteric) 40 mg (as magnesium) | Oral | Noxicid Caps |
Esomeprazole | GRP-17061 | Tablet (enteric coated) 40 mg (as magnesium trihydrate) | Oral | APO-Esomeprazole |
Esomeprazole | GRP-17188 | Capsule (enteric) 20 mg (as magnesium) | Oral | Noxicid Caps |
Esomeprazole | GRP-17188 | Tablet (enteric coated) 20 mg (as magnesium trihydrate) | Oral | APO-Esomeprazole |
Esomeprazole and clarithromycin and amoxicillin | GRP-20639 | Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium trihydrate), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) | Oral | Nexium Hp7 |
Esomeprazole and clarithromycin and amoxicillin | GRP-20639 | Pack containing 14 tablets (enteric coated) containing esomeprazole 20 mg (as magnesium), 14 tablets clarithromycin 500 mg and 28 capsules amoxicillin 500 mg (as trihydrate) | Oral | ESOMEPRAZOLE SANDOZ Hp7 |
Estradiol | GRP-28649 | Transdermal patches 585 micrograms, 8 | Transdermal | Estradiol Transdermal System (Sandoz, USA) |
Estradiol | GRP-28651 | Transdermal patches 1.17 mg, 8 | Transdermal | Estradiol Transdermal System (Sandoz, USA) |
Estradiol | GRP-28652 | Transdermal patches 1.56 mg, 8 | Transdermal | Estradiol Transdermal System (Sandoz, USA) |
Estradiol | GRP-27217 | Pessary (modified release) 10 micrograms (as hemihydrate) | Vaginal | Estro-Pess |
Etanercept | GRP- 26053 | Injection 50 mg in 1 mL single use auto-injector, 4 | Injection | Brenzys |
Etanercept | GRP- 26053 | Injections 50 mg in 1 mL single use pre-filled syringes, 4 | Injection | Brenzys |
Ethosuximide | GRP-23067 | Capsule 250 mg | Oral | Zarontin |
Ethosuximide | GRP-23067 | Capsule 250 mg (s19A) | Oral | Ethosuximide Essential Generics (UK) |
Everolimus | GRP-25323 | Tablet 1 mg | Oral | Certican |
Everolimus | GRP-25324 | Tablet 0.25 mg | Oral | Certican |
Everolimus | GRP-25326 | Tablet 0.5 mg | Oral | Certican |
Everolimus | GRP-25328 | Tablet 0.75 mg | Oral | Certican |
Exemestane | GRP-20304 | Tablet 25 mg | Oral | APO-Exemestane |
Ezetimibe | GRP-22396 | Tablet 10 mg | Oral | APO-Ezetimibe |
Ezetimibe and rosuvastatin | GRP-22369 | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) | Oral | Ezalo Composite Pack 10mg+40mg |
Ezetimibe and rosuvastatin | GRP-22388 | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) | Oral | Ezalo Composite Pack 10mg+10mg |
Ezetimibe and rosuvastatin | GRP-22395 | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) | Oral | Ezalo Composite Pack 10mg+20mg |
Ezetimibe and rosuvastatin | GRP-22399 | Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) | Oral | Ezalo Composite Pack 10mg+5mg |
Ezetimibe with atorvastatin | GRP-23702 | Tablet 10 mg-40 mg | Oral | Atozet |
Ezetimibe with atorvastatin | GRP-23705 | Tablet 10 mg-80 mg | Oral | Atozet |
Ezetimibe with atorvastatin | GRP-23706 | Tablet 10 mg-20 mg | Oral | Atozet |
Ezetimibe with atorvastatin | GRP-23708 | Tablet 10 mg-10 mg | Oral | Atozet |
Ezetimibe with simvastatin | GRP-22376 | Tablet 10 mg-40 mg | Oral | APO-Ezetimibe/Simvastatin 10/40 |
Ezetimibe with simvastatin | GRP-22381 | Tablet 10 mg-10 mg | Oral | APO-Ezetimibe/Simvastatin 10/10 |
Ezetimibe with simvastatin | GRP-22383 | Tablet 10 mg-20 mg | Oral | APO-Ezetimibe/Simvastatin 10/20 |
Ezetimibe with simvastatin | GRP-22393 | Tablet 10 mg-80 mg | Oral | APO-Ezetimibe/Simvastatin 10/80 |
Famciclovir | GRP-19771 | Tablet 125 mg | Oral | APO-Famciclovir |
Famciclovir | GRP-19828 | Tablet 250 mg | Oral | APO-Famciclovir |
Famciclovir | GRP-19913 | Tablet 500 mg | Oral | APO-Famciclovir |
Felodipine | GRP-19647 | Tablet 10 mg (extended release) | Oral | Felodil XR 10 |
Felodipine | GRP-19691 | Tablet 2.5 mg (extended release) | Oral | Felodur ER 2.5 mg |
Felodipine | GRP-19853 | Tablet 5 mg (extended release) | Oral | Felodil XR 5 |
Fenofibrate | GRP-20716 | Tablet 145 mg | Oral | APO-Fenofibrate |
Fenofibrate | GRP-20725 | Tablet 48 mg | Oral | APO-Fenofibrate |
Fentanyl | GRP-15510 | Transdermal patch 7.65 mg | Transdermal | Denpax |
Fentanyl | GRP-15510 | Transdermal patch 12.375 mg | Transdermal | Fenpatch 75 |
Fentanyl | GRP-15510 | Transdermal patch 12.6 mg | Transdermal | APO-Fentanyl |
Fentanyl | GRP-15577 | Transdermal patch 2.55 mg | Transdermal | Denpax |
Fentanyl | GRP-15577 | Transdermal patch 4.125 mg | Transdermal | Fenpatch 25 |
Fentanyl | GRP-15577 | Transdermal patch 4.2 mg | Transdermal | APO-Fentanyl |
Fentanyl | GRP-15659 | Transdermal patch 5.10 mg | Transdermal | Denpax |
Fentanyl | GRP-15659 | Transdermal patch 8.25 mg | Transdermal | Fenpatch 50 |
Fentanyl | GRP-15659 | Transdermal patch 8.4 mg | Transdermal | APO-Fentanyl |
Fentanyl | GRP-15747 | Transdermal patch 10.20 mg | Transdermal | Denpax |
Fentanyl | GRP-15747 | Transdermal patch 16.5 mg | Transdermal | Fenpatch 100 |
Fentanyl | GRP-15747 | Transdermal patch 16.8 mg | Transdermal | APO-Fentanyl |
Fentanyl | GRP-15898 | Transdermal patch 1.28 mg | Transdermal | Denpax |
Fentanyl | GRP-15898 | Transdermal patch 2.063 mg | Transdermal | Fenpatch 12 |
Fentanyl | GRP-15898 | Transdermal patch 2.1 mg | Transdermal | APO-Fentanyl |
Filgrastim | GRP-23379 | Injection 300 micrograms in 0.5 mL single-use pre-filled syringe | Injection | Nivestim |
Filgrastim | GRP-23385 | Injection 480 micrograms in 0.5 mL single-use pre-filled syringe | Injection | Nivestim |
Fingolimod | GRP-26766 | Capsule 500 micrograms (as hydrochloride) | Oral | AKM Fingolimod |
Flecainide | GRP-19776 | Tablet containing flecainide acetate 100 mg | Oral | APO-Flecainide |
Flecainide | GRP-21022 | Tablet containing flecainide acetate 50 mg | Oral | APO-Flecainide |
Flucloxacillin | GRP-23238 | Capsule 250 mg (as sodium monohydrate) | Oral | Flopen |
Flucloxacillin | GRP-23239 | Capsule 500 mg (as sodium monohydrate) | Oral | Flopen |
Fluconazole | GRP-19858 | Capsule 200 mg | Oral | Diflucan |
Fluconazole | GRP-19877 | Capsule 50 mg | Oral | Diflucan |
Fluconazole | GRP-19878 | Capsule 100 mg | Oral | Diflucan |
Fludrocortisone | GRP-25994 | Tablet containing fludrocortisone acetate 100 micrograms | Oral | FLUDROCORTISONE MEDSURGE |
Fluoxetine | GRP-24550 | Capsule 20 mg (as hydrochloride) | Oral | APO-Fluoxetine |
Fluticasone propionate | GRP-21526 | Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Axotide |
Fluticasone propionate | GRP-21532 | Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Axotide |
Fluticasone propionate | GRP-24883 | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses | Inhalation by mouth | Axotide Junior Accuhaler |
Fluticasone propionate | GRP-24884 | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses | Inhalation by mouth | Axotide Accuhaler |
Fluticasone propionate | GRP-24885 | Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Axotide Junior |
Fluticasone propionate with salmeterol | GRP-21522 | Pressurised inhalation containing fluticasone propionate 250 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Evocair MDI |
Fluticasone propionate with salmeterol | GRP-21527 | Pressurised inhalation containing fluticasone propionate 125 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | Evocair MDI |
Fluticasone propionate with salmeterol | GRP-24889 | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | PAVTIDE ACCUHALER 100/50 |
Fluticasone propionate with salmeterol | GRP-24890 | Pressurised inhalation containing fluticasone propionate 50 micrograms with salmeterol 25 micrograms (as xinafoate) per dose, 120 doses (CFC-free formulation) | Inhalation by mouth | PAVTIDE MDI 50/25 |
Fluticasone propionate with salmeterol | GRP-24904 | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Fluticasone Salmeterol Ciphaler 250/50 |
Fluticasone propionate with salmeterol | GRP-24913 | Powder for oral inhalation in breath actuated device containing fluticasone propionate 500 micrograms with salmeterol 50 micrograms (as xinafoate) per dose, 60 doses | Inhalation by mouth | Fluticasone Salmeterol Ciphaler 500/50 |
Fluvoxamine | GRP-19729 | Tablet containing fluvoxamine maleate 50 mg | Oral | APO-Fluvoxamine |
Fluvoxamine | GRP-19862 | Tablet containing fluvoxamine maleate 100 mg | Oral | APO-Fluvoxamine |
Folic acid | GRP-20411 | Tablet 500 micrograms | Oral | Foltabs 500 |
Follitropin alfa | GRP-25866 | Injection 300 I.U. in 0.5 mL multi-dose cartridge | Injection | Gonal-f Pen |
Follitropin alfa | GRP-25867 | Injection 450 I.U. in 0.75 mL multi-dose cartridge | Injection | Gonal-f Pen |
Follitropin alfa | GRP-25879 | Injection 900 I.U. in 1.5 mL multi-dose cartridge | Injection | Gonal-f Pen |
Follitropin beta | GRP-27212 | Solution for injection 600 I.U. in 0.72 mL multi-dose cartridge | Injection | Puregon 600 IU/0.72 mL |
Follitropin beta | GRP-27211 | Solution for injection 900 I.U. in 1.08 mL multi-dose cartridge | Injection | Puregon 900 IU/1.08 mL |
Follitropin beta | GRP-27207 | Solution for injection 300 I.U. in 0.36 mL multi-dose cartridge | Injection | Puregon 300 IU/0.36 mL |
Fosaprepitant | GRP-27398 | Powder for I.V. infusion 150 mg | Injection | Emend IV |
Fosinopril | GRP-19769 | Tablet containing fosinopril sodium 20 mg | Oral | APO-Fosinopril |
Fosinopril | GRP-19785 | Tablet containing fosinopril sodium 10 mg | Oral | APO-Fosinopril |
Fremanezumab | GRP-26651 | Solution for injection 225 mg in 1.5 mL single dose pre-filled pen | Injection | Ajovy |
Fremanezumab | GRP-26651 | Solution for injection 225 mg in 1.5 mL single dose pre-filled syringe | Injection | Ajovy |
Fulvestrant | GRP-25877 | Injection 250 mg in 5 mL pre-filled syringe | Injection | FULVESTRANT ACCORD |
Furosemide | GRP-15441 | Tablet 20 mg | Oral | APO-Frusemide |
Furosemide | GRP-19673 | Tablet 40 mg | Oral | APO-Frusemide |
Gabapentin | GRP-19792 | Capsule 400 mg | Oral | APX-Gabapentin |
Gabapentin | GRP-19876 | Tablet 600 mg | Oral | GAPENTIN |
Gabapentin | GRP-20038 | Capsule 100 mg | Oral | APX-Gabapentin |
Gabapentin | GRP-20089 | Tablet 800 mg | Oral | GAPENTIN |
Gabapentin | GRP-20136 | Capsule 300 mg | Oral | APX-Gabapentin |
Galantamine | GRP-19984 | Capsule (prolonged release) 24 mg (as hydrobromide) | Oral | APO-Galantamine MR |
Galantamine | GRP-20010 | Capsule (prolonged release) 8 mg (as hydrobromide) | Oral | APO-Galantamine MR |
Galantamine | GRP-20219 | Capsule (prolonged release) 16 mg (as hydrobromide) | Oral | APO-Galantamine MR |
Ganciclovir | GRP-22142 | Powder for I.V. infusion 500 mg (as sodium) | Injection | Cymevene |
Ganirelix | GRP-24916 | Injection 250 micrograms (as acetate) in 0.5 mL pre-filled syringe | Injection | GANIRELIX SUN |
Gemfibrozil | GRP-20148 | Tablet 600 mg | Oral | Ausgem |
Glatiramer | GRP-26552 | Injection containing glatiramer acetate 40 mg in 1 mL single dose pre-filled pen | Injection | Copaxone |
Glatiramer | GRP-26552 | Injection containing glatiramer acetate 40 mg in 1 mL single dose pre-filled syringe | Injection | Copaxone |
Gliclazide | GRP-19611 | Tablet 60 mg (modified release) | Oral | ARDIX GLICLAZIDE 60mg MR |
Gliclazide | GRP-19637 | Tablet 30 mg (modified release) | Oral | APO-Gliclazide MR |
Gliclazide | GRP-19933 | Tablet 80 mg | Oral | APO-Gliclazide |
Glimepiride | GRP-19711 | Tablet 2 mg | Oral | ARX-GLIMEPIRIDE |
Glimepiride | GRP-19770 | Tablet 3 mg | Oral | ARX-GLIMEPIRIDE |
Glimepiride | GRP-19855 | Tablet 4 mg | Oral | ARX-GLIMEPIRIDE |
Glimepiride | GRP-19887 | Tablet 1 mg | Oral | ARX-GLIMEPIRIDE |
Glipizide | GRP-19686 | Tablet 5 mg | Oral | Melizide |
Granisetron | GRP-20012 | Concentrated injection 3 mg (as hydrochloride) in 3 mL | Injection | Granisetron-AFT |
Hydrocortisone | GRP-20005 | Ointment containing hydrocortisone acetate 10 mg per g, 50 g | Application | Cortic-DS 1% |
Hydrocortisone | GRP-20194 | Cream containing hydrocortisone acetate 10 mg per g, 50 g | Application | Cortic-DS 1% |
Hydrocortisone | GRP-22370 | Tablet 4 mg | Oral | Hydrocortisone Viatris 4 |
Hydrocortisone | GRP-22397 | Tablet 20 mg | Oral | Hydrocortisone Viatris 20 |
Hydromorphone | GRP-23240 | Injection containing hydromorphone hydrochloride 10 mg in 1 mL | Injection | Dilaudid-HP |
Hydromorphone | GRP-23244 | Injection containing hydromorphone hydrochloride 2 mg in 1 mL | Injection | Dilaudid |
Hydromorphone | GRP-28212 | Oral solution containing hydromorphone hydrochloride 1mg per mL, 1mL (S19A) | Oral | Hydromorphone hydrochloride oral solution, USP (Medsurge) |
Hydromorphone | GRP-28212 | Oral solution containing hydromorphone hydrochloride 1 mg per mL, 1 mL | Oral | Hikma |
Hydroxocobalamin | GRP-17689 | Injection 1 mg (as acetate) in 1 mL | Injection | Cobal-B12 |
Hydroxocobalamin | GRP-17689 | Injection 1 mg (as chloride) in 1 mL | Injection | Hydroxo-B12 |
Hydroxycarbamide | GRP-24269 | Capsule 500 mg | Oral | HYDROXYCARBAMIDE MEDSURGE |
Hydroxychloroquine | GRP-19846 | Tablet containing hydroxychloroquine sulfate 200 mg | Oral | APO- Hydroxychloroquine |
Hyoscine | GRP-21879 | Injection containing hyoscine butylbromide 20 mg in 1 mL | Injection | Buscopan |
Hypromellose | GRP-22878 | Eye drops 3 mg per mL, 10 mL | Application to the eye | Genteal |
Hypromellose with carbomer 980 | GRP-20137 | Ocular lubricating gel 3 mg-2 mg per g, 10 g | Application to the eye | Genteal gel |
Hypromellose with dextran | GRP-20049 | Eye drops containing 3 mg hypromellose 4500 with 1 mg dextran 70 per mL, 15 mL | Application to the eye | Poly-Tears |
Ibuprofen | GRP-21741 | Tablet 400 mg | Oral | APO-Ibuprofen 400 |
Icatibant | GRP-24276 | Injection 30 mg (as acetate) in 3 mL single use pre-filled syringe | Injection | Cipla Icatibant |
Imatinib | GRP-21074 | Capsule 100 mg (as mesilate) | Oral | ARX-IMATINIB |
Imatinib | GRP-21074 | Tablet 100 mg (as mesilate) | Oral | Gilmat |
Imatinib | GRP- 21079 | Capsule 400 mg (as mesilate) | Oral | IMATINIB-DRLA |
Imatinib | GRP- 21079 | Tablet 400 mg (as mesilate) | Oral | Gilmat |
Imipramine | GRP-24222 | Tablet containing imipramine hydrochloride 25 mg | Oral | Tofranil 25 |
Imipramine | GRP-24222 | Tablet containing imipramine hydrochloride 25 mg (s19A) | Oral | Imipramine (Leading) |
Imiquimod | GRP-17129 | Cream 50 mg per g, 2 g, 2 | Application | Aldara Pump |
Imiquimod | GRP-17129 | Cream 50 mg per g, 250 mg single use sachets, 12 | Application | APO-Imiquimod |
Indapamide | GRP-19607 | Tablet containing indapamide hemihydrate 1.5 mg (sustained release) | Oral | APO-Indapamide SR |
Indapamide | GRP-19781 | Tablet containing indapamide hemihydrate 2.5 mg | Oral | Dapa-Tabs |
Indometacin | GRP-20071 | Capsule 25 mg | Oral | Arthrexin |
Infliximab | GRP-20382 | Powder for I.V. infusion 100 mg | Injection | Inflectra |
Ipratropium | GRP-19679 | Nebuliser solution containing ipratropium bromide 500 micrograms (as monohydrate) in 1 mL single dose units, 30 | Inhalation | Atrovent Adult |
Ipratropium | GRP-19908 | Nebuliser solution containing ipratropium bromide 250 micrograms (as monohydrate) in 1 mL single dose units, 30 | Inhalation | Atrovent |
Irbesartan | GRP-19646 | Tablet 75 mg | Oral | APO-Irbesartan |
Irbesartan | GRP-19659 | Tablet 150 mg | Oral | APO-Irbesartan |
Irbesartan | GRP-19742 | Tablet 300 mg | Oral | APO-Irbesartan |
Irbesartan with hydrochlorothiazide | GRP-19699 | Tablet 300 mg-25 mg | Oral | APO-Irbesartan HCTZ |
Irbesartan with hydrochlorothiazide | GRP-19743 | Tablet 300 mg-12.5 mg | Oral | APO-Irbesartan HCTZ |
Irbesartan with hydrochlorothiazide | GRP-19958 | Tablet 150 mg-12.5 mg | Oral | APO-Irbesartan HCTZ |
Isosorbide mononitrate | GRP-19675 | Tablet 120 mg (sustained release) | Oral | Imdur 120 mg |
Isosorbide mononitrate | GRP-19856 | Tablet 60 mg (sustained release) | Oral | APO-Isosorbide Mononitrate |
Isotretinoin | GRP-19603 | Capsule 40 mg | Oral | Dermatane |
Isotretinoin | GRP-19867 | Capsule 10 mg | Oral | APO-Isotretinoin |
Isotretinoin | GRP-22820 | Capsule 20 mg | Oral | APO-Isotretinoin |
Itraconazole | GRP-21159 | Capsule 100 mg | Oral | APO-Itraconazole |
Ivabradine | GRP-22577 | Tablet 5 mg (as hydrochloride) | Oral | APO-Ivabradine |
Ivabradine | GRP-22578 | Tablet 7.5 mg (as hydrochloride) | Oral | APO-Ivabradine |
Ketoprofen | GRP-20014 | Capsule 200 mg (sustained release) | Oral | Orudis SR 200 |
Lacosamide | GRP-26166 | Tablet 100 mg | Oral | Lacoress |
Lacosamide | GRP-26170 | Tablet 150 mg | Oral | Lacoress |
Lacosamide | GRP-26173 | Tablet 200 mg | Oral | Lacoress |
Lacosamide | GRP-26169 | Tablet 50 mg | Oral | Lacoress |
Lamivudine | GRP-19748 | Tablet 300 mg | Oral | 3TC |
Lamivudine | GRP-19806 | Tablet 100 mg | Oral | Zeffix |
Lamivudine | GRP-19929 | Tablet 150 mg | Oral | 3TC |
Lamivudine with zidovudine | GRP-19570 | Tablet 150 mg-300 mg | Oral | Combivir |
Lamotrigine | GRP-19640 | Tablet 200 mg | Oral | APX-Lamotrigine |
Lamotrigine | GRP-19706 | Tablet 100 mg | Oral | APX-Lamotrigine |
Lamotrigine | GRP-19758 | Tablet 50 mg | Oral | APX-Lamotrigine |
Lamotrigine | GRP-19807 | Tablet 25 mg | Oral | APX-Lamotrigine |
Lanreotide | GRP-27570 | Injection 90 mg (as acetate) in single dose pre-filled syringe | Injection | Mytolac |
Lanreotide | GRP-27567 | Injection 120 mg (as acetate) in single dose pre-filled syringe | Injection | Mytolac |
Lanreotide | GRP-27569 | Injection 60 mg (as acetate) in single dose pre-filled syringe | Injection | Mytolac |
Lansoprazole | GRP-14641 | Capsule 30 mg | Oral | APO-Lansoprazole |
Lansoprazole | GRP-14641 | Tablet 30 mg (orally disintegrating) | Oral | APO-Lansoprazole ODT |
Lansoprazole | GRP-19832 | Tablet 15 mg (orally disintegrating) | Oral | APO-Lansoprazole ODT |
Latanoprost | GRP-20084 | Eye drops 50 micrograms per mL, 2.5 mL | Application to the eye | APO-Latanoprost |
Latanoprost with timolol | GRP-20063 | Eye drops 50 micrograms latanoprost with timolol 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | APO-Latanoprost/Timolol 0.05/5 |
Leflunomide | GRP-19639 | Tablet 20 mg | Oral | APO-LEFLUNOMIDE |
Leflunomide | GRP-19866 | Tablet 10 mg | Oral | APO-LEFLUNOMIDE |
Lercanidipine | GRP-19829 | Tablet containing lercanidipine hydrochloride 20 mg | Oral | ARX-LERCANIDIPINE |
Lercanidipine | GRP-19911 | Tablet containing lercanidipine hydrochloride 10 mg | Oral | ARX-LERCANIDIPINE |
Letrozole | GRP-19884 | Tablet 2.5 mg | Oral | ARX-LETROZOLE |
Levetiracetam | GRP-19643 | Tablet 500 mg | Oral | APO-Levetiracetam |
Levetiracetam | GRP-19648 | Tablet 250 mg | Oral | APO-Levetiracetam |
Levetiracetam | GRP-19680 | Tablet 1 g | Oral | APO-Levetiracetam |
Levetiracetam | GRP-20362 | Oral solution 100 mg per mL, 300 mL | Oral | APO-Levetiracetam |
Levodopa with carbidopa | GRP-19870 | Tablet 100 mg-25 mg (as monohydrate) | Oral | APO-Levodopa/Carbidopa |
Levodopa with carbidopa | GRP-22958 | Tablet 250 mg-25 mg (as monohydrate) | Oral | APO-Levodopa/Carbidopa |
Levodopa with carbidopa and entacapone | GRP-24192 | Tablet 50 mg-12.5 mg (as monohydrate)-200 mg | Oral | Carlevent |
Levodopa with carbidopa and entacapone | GRP-24193 | Tablet 125 mg-31.25 mg (as monohydrate)-200 mg | Oral | Carlevent |
Levodopa with carbidopa and entacapone | GRP-24197 | Tablet 150 mg-37.5 mg (as monohydrate)-200 mg | Oral | Carlevent |
Levodopa with carbidopa and entacapone | GRP-24198 | Tablet 75 mg-18.75 mg (as monohydrate)-200 mg | Oral | Carlevent |
Levodopa with carbidopa and entacapone | GRP-24201 | Tablet 100 mg-25 mg (as monohydrate)-200 mg | Oral | Carlevent |
Levodopa with carbidopa and entacapone | GRP-24203 | Tablet 200 mg-50 mg (as monohydrate)-200 mg | Oral | Carlevent |
Levonorgestrel with ethinylestradiol | GRP-19824 | Pack containing 6 tablets 50 micrograms-30 micrograms, 5 tablets 75 micrograms-40 micrograms, 10 tablets 125 micrograms-30 micrograms and 7 inert tablets | Oral | Logynon ED |
Levonorgestrel with ethinylestradiol | GRP-19827 | Pack containing 21 tablets 150 micrograms-30 micrograms and 7 inert tablets | Oral | Eleanor 150/30 ED |
Levothyroxine | GRP-27400 | Tablet containing 200 micrograms anhydrous levothyroxine sodium | Oral | Eltroxin |
Levothyroxine | GRP-26246 | Tablet containing 200 micrograms anhydrous levothyroxine sodium | Oral | APO-Levothyroxine |
Levothyroxine | GRP 27402 | Tablet containing 50 micrograms anhydrous levothyroxine sodium | Oral | Eltroxin |
Levothyroxine | GRP-26247 | Tablet containing 50 micrograms anhydrous levothyroxine sodium | Oral | APO-Levothyroxine |
Levothyroxine | GRP-27411 | Tablet containing 100 micrograms anhydrous levothyroxine sodium | Oral | Eltroxin |
Levothyroxine | GRP-26248 | Tablet containing 100 micrograms anhydrous levothyroxine sodium | Oral | APO-Levothyroxine |
Levothyroxine | GRP-27401 | Tablet containing 75 micrograms anhydrous levothyroxine sodium | Oral | Eltroxin |
Levothyroxine | GRP-26249 | Tablet containing 75 micrograms anhydrous levothyroxine sodium | Oral | APO-Levothyroxine |
Lincomycin | GRP-22364 | Injection 600 mg (as hydrochloride monohydrate) in 2 mL | Injection | LINCOMYCIN SXP |
Lisinopril | GRP-19761 | Tablet 20 mg | Oral | APO-Lisinopril |
Lisinopril | GRP-19764 | Tablet 10 mg | Oral | APO-Lisinopril |
Lisinopril | GRP-19823 | Tablet 5 mg | Oral | APO-Lisinopril |
Loperamide | GRP-20401 | Capsule containing loperamide hydrochloride 2 mg | Oral | Gastrex |
Lurasidone | GRP-24194 | Tablet containing lurasidone hydrochloride 80 mg | Oral | APO-Lurasidone |
Lurasidone | GRP-24195 | Tablet containing lurasidone hydrochloride 40 mg | Oral | APO-Lurasidone |
Macrogol 3350 | GRP-20122 | Sachets containing powder for oral solution 13.125 g with electrolytes, 30 | Oral | APO-MACROGOL plus ELECTROLYTES |
Medroxyprogesterone | GRP-28650 | Injection containing medroxyprogesterone acetate 150 mg in 1 mL | Injection | Depo-Provera |
Medroxyprogesterone | GRP-28650 | Injection containing medroxyprogesterone acetate 150 mg in 1 mL pre-filled syringe | Injection | Depo-Provera |
Medroxyprogesterone | GRP-19676 | Tablet containing medroxyprogesterone acetate 10 mg | Oral | Provera |
Medroxyprogesterone | GRP-19872 | Tablet containing medroxyprogesterone acetate 5 mg | Oral | Provera |
Mefenamic acid | GRP-25998 | Capsule 250 mg | Oral | FEMIN |
Meloxicam | GRP-15468 | Capsule 15 mg | Oral | APO-Meloxicam |
Meloxicam | GRP-15468 | Tablet 15 mg | Oral | APX-Meloxicam |
Meloxicam | GRP-15658 | Capsule 7.5 mg | Oral | APO-Meloxicam |
Meloxicam | GRP-15658 | Tablet 7.5 mg | Oral | APX-Meloxicam |
Memantine | GRP- 19971 | Tablet containing memantine hydrochloride 20 mg | Oral | APO-Memantine |
Memantine | GRP- 20090 | Tablet containing memantine hydrochloride 10 mg | Oral | APO-Memantine |
Mercaptopurine | GRP-23857 | Tablet containing mercaptopurine monohydrate 50 mg | Oral | MERCAPTOPURINE-LINK |
Mesalazine | GRP-27214 | Tablet 1.2 g (prolonged release) | Oral | MESALZ |
Metformin | GRP-19608 | Tablet (extended release) containing metformin hydrochloride 1 g | Oral | APO-Metformin XR 1000 |
Metformin | GRP-19682 | Tablet containing metformin hydrochloride 850 mg | Oral | APX-Metformin |
Metformin | GRP-19880 | Tablet containing metformin hydrochloride 500 mg | Oral | APX-Metformin |
Metformin | GRP-19944 | Tablet containing metformin hydrochloride 1 g | Oral | APX-Metformin |
Metformin | GRP-24200 | Tablet (extended release) containing metformin hydrochloride 500 mg | Oral | APO-Metformin XR 500 |
Methadone | GRP-27510 | Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 200 mL bottle, 1 mL | Oral | Aspen Methadone Syrup |
Methadone | GRP-27523 | Oral liquid containing methadone hydrochloride 25 mg per 5 mL in 1 L bottle, 1 mL | Oral | Aspen Methadone Syrup |
Methenamine | GRP-24551 | Tablet containing methenamine hippurate 1 g | Oral | Hiprex |
Methotrexate | GRP-19736 | Tablet 2.5 mg | Oral | ARX-Methotrexate |
Methotrexate | GRP- 27896 | Tablet 10 mg | Oral | ARX-Methotrexate |
Methyldopa | GRP-19840 | Tablet 250 mg (as sesquihydrate) | Oral | Aldomet |
Methylphenidate | GRP-21745 | Tablet containing methylphenidate hydrochloride 10 mg | Oral | Artige |
Methylphenidate | GRP-25859 | Tablet containing methylphenidate hydrochloride 27 mg (extended release) | Oral | Concerta |
Methylphenidate | GRP-25885 | Tablet containing methylphenidate hydrochloride 18 mg (extended release) | Oral | Concerta |
Methylphenidate | GRP-25891 | Tablet containing methylphenidate hydrochloride 36 mg (extended release) | Oral | Concerta |
Methylphenidate | GRP-25892 | Tablet containing methylphenidate hydrochloride 54 mg (extended release) | Oral | Concerta |
Methylphenidate | GRP-27206 | Capsule containing methylphenidate hydrochloride 40 mg (modified release) | Oral | Ritalin LA |
Methylphenidate | GRP-27208 | Capsule containing methylphenidate hydrochloride 60 mg (modified release) | Oral | Ritalin LA |
Methylphenidate | GRP-27209 | Capsule containing methylphenidate hydrochloride 30 mg (modified release) | Oral | Ritalin LA |
Methylphenidate | GRP-27210 | Capsule containing methylphenidate hydrochloride 10 mg (modified release) | Oral | Ritalin LA |
Methylphenidate | GRP-27215 | Capsule containing methylphenidate hydrochloride 20 mg (modified release) | Oral | Ritalin LA |
Methylprednisolone | GRP-27888 | Fatty ointment containing methylprednisolone aceponate 1 mg per g, 15 g | Application | Advantan (Fatty) |
Methylprednisolone | GRP-27997 | Cream containing methylprednisolone aceponate 1 mg per g, 15 g | Application | Advantan |
Methylprednisolone | GRP-27999 | Ointment containing methylprednisolone aceponate 1 mg per g, 15 g | Application | Advantan |
Methylprednisolone | GRP-19893 | Powder for injection 1 g (as sodium succinate) | Injection | Methylpred |
Methylprednisolone | GRP-20006 | Injection containing methylprednisolone acetate 40 mg in 1 mL | Injection | Depo-Medrol |
Metoclopramide | GRP-28223 | Injection containing 10 mg metoclopramide hydrochloride (as monohydrate) in 2 mL | Injection | METOCLOPRAMIDE INJECTION BP |
Metoclopramide | GRP-20027 | Tablet containing 10 mg metoclopramide hydrochloride (as monohydrate) | Oral | APO-Metoclopramide |
Metoprolol | GRP-19759 | Tablet containing metoprolol tartrate 50 mg | Oral | APO-Metoprolol |
Metoprolol | GRP-19804 | Tablet containing metoprolol tartrate 100 mg | Oral | APO-Metoprolol |
Metoprolol succinate | GRP-19592 | Tablet 47.5 mg (controlled release) | Oral | Metrol-XL 47.5 |
Metoprolol succinate | GRP-19594 | Tablet 190 mg (controlled release) | Oral | Metrol-XL 190 |
Metoprolol succinate | GRP-19595 | Tablet 95 mg (controlled release) | Oral | Metrol-XL 95 |
Metoprolol succinate | GRP-19596 | Tablet 23.75 mg (controlled release) | Oral | Metrol-XL 23.75 |
Metronidazole | GRP-20212 | Tablet 400 mg | Oral | Flagyl |
Minocycline | GRP-19899 | Tablet 50 mg (as hydrochloride) | Oral | Akamin 50 |
Mirtazapine | GRP-19628 | Tablet 30 mg | Oral | APX-Mirtazapine |
Mirtazapine | GRP-19718 | Tablet 15 mg | Oral | APX-Mirtazapine |
Mirtazapine | GRP-19763 | Tablet 45 mg | Oral | APX-Mirtazapine |
Moclobemide | GRP-19630 | Tablet 150 mg | Oral | Amira 150 |
Moclobemide | GRP-19932 | Tablet 300 mg | Oral | Amira 300 |
Modafinil | GRP-20604 | Tablet 100 mg | Oral | APO-Modafinil |
Mometasone | GRP-19629 | Lotion containing mometasone furoate 1 mg per g, 30 mL | Application | Elocon |
Mometasone | GRP-19755 | Ointment containing mometasone furoate 1 mg per g, 15 g | Application | Elocon |
Mometasone | GRP-19924 | Cream containing mometasone furoate 1 mg per g, 15 g | Application | Elocon Alcohol Free |
Montelukast | GRP-19556 | Tablet, chewable, 4 mg (as sodium) | Oral | MONTELAIR 4 |
Montelukast | GRP-19572 | Tablet, chewable, 5 mg (as sodium) | Oral | MONTELAIR 5 |
Morphine | GRP-20890 | Injection containing morphine hydrochloride trihydrate 10 mg in 1 mL | Injection | Morphine Juno |
Morphine | GRP-20890 | Injection containing morphine sulfate pentahydrate 10 mg in 1 mL | Injection | MORPHINE SULFATE 10 mg/1 mL MEDSURGE |
Morphine | GRP-19707 | Tablet containing morphine sulfate pentahydrate 60 mg (controlled release) | Oral | MORPHINE MR APOTEX |
Morphine | GRP-19730 | Tablet containing morphine sulfate pentahydrate 100 mg (controlled release) | Oral | MORPHINE MR APOTEX |
Morphine | GRP-19885 | Tablet containing morphine sulfate pentahydrate 10 mg (controlled release) | Oral | MORPHINE MR APOTEX |
Morphine | GRP-19923 | Tablet containing morphine sulfate pentahydrate 30 mg (controlled release) | Oral | MORPHINE MR APOTEX |
Morphine | GRP-28109 | Oral solution containing morphine hydrochloride trihydrate 2 mg per mL, 1 mL | Oral | Ordine 2 |
Morphine | GRP-28109 | Oral solution containing morphine sulfate 2 mg per mL in 100 mL bottle, 1 mL (S19A) | Oral | Morphine Sulfate (Hikma) 10 mg/5 mL (2 mg/mL) |
Morphine | GRP-28109 | Oral solution containing morphine sulfate 10 mg per 5 mL in 100 mL bottle, 1 mL (S19A) | Oral | Morphine Oral Solution (Martindale Pharma) 10 mg/5 mL |
Morphine | GRP-28109 | Oral solution containing morphine sulfate 2 mg per mL in 500 mL bottle, 1 mL (S19A) | Oral | Morphine Sulfate (Hikma) 10 mg/5 mL (2 mg/mL) |
Morphine | GRP-28109 | Oral solution containing morphine sulfate 10 mg per 5 mL in 300 mL bottle, 1 mL (S19A) | Oral | Morphine Oral Solution (Martindale Pharma) 10 mg/5 mL |
Morphine | GRP-28497 | Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 1 mL | Oral | Ordine 10 |
Morphine | GRP-28497 | Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 1 mL (RA-Morph)(S19A) | Oral | RA-Morph (NZ) |
Morphine | GRP-28497 | Oral solution containing morphine hydrochloride trihydrate 10 mg per mL, 1 mL (S19A) | Oral | Morphini HCl Streuli |
Morphine | GRP-28763 | Oral solution containing morphine hydrochloride trihydrate 5 mg per mL, 1 mL | Oral | Ordine 5 |
Morphine | GRP-28763 | Oral solution containing morphine hydrochloride trihydrate 5 mg per mL, 1 mL (S19A) | Oral | RA-Morph (NZ) |
Moxonidine | GRP-22366 | Tablet 200 micrograms | Oral | APO-Moxonidine |
Moxonidine | GRP-22375 | Tablet 400 micrograms | Oral | APO-Moxonidine |
Mycophenolic acid | GRP-17217 | Capsule containing mycophenolate mofetil 250 mg | Oral | APO-Mycophenolate |
Mycophenolic acid | GRP-20011 | Tablet containing mycophenolate mofetil 500 mg | Oral | ARX-MYCOPHENOLATE |
Mycophenolic acid | GRP-26876 | Powder for oral suspension containing mycophenolate mofetil 1 g per 5 mL, 165 mL | Oral | CellCept |
Mycophenolic acid | GRP-28115 | Tablet (enteric coated) containing mycophenolate sodium equivalent to 360 mg mycophenolic acid | Oral | MYCOTEX |
Mycophenolic acid | GRP-28293 | Tablet (enteric coated) containing mycophenolate sodium equivalent to 180 mg mycophenolic acid | Oral | Mycophenolic Acid ARX |
Naloxone | GRP-21362 | Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule | Injection | NALOXONE SXP |
Naloxone | GRP-27818 | Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2 | Nasal | Nyxoid |
Naloxone | GRP-27818 | Nasal spray 1.8 mg (as hydrochloride dihydrate) in 0.1 mL single dose unit, 2 (s19A) | Nasal | Nyxoid (UK) |
Naltrexone | GRP-19914 | Tablet containing naltrexone hydrochloride 50 mg | Oral | ARX-NALTREXONE |
Naproxen | GRP-20035 | Tablet 1 g (sustained release) | Oral | Naprosyn SR1000 |
Naproxen | GRP-20020 | Tablet containing naproxen sodium 550 mg | Oral | Anaprox 550 |
Naproxen | GRP-20009 | Tablet 750 mg (sustained release) | Oral | Naprosyn SR750 |
Nebivolol | GRP-22506 | Tablet 1.25 mg (as hydrochloride) | Oral | APO-Nebivolol |
Nebivolol | GRP-22511 | Tablet 5 mg (as hydrochloride) | Oral | APO-Nebivolol |
Nebivolol | GRP-22512 | Tablet 10 mg (as hydrochloride) | Oral | APO-Nebivolol |
Nevirapine | GRP-19845 | Tablet 200 mg | Oral | Nevirapine Alphapharm |
Nicorandil | GRP-19963 | Tablets 20 mg, 60 | Oral | APO-Nicorandil |
Nicorandil | GRP-19964 | Tablets 10 mg, 60 | Oral | APO-Nicorandil |
Nifedipine | GRP-19687 | Tablet 30 mg (controlled release) | Oral | APO-Nifedipine XR |
Nifedipine | GRP-19801 | Tablet 60 mg (controlled release) | Oral | APO-Nifedipine XR |
Niraparib | GRP-28761 | Capsule 100 mg (as tosilate monohydrate) | Oral | Zejula |
Niraparib | GRP-28761 | Tablet 100 mg (as tosilate monohydrate) | Oral | Zejula |
Nitrazepam | GRP-20002 | Tablet 5 mg | Oral | Alodorm |
Nitrofurantoin | GRP-24202 | Capsule 100 mg | Oral | ARX-Nitrofurantoin |
Nitrofurantoin | GRP-25565 | Capsule 50 mg | Oral | ARX-Nitrofurantoin |
Nizatidine | GRP-19651 | Capsule 300 mg | Oral | Nizac |
Nizatidine | GRP-19784 | Capsule 150 mg | Oral | Nizac |
Norfloxacin | GRP-19724 | Tablet 400 mg | Oral | APO-Norfloxacin |
Nortriptyline | GRP-21633 | Tablet 25 mg (as hydrochloride) | Oral | Allegron |
Nortriptyline | GRP-21641 | Tablet 10 mg (as hydrochloride) | Oral | Allegron |
Octreotide | GRP-17613 | Injection (modified release) 10 mg (as acetate), vial and diluent syringe | Injection | Octreotide Depot |
Octreotide | GRP-17622 | Injection (modified release) 20 mg (as acetate), vial and diluent syringe | Injection | Octreotide Depot |
Octreotide | GRP-17615 | Injection (modified release) 30 mg (as acetate), vial and diluent syringe | Injection | Octreotide Depot |
Octreotide | GRP-28766 | Injection 50 micrograms (as acetate) in 1 mL (S19A) | Injection | Octreotide Acetate Omega (Canada) |
Octreotide | GRP-28766 | Injection 50 micrograms (as acetate) in 1 mL | Injection | Octreotide (SUN) |
Octreotide | GRP-28775 | Injection 100 micrograms (as acetate) in 1 mL | Injection | Octreotide (SUN) |
Octreotide | GRP-28775 | Injection 100 micrograms (as acetate) in 1 mL (S19A) | Injection | Octreotide Acetate Omega (Canada) |
Octreotide | GRP-28781 | Injection 500 micrograms (as acetate) in 1 mL | Injection | Octreotide (SUN) |
Olanzapine | GRP-15492 | Tablet 2.5 mg | Oral | APO-OLANZAPINE |
Olanzapine | GRP-15513 | Tablet 10 mg | Oral | APO-OLANZAPINE |
Olanzapine | GRP-15643 | Tablet 20 mg (orally disintegrating) | Oral | APO-Olanzapine ODT |
Olanzapine | GRP-15643 | Wafer 20 mg | Oral | Zyprexa Zydis |
Olanzapine | GRP-15723 | Tablet 10 mg (orally disintegrating) | Oral | APO-Olanzapine ODT |
Olanzapine | GRP-15723 | Wafer 10 mg | Oral | Zyprexa Zydis |
Olanzapine | GRP-15797 | Tablet 5 mg (orally disintegrating) | Oral | APO-Olanzapine ODT |
Olanzapine | GRP-15797 | Wafer 5 mg | Oral | Zyprexa Zydis |
Olanzapine | GRP-15884 | Tablet 7.5 mg | Oral | APO-OLANZAPINE |
Olanzapine | GRP-15921 | Tablet 5 mg | Oral | Olanzapine APOTEX |
Olanzapine | GRP-15953 | Tablet 15 mg (orally disintegrating) | Oral | APO-Olanzapine ODT |
Olanzapine | GRP-15953 | Wafer 15 mg | Oral | Zyprexa Zydis |
Olmesartan | GRP-21158 | Tablet containing olmesartan medoxomil 20 mg | Oral | APO-Olmesartan |
Olmesartan | GRP-21168 | Tablet containing olmesartan medoxomil 40 mg | Oral | APO-Olmesartan |
Olmesartan with amlodipine | GRP-21156 | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) | Oral | APO-OLMESARTAN/AMLODIPINE 20/5 |
Olmesartan with amlodipine | GRP-21157 | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) | Oral | OLMEKAR |
Olmesartan with amlodipine | GRP-21160 | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) | Oral | OLMEKAR |
Olmesartan with amlodipine and hydrochlorothiazide | GRP-23699 | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | APO-Olmesartan/Amlodipine/HCTZ 40/5/25 tablet |
Olmesartan with amlodipine and hydrochlorothiazide | GRP-23700 | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | APO-Olmesartan/Amlodipine/HCTZ 40/10/12.5 |
Olmesartan with amlodipine and hydrochlorothiazide | GRP-23701 | Tablet containing olmesartan medoxomil 20 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | APO-Olmesartan/Amlodipine/HCTZ 20/5/12.5 |
Olmesartan with amlodipine and hydrochlorothiazide | GRP-23703 | Tablet containing olmesartan medoxomil 40 mg with amlodipine 5 mg (as besilate) and hydrochlorothiazide 12.5 mg | Oral | APO-Olmesartan/Amlodipine/HCTZ 40/5/12.5 tablet |
Olmesartan with amlodipine and hydrochlorothiazide | GRP-23710 | Tablet containing olmesartan medoxomil 40 mg with amlodipine 10 mg (as besilate) and hydrochlorothiazide 25 mg | Oral | APO-Olmesartan/Amlodipine/HCTZ 40/10/25 |
Olmesartan with hydrochlorothiazide | GRP-21154 | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg | Oral | APO-Olmesartan/HCTZ 40/12.5 |
Olmesartan with hydrochlorothiazide | GRP-21155 | Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg | Oral | APO-Olmesartan/HCTZ 20/12.5 |
Olmesartan with hydrochlorothiazide | GRP-21161 | Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg | Oral | APO-Olmesartan/HCTZ 40/25 |
Omeprazole | GRP-14650 | Capsule 20 mg | Oral | APO-Omeprazole |
Omeprazole | GRP-14650 | Tablet 20 mg | Oral | APO-Omeprazole |
Omeprazole | GRP-14650 | Tablet 20 mg (as magnesium) | Oral | Acimax Tablets |
Ondansetron | GRP-15402 | Wafer 8 mg | Oral | Zofran Zydis |
Ondansetron | GRP-15983 | Wafer 4 mg | Oral | Zofran Zydis |
Ondansetron | GRP-15983 | Tablet (orally disintegrating) 4 mg | Oral | APX-Ondansetron ODT |
Ondansetron | GRP-15402 | Tablet (orally disintegrating) 8 mg | Oral | APX-Ondansetron ODT |
Ondansetron | GRP-19791 | Tablet 4 mg (as hydrochloride dihydrate) | Oral | APO-Ondansetron |
Ondansetron | GRP-19626 | Tablet 8 mg (as hydrochloride dihydrate) | Oral | APO-Ondansetron |
Oxazepam | GRP-20046 | Tablet 15 mg | Oral | Alepam 15 |
Oxazepam | GRP-19993 | Tablet 30 mg | Oral | APO-Oxazepam |
Oxycodone | GRP-19609 | Tablet containing oxycodone hydrochloride 80 mg (controlled release) | Oral | OxyContin |
Oxycodone | GRP-19610 | Tablet containing oxycodone hydrochloride 10 mg (controlled release) | Oral | OxyContin |
Oxycodone | GRP-19617 | Tablet containing oxycodone hydrochloride 40 mg (controlled release) | Oral | OxyContin |
Oxycodone | GRP-19619 | Tablet containing oxycodone hydrochloride 20 mg (controlled release) | Oral | OxyContin |
Oxycodone | GRP-22722 | Capsule containing oxycodone hydrochloride 5 mg | Oral | OxyNorm |
Oxycodone | GRP-23065 | Capsule containing oxycodone hydrochloride 20 mg | Oral | OxyNorm |
Oxycodone | GRP- 23063 | Capsule containing oxycodone hydrochloride 10 mg | Oral | OxyNorm |
Oxycodone | GRP-22722 | Tablet containing oxycodone hydrochloride 5 mg | Oral | ENDONE |
Palonosetron | GRP-26174 | Injection 250 micrograms (as hydrochloride) in 5 mL | Injection | Aloxi |
Pantoprazole | GRP-19833 | Tablet (enteric coated) 20 mg (as sodium sesquihydrate) | Oral | APO-Pantoprazole |
Pantoprazole | GRP-20087 | Tablet (enteric coated) 40 mg (as sodium sesquihydrate) | Oral | APO-Pantoprazole |
Paracetamol | GRP-20015 | Tablet 500 mg | Oral | APO-Paracetamol |
Paracetamol | GRP-20761 | Tablet 665 mg (modified release) | Oral | APOHEALTH Osteo Relief Paracetamol 665 mg |
Paroxetine | GRP-15790 | Tablet 20 mg (as hydrochloride) | Oral | APO-Paroxetine |
Pegfilgrastim | GRP-21364 | Injection 6 mg in 0.6 mL single use pre-filled syringe | Injection | Pelgraz |
Perindopril | GRP-15442 | Tablet containing perindopril arginine 5 mg | Oral | APO-Perindopril Arginine |
Perindopril | GRP-15442 | Tablet containing perindopril erbumine 4 mg | Oral | APO-Perindopril |
Perindopril | GRP-15525 | Tablet containing perindopril arginine 10 mg | Oral | APO-Perindopril Arginine |
Perindopril | GRP-15525 | Tablet containing perindopril erbumine 8 mg | Oral | APO-Perindopril |
Perindopril | GRP-15965 | Tablet containing perindopril arginine 2.5 mg | Oral | APO-Perindopril Arginine |
Perindopril | GRP-15965 | Tablet containing perindopril erbumine 2 mg | Oral | APO-Perindopril |
Perindopril with amlodipine | GRP-19627 | Tablet containing 10 mg perindopril arginine with 10 mg amlodipine (as besilate) | Oral | APO-Perindopril Arginine/Amlodipine 10/10 |
Perindopril with amlodipine | GRP-19798 | Tablet containing 10 mg perindopril arginine with 5 mg amlodipine (as besilate) | Oral | APO-Perindopril Arginine/Amlodipine 10/5 |
Perindopril with amlodipine | GRP-19886 | Tablet containing 5 mg perindopril arginine with 10 mg amlodipine (as besilate) | Oral | APO-Perindopril Arginine/Amlodipine 5/10 |
Perindopril with amlodipine | GRP-19936 | Tablet containing 5 mg perindopril arginine with 5 mg amlodipine (as besilate) | Oral | APO-Perindopril Arginine/Amlodipine 5/5 |
Perindopril with indapamide | GRP-15765 | Tablet containing perindopril arginine 5 mg with indapamide hemihydrate 1.25 mg | Oral | Coversyl Plus 5mg/1.25mg |
Perindopril with indapamide | GRP-15765 | Tablet containing perindopril erbumine 4 mg with indapamide hemihydrate 1.25 mg | Oral | APO-Perindopril/Indapamide |
Perindopril with indapamide | GRP-21205 | Tablet containing perindopril arginine 2.5 mg with indapamide hemihydrate 0.625 mg | Oral | Coversyl Plus LD 2.5mg/0.625mg |
Pioglitazone | GRP-19790 | Tablet 45 mg (as hydrochloride) | Oral | APOTEX-Pioglitazone |
Pioglitazone | GRP-19814 | Tablet 15 mg (as hydrochloride) | Oral | APOTEX-Pioglitazone |
Pioglitazone | GRP-19943 | Tablet 30 mg (as hydrochloride) | Oral | APOTEX-Pioglitazone |
Pirfenidone | GRP-27890 | Tablet 267 mg | Oral | Pirfenidet |
Pirfenidone | GRP-27892 | Tablet 801mg | Oral | Pirfenidet |
Plerixafor | GRP-26646 | Injection 24 mg in 1.2 mL | Injection | Mozobil |
Polyethylene glycol 400 with propylene glycol | GRP-26947 | Eye drops 4 mg-3 mg per mL, 15 mL | Application to the eye | Optix |
Posaconazole | GRP-24439 | Tablet (modified release) 100 mg | Oral | POSACONAZOLE DR.REDDY'S |
Pramipexole | GRP-19734 | Tablet containing pramipexole dihydrochloride monohydrate 1 mg | Oral | APO-Pramipexole |
Pramipexole | GRP-19836 | Tablet containing pramipexole dihydrochloride monohydrate 125 micrograms | Oral | APO-Pramipexole |
Pramipexole | GRP-19688 | Tablet containing pramipexole dihydrochloride monohydrate 250 micrograms | Oral | APO-Pramipexole |
Pramipexole | GRP-20529 | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 375 micrograms | Oral | APO-Pramipexole ER |
Pramipexole | GRP-20530 | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 2.25 mg | Oral | APO-Pramipexole ER |
Pramipexole | GRP-20531 | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 750 micrograms | Oral | APO-Pramipexole ER |
Pramipexole | GRP-20532 | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg | Oral | APO-Pramipexole ER |
Pramipexole | GRP-20533 | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg | Oral | APO-Pramipexole ER |
Pramipexole | GRP-20534 | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg | Oral | APO-Pramipexole ER |
Pramipexole | GRP-20535 | Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg | Oral | APO-Pramipexole ER |
Pravastatin | GRP-20082 | Tablet containing pravastatin sodium 80 mg | Oral | APX-Pravastatin |
Pravastatin | GRP-20142 | Tablet containing pravastatin sodium 40 mg | Oral | APX-Pravastatin |
Pravastatin | GRP-20150 | Tablet containing pravastatin sodium 20 mg | Oral | APX-Pravastatin |
Pravastatin | GRP-20171 | Tablet containing pravastatin sodium 10 mg | Oral | APX-Pravastatin |
Prazosin | GRP-19831 | Tablet 2 mg (as hydrochloride) | Oral | APO-Prazosin |
Prazosin | GRP-19871 | Tablet 5 mg (as hydrochloride) | Oral | APO-Prazosin |
Prazosin | GRP-19942 | Tablet 1 mg (as hydrochloride) | Oral | APO-Prazosin |
Prednisolone | GRP-19757 | Tablet 1 mg | Oral | Panafcortelone |
Prednisolone | GRP-19768 | Oral solution 5 mg (as sodium phosphate) per mL, 30 mL | Oral | PredMix |
Prednisone | GRP-19658 | Tablet 1 mg | Oral | Panafcort |
Pregabalin | GRP-21628 | Capsule 300 mg | Oral | APO-Pregabalin |
Pregabalin | GRP-21634 | Capsule 75 mg | Oral | APO-Pregabalin |
Pregabalin | GRP-21640 | Capsule 150 mg | Oral | APO-Pregabalin |
Pregabalin | GRP-21642 | Capsule 25 mg | Oral | APO-Pregabalin |
Prochlorperazine | GRP-28600 | Tablet containing prochlorperazine maleate 5 mg (S19A) | Oral | Stemetil (Ireland) |
Prochlorperazine | GRP-28600 | Tablet containing prochlorperazine maleate 5 mg | Oral | APO-Prochlorperazine |
Propranolol | GRP-20367 | Tablet containing propranolol hydrochloride 40 mg | Oral | APO-Propranolol |
Propranolol | GRP-20376 | Tablet containing propranolol hydrochloride 10 mg | Oral | APO-Propranolol |
Quetiapine | GRP-19663 | Tablet 300 mg (as fumarate) | Oral | APX-QUETIAPINE |
Quetiapine | GRP-19709 | Tablet 200 mg (as fumarate) | Oral | APX-QUETIAPINE |
Quetiapine | GRP-19767 | Tablet 100 mg (as fumarate) | Oral | APX-QUETIAPINE |
Quetiapine | GRP-19935 | Tablet 25 mg (as fumarate) | Oral | APX-QUETIAPINE |
Quetiapine | GRP-20702 | Tablet (modified release) 200 mg (as fumarate) | Oral | APX-Quetiapine XR |
Quetiapine | GRP-20713 | Tablet (modified release) 300 mg (as fumarate) | Oral | APX-Quetiapine XR |
Quetiapine | GRP-20726 | Tablet (modified release) 400 mg (as fumarate) | Oral | APX-Quetiapine XR |
Quetiapine | GRP-20779 | Tablet (modified release) 50 mg (as fumarate) | Oral | APX-Quetiapine XR |
Quetiapine | GRP-21163 | Tablet (modified release) 150 mg (as fumarate) | Oral | APX-Quetiapine XR |
Quinapril | GRP-19716 | Tablet 20 mg (as hydrochloride) | Oral | ACQUIN |
Quinapril | GRP-19789 | Tablet 5 mg (as hydrochloride) | Oral | ACQUIN |
Quinapril | GRP-19902 | Tablet 10 mg (as hydrochloride) | Oral | ACQUIN |
Rabeprazole | GRP-19921 | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | APO-Rabeprazole |
Rabeprazole | GRP-20107 | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | APO-Rabeprazole |
Raloxifene | GRP-19622 | Tablet containing raloxifene hydrochloride 60 mg | Oral | Evista |
Ramipril | GRP-15424 | Capsule 5 mg | Oral | APO-Ramipril |
Ramipril | GRP-15424 | Tablet 5 mg | Oral | APO-Ramipril |
Ramipril | GRP-15431 | Capsule 10 mg | Oral | APO-Ramipril |
Ramipril | GRP-15431 | Tablet 10 mg | Oral | APO-Ramipril |
Ramipril | GRP-15640 | Capsule 1.25 mg | Oral | Tryzan Caps 1.25 |
Ramipril | GRP-15640 | Tablet 1.25 mg | Oral | Prilace |
Ramipril | GRP-15769 | Capsule 2.5 mg | Oral | APO-Ramipril |
Ramipril | GRP-15769 | Tablet 2.5 mg | Oral | APO-Ramipril |
Ranibizumab | GRP-17312 | Solution for intravitreal injection 1.65 mg in 0.165 mL pre-filled syringe | Injection | Lucentis |
Ranibizumab | GRP-17312 | Solution for intravitreal injection 2.3 mg in 0.23 mL | Injection | Lucentis |
Rasagiline | GRP-22819 | Tablet 1 mg (as mesilate) | Oral | Alziras |
Riluzole | GRP-19669 | Tablet 50 mg | Oral | APO-Riluzole |
Risedronic acid | GRP-19671 | Tablet containing risedronate sodium 150 mg | Oral | APO-Risedronate |
Risedronic acid | GRP-19999 | Tablet containing risedronate sodium 35 mg | Oral | APO-Risedronate |
Risperidone | GRP-14646 | Tablet 0.5 mg | Oral | APO-Risperidone |
Risperidone | GRP-19844 | Tablet 4 mg | Oral | APO-Risperidone |
Risperidone | GRP-19938 | Tablet 3 mg | Oral | APO-Risperidone |
Risperidone | GRP-20017 | Tablet 2 mg | Oral | APO-Risperidone |
Risperidone | GRP-20120 | Tablet 1 mg | Oral | APO-Risperidone |
Risperidone | GRP-24014 | Oral solution 1 mg per mL, 100 mL | Oral | Risperdal |
Rituximab | GRP-26546 | Solution for I.V. infusion 500 mg in 50 mL | Injection | Riximyo |
Rituximab | GRP-26547 | Solution for I.V. infusion 100 mg in 10 mL | Injection | Riximyo |
Rizatriptan | GRP-17623 | Tablet (orally disintegrating) 10 mg (as benzoate) | Oral | APO-Rizatriptan |
Rizatriptan | GRP-17623 | Wafer 10 mg (as benzoate) | Oral | Maxalt |
Rosuvastatin | GRP-19557 | Tablet 20 mg (as calcium) | Oral | APO-ROSUVASTATIN |
Rosuvastatin | GRP-19558 | Tablet 10 mg (as calcium) | Oral | APO-ROSUVASTATIN |
Rosuvastatin | GRP-19562 | Tablet 40 mg (as calcium) | Oral | APO-ROSUVASTATIN |
Rosuvastatin | GRP-19569 | Tablet 5 mg (as calcium) | Oral | APO-ROSUVASTATIN |
Roxithromycin | GRP-20052 | Tablet 150 mg | Oral | APO-Roxithromycin |
Roxithromycin | GRP-20144 | Tablet 300 mg | Oral | APO-Roxithromycin |
Salbutamol | GRP-21361 | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation | Ventolin Nebules |
Salbutamol | GRP-21361 | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30 | Inhalation | Salbutamol Cipla |
Salbutamol | GRP-21535 | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation | Ventolin Nebules |
Salbutamol | GRP-21535 | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 (S19A) | Inhalation | pms-SALBUTAMOL |
Salbutamol | GRP-21535 | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30 | Inhalation | Salbutamol Cipla |
Salbutamol | GRP-24211 | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation) | Inhalation by mouth | Asmol CFC-Free with dose counter |
Sertraline | GRP-24879 | Tablet 50 mg (as hydrochloride) | Oral | APO-Sertraline |
Sertraline | GRP-24880 | Tablet 100 mg (as hydrochloride) | Oral | APO-Sertraline |
Sevelamer | GRP-23578 | Tablet containing sevelamer carbonate 800 mg | Oral | ARX-SEVELAMER |
Sevelamer | GRP-23578 | Tablet containing sevelamer hydrochloride 800 mg | Oral | Renagel |
Sildenafil | GRP-20013 | Tablet 20 mg (as citrate) | Oral | Revatio |
Simvastatin | GRP-20109 | Tablet 80 mg | Oral | APO-Simvastatin |
Simvastatin | GRP-20174 | Tablet 20 mg | Oral | APO-Simvastatin |
Simvastatin | GRP-20182 | Tablet 40 mg | Oral | APO-Simvastatin |
Simvastatin | GRP-20328 | Tablet 10 mg | Oral | APO-Simvastatin |
Simvastatin | GRP-20357 | Tablet 5 mg | Oral | Simvastatin Sandoz |
Sitagliptin | GRP-26493 | Tablet 50 mg | Oral | Januvia |
Sitagliptin | GRP-26495 | Tablet 25 mg | Oral | Januvia |
Sitagliptin | GRP-26496 | Tablet 100 mg | Oral | Januvia |
Sitagliptin with metformin | GRP-26448 | Tablet containing 50 mg sitagliptin with 850 mg metformin hydrochloride | Oral | Janumet |
Sitagliptin with metformin | GRP-26451 | Tablet containing 50 mg sitagliptin with 500 mg metformin hydrochloride | Oral | Janumet |
Sitagliptin with metformin | GRP-26455 | Tablet containing 50 mg sitagliptin with 1000 mg metformin hydrochloride | Oral | Janumet |
Sitagliptin with metformin | GRP-28124 | Tablet (modified release) containing 50 mg sitagliptin with 1000 mg metformin hydrochloride | Oral | Janumet XR |
Sitagliptin with metformin | GRP-28131 | Tablet (modified release) containing 100 mg sitagliptin with 1000 mg metformin hydrochloride | Oral | Janumet XR |
Sotalol | GRP-19704 | Tablet containing sotalol hydrochloride 160 mg | Oral | APX-Sotalol |
Sotalol | GRP-19874 | Tablet containing sotalol hydrochloride 80 mg | Oral | APX-Sotalol |
Spironolactone | GRP-19653 | Tablet 100 mg | Oral | Aldactone |
Spironolactone | GRP-19873 | Tablet 25 mg | Oral | Aldactone |
Sulfasalazine | GRP-20249 | Tablet 500 mg (enteric coated) | Oral | Pyralin EN |
Sumatriptan | GRP-15928 | Tablet 50 mg (as succinate) | Oral | APO-Sumatriptan |
Sumatriptan | GRP-15928 | Tablet (fast disintegrating) 50 mg (as succinate) | Oral | Imigran FDT |
Sunitinib | GRP-25556 | Capsule 37.5 mg | Oral | ARX-Sunitinib |
Sunitinib | GRP-25554 | Capsule 25 mg | Oral | ARX-Sunitinib |
Sunitinib | GRP-25561 | Capsule 12.5 mg | Oral | Sunitinib MSN |
Sunitinib | GRP-25553 | Capsule 50 mg | Oral | ARX-Sunitinib |
Tacrolimus | GRP-19985 | Capsule 1 mg | Oral | Pacrolim |
Tacrolimus | GRP-20056 | Capsule 5 mg | Oral | Pharmacor Tacrolimus 5 |
Tacrolimus | GRP-20053
| Capsule 0.5 mg | Oral | Pacrolim |
Tacrolimus | GRP-20887 | Capsule 5 mg (once daily prolonged release) | Oral | ADVAGRAF XL |
Tacrolimus | GRP-20891 | Capsule 1 mg (once daily prolonged release) | Oral | ADVAGRAF XL |
Tacrolimus | GRP- 20892 | Capsule 0.5 mg (once daily prolonged release) | Oral | ADVAGRAF XL |
Tacrolimus | GRP-28602 | Capsule 3 mg (once daily prolonged release) | Oral | ADVAGRAF XL |
Tadalafil | GRP-24271 | Tablet 20 mg | Oral | Adcirca |
Tamoxifen | GRP-15405 | Tablet 20 mg (as citrate) | Oral | GenRx Tamoxifen |
Telmisartan | GRP-19601 | Tablet 80 mg | Oral | APO-Telmisartan |
Telmisartan | GRP-19604 | Tablet 40 mg | Oral | APO-Telmisartan |
Telmisartan with amlodipine | GRP-19587 | Tablet 40 mg-5 mg (as besilate) | Oral | Pritor/Amlodipine |
Telmisartan with amlodipine | GRP-19588 | Tablet 40 mg-10 mg (as besilate) | Oral | Pritor/Amlodipine |
Telmisartan with amlodipine | GRP-19589 | Tablet 80 mg-10 mg (as besilate) | Oral | Pritor/Amlodipine |
Telmisartan with amlodipine | GRP-19590 | Tablet 80 mg-5 mg (as besilate) | Oral | Pritor/Amlodipine |
Telmisartan with hydrochlorothiazide | GRP-19555 | Tablet 40 mg-12.5 mg | Oral | APO-Telmisartan HCTZ 40/12.5 |
Telmisartan with hydrochlorothiazide | GRP-19561 | Tablet 80 mg-12.5 mg | Oral | APO-Telmisartan HCTZ 80/12.5 |
Telmisartan with hydrochlorothiazide | GRP-19571 | Tablet 80 mg-25 mg | Oral | APO-Telmisartan HCTZ 80/25 |
Temazepam | GRP-19980 | Tablet 10 mg | Oral | APO-Temazepam |
Temozolomide | GRP-19803 | Capsule 250 mg | Oral | APO-Temozolomide |
Temozolomide | GRP-19977 | Capsule 20 mg | Oral | APO-Temozolomide |
Temozolomide | GRP-19997 | Capsule 5 mg | Oral | APO-Temozolomide |
Temozolomide | GRP-20004 | Capsule 180 mg | Oral | APO-Temozolomide |
Temozolomide | GRP-20068 | Capsule 140 mg | Oral | APO-Temozolomide |
Temozolomide | GRP-20268 | Capsule 100 mg | Oral | APO-Temozolomide |
Tenecteplase | GRP-26656 | Powder for injection 50 mg with solvent | Injection | Metalyse |
Tenecteplase | GRP-26656 | Powder for injection 50 mg with solvent (s19A) | Injection | TNKase (Canada) |
Tenofovir | GRP-21636 | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | TENOFOVIR ARX |
Tenofovir | GRP-21636 | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Tenofovir Disoproxil Mylan |
Tenofovir | GRP-21636 | Tablet containing tenofovir disoproxil phosphate 291 mg | Oral | Tenofovir GH |
Tenofovir with emtricitabine | GRP- 21638 | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | CIPLA TENOFOVIR + EMTRICITABINE 300/200 |
Tenofovir with emtricitabine | GRP-21638 | Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg | Oral | Tenofovir Disoproxil Emtricitabine Viatris 300/200 |
Tenofovir with emtricitabine | GRP-21638 | Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg | Oral | Tenofovir EMT GH |
Tenofovir with emtricitabine | GRP- 21638 | Tablet containing tenofovir disoproxil succinate 301 mg with emtricitabine 200 mg | Oral | Tenofovir/Emtricitabine Sandoz 301/200 |
Terbinafine | GRP-20256 | Tablet 250 mg (as hydrochloride) | Oral | APO-Terbinafine |
Teriflunomide | GRP-23068 | Tablet 14 mg | Oral | APO-TERIFLUNOMIDE |
Teriparatide | GRP-25564 | Injection 250 micrograms per mL, 2.4 mL in multi-dose pre-filled pen | Injection | Teriparatide Lupin |
Testosterone | GRP-28648 | I.M. injection containing testosterone undecanoate 1,000 mg in 4 mL | Injection | Gonadron |
Tetrabenazine | GRP-26950 | Tablet 25 mg | Oral | Tetrabenazine SUN |
Timolol | GRP-28880 | Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL | Application to the eye | Timoptol XE |
Timolol | GRP-28880 | Eye drops (gellan gum solution) 5 mg (as maleate) per mL, 2.5 mL (S19A) | Application to the eye | Timoptol XE 0.50% (South Africa) |
Tiotropium | GRP-23704 | Capsule containing powder for oral inhalation 13 micrograms (as bromide) (for use in Zonda device) | Inhalation by mouth | Braltus |
Tiotropium | GRP-23704 | Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in HandiHaler) | Inhalation by mouth | Spiriva |
Tiotropium | GRP-23704 | Capsule containing powder for oral inhalation 18 micrograms (as bromide monohydrate) (for use in LupinHaler) | Inhalation by mouth | Tiotropium Lupin |
Tirofiban | GRP-19593 | Solution concentrate for I.V. infusion 12.5 mg (as hydrochloride) in 50 mL | Injection | Aggrastat |
Tobramycin | GRP-20899 | Solution for inhalation 300 mg in 5 mL | Inhalation | TOBRAMYCIN SUN |
Topiramate | GRP-19668 | Tablet 200 mg | Oral | APO-Topiramate |
Topiramate | GRP-19765 | Tablet 50 mg | Oral | APO-Topiramate |
Topiramate | GRP-19766 | Tablet 100 mg | Oral | APO-Topiramate |
Topiramate | GRP-19896 | Tablet 25 mg | Oral | APO-Topiramate |
Tramadol | GRP-20129 | Injection containing tramadol hydrochloride 100 mg in 2 mL | Injection | Tramadol AN |
Tramadol | GRP-19670 | Tablet (sustained release) containing tramadol hydrochloride 100 mg | Oral | APO-Tramadol SR |
Tramadol | GRP-19805 | Tablet (sustained release) containing tramadol hydrochloride 200 mg | Oral | APO-Tramadol SR |
Tramadol | GRP-19815 | Tablet (sustained release) containing tramadol hydrochloride 150 mg | Oral | APO-Tramadol SR |
Tramadol | GRP-20030 | Capsule containing tramadol hydrochloride 50 mg | Oral | APO-Tramadol |
Trandolapril | GRP-19654 | Capsule 2 mg | Oral | Dolapril 2 |
Trandolapril | GRP-19735 | Capsule 500 micrograms | Oral | Dolapril 0.5 |
Trandolapril | GRP-19830 | Capsule 1 mg | Oral | Dolapril 1 |
Trandolapril | GRP-19912 | Capsule 4 mg | Oral | Dolapril 4 |
Tranexamic acid | GRP-21497 | Tablet 500 mg | Oral | APO-Tranexamic Acid |
Triamcinolone | GRP-19701 | Ointment containing triamcinolone acetonide 200 micrograms per g, 100 g | Application | Aristocort 0.02% |
Triamcinolone | GRP-19745 | Cream containing triamcinolone acetonide 200 micrograms per g, 100 g | Application | Aristocort 0.02% |
Triamcinolone with neomycin, gramicidin and nystatin | GRP-19681 | Ear ointment containing triamcinolone acetonide 1 mg with neomycin 2.5 mg (as sulfate), gramicidin 250 micrograms and nystatin 100,000 units per g, 5 g | Application to the ear | Kenacomb Otic |
Triamcinolone with neomycin, gramicidin and nystatin | GRP-19728 | Ear drops containing triamcinolone acetonide 0.9 mg with neomycin 2.25 mg (as sulfate), gramicidin 225 micrograms and nystatin 90,000 units per mL, 7.5 mL | Application to the ear | Kenacomb Otic |
Trientine | GRP-28298 | Capsule containing trientine dihydrochloride 250 mg (equivalent to 166.7 mg trientine) | Oral | Trientine Dr. Reddy's |
Trimethoprim | GRP-20308 | Tablet 300 mg | Oral | Alprim |
Trimethoprim with sulfamethoxazole | GRP-20094 | Tablet 160 mg-800 mg | Oral | Bactrim DS |
Ursodeoxycholic acid | GRP-19961 | Capsule 250 mg | Oral | APO-Ursodeoxycholic acid |
Valaciclovir | GRP-19634 | Tablet 500 mg (as hydrochloride) | Oral | APX-Valaciclovir |
Valganciclovir | GRP-21630 | Tablet 450 mg (as hydrochloride) | Oral | Valganciclovir Sandoz |
Valproic acid | GRP-19751 | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | APO-Sodium Valproate |
Valproic acid | GRP-19922 | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | APO-Sodium Valproate |
Valsartan | GRP-19598 | Tablet 40 mg | Oral | Dilart |
Valsartan | GRP-19599 | Tablet 160 mg | Oral | Dilart |
Valsartan | GRP-19600 | Tablet 320 mg | Oral | Dilart |
Valsartan | GRP-19602 | Tablet 80 mg | Oral | Dilart |
Valsartan with hydrochlorothiazide | GRP-19612 | Tablet 160 mg-12.5 mg | Oral | Co-Diovan 160/12.5 |
Valsartan with hydrochlorothiazide | GRP-19614 | Tablet 320 mg-12.5 mg | Oral | Co-Diovan 320/12.5 |
Valsartan with hydrochlorothiazide | GRP-19615 | Tablet 320 mg-25 mg | Oral | Co-Diovan 320/25 |
Valsartan with hydrochlorothiazide | GRP-19965 | Tablet 80 mg-12.5 mg | Oral | Co-Diovan 80/12.5 |
Valsartan with hydrochlorothiazide | GRP-19966 | Tablet 160 mg-25 mg | Oral | Co-Diovan 160/25 |
Vancomycin | GRP-26946 | Capsule 125 mg (125,000 I.U.) (as hydrochloride) | Oral | Vancocin |
Vancomycin | GRP-26952 | Capsule 250 mg (250,000 I.U.) (as hydrochloride) | Oral | Vancocin |
Varenicline | GRP-26245 | Tablet 1 mg (as tartrate) | Oral | Champix |
Varenicline | GRP-27996 | Box containing 11 tablets 0.5 mg (as tartrate) and 14 tablets 1 mg (as tartrate) in the first pack and 28 tablets 1 mg (as tartrate) in the second pack | Oral | Champix |
Venlafaxine | GRP-19721 | Capsule (modified release) 37.5 mg (as hydrochloride) | Oral | Efexor-XR |
Venlafaxine | GRP-19796 | Capsule (modified release) 150 mg (as hydrochloride) | Oral | APO-Venlafaxine XR |
Venlafaxine | GRP-19797 | Capsule (modified release) 75 mg (as hydrochloride) | Oral | APO-Venlafaxine XR |
Verapamil | GRP-19760 | Tablet containing verapamil hydrochloride 180 mg (sustained release) | Oral | Cordilox 180 SR |
Verapamil | GRP-19780 | Tablet containing verapamil hydrochloride 240 mg (sustained release) | Oral | Cordilox SR |
Verapamil | GRP-19898 | Tablet containing verapamil hydrochloride 80 mg | Oral | Anpec 80 |
Vinorelbine | GRP-27399 | Capsule 30 mg (as tartrate) | Oral | Navelbine |
Vinorelbine | GRP-27405 | Capsule 20 mg (as tartrate) | Oral | Navelbine |
Voriconazole | GRP-20447 | Tablet 200 mg | Oral | Voriconazole Sandoz |
Voriconazole | GRP-20450 | Tablet 50 mg | Oral | Voriconazole Sandoz |
Ziprasidone | GRP-19574 | Capsule 20 mg (as hydrochloride) | Oral | ZIPROX |
Ziprasidone | GRP-19575 | Capsule 40 mg (as hydrochloride) | Oral | ZIPROX |
Ziprasidone | GRP-19576 | Capsule 80 mg (as hydrochloride) | Oral | ZIPROX |
Ziprasidone | GRP-19577 | Capsule 60 mg (as hydrochloride) | Oral | ZIPROX |
Zoledronic acid | GRP-17612 | Solution for I.V. infusion 5 mg (as monohydrate) in 100 mL | Injection | Aclasta |
Zoledronic acid | GRP-17614 | Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL | Injection | APO-Zoledronic Acid |
Zolmitriptan | GRP-19573 | Tablet 2.5 mg | Oral | APO-Zolmitriptan |